WorldWideScience

Sample records for aplastic anemia patients

  1. Aplastic Anemia

    Science.gov (United States)

    Aplastic anemia is a rare but serious blood disorder. If you have it, your bone marrow doesn't make ... blood cells. There are different types, including Fanconi anemia. Causes include Toxic substances, such as pesticides, arsenic, ...

  2. What Is Aplastic Anemia?

    Science.gov (United States)

    ... from the NHLBI on Twitter. What Is Aplastic Anemia? Aplastic anemia (a-PLAS-tik uh-NEE-me-uh) is ... heart, heart failure , infections, and bleeding. Severe aplastic anemia can even cause death. Overview Aplastic anemia is ...

  3. Aplastic Anemia in Two Patients with Sex Chromosome Aneuploidies.

    Science.gov (United States)

    Rush, Eric T; Schaefer, G Bradley; Sanger, Warren G; Coccia, Peter F

    2015-01-01

    Sex chromosome aneuploidies range in incidence from rather common to exceedingly rare and have a variable phenotype. We report 2 patients with sex chromosome aneuploidies who developed severe aplastic anemia requiring treatment. The first patient had tetrasomy X (48,XXXX) and presented at 9 years of age, and the second patient had trisomy X (47,XXX) and presented at 5 years of age. Although aplastic anemia has been associated with other chromosomal abnormalities, sex chromosome abnormalities have not been traditionally considered a risk factor for this condition. A review of the literature reveals that at least one other patient with a sex chromosome aneuploidy (45,X) has suffered from aplastic anemia and that other autosomal chromosomal anomalies have been described. Despite the uncommon nature of each condition, it is possible that the apparent association is coincidental. A better understanding of the genetic causes of aplastic anemia remains important.

  4. APLASTIC ANEMIA

    Directory of Open Access Journals (Sweden)

    Ni Made Dharma Laksmi

    2013-07-01

    Full Text Available Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 Aplastic Anemia describes a disorder of the clinical syndrome is marked by a deficiency of red blood cells, neutrophils, monocytes and platelets in the absence of other forms of bone marrow damage. Aplastic anemia is classified as a rare disease in developed countries the incidence of 3-6 cases / 1 million inhabitants / year. The exact cause of someone suffering from aplastic anemia also can not be established with certainty, but there are several sources of potential risk factors. Prognosis or course of the disease varies widely aplastic anemia, but without treatment generally gives a poor prognosis /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;}

  5. Immunosuppressive therapy for transplant-ineligible aplastic anemia patients.

    Science.gov (United States)

    Schrezenmeier, Hubert; Körper, Sixten; Höchsmann, Britta

    2015-02-01

    Aplastic anemia is a rare life-threatening bone marrow failure that is characterized by bicytopenia or pancytopenia in the peripheral blood and a hypoplastic or aplastic bone marrow. The patients are at risk of infection and hemorrhage due to neutropenia and thrombocytopenia and suffer from symptoms of anemia. The main treatment approaches are allogeneic stem cell transplantation and immunosuppression. Here, we review current standard immunosuppression and the attempts that have been made in the past two decades to improve results: review of recent developments also reveals that sometimes not only the advent of new drugs, good ideas and well-designed clinical trials decide the progress in the field but also marketing considerations of pharmaceutical companies. Aplastic anemia experts unfortunately had to face the situation that efficient drugs were withdrawn simply for marketing considerations. We will discuss the current options and challenges in first-line treatment and management of relapsing and refractory patients with an emphasis on adult patients. Some promising new approaches are currently under investigation in prospective, randomized trials. PMID:25572607

  6. Aplastic Anemia and Myelodysplastic Syndromes

    Science.gov (United States)

    ... Organizations (PDF, 270 KB). Alternate Language URL Aplastic Anemia and Myelodysplastic Syndromes Page Content On this page: ... References For More Information Acknowledgments What are aplastic anemia and myelodysplastic syndromes (MDS)? Aplastic anemia and myelodysplastic ...

  7. How Is Aplastic Anemia Treated?

    Science.gov (United States)

    ... from the NHLBI on Twitter. How Is Aplastic Anemia Treated? Treatments for aplastic anemia include blood transfusions , blood and marrow stem cell ... a transplant. Removing a known cause of aplastic anemia, such as exposure to a toxin, also may ...

  8. Epidemiologic and HLA Antigen Profile in Patients with Aplastic Anemia

    International Nuclear Information System (INIS)

    Objective: To analyze patients suffering from aplastic anemia (AA, peripheral pancytopenia and hypocellular bone marrow in the absence of dysplasia, infiltration and fibrosis) for documenting patient's baseline characteristics and association with various human leucocyte antigens. Study Design: An observational, cross-sectional study. Place and Duration of Study: The National Institute of Blood Disease (NIBD), Karachi, from March 2003 to August 2008. Methodology: All consecutive patients with confirmed diagnosis of AA were evaluated. Data included the baseline characteristics, complete blood counts (CBC), bone marrow biopsy findings, severity of disease, exposure to drugs or chemicals, viral serology and their HLA expression. The data was analyzed on SPSS programme and frequencies were documented. Results: Among 318 patients, there were 236 (74.21%) males and 82 (25.78%) females. Median age was 16 and 70% belonged to urban population. Drug exposure could be established in 23 (7.23%) of cases, while 4 (1.25%) were HBV surface antigen positive and 7 (2.2%) were HCV antibodies positive. In all, 73 (22.9%) had very severe AA, 195 (61.32%) had severe AA while 50 (15.7%) cases had non-severe AA. HLA B5 (52) showed high expression in 83 patients (26%) in comparison to 5.9% reported in healthy population. Conclusion: AA was found to affect young adult males living in urban areas. HLA B5 (52) showed higher expression in patients with aplastic anemia. (author)

  9. How Is Aplastic Anemia Diagnosed?

    Science.gov (United States)

    ... from the NHLBI on Twitter. How Is Aplastic Anemia Diagnosed? Your doctor will diagnose aplastic anemia based on your medical and family histories, a ... your primary care doctor thinks you have aplastic anemia, he or she may refer you to a ...

  10. Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide

    Energy Technology Data Exchange (ETDEWEB)

    Kopecky, Jindrich; Priester, Peter; Slovacek, Ladislav; Petera, Jiri; Macingova, Zuzana [Dept. of Clinical Oncology and Radiotherapy, Charles Univ. Hospital and Faculty of Medicine in Hradec Kralove (Czech Republic); Kopecky, Otakar [Clinical Oncology, Regional Hospital Nachod (Czech Republic)

    2010-08-15

    Background: Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy. Serious hematologic complications are rarely reported. Case Report and Results: The authors present the case of a 61-year-old female patient with glioblastoma multiforme treated with external-beam radiation therapy and concomitant temozolomide. After completion of treatment, the patient developed symptoms of serious aplastic anemia that eventually led to death due to prolonged neutro- and thrombocytopenia followed by infectious complications. Conclusion: Lethal complications following temozolomide are, per se, extremely rare, however, a total of four other cases of aplastic anemia have been reported in the literature so far. (orig.)

  11. Special Issues for People with Aplastic Anemia

    Science.gov (United States)

    ... Menu Donate Special Issues for People with Aplastic Anemia Because you have aplastic anemia , everyday events can ... bleeding, such as contact sports. Pregnancy and Aplastic Anemia Pregnancy is possible for women who have been ...

  12. Circulating thrombopoietin levels in normal healthy blood donors and in aplastic anemia patients in relation to disease severity

    Directory of Open Access Journals (Sweden)

    Abhay Singh

    2015-01-01

    Full Text Available Background: Thrombopoietin (TPO is the key hematopoietic growth factor regulating the production of platelets from bone marrow megakaryocytes and maintaining platelet hemostasis. This study was done to find any relationship between the levels of thrombopoietin and the severity of disease in patients with aplastic anemia. Materials and Methods: Serum samples were collected from 52 patients with a confirmed diagnosis of aplastic anemia and 45 normal healthy blood donors of both sexes over a period of 2 years, and TPO was estimated by using commercially available TPO-specific-enzyme-linked immunosorbent assay. Results: The median TPO level of 1190 pg/ml (range 625-7651 pg/ml in aplastic anemia patients was significantly higher than the median TPO level of 121.1 pg/ml (81.25-237.7 pg/ml in normal healthy blood donors (P = 0.000. No significant difference was observed in TPO levels of male and female patients (P = 0.453. The median TPO concentrations observed in very severe aplastic anemia, severe aplastic anemia, and nonsevere aplastic anemia were 2765 pg/ml (range 625-6451 pg/ml, 1190 pg/ml (range 672.1-7651 pg/ml, and 1111.5 pg/ml (range 761.1-2289.2 pg/ml, respectively. TPO in patients of very severe aplastic anemia was significantly higher than patients of nonsevere aplastic anemia (P = 0.043, with no significant relation among rest of the groups. Discussion: TPO levels in aplastic anemia patients were significantly higher than in healthy blood donors; however, in aplastic anemia patients TPO levels were significantly higher only in patients with very severe disease.

  13. Clinical observation of treating 62 patients with severe aplastic anemia failing in immunosuppressive therapy by integrative medicine

    Institute of Scientific and Technical Information of China (English)

    苏尔云

    2013-01-01

    Objective To explore treatment methods for patients with severe aplastic anemia(SAA) failing in immunosuppressive therapy(IST). Methods Totally 62 SAA patients failing in IST were treated by integrative medicine(IM).

  14. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

    DEFF Research Database (Denmark)

    Lee, Jong Wook; Yoon, Sung-Soo; Shen, Zhi Xiang;

    2010-01-01

    The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of deferasirox in this patient population. After 1 year, median serum ferritin decreased...... neutrophil and platelet counts remained stable during treatment, and there were no drug-related cytopenias. This prospective dataset confirms the efficacy and well characterizes the tolerability profile of deferasirox in a large population of patients with aplastic anemia. This study was registered at www...

  15. Study on abnormal iron metabolism and iron overload in patients with aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    金朋

    2013-01-01

    Objective To investigate the abnormalities of iron metabolism,the prevalence and risk factors of iron overload and clinical characteristics of patients with aplastic anemia (AA) .Methods A cross-sectional study was conducted on 520 newly diagnosed AA patients.Results Iron overload was observed in 66 (13%) of 520 AA patients,in which a higher prevalence of iron overload was seen not only in patients with infections (19/86,22%) than those without infections (47/434,11%,P<0.01) ,but also in patients with hepatitis associated AA

  16. Syngeneic transplantation in aplastic anemia

    DEFF Research Database (Denmark)

    Gerull, Sabine; Stern, Martin; Apperley, Jane;

    2013-01-01

    . About half of transplants with data available (39 of 86) were followed by posttransplant immunosuppression. Graft source was bone marrow in the majority of cases (n=77). Transplant practice changed over time with more transplants with conditioning and anti-thymocyte globulin as well as peripheral blood...... stem cells performed in later years. Ten year overall survival was 93% with 5 transplant-related deaths. Graft failure occurred in 32% of transplants. Risk of graft failure was significantly increased in transplants without conditioning, and with bone marrow as graft source. Lack of posttransplant...... a retrospective analysis of all syngeneic transplants for aplastic anemia reported to the European Group for Blood and Marrow Transplantation. Between 1976 and 2009, 88 patients received 113 transplants. Most transplants (n=85) were preceded by a conditioning regimen, 22 of these including anti-thymocyte globulin...

  17. Persistent elevated bone marrow plasma levels of thrombopoietin in patients with aplastic anemia.

    Science.gov (United States)

    Zhang, Jizhou; Wu, Qingqing; Zheng, Yizhou

    2016-09-01

    Acquired aplastic anemia (AA) is an immune-mediated bone marrow (BM) failure syndrome. Plasma thrombopoietin (TPO) levels are elevated in AA patients with reduced blood counts. However, whether elevated TPO can recover to normal level in AA patients in complete remission (CR) after efficient immunosuppressive therapy (IST) is unknown. We measured TPO levels of BM plasma in a large cohort of AA patients with focusing on patients in CR after IST. Our data showed that BM plasma TPO levels were still high in patients who had reached normal blood counts levels for a long time. We speculate that downregulated expression of MPL (TPO receptor) in HSPC (hematopoietic stem and progenitor cells) may be related to the upregulated TPO in AA. PMID:27269179

  18. Development of cerebral venous sinus thrombosis in an aplastic anemia patient with antiphospholipid syndrome

    Institute of Scientific and Technical Information of China (English)

    CHEN Jian-hua; YOU Xin; QIAN Min

    2010-01-01

    @@ Aplastic anemia (AA) is an acquired disorder in which bone marrow fails to produce or release sufficient amounts of blood cell. Antiphospholipid syndrome (APS)is an autoimmune disease characterised by recurrent arterial or venous thrombosis, pregnancy morbidity and the persistence of positive antiphospholipid antibodies (aPL), including anticardiolipin antibody (ACL) and lupus anticoagulant (LA).

  19. Immunosuppression prior to marrow transplantation for sensitized aplastic anemia patients: comparison of TLI with TBI

    International Nuclear Information System (INIS)

    From May 1980 through July 1986, 26 patients with severe aplastic anemia, sensitized with multiple transfusions of blood products, were treated on either of two immunosuppressive regimens in preparation for bone marrow transplantation from a matched donor. There were 10 patients treated with total body irradiation (TBI), 200 cGy/fraction X 4 daily fractions (800 cGy total dose), followed by cyclophosphamide, 60 mg/kg/d X 2 d. An additional 16 patients were treated with total lymphoid irradiation (TLI) [or, if they were infants, a modified TLI or thoracoabdominal irradiation (TAI)], 100 cGy/fraction, 3 fractions/d X 2 d (600 cGy total dose), followed by cyclophosphamide, 40 mg/kg/d X 4 d. The extent of immunosuppression was similar in both groups as measured by peripheral blood lymphocyte depression at the completion of the course of irradiation (5% of initial concentration for TBI and 24% for TLI), neutrophil engraftment (10/10 for TBI and 15/16 for TLI), and time to neutrophil engraftment (median of 22 d for TBI and 17 d for TLI). Marrow and peripheral blood cytogenetic analysis for assessment of percent donor cells was also compared in those patients in whom it was available. 2/2 patients studied with TBI had 100% donor cells, whereas 6/11 with TLI had 100% donor cells. Of the five who did not, three were stable mixed chimeras with greater than or equal to 70% donor cells, one became a mixed chimera with about 50% donor cells, but became aplastic again after Cyclosporine A cessation 5 mo post-transplant, and the fifth reverted to all host cells by d. 18 post-transplant. Overall actuarial survival at 2 years was 56% in the TLI group compared with 30% in the TBI group although this was not statistically significant. No survival decrement has been seen after 2 years in either group

  20. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial

    DEFF Research Database (Denmark)

    Lee, Jong Wook; Yoon, Sung-Soo; Shen, Zhi Xiang;

    2010-01-01

    The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of deferasirox in this patient population. After 1 year, median serum ferritin decreased...... significantly from 3254 ng/mL at baseline to 1854 ng/mL (P chelation-naive (3229-1520 ng/mL; P chelated (3263-2585 ng/mL; P = .21, last-observation-carried-forward analysis) patients and were reflective of dose...

  1. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia.

    Science.gov (United States)

    Bacigalupo, Andrea; Giammarco, Sabrina; Sica, Simona

    2016-08-01

    Standard front-line treatment for acquired aplastic anemia (AA) for patients is either immunosuppressive therapy (IST) or bone marrow transplantation (BMT), usually from an HLA identical sibling. Whereas long-term survival is comparable with either treatment, important differences remain: IST patients may have incomplete or no recovery, are exposed to late clonal disorders and relapse of the original disease. Transplantation is a curative treatment, but patients are exposed to transplant-related complications both acute and chronic, such as chronic graft versus host disease (cGvHD). In the year 2000, a study by the European Group for Blood and Marrow Transplantation (EBMT), looked at failure free survival (FFS), in patients receiving first-line BMT from an HLA identical sibling, or the first-line IST. Young patients with low neutrophil counts benefited of the first-line BMT; the opposite was true for older patients with higher neutrophil counts; and a third intermediate group of patients had comparable survival irrespective of the first-line therapy. We have now studied a more recent cohort of patients to assess whether things have changed over the years. We have found similar results, although overall survival has improved, as a consequence of changes in the IST and BMT protocols. PMID:27278666

  2. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia

    OpenAIRE

    Scheinberg, Phillip; Fischer, Steven H.; Li, Li; Nunez, Olga; Wu, Colin O.; Sloand, Elaine M.; Cohen, Jeffrey I.; Young, Neal S; A. John Barrett

    2007-01-01

    The natural history of EBV and CMV reactivation and the potential for serious complications following antibody-based immunosuppressive treatment for bone marrow failure syndromes in the absence of transplantation is not known. We monitored blood for EBV and CMV reactivation by polymerase chain reaction (PCR) weekly in 78 consecutive patients (total of 99 immunosuppressive courses) with aplastic anemia. Four regimens were studied: (1) HC, horse ATG/cyclosporine; (2) HCS, horse ATG/CsA/sirolimu...

  3. What Are the Signs and Symptoms of Aplastic Anemia?

    Science.gov (United States)

    ... What Are the Signs and Symptoms of Aplastic Anemia? Lower than normal numbers of red blood cells, ... most of the signs and symptoms of aplastic anemia. Signs and Symptoms of Low Blood Cell Counts ...

  4. Role of myeloperoxidase index in differentiation of megaloblastic and aplastic anemia

    Directory of Open Access Journals (Sweden)

    Ziaei Jamal Eivazi

    2004-08-01

    Full Text Available BACKGROUND: Elevated neutrophil myeloperoxidase may have a role in the diagnosis of megaloblastic erythropoiesis. AIMS: To study the differentiating role of myeloperoxidase index in megaloblastic and aplastic anemia. SETTINGS AND DESIGN: The myeloperoxidase index (MPXI was studied in 96 patients with megaloblastic and aplastic anemia diagnosed on bone marrow aspiration and biopsy examinations. METHODS AND MATERIALS: MPXI was measured with Technicon H1 (Bayer automated analyzer. Nonparametric Mann-Whitney statistical test was used to compare the MPXI values between groups. RESULTS: The mean MPXI in megaloblastics and aplastic anemia was 18.3 and 1.8 (p<0.001 respectively. MPXI >20 denoted megaloblastic and MPXI <-11.6 denoted aplastic anemia. CONCLUSION: MPXI measurement may assist differentiation of megaloblastic from aplastic anemia, while MPXI >20 rules out aplastic and MPXI <-11.6 rules out megaloblastic anemia.

  5. F-18 FLT PET : A Noninvasive Diagnostic Tool for Visualization of the Bone Marrow Compartment in Patients With Aplastic Anemia A Pilot Study

    NARCIS (Netherlands)

    Agool, Ali; Slart, Riemer H. J. A.; Kluin, Philip M.; de Wolf, Joost Th. M.; Dierckx, Rudi A. J. O.; Vellenga, Edo

    2011-01-01

    Rationale: A discordant relationship between bone marrow cellularity and peripheral blood findings is regularly noticed in patients with aplastic anemia (AA). Therefore, the feasibility of 3-F-18 fluoro-3-deoxy-L-thymidine (F-18 FLT PET was tested as a noninvasive tool to visualize the total distrib

  6. Silent hepatic lesions detected with computed tomography in aplastic anemia patients administered androgens for a long period

    Energy Technology Data Exchange (ETDEWEB)

    Yamagishi, Morihisa (Shiga Univ., Otsu (Japan)); Hiraoka, Atsumobu; Uchino, Haruto

    1982-07-01

    Macroscopic liver lesions were investigated with the use of computed tomography (CT) and radionuclide imaging (RN) in 15 aplastic anemia patients who were administered anabolic steroids for over one year and who showed no apparent physical and biochemical sign of liver tumor. In 3 patients, CT scans showed radiolucent areas in the liver. Contrast enhancements revealed these lesions to be well vascularized, suggesting they were not cysts but probably tumors. RN imaging could not demonstrate any definite space occupying lesions. Total dose of AS administered to each of the three patients exceeded 30,000 mg. It was felt that attention should be paid to the possible development of hepatic tumor when the dose of AS administered exceeds 30,000 mg.

  7. Telomere length and gene expression of shelterin in CD3~+ T cell of severe aplastic anemia patients

    Institute of Scientific and Technical Information of China (English)

    王婷

    2013-01-01

    Objective To explore the changes in telomere length and gene expression of complex shelterin (composed of 6core components:TRF1,TRF2,POT1,TIN2,TPP1and RAP1) in severe aplastic anemia (SAA) .Methods Bone marrow samples were obtained from 20 SAA

  8. Unexpected unrelated umbilical cord blood stem cell engraft in two patients with severe aplastic anemia that received immunosuppressive treatment: A case report and literature review

    OpenAIRE

    XIE, LIN-NA; Zhou, Fang

    2015-01-01

    Severe aplastic anemia (SAA) is a life-threatening bone marrow disorder. Bone marrow transplantation is the primary therapy for SAA; however, its efficacy is limited by numerous factors, including lack of histocompatible sibling donor, patient age and graft-versus-host-disease (GVHD) following transplantation. Immunosuppressive treatment (IST) is the first procedure developed for patients without a sibling donor. Our previous study reported that patients administered enhanced IST, in addition...

  9. Psoas abscess localization by gallium scan in aplastic anemia

    International Nuclear Information System (INIS)

    Gallium 67 scanning is an effective method of detecting inflammatory lesions, especially abscesses. A 10-year-old boy with aplastic anemia and severe leukopenia and granulocytopenia had a psoas abscess diagnosed by gallium scan. The patient died with Candida sepsis 18 days after bone marrow transplantation. At autopsy, a chronic psoas abscess with Candida was found. The gallium scan offers a clinically effective and noninvasive means of evaluating suspected infection in the granulocytopenia patient. (U.S.)

  10. Danazol-induced peliosis hepatis accompanied by disseminated intravascular coagulation in a patient with myelodysplastic syndrome transformed from aplastic anemia.

    Science.gov (United States)

    Tsukamoto, Yasuhiro; Kiyasu, Junichi; Utsunomiya, Hayato; Nakashima, Yasuhiro; Choi, Ilseung; Suehiro, Youko; Aratake, Yoshifusa; Abe, Yasunobu

    2016-08-01

    Peliosis hepatis (PH) is a condition involving benign tumors pathologically characterized by multiple blood-filled cavities, mostly affecting the liver and spleen. Androgenic-steroids are widely used in patients with bone marrow failure syndromes (e.g.: aplastic anemia) and these patients are at increased risk of developing PH. Although patients with PH are generally asymptomatic, PH can progress to liver failure and even fatal spontaneous intraabdominal hemorrhage. Therefore, early diagnosis is critical in order to prevent life-threatening complications of PH. We herein report a patient with PH which had been treated with danazol, who presented with liver dysfunction and multiple hepatic lesions on imaging studies at the time of diagnosis. Although the patient presented with disseminated intravascular coagulation (DIC), a bone marrow biopsy revealed no evidence of leukemic transformation. The patient was diagnosed as having danazol-induced PH, and these abnormalities spontaneously resolved after the discontinuation of danazol. PH is one of the most important complications of long-term administration of androgenic-steroids. Although the mechanisms remain unclear, the multiple blood-filled cavities characteristic of PH may be responsible for the development of DIC. Therefore, monitoring of coagulation markers might also be a key strategy for early diagnosis of PH. PMID:27599419

  11. Aplastic anemia and membranous nephropathy induced by intravenous mercury

    OpenAIRE

    Priya, N.; Nagaprabhu, V. N.; Kurian, G.; Seethalakshmi, N.; Rao, G. G.; Unni, V. N.

    2012-01-01

    Self-injection of mercury can be life-threatening. We report a case of attempted suicide by self-intravenous injection of elemental mercury. The patient suffered from two side effects : membranous nephropathy and aplastic anemia. She was treated and the systemic effects of mercury were reversed after 4 years. The toxicology of mercury, mechanisms of renal and systemic toxicities, and the various therapeutic measures for mercury poisoning are discussed.

  12. Syngeneic peripheral blood stem cell transplantation with immunosuppression for hepatitis-associated severe aplastic anemia

    Directory of Open Access Journals (Sweden)

    Aleksandar Savic

    2010-12-01

    Full Text Available Hepatitis-associated aplastic anemia occurs in up to 10% of all aplastic anemia cases. Syngeneic bone marrow transplantation is rare in patients with severe aplastic anemia and usually requires pre-transplant conditioning to provide engraftment. We report on a 29-year-old male patient with hepatitis-associated severe aplastic anemia who had a series of severe infectious conditions before transplantation, including tracheal inflammation. Life-threatening bleeding, which developed after bronchoscopy, was successfully treated with activated recombinant factor VII and platelet transfusions. Syngeneic peripheral blood stem cell transplantation using immunosuppressive treatment with antithymocyte globulin and cyclosporin A without high-dose pre-transplant conditioning was performed, followed by complete hematologic and hepatic recovery.

  13. Role of myeloperoxidase index in differentiation of megaloblastic and aplastic anemia

    OpenAIRE

    Ziaei Jamal Eivazi; Dastgiri Saeed

    2004-01-01

    BACKGROUND: Elevated neutrophil myeloperoxidase may have a role in the diagnosis of megaloblastic erythropoiesis. AIMS: To study the differentiating role of myeloperoxidase index in megaloblastic and aplastic anemia. SETTINGS AND DESIGN: The myeloperoxidase index (MPXI) was studied in 96 patients with megaloblastic and aplastic anemia diagnosed on bone marrow aspiration and biopsy examinations. METHODS AND MATERIALS: MPXI was measured with Technicon H1 (Bayer) automated analyzer. Nonparametri...

  14. Changes and significances of Th1/Th2, related cytokines and T cell subgroup in aplastic anemia patients

    Institute of Scientific and Technical Information of China (English)

    Hong-Xia Zhang; Guang-Sheng Wu; Wei-Ling Guo

    2016-01-01

    Objective:To investigate the changes and significances of Th1/Th2, related cytokines and T cell subgroup in aplastic anemia(AA) patients.Methods:A total of 87 cases AA patients were chosen. They were set as observation group, and they were divided into acute group (n=21) and chronic group (n=66) according to the condition, chose another 30 cases healthy volunteers as control group, detected the Th1 cytokine interferon-γ (IFN-γ) and Th2 cytokines interleukin-4 (IL-4) with nzyme-linked immunosorbent method, detected the Th1/Th2 cells and T cells subgroup with flow cytometry instrument between groups.Results:The Th1 cells and Th1/Th2 cells in observation group were significantly higher than control group. Th1 cells and Th1/Th2 cells in acute group were significantly higher than chronic group; The IFN-γ, IL-4 and IFN-γ/IL-4 in observation group were significantly higher than that of control group, and the IFN-γ, IL-4 and IFN-γ/IL-4 in acute group were significantly higher than chronic group; The blood CD4+, CD4+/CD8+ in observation group were significantly lower than the control group, CD8+ was significantly higher than the control group, and the blood CD4+, CD4+/CD8+ in acute group were significantly lower than the chronic group, CD8+ was significantly higher than the chronic group, all the difference was statistically significant.Conclusion:T cell subgroup imbalances and Th1 migration plays the important role in the onset of AA, and may relate to a certain degree of disease state.

  15. 获得性再生障碍性贫血患者端粒-端粒酶活性的变化及其意义%Changes of telomere-telomerase activity in patients with acquired aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    宋佳音; 王耀春; 肖扬

    2013-01-01

    Summary To summarize (he research progress of iclomcrc length and telomerase activity in acquired aplastic anemia(Aaa). A full text database system based on PUBMED and CNK1 was adopted for searching relevant literature from 1996 to 2012 with the key words of "telomere.telomerase and acquired aplastic anemia". Criterion for data selection-The literature about advances of telomere, telomerase and acquired aplastic anemia was selected for a-nalysis. According to the standard.236 articles were analyzed. Acquired aplastic anemia is hone marrow failure syndromes that mainly results from immune-mediated destruction of hematopoiesis. About one-third of patients with Aaa have short telomeres in peripheral white blood cells.some of which have heterozygous mutations in genes encoding the telomerase components of TERT or TERC Clinical observation found that most Aaa patients with telomere shortening were insensitive to immunosuppressive therapy;the disease duration increased and the prognosis was poor. Short telomeres may cause malignant clonal diseases in the advanced .stage.such as MDS.AML. Treatment plan for these Aaa patients with shortening telomere should he adjusted. They must undergo haematopoietic stem cell transplant ( HSCT) as soon as possible,and family donors with relevant mutations must he avoided. The Aaa patients with telomere related abnormality are different from other patients regarding pathological mechanism,disease progress, treatment and prognosis. Only a small proportion of these eases could be explained by TERT or TERC mutation. Other mutation or causes may remain unknown .

  16. Dynamics of Graft Function Measured by DNA-Technology in a Patient with Severe Aplastic Anemia and Repeated Stem Cell Transplantation

    Directory of Open Access Journals (Sweden)

    Anna Karastaneva

    2014-01-01

    Full Text Available Although bone marrow transplantation (BMT from an HLA identical sibling is considered as treatment of choice in pediatric patients with severe aplastic anemia (SAA, a significant number of them experience graft failure (GF after BMT. We report a case of an 8-year-old male patient with SAA who presented with a complicated posttransplant course due to parvovirus B19 infection and GF. A subsequent attempt to support the graft by antithymocyte globulin (ATG and a peripheral stem cell boost resulted in transitory autologous recovery of hematopoiesis followed by mixed chimerism, supported by donor lymphocyte infusions (DLIs and finally graft rejection with relapse of SAA. Permanent complete chimerism was achieved by a second BMT. Dynamics of graft function, measured by a single nucleotide polymorphism (SNPs analysis, are discussed.

  17. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.

    Science.gov (United States)

    Narita, Atsushi; Muramatsu, Hideki; Sekiya, Yuko; Okuno, Yusuke; Sakaguchi, Hirotoshi; Nishio, Nobuhiro; Yoshida, Nao; Wang, Xinan; Xu, Yinyan; Kawashima, Nozomu; Doisaki, Sayoko; Hama, Asahito; Takahashi, Yoshiyuki; Kudo, Kazuko; Moritake, Hiroshi; Kobayashi, Masao; Kobayashi, Ryoji; Ito, Etsuro; Yabe, Hiromasa; Ohga, Shouichi; Ohara, Akira; Kojima, Seiji

    2015-12-01

    Acquired aplastic anemia is an immune-mediated disease characterized by severe defects in stem cell number resulting in hypocellular marrow and peripheral blood cytopenias. Minor paroxysmal nocturnal hemoglobinuria populations and a short telomere length were identified as predictive biomarkers of immunosuppressive therapy responsiveness in aplastic anemia. We enrolled 113 aplastic anemia patients (63 boys and 50 girls) in this study to evaluate their response to immunosuppressive therapy. The paroxysmal nocturnal hemoglobinuria populations and telomere length were detected by flow cytometry. Forty-seven patients (42%) carried a minor paroxysmal nocturnal hemoglobinuria population. The median telomere length of aplastic anemia patients was -0.99 standard deviation (SD) (range -4.01-+3.01 SD). Overall, 60 patients (53%) responded to immunosuppressive therapy after six months. Multivariate logistic regression analysis identified the absence of a paroxysmal nocturnal hemoglobinuria population and a shorter telomere length as independent unfavorable predictors of immunosuppressive therapy response at six months. The cohort was stratified into a group of poor prognosis (paroxysmal nocturnal hemoglobinuria negative and shorter telomere length; 37 patients) and good prognosis (paroxysmal nocturnal hemoglobinuria positive and/or longer telomere length; 76 patients), respectively. The response rates of the poor prognosis and good prognosis groups at six months were 19% and 70%, respectively (Ptelomere length is an efficient predictor of poor immunosuppressive therapy response, which should be considered while deciding treatment options: immunosuppressive therapy or first-line hematopoietic stem cell transplantation. The trial was registered in www.umin.ac.jp with number UMIN000017972.

  18. HLA-matched sibling transplantation with G-CSF mobilized PBSCs and BM decreases GVHD in adult patients with severe aplastic anemia

    Directory of Open Access Journals (Sweden)

    Bo-lin Tang

    2010-12-01

    Full Text Available Abstract Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT is an effective treatment for severe aplastic anemia (SAA. However, graft failure and graft-versus-host disease (GVHD are major causes of the early morbidity in Allo-HSCT. Methods To reduce graft failure and GVHD, we treated fifteen patients with SAA using high- dose of HSCT with both G-CSF mobilized PB and BMSCs from HLA-identical siblings to treat patients with SAA. Results All patients had successful bone marrow engraftment. Only one patient had late rejection. Median time to ANC greater than 0.5 × 109/L and platelet counts greater than 20 × 109/L was 12 and 16.5 days, respectively. No acute GVHD was observed. The incidence of chronic GVHD was 6.67%. The total three-year probability of disease-free survival was 79.8%. Conclusion HSCT with both G-CSF mobilized PB and BMSCs is a promising approach for heavily transfused and/or allo-immunized patients with SAA.

  19. [Successful treatment of an overwhelming infection with granulocyte transfusion in severe aplastic anemia patient undergoing allogeneic peripheral blood stem cell transplantation].

    Science.gov (United States)

    Kazuma, Yasuhiro; Ono, Yuichiro; Yonetani, Noboru; Imai, Yukihiro; Kawakami, Manabu; Hashimoto, Hisako; Ishikawa, Takayuki

    2016-04-01

    A 19-year-old woman complaining of fever and a sore throat was diagnosed with very severe aplastic anemia (AA) by bone marrow examination at a local hospital. Despite administration of antibiotics and granulocyte-colony stimulating factor to treat the soft tissue infection in her neck, her neutrophil count showed no increase. Because emergent allogeneic stem cell transplantation (SCT) was necessary, she was referred to our hospital. On admission, computed tomography revealed right-sided severe pharyngitis and lymphadenitis causing tracheal stenosis, and emergent intubation was required the next day. Granulocyte transfusion therapy (GTX) from related donors coupled with broad-spectrum antibiotic administration controlled the otherwise overwhelming infection. The patient received allogeneic peripheral blood SCT using a reduced-intensity conditioning regimen. After allogeneic SCT, successful engraftment was obtained. She was discharged from the hospital 59 days after allogeneic SCT. She remains alive and well, as of the latest follow up. This case clearly demonstrates that GTX is useful for controlling severe infection and enables patients with severe AA to receive allogeneic SCT safely. PMID:27169447

  20. RELATIONSHIP BETWEEN HUMAN PARVOVIRUS B19 INFECTION AND APLASTIC ANEMIA

    Institute of Scientific and Technical Information of China (English)

    钱新宏; 郑跃杰; 张国成; 焦西英; 李佐华

    2001-01-01

    Objective. To explore the relationship between human parvovirus B 19 (HPV B 19) infection and aplastic anemia (AA) and to investigate the role of HPV B19 in the occurrence of AA.``Methods. The presence of HPV B19 DNA was detected in the peripheral blood samples of 60 patients with AA (children 38 and adults 22) by nested polymerase chain reaction (PCR) assay, and 30 healthy persons were selected as control.``Results. Sixteen (26. 7 % ) of 60 AA cases were HPV B19 DNA positive, while all the samples in the control group were negative for HPV B19 ( P = 0. 000914). Among the case group, the positive rates of HPV B19DNA were 21.4% (6 /28), 30.0% (3 / 10), 20.0% (1 / 5) and 35.3 % (6 / 17) in children acute AA (AAA), children chronic AA (CAA), adults AAA and adults CAA patients respectively, which were significantly higher than that in the control group. Furthermore, there was no remarkable difference between children AA and adults AA in the 16 HPV B19 DNA positive patients; neither was there between AAA and CAA.``Conclusions. HPV B19 infection is not only correlated with the occurrence of children AAA and CAA, but also with adults AAA and CAA, and might be an important viral cause for AA in humans.

  1. RELATIONSHIP BETWEEN HUMAN PARVOVIRUS B19 INFECTION AND APLASTIC ANEMIA

    Institute of Scientific and Technical Information of China (English)

    钱新宏; 郑跃杰; 张国成; 焦西英; 李佐华

    2001-01-01

    Objective. To explore the relationship between human parvovirus B19 (HPV B19) infection and aplastic anemia (AA) and to investigate the role of HPV B19 in the occurrence of AA. Methods. The presence of HPV B19 DNA was detected in the peripheral blood samples of 60 patients with AA (children 38 and adults 22) by nested polymerase chain reaction (PCR) assay, and 30 healthy persons were selected as control. Results. Sixteen (26. 7 % ) of 60 AA cases were HPV B19 DNA positive, while all the samples in the control group were negative for HPV B19 (P = 0. 000914). Among the case group, the positive rates of HPV B19 DNA were21.4% (6 /28), 30.0% (3 / 10), 20.0% (1 /5) and 35.3% (6 / 17) in children acute AA (AAA), children chronic AA (CAA), adults AAA and adults CAA patients respectively, which were significant-ly higher than that in the control group, Furthermore, there was no remarkable difference between children AA and adults AA in the 16 HPV B19 DNA positive patients; neither was there between AAA and CAA. Conclusions. HPV B19 infection is not only correlated with the occurrence of children AAA and CAA, but also with adults AAA and CAA, and might be an important viral cause for AA in humans.

  2. Further Evaluation of Androgen Therapy In Aplastic Anemia: With Special Reference to Correlation Between Response to Androgen and EEI

    International Nuclear Information System (INIS)

    Patients with aplastic anemia were treated with a combination of depo-testosterone cyclopentylpropionate (Upjohn) and dexamethasone. In 7 of 15 patients treated, there was response in which either a significant increase in hemoglobin concentration, a prolonged interval or a cessation of blood transfusion requirement developed during androgen therapy. Younger patients with cellular marrow appeared to be better responding to androgen. EEI (Effective Erythropoietic Index) formulated by Gardner and Nathan (1966) which was a helpful measurement as to whether patients with myelofibrosis would response to androgen, was evaluated in patients with aplastic anemia. It was concluded that EEI as well as ferrokinetics indices (Plasma-59Fe-disappearance rate, RBC 59Fe net incorporation) did not significantly correlate with the degree of response to androgen in aplastic anemia.

  3. Salvage therapy for severe aplastic anemia after allogenenic hematopoietic cell transplant

    Institute of Scientific and Technical Information of China (English)

    张静

    2014-01-01

    Objective To probe a practical salvage strategy for relapse or failure patients with severe aplastic anemia(SAA)after allogenenic hematopoietic cell transplant(allo-HSCT).Methods The clinical characteristics and initial treatments of allo-HSCT,and the responses of a novel salvage therapy of cyclosporine alternately combined with levamisole(CsA&LMS regimen)plus danazol(DNZ)in 2 patients were reviewed and evaluated.

  4. Mechanism of immunosuppressants combined with cord blood for severe aplastic anemia

    OpenAIRE

    Yu, Zhe; Zhou, Fang; Ge, Lin-Fu; Liu, Xi-Min; Fang, Yuan; XIE, LIN-NA; Kong, Fan-Sheng; Song, Ning-Xia; Yu, Qing-Qing

    2015-01-01

    This study aims to explore the mechanism of immunosuppressants combined with cord blood (IS + CBI) for severe aplastic anemia. Selecting 30 patients with SAA and all treated with IS + CBI (newly diagnosed group). 23 patients who were treated effectively (effective group) while 7 cases were treated invalidly (invalid group). Another 20 healthy individuals were selected as control group. To detect the expression levels of IL-17, IL-22 and other cytokines by ELISA method in each group. To detect...

  5. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia

    DEFF Research Database (Denmark)

    Bacigalupo, Andrea; Socié, Gerard; Hamladji, Rose Marie;

    2015-01-01

    .04). In conclusion, in multivariate analysis, the outcome of unrelated donor transplants for acquired aplastic anemia, is currently not statistically inferior when compared to sibling transplants, although patients are at greater risk of acute and chronic graft-versus-host disease. The use of peripheral blood grafts....... 13%) and significantly more chronic graft-versus-host disease (26% vs. 14%). In multivariate analysis, the risk of death of unrelated donor grafts was higher, but not significantly higher, compared to a sibling donor (P=0.16). The strongest negative predictor of survival was the use of peripheral......We have analyzed 1448 patients with acquired aplastic anemia grafted between 2005 and 2009, and compared outcome of identical sibling (n=940) versus unrelated donor (n=508) transplants. When compared to the latter, sibling transplants were less likely to be performed beyond 180 days from diagnosis...

  6. Experience of Nursing During the Treatment of Aplastic Anemia Patients to Prevent Infection%再生障碍性贫血患者治疗期间预防感染的护理体会

    Institute of Scientific and Technical Information of China (English)

    王芳

    2014-01-01

    目的浅析再生障碍性贫血患者治疗期间预防感染的护理体会。方法我院对60例再障患者予以有效的预防感染和护理。结果60例患者中,基本治愈13例,好转38例,无变化9例,总有效率85%。结论再障患者住院期间如发生粒细胞减少或缺乏,应及时采取隔离措施。同时,要做好相应基础及心理护理,并予以升白细胞类及抗感染药物治疗,以使患者快速、安全地渡过感染期,避免致命感染,促进疾病及早康复。%Objective Nursing experience of regeneration in the treatment of aplastic anemia patients during infection prevention. Methods Our hospital to prevent infection and ef ective nursing care of 60 cases of aplastic anemia patients. Results The 60 patients, 13 patients were cured, 38 cases improved, no change in 9 cases, the total ef iciency of 85%. Conclusion During such as the occurrence of neutropenia or agranulocytosis in aplastic anemia patients, should take timely measures. At the same time, to do a good job in the basic nursing and psychological nursing, and to increase white blood cell and anti infection therapy, to enable the patients quickly, safely through the period of infection, avoid fatal infection disease, promote early rehabilitation.

  7. Listeria monocytogenes meningitis in an atomic bomb survivor receiving corticosteroid therapy for aplastic anemia

    International Nuclear Information System (INIS)

    We report a case of successfully treated Listeria monocytogenes (Lm) meningitis in a atomic bomb survivor receiving steroid therapy for aplastic anemia. The patient was a 62-year-old woman and the past medical history included hypothyroidism due to radioiodide therapy for Basedow disease, breast cancer, aplastic anemia, steroid-induced diabetes mellitus, and pulmonary tuberculosis. At the time of onset, she was receiving corticosteroid, anabolic steroid, an H2-blocker (famotidine), and other medication. Since she developed symptoms of meningitis when she visited our hospital for regular medical check-up for aplastic anemia, she was hospitalized and given antibiotic therapy, including ABPC, without delay. With this effective antibiotic therapy and successful management of the co-existing medical conditions, she was cured except for being a little euphoric. Lm meningitis is known to occur in aged and immunocompromised patients. Since most of the atomic bomb survivors are now aged and the prevalence of malignancy, diabetes mellitus, and other diseases which cause immunodeficiency have been rising year by year, Lm meningitis is one of the emergency neurologic conditions whose diagnosis should not be delayed in this population. (author)

  8. Listeria monocytogenes meningitis in an atomic bomb survivor receiving corticosteroid therapy for aplastic anemia

    Energy Technology Data Exchange (ETDEWEB)

    Fujihara, Kazuo; Shida, Norihiko; Ohta, Michiya [Hiroshima Atomic Bomb Hospital (Japan)

    1995-12-01

    We report a case of successfully treated Listeria monocytogenes (Lm) meningitis in a atomic bomb survivor receiving steroid therapy for aplastic anemia. The patient was a 62-year-old woman and the past medical history included hypothyroidism due to radioiodide therapy for Basedow disease, breast cancer, aplastic anemia, steroid-induced diabetes mellitus, and pulmonary tuberculosis. At the time of onset, she was receiving corticosteroid, anabolic steroid, an H{sub 2}-blocker (famotidine), and other medication. Since she developed symptoms of meningitis when she visited our hospital for regular medical check-up for aplastic anemia, she was hospitalized and given antibiotic therapy, including ABPC, without delay. With this effective antibiotic therapy and successful management of the co-existing medical conditions, she was cured except for being a little euphoric. Lm meningitis is known to occur in aged and immunocompromised patients. Since most of the atomic bomb survivors are now aged and the prevalence of malignancy, diabetes mellitus, and other diseases which cause immunodeficiency have been rising year by year, Lm meningitis is one of the emergency neurologic conditions whose diagnosis should not be delayed in this population. (author).

  9. Proliferation and Apoptosis of Bone Marrow CD4~+ T Cells in Patients with Aplastic Anemia and Impacts of the Secreted Cytokines on Hematopoietic Stem Cells from Umbilical Cord Blood

    Institute of Scientific and Technical Information of China (English)

    郑邈; 孙汉英; 周剑峰; 徐慧珍; 黄丽芳; 刘文励

    2010-01-01

    Recent studies indicate that immune-associated aplastic anemia(AA)resembles such autoimmune diseases as insulin-dependent diabetes and chronic autoimmune thyroiditis that belong to organ-specific autoimmune diseases.Many independent investigation groups have successfully isolated the pathopoiesis-associated T cell clone causing hematopoiesis failure with a CD4 phenotype from peripheral blood and bone marrow(BM)in AA patients.In the current study,BM CD4+ T cells were isolated from AA patients and healthy con...

  10. Enhanced Adipogenicity of Bone Marrow Mesenchymal Stem Cells in Aplastic Anemia

    OpenAIRE

    Naresh Kumar Tripathy; Saurabh Pratap Singh; Soniya Nityanand

    2014-01-01

    Fatty bone marrow (BM) and defective hematopoiesis are a pathologic hallmark of aplastic anemia (AA). We have investigated adipogenic and osteogenic potential of BM mesenchymal stem cells (BM-MSC) in 10 AA patients (08 males and 02 females) with median age of 37 years (range: 06 to 79 years) and in the same number of age and sex matched controls. It was observed that BM-MSC of AA patients had a morphology, phenotype, and osteogenic differentiation potential similar to control subjects but adi...

  11. Short-term therapeutic effects of combined therapy with metformin hydrochloride for aplastic anemia

    Directory of Open Access Journals (Sweden)

    Xue-chun LU

    2012-03-01

    Full Text Available Objective To screen and select new drugs for aplastic anemia (AA and evaluate their clinical efficacy by clinical bioinformatics methods. Methods First, we established genome expression profiles of AA patients, and conducted similarity analyses with the pharmacogenomics database to screen and select drugs with possible efficacy. Intractable AA patients who received immunosuppressors and/or androgen for more than six months showing no clinical efficacy were enrolled in the study to evaluate therapeutic effects of the therapeutic regime. Clinical efficacy and adverse effects were evaluated after six months. Results The clinical bioinformatics results showed therapeutic effects of metformin hydrochloride on AA. Forty-three intractable AA patients (15 with severe AA were treated with metformin hydrochloride combined with cyclosporin A (CsA and stanozolol. Twenty-seven transfusion-dependent patients (100% became transfusion independent after a 6-month therapy. The hemoglobin level completely returned to normal in 37 out of 40 anemia patients (92.5%. In the 40 patients with platelet count lower than 20×109/L, the platelet count of 28 patients (90.3% increased to higher than 50×109/L. The white cell count increased to higher than 3.5×109/L in 30 out of 35 patients (88.6% with white cell count lower than 2.5×109/L. Among 40 anemic patients, 1 was found to have abnormal renal function, but it recovered to the normal range after ending CsA treatment. Eighteen patients were found to have elevated transaminase levels which were lowered to normal range after using liver protectants and reducing the dosage of stanozolol. There were no instances of hypoglycemia in all patients throughout the treatment. Conclusion Combination of metformin hydrochloride, CsA and stanozolol is effective in refractory aplastic anemia with acceptable toxicity.

  12. Magnetic resonance imaging of the bone marrow after bone marrow transplantation or immunosuppressive therapy in aplastic anemia.

    OpenAIRE

    Park, J M; Jung, H.A.; Kim, D. W.; Lee, J. W.; Kim, C. C.; Hahn, S. T.

    2001-01-01

    To compare magnetic resonance (MR) images of the bone marrow (BM) after bone marrow transplantation or immunosuppressive therapy in patients with aplastic anemia (AA), MR imaging of BM was reviewed retrospectively in 16 patients (13 males and 3 females, mean age 26 yr) with AA who completely responded clinically after transplantation or immunosuppressive therapy. The signal intensity (SI) of BM was classified into four patterns according to the increasing amount of cellular marrow, i.e., patt...

  13. B-cell-rich T-cell lymphoma associated with Epstein-Barr virus-reactivation and T-cell suppression following antithymocyte globulin therapy in a patient with severe aplastic anemia

    Directory of Open Access Journals (Sweden)

    Nobuyoshi Hanaoka

    2015-09-01

    Full Text Available B-cell lymphoproliferative disorder (B-LPD is generally characterized by the proliferation of Epstein-Barr virus (EBV-infected B lymphocytes. We here report the development of EBV-negative B-LPD associated with EBV-reactivation following antithymocyte globulin (ATG therapy in a patient with aplastic anemia. The molecular autopsy study showed the sparse EBV-infected clonal T cells could be critically involved in the pathogenesis of EBV-negative oligoclonal B-LPD through cytokine amplification and escape from T-cell surveillances attributable to ATG-based immunosuppressive therapy, leading to an extremely rare B-cell-rich T-cell lymphoma. This report helps in elucidating the complex pathophysiology of intractable B-LPD refractory to rituximab.

  14. Hematopoietic Acute Radiation Syndrome (Bone marrow syndrome, Aplastic Anemia): Molecular Mechanisms of Radiation Toxicity.

    Science.gov (United States)

    Popov, Dmitri

    Key Words: Aplastic Anemia (AA), Pluripotential Stem Cells (PSC) Introduction: Aplastic Anemia (AA) is a disorder of the pluripotential stem cells involve a decrease in the number of cells of myeloid, erythroid and megakaryotic lineage [Segel et al. 2000 ]. The etiology of AA include idiopathic cases and secondary aplastic anemia after exposure to drugs, toxins, chemicals, viral infections, lympho-proliferative diseases, radiation, genetic causes, myelodisplastic syndromes and hypoplastic anemias, thymomas, lymphomas. [Brodskyet al. 2005.,Modan et al. 1975., Szklo et al. 1975]. Hematopoietic Acute Radiation Syndrome (or Bone marrow syndrome, or Radiation-Acquired Aplastic Anemia) is the acute toxic syndrome which usually occurs with a dose of irradiation between 0.7 and 10 Gy (70- 1000 rads), depending on the species irradiated. [Waselenko et al., 2004]. The etiology of bone morrow damage from high-level radiation exposure results depends on the radiosensitivity of certain bone marrow cell lines. [Waselenko et al. 2004] Aplastic anemia after radiation exposure is a clinical syndrome that results from a marked disorder of bone marrow blood cell production. [Waselenko et al. 2004] Radiation hematotoxicity is mediated via genotoxic and other specific toxic mechanisms, leading to aplasia, cell apoptosis or necrosis, initiation via genetic mechanisms of clonal disorders, in cases such as the acute radiation-acquired form of AA. AA results from radiation injury to pluripotential and multipotential stem cells in the bone marrow. The clinical signs displayed in reticulocytopenia, anemia, granulocytopenia, monocytopenia, and thrombocytopenia. The number of marrow CD34+ cells (multipotential hematopoietic progenitors) and their derivative colony-forming unit{granulocyte-macrophage (CFU-GM) and burst forming unit {erythroid (BFU{E) are reduced markedly in patients with AA. [Guinan 2011, Brodski et al. 2005, Beutler et al.,2000] Cells expressing CD34 (CD34+ cell) are normally

  15. Enhanced Adipogenicity of Bone Marrow Mesenchymal Stem Cells in Aplastic Anemia

    Directory of Open Access Journals (Sweden)

    Naresh Kumar Tripathy

    2014-01-01

    Full Text Available Fatty bone marrow (BM and defective hematopoiesis are a pathologic hallmark of aplastic anemia (AA. We have investigated adipogenic and osteogenic potential of BM mesenchymal stem cells (BM-MSC in 10 AA patients (08 males and 02 females with median age of 37 years (range: 06 to 79 years and in the same number of age and sex matched controls. It was observed that BM-MSC of AA patients had a morphology, phenotype, and osteogenic differentiation potential similar to control subjects but adipocytes differentiated from AA BM-MSC had a higher density and larger size of lipid droplets and they expressed significantly higher levels of adiponectin and FABP4 genes and proteins as compared to control BM-MSC (P<0.01 for both. Thus our data shows that AA BM-MSC have enhanced adipogenicity, which may have an important implication in the pathogenesis of the disease.

  16. Aplastic crisis caused by parvovirus B19 in an adult patient with sickle-cell disease

    OpenAIRE

    Setúbal Sérgio; Gabriel Adelmo H.D.; Nascimento Jussara P.; Oliveira Solange A.

    2000-01-01

    We describe a case of aplastic crisis caused by parvovirus B19 in an adult sickle-cell patient presenting with paleness, tiredness, fainting and dyspnea. The absence of reticulocytes lead to the diagnosis. Anti-B19 IgM and IgG were detected. Reticulocytopenia in patients with hereditary hemolytic anemia suggests B19 infection.

  17. Aldehyde dehydrogenase 2 in aplastic anemia, Fanconi anemia and hematopoietic stem cells.

    Science.gov (United States)

    Van Wassenhove, Lauren D; Mochly-Rosen, Daria; Weinberg, Kenneth I

    2016-09-01

    Maintenance of the hematopoietic stem cell (HSC) compartment depends on the ability to metabolize exogenously and endogenously generated toxins, and to repair cellular damage caused by such toxins. Reactive aldehydes have been demonstrated to cause specific genotoxic injury, namely DNA interstrand cross-links. Aldehyde dehydrogenase 2 (ALDH2) is a member of a 19 isoenzyme ALDH family with different substrate specificities, subcellular localization, and patterns of expression. ALDH2 is localized in mitochondria and is essential for the metabolism of acetaldehyde, thereby placing it directly downstream of ethanol metabolism. Deficiency in ALDH2 expression and function are caused by a single nucleotide substitution and resulting amino acid change, called ALDH2*2. This genetic polymorphism affects 35-45% of East Asians (about ~560 million people), and causes the well-known Asian flushing syndrome, which results in disulfiram-like reactions after ethanol consumption. Recently, the ALDH2*2 genotype has been found to be associated with marrow failure, with both an increased risk of sporadic aplastic anemia and more rapid progression of Fanconi anemia. This review discusses the unexpected interrelationship between aldehydes, ALDH2 and hematopoietic stem cell biology, and in particular its relationship to Fanconi anemia. PMID:27650066

  18. [Clinical study of TCM-WM on aplastic anemia complicated with hepatitis C].

    Science.gov (United States)

    Liu, Q C; Zheng, B R; Zhang, C L

    1995-04-01

    The testing kit of second generation for serum anti-HCV was used in 82 cases of aplastic anemia (AA). The results showed that positive rate was 69.4% (43/62) in the patients of AA with transfusion, this was significantly higher than that in the patients of AA without transfusion. There was no difference of anti-HCV antibody positive rate between chronic AA and acute AA (P > 0.05), incidence rate of post-transfusion hepatitis C (PTHC) in AA was 33.9% (21/62), among which the incidence rate in acute and chronic AA were 68.8% (11/16) and 21.7% (10/46) respectively (P PTHC and non-PTHC, there was no statistical difference of their transfusion volume, hemoglobin, white blood cell between these groups. Response rate of AA was lower in anti-HCV positive patients than that in negative patients (P PTHC was predominant in patients with AA. The patients with AA complicated with PTHC was liable to bleed and be infected. PTHC has been an important complication in patients with AA. The better response was obtained by TCM-WM therapy in the patients. PMID:7544177

  19. llogeneic peripheral blood stem cell transplantation in the treatment of severe aplastic anemia and severe infection

    Institute of Scientific and Technical Information of China (English)

    万理萍; 颜式可; 王椿; 杨新潮; 周柱; 高彦荣; 蔡琦; 张冰

    2003-01-01

    Objective To investigate the efficacy of allogeneic peripheral blood stem cell transplantation (PBSCT) in the treatment of severe aplastic anemia (SAA) and severe infection. Methods A patient with SAA and pseudomonas aeruginosa septicemia was treated with PBSCT from an HLA-identical sibling with cyclophosphamide (CY) and total body irradiation (TBI) for conditioning. The patient was infused with 20.3×108/kg mononuclear cells including 61.0×106/kg CD34+cells following the conditioning regimen. Results Twenty days after PBSCT, the absolute neutrophil count (ANC) of 1.0×109/L was achieved, with platelet count >50×109/L. The donor origin of engraftment was confirmed by polymerase chain reaction (PCR) analysis of short tandem repeats at the end of the first, sixth and twelfth month. The patient's body temperature dropped to normal level when her ANC reached 0.5×109/L on day 10, and the bacterial culture of blood sample became negative subsequently. Symptoms and signs of acute or chronic graft versus host disease (GVHD) were not observed in 30 months after PBSCT. Conclusions Hematopoiesis was reconstituted shortly after PBSCT. The combination of CY and TBI and the infusion of sufficient peripheral blood stem cells may contribute to the successful engraftment. PBSCT may be considered as the first choice when hematopoietic stem cell transplantation is needed for SAA patients complicated with severe infection.

  20. Association of Human Leukocyte Antigen DRB1*15 and DRB1*15:01 Polymorphisms with Response to Immunosuppressive Therapy in Patients with Aplastic Anemia: A Meta-Analysis.

    Science.gov (United States)

    Liu, Shan; Li, Qing; Zhang, Ying; Li, Qiushuang; Ye, Baodong; Wu, Dijiong; Wu, Li; Lu, Hanti; Ji, Conghua

    2016-01-01

    This study aimed to review and quantitatively analyze (1) the association of aplastic anemia (AA) with human leukocyte antigen (HLA)-DRB1*15 and HLA-DRB1*15:01 polymorphisms and (2) the association of HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms with response to immunosuppressive therapy (IST) in AA. Published studies have reported conflicting and heterogeneous results regarding the association of HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms with response to IST in AA. The PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese BioMedical Literature, Wangfang and Chinese Social Sciences Citation Index databases were searched. All relevant publications were searched through December 2015. Odds ratio (OR), risk ratio (RR), and 95% confidence intervals (CI) for the comparison between case-control or cohort studies were evaluated. Finally, 24 articles were identified. For HLA-DRB1*15 and HLA-DRB1*15:01, the OR (95% CI) was 2.24(1.33-3.77), P 0.05). Sensitivity analyses revealed that the results were statistically robust. The meta-analysis suggested that HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms might be associated with increased AA risk in Asians. IST might be more effective in HLA-DRB1*15+ and HLA-DRB1*15:01+ Asian patients with AA than in HLA-DRB1*15- and HLA-DRB1*15:01- Asian patients with AA. Future studies with adequate methodological quality on gene-gene and gene-environment interactions and gene treatment may yield valid results. PMID:27611583

  1. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia.

    Science.gov (United States)

    Narita, Atsushi; Kojima, Seiji

    2016-08-01

    The decision to select hematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST) as initial therapy in acquired aplastic anemia (AA) is currently based on patient age and the availability of a human leukocyte antigen (HLA)-matched donor. Although IST is a promising treatment option, the ability to predict its long-term outcomes remains poor due to refractoriness, relapses, and the risk of clonal evolution. Several predictive biomarkers for response to IST have been posited, including age, gender, pre-treatment blood cell counts, cytokines, gene mutations, paroxysmal nocturnal hemoglobinuria (PNH), and telomere length (TL). While previous studies have provided substantial biological insights into the utility of IST, the prognostic power of the reported biomarkers is currently insufficient to contribute to clinical decision making. Recently, a large retrospective analysis proposed the combination of minor PNH clones and TL as an efficient predictor of IST response. Identification of a reliable predictor would provide a useful tool for determining the most appropriate treatment choice for AA patients, including up-front HSCT from HLA-matched unrelated donor. The present review summarizes studies evaluating the utility of biomarkers in predicting the clinical response to IST of patients with AA, and provides a baseline for prospective studies aimed at validating previously reported biomarkers. PMID:27091471

  2. Total lymphoid irradiation based conditioning for hematopoietic stem cell transplantation in severe aplastic anemia

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Yun Hee; Kim, Ji Yoon; Choi, Byung Ock; Ryu, Mi Ryeong; Chung, Su Mi [Dept. of Radiation Oncology, The Catholic University of Korea College of Medicine, Seoul (Korea, Republic of)

    2012-12-15

    To retrospectively evaluate the outcome and toxicity of total lymphoid irradiation (TLI) based conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in severe aplastic anemia (SAA) patients who experienced an engraftment failure from prior HSCT or were heavily transfused. Between 1995 and 2006, 20 SAA patients received TLI for conditioning of HSCT. All patients were multi-transfused or had long duration of disease. Fifteen (75%) patients had graft failure from prior HSCT. In 18 (90%) patients, the donors were human leukocyte antigen identical siblings. The stem cell source was the peripheral blood stem cell in 15 (75%) patients. The conditioning regimen was composed of antithymocyte globulin plus TLI with a median dose of 750 cGy in 1 fraction. The graft-versus-host disease (GVHD) prophylaxis used cyclosporine with methotrexate. With a median follow-up of 10.8 years, graft failures developed in 6 patients. Among them, 3 patients received their third HSCT to be engrafted finally. The Kaplan-Meier overall survival rate was 85.0% and 83.1% at 5 and 10 years, respectively. The incidence of acute and chronic GVHD was 20% and 20%, respectively. None of the patients have developed a malignancy after HSCT. In our study, TLI based conditioning in allogeneic HSCT was feasible with acceptable rates of GVHD in SAA patients who experienced graft failure from prior HSCT or was at a high risk of graft rejection. We achieved relatively better results of engraftment and survival with a long term follow-up.

  3. Distinct Overexpression of Fas Ligand on T Lymphocytes in Aplastic Anemia

    Institute of Scientific and Technical Information of China (English)

    Wenxin Li; Jinxiang Fu; Fengming Wang; Gehua Yu; Yong Wang; Xueguang Zhang

    2004-01-01

    Increased expression of Fas by hematopoietic progenitors in aplastic anemia (AA) suggests that Fas/Fas ligand (FasL) system plays a key role in the formation of severe pancytopenia. To further confirm the above hypothesis, T cells from 8 patients with AA were systematically studied for their FasL's distribution pattern,releasing manner and proapoptotic activity, compared with normal resting T cells and artificially activated Tcell blasts. The results demonstrated that AA T cells abnormally expressed low levels of membrane-bound FasL and contained high levels of intracellular FasL which could be triggered to release by high-dose phytohemagglutinin (PHA) pulse-stimulation. The supernatants from the PHA-stimulated AA T cells had apparent cytotoxicity against FasL-sensitive Jurkat cells, which could be significantly inhibited by monoclonal antibody against FasL in a dose-dependent manner, or nearly completely abrogated by ultracentrifugation. The above phenomena also appeared on artificially activated T cell blasts, but this was not the case on normal resting Tcells. These results indicate that AA T cell is a type of "preactivated" T lymphocyte, characterized by overexpression of FasL, especially intracellular FasL which can be stimulated to release in bioavtive exosomesbound form. Taken together, our data provide further and direct evidence for the hypothesis that T cells might mediate the destruction of hematopietic progenitor in AA through Fas/FasL system.

  4. Distinct Overexpression of Fas Ligand on T Lymphocytes in Aplastic Anemia

    Institute of Scientific and Technical Information of China (English)

    WenxinLi; JinxiangFu; FengmingWang; GehuaYu; YongWang; XueguangZhang

    2004-01-01

    Increased expression of Fas by hematopoietic progenitors in aplastic anemia (AA) suggests that Fas/Fas ligand (FasL) system plays a key role in the formation of severe pancytopenia. To further confirm the above hypothesis, T cells from 8 patients with AA were systematically studied for their FasL's distribution pattern, releasing manner and proapoptotic activity, compared with normal resting T cells and artificially activated T cell blasts. The results demonstrated that AA T cells abnormally expressed low levels of membrane-bound FasL and contained high levels of intracellular FasL which could be triggered to release by high-dose phytohemagglutinin (PHA) pulse-stimulation. The supernatants from the PHA-stimulated AA T cells had apparent cytotoxicity against FasL-sensitive Jurkat cells, which could be significantly inhibited by monoclonal antibody against FasL in a dose-dependent manner, or nearly completely abrogated by ultracentrifugation. The above phenomena also appeared on artificially activated T cell blasts, but this was not the case on normal resting T cells. These results indicate that AA T cell is a type of "preactivated" T lymphocyte, characterized by overexpression of FasL, especially intracellular FasL which can be stimulated to release in bioavtive exosomesbound form. Taken together, our data provide further and direct evidence for the hypothesis that T cells might mediate the destruction of hematopietic progenitor in AA through Fas/FasL system. Cellular & Molecular Immunology. 2004;1(2):142-147.

  5. Complete sequence analysis of mitochondrial DNA and telomere length in aplastic anemia.

    Science.gov (United States)

    Cui, Xing; Wang, Junqiang; Cai, Zhiguo; Wang, Jingyi; Liu, Kui; Cui, Siyuan; Zhang, Jie; Luo, Yaqin; Wang, Xin; Li, Weiwei; Jing, Jingyan

    2014-11-01

    The present study was primarily undertaken to examine the hypothesis that mitochondrial DNA (mtDNA) mutations and telomere length may be associated with aplastic anemia (AA). Our study included a single institution analysis of 40 patients presenting with AA first diagnosed at the Affiliated Hospital of Shandong, University of Traditional Chinese Medicine between 2010 and 2013. Bone marrow and oral epithelial samples were collected from patients with AA (n=40) for mtDNA mutation and telomere length determinations. Bone marrow specimens were collected from 40 healthy volunteers as controls for the examination of telomere length. The mitochondrial genome was amplified by polymerase chain reaction (PCR), and the products were used for sequencing and analysis. We detected 146 heteroplasmic mutations in 18 genes from 40 patients with AA, including 39 silent mutations and 28 frameshift mutations. We used the gamma globin gene (HBG) as the control gene in real-time PCR to survey the relative telomere length measurements of the patients with AA and the healthy volunteers. Telomere length was expressed as the relative T/S value. We observed a negative correlation between the mtDNA non-silent mutation and the white blood cell (WBC) count, hemoglobin and platelet count. Of note, there was a positive correlation between the relative T/S value and WBC count, hemoglobin and platelet count, and a negative correlation between the non-silent mutation and the relative T/S value. We conclude that the functional impairment of the mitochondrial respiratory chain induced by mutation and telomere length shortening may play an important role in the process of hematopoietic failure in patients with AA. Additionally, mtDNA mutations and telomere length shortening influenced each other.

  6. Treatment of Aplastic Anemia by the Kidney-Tonifying and Mediating Method

    Institute of Scientific and Technical Information of China (English)

    俞亚琴; 孙伟正; 曹克俭; 王祥祺

    2001-01-01

    In this series of 65 cases of aplastic anemia, 26 cases were treated by the kidney-tonifying and mediating method, 19 cases by western drugs, and the remaining 20 cases only by tonifying the kidney as controls. The results showed that the kidney-tonifying and mediating method was significantly superior in the total effective rate to the method of western drugs and that of tonifying the kidney alone (P<0.01), and it was also superior in the improvement of symptoms, myelogram, and peripheral blood count to the other two methods.

  7. 异基因BMSC对重型再障患者T细胞免疫功能影响的研究%Effects of allogeneic bone marrow mesenchymal stem cells on T lymphocytes in patients with severe aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    余卫; 李萡; 罗英; 谭雪芳; 陈玲珍

    2014-01-01

    目的:探索异基因骨髓间充质干细胞( allo-BMSC)对重型再生障碍性贫血( SAA)患者T细胞免疫功能的影响。方法:将allo-BMSC与SAA患者( n=15)外周血T细胞按不同比例( allo-BMSC:T cell分别为0∶1,1∶100,1∶50,1∶25)及进行共培养。72 h后,检测T cell数及allo-BMSC:T cell分别为0∶1(对照组)和1∶25(allo-BMSC组)上清中IL-10、IFN-γ、TNFα的含量。结果:(1).不同比例allo-BMSC(0∶1,1∶100,1∶50,1∶25)对SAA患者T淋巴细胞增殖抑制率分别为3%±2%,51%±17%,64%±21%,73%±18%,抑制作用与allo-BMSC的数量呈正相关(r=0.684,P<0.001);(2).allo-BMSC组IL-10浓度显著增加[(300±175)ng/mL vs (25±14)pg/mL,P<0.05],allo-BMSC组IFN-γ浓度显著降低[(2.1±1.5)ng/mL vs(3.5±1.9) ng/mL,P<0.05];allo-BMSC组TNFα浓度显著降低[(8±5)pg/mL vs (17±11)pg/mL,P<0.05]。结论:allo-BMSC可以抑制SAA患者T细胞增殖,并减低Th1细胞炎性因子的表达,而增加Th2细胞因子的表达。%Objective:To explore the effects of allogeneic bone marrow mesenchymal stem cells ( allo-BMSCs) on T lymphocytes in patients with severe aplastic anemia. Methods: The allo-BMSCs were cocultured with T cells derived from 15 patients with severe aplastic anemia ( allo-BMSC/T cell ratio, 0∶1, 1∶100, 1∶50 and 1∶25 ) . T cells count and cytokine levels ( IL-10, IFN-γ and TNF-α) in culture supernatants were determined in control group ( allo-BMSC/T cell ratio, 0:1) and allo-BMSC group ( allo-BMSC/T cell ratio, 0:25) after 72 hours of cultivation. Results: The allo-BMSCs of different ratios ( 0∶1, 1∶100, 1∶50, 1∶25) resulted in the suppression rate of proliferation of 3%± 2%, 51%± 17%,64%± 21% and 73%± 18%,respectively,suggesting a positive correlation between the inhibitory effects and allo-BMSC count ( r=0.684,P<0.001). The allo-BMSCs group was associated with markedly higher levels of IL-10 [(300±175)ng/mL vs (25

  8. Análise da rejeição nos pacientes transplantados por anemia aplástica severa condicionados com ciclofosfamida ou a associação desta ao bussulfano Analysis of rejection in transplanted patients suffering severe aplastic anemia conditioned with cyclophosphamide alone or associated with busulfan

    Directory of Open Access Journals (Sweden)

    Lídice C. Lenz e Silva

    2005-03-01

    Full Text Available O transplante de medula óssea é um tratamento eficaz para pacientes com anemia aplástica severa (AAS e é a modalidade terapêutica de escolha para pacientes jovens com doador aparentado HLA idêntico. A rejeição é uma importante complicação do transplante de medula, que, independentemente do tipo de tratamento imunossupressor pré e pós-transplante, ocorre em 55% a 60% dos pacientes. O serviço de TMO da Universidade Federal do Paraná (UFPR acumula a experiência de 178 casos de AAS transplantados no período de 1993 a 2001, usando como condicionamento tanto a ciclofosfamida (CFA como a combinação desta ao bussulfano (CFA + BU. Dentre eles, 39 apresentaram rejeição ou falha de pega. Dos pacientes condicionados com ciclofosfamida, 24 (46% apresentaram rejeição, sendo 3 (6% com falha primária de pega (FPP e 21 (40% com pega transitória (PT. Entre os pacientes condicionados com BU+CFA, 15 (12% apresentaram rejeição, sendo 4 (3% com FPP e 11 (9% com pega transitória. Os pacientes condicionados com ciclofosfamida (200 mg/kg que apresentaram rejeição tiveram uma sobrevida global alta (aproximadamente 80%, pois conseguiram ser resgatados por um novo transplante ou pelo tratamento imunossupressor com ciclosporina. A sobrevida dos pacientes politransfundidos condicionados com a associação de ciclofosfamida e bussulfano foi de aproximadamente 35%.Bone marrow transplantation is an effective therapy for severe aplastic anemia and is generally considered the preferable treatment for young patients who have an HLA (Human Leukocyte Antigen identical sibling donor. Recent studies report 55% to 80% extended survival. Graft failure owing to rejection or others causes remains an important life-threatening complication following allogeneic bone marrow transplantation for aplastic anemia. It occurs in 55% to 60% of patients receiving HLA identical transplants, using different immunosuppressive therapies before and after transplant. The BMT

  9. Aplasia medular após transplante hepático em pediatria Aplastic anemia after pediatric liver transplantation

    Directory of Open Access Journals (Sweden)

    Marlene P. Garanito

    2009-01-01

    Full Text Available A aplasia de medula é uma das mais raras (Aplastic anemia (AA is one of the rarest (<1% and most serious complications of liver transplantation for fulminant non-A, non-B and non-C hepatitis. It was first described in 1987 by Stock; the mechanism involved is an immunologically mediated condition secondary to an unknown viral infection. The disease is associated with a dismal prognosis. Spontaneous recovery from acquired AA is very rare however some patients (50-70% recover after immunosuppressive therapy, such as Cyclosporin A (CsA and Antithymocyte globulin (ATG, even after liver transplantation. Another treatment option is bone marrow transplantation. We report on a child who developed AA following liver transplantation for fulminant viral hepatitis that was treated with intensive immunosuppression including CsA and ATG and achieved complete recovery.

  10. Association of Mitochondrial DNA Mutation with Telomere Length in Patients with Aplastic Anemia%再生障碍性贫血线粒体突变与端粒长度相关性的研究

    Institute of Scientific and Technical Information of China (English)

    曹慧琴; 韦玮; 崔兴

    2016-01-01

    Objective To examine the association of mitochondrial DNA ( mtDNA) mutations with telomere length in patients with aplastic anemia ( AA) . Methods Bone marrow and oral epi-thelial samples were collected from 45 patients diagnosed as having AA between 2010-2014 for de-tection of mtDNA mutation and telomere length. Complete sequence analysis of mtDNA revealed 151 mutations in 18 genes, including 40 silent mutations and 28 frameshift mutations. Moreover, the relative length of telomere ( relative T/S value) was detected in AA patients and healthy volunteers, with HBG as internal control gene. Results Non-silent mutation of mtDNA was negatively correla-ted with the WBC count, hemoglobin level and platelet count. Relative T/S value was positively correlated with the WBC count, hemoglobin level and platelet count, and a negative correlation was found between the non-silent mutation of mtDNA and relative T/S value. Conclusion Mutation-caused functional impairment of the mitochondrial respiratory chain and telomere length shortening may play important roles in the process of hematopoietic failure in AA patients. Additionally, mtD-NA mutations and telomere length shortening influence each other.%目的:研究再生障碍性贫血患者线粒体突变及端粒长度情况,了解两者间的相关性。方法选择2010~2014年确诊为再生障碍性贫血的患者45例,留取骨髓及口腔黏膜上皮标本以进行线粒体DNA ( mitochondrial DNA, mtDNA)突变和端粒长度的检测。线粒体全测序检测到了151个突变,分布在18个基因中,其中包括了40个沉默突变及28个框移突变。同时使用HBG作为内参基因,检测了再障患者和健康志愿者端粒的相对长度( relative T/S value,端粒长度)。结果分析发现非沉默突变的mtDNA突变与白细胞数、血红蛋白水平及血小板数成负相关。端粒长度与白细胞数、血红蛋白水平及血小板数成正相关性,而且非沉默突变的mtDNA突变与端粒长

  11. Treatment of Severe Aplastic Anemia by Immunosuppressor Anti-lymphocyte Globulin/Anti-thymus Globulin as the Chief Medicine in Combination with Chinese Drugs

    Institute of Scientific and Technical Information of China (English)

    郑兵荣; 沈建平; 庄海峰; 林圣云; 沈一平; 周郁鸿

    2009-01-01

    Objective:To study the therapeutic effect of combined therapy with Chinese drugs and immunosuppressors, mainly anti-lymphocyte globulin/anti-thymus globulin(ALG/ATG),for the treatment of severe aplastic anemia(SAA),the efficacy associated factors and adverse effects as well.Methods:A retrospective analysis was conducted on 65 patients with SAA treated by combined therapy which was supplemented with cyclosporin A,androgen,hematopoietic growth factor,etc.Results:Of the 57 patients followed-up,26 (45.6%) we...

  12. Monosomy 7 in donor cell-derived leukemia after bone marrow transplantation for severe aplastic anemia: report of a new case and review of the literature

    Directory of Open Access Journals (Sweden)

    Luize Otero

    2012-01-01

    Full Text Available Monosomy 7 arises as a recurrent chromosome aberration in donor cell leukemia after hematopoietic stem cell transplantation. We report a new case of donor cell leukemia with monosomy 7 following HLA-identical allogenic bone marrow transplantation for severe aplastic anemia (SAA. The male patient received a bone marrow graft from his sister, and monosomy 7 was detected only in the XX donor cells, 34 months after transplantation. The patient's bone marrow microenvironment may have played a role in the leukemic transformation of the donor hematopoietic cells.

  13. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.

    Science.gov (United States)

    Lens, Sabela; Calleja, Jose L; Campillo, Ana; Carrión, Jose A; Broquetas, Teresa; Perello, Christie; de la Revilla, Juan; Mariño, Zoe; Londoño, María-Carlota; Sánchez-Tapias, Jose M; Urbano-Ispizua, Álvaro; Forns, Xavier

    2015-05-01

    Telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and ribavirin. Pancytopenia due to myelotoxicity caused by these drugs may occur, but severe hematological abnormalities or aplastic anemia (AA) have not been described. We collected all cases of severe pancytopenia observed during triple therapy with telaprevir in four Spanish centers since approval of the drug in 2011. Among 142 cirrhotic patients receiving treatment, 7 cases of severe pancytopenia (5%) were identified and three were consistent with the diagnosis of AA. Mean age was 59 years, five patients had compensated cirrhosis and two patients had severe hepatitis C recurrence after liver transplantation. Severe pancytopenia was diagnosed a median of 10 wk after the initiation of therapy. Three patients had pre-treatment hematological abnormalities related to splenomegaly. In six patients, antiviral treatment was interrupted at the onset of hematological abnormalities. Two patients died due to septic complications and one patient due to acute alveolar hemorrhage. The remaining patients recovered. Severe pancytopenia and especially AA, are not rare during triple therapy with telaprevir in patients with advanced liver disease. Close monitoring is imperative in this setting to promptly detect serious hematological disorders and to prevent further complications. PMID:25954117

  14. Anemia aplásica adquirida e anemia de Fanconi - Diretrizes Brasileiras em Transplante de Células-Tronco Hematopoéticas Acquired aplastic anemia and Fanconi anemia - Brazilian Guidelines in Hematopoietic Stem Cell Transplantation

    Directory of Open Access Journals (Sweden)

    Larissa A. Medeiros

    2010-05-01

    clinical characteristics of each patient, including the number of transfusions, in order to minimize the primary and secondary rejection, ensuring better overall and disease-free survival observed in literature and already validated by the results in our population. In the Fanconi Anemia, transplantation is the only curative option for the aplastic bone marrow component, although insignificant for the other components of the syndrome, it also requires skill and agility in finding a donor with important results.

  15. Differential gene expression profile associated with the abnormality of bone marrow mesenchymal stem cells in aplastic anemia.

    Directory of Open Access Journals (Sweden)

    Jianping Li

    Full Text Available Aplastic anemia (AA is generally considered as an immune-mediated bone marrow failure syndrome with defective hematopoietic stem cells (HSCs and marrow microenvironment. Previous studies have demonstrated the defective HSCs and aberrant T cellular-immunity in AA using a microarray approach. However, little is known about the overall specialty of bone marrow mesenchymal stem cells (BM-MSCs. In the present study, we comprehensively compared the biological features and gene expression profile of BM-MSCs between AA patients and healthy volunteers. In comparison with healthy controls, BM-MSCs from AA patients showed aberrant morphology, decreased proliferation and clonogenic potential and increased apoptosis. BM-MSCs from AA patients were susceptible to be induced to differentiate into adipocytes but more difficult to differentiate into osteoblasts. Consistent with abnormal biological features, a large number of genes implicated in cell cycle, cell division, proliferation, chemotaxis and hematopoietic cell lineage showed markedly decreased expression in BM-MSCs from AA patients. Conversely, more related genes with apoptosis, adipogenesis and immune response showed increased expression in BM-MSCs from AA patients. The gene expression profile of BM-MSCs further confirmed the abnormal biological properties and provided significant evidence for the possible mechanism of the destruction of the bone marrow microenvironment in AA.

  16. Differential Gene Expression Profile Associated with the Abnormality of Bone Marrow Mesenchymal Stem Cells in Aplastic Anemia

    OpenAIRE

    Li, Jianping; Yang, Shaoguang; Lu, Shihong; Zhao, Hui; Feng, Jianming; Li, Wenqian; Ma, Fengxia; Ren, Qian; Liu, Bin; Zhang, Lei; Zheng, Yizhou; Han, Zhong Chao

    2012-01-01

    Aplastic anemia (AA) is generally considered as an immune-mediated bone marrow failure syndrome with defective hematopoietic stem cells (HSCs) and marrow microenvironment. Previous studies have demonstrated the defective HSCs and aberrant T cellular-immunity in AA using a microarray approach. However, little is known about the overall specialty of bone marrow mesenchymal stem cells (BM-MSCs). In the present study, we comprehensively compared the biological features and gene expression profile...

  17. Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration

    Institute of Scientific and Technical Information of China (English)

    Shao-qing NI; Wei ZHAO; Jue WANG; Su ZENG; Shu-qing CHEN; Evelyne JACQZ-AIGRAIN; Zheng-yan ZHAO

    2013-01-01

    Aim:To develop a population pharmacokinetic model for the immunosuppressant ciclosporin in Chinese children with aplastic anemia and to identify covariates influencing ciclosporin pharmacokinetics.Methods:A total of 102 children with either acquired or congenital aplastic anemia aged 8.8±3.6 years (range 0.9-17.6 years) were included.Therapeutic drug monitoring (TDM) data for ciclosporin were collected.The population pharmacokinetic model of ciclosporin was described using the nonlinear mixed-effects modeling (NONMEM) Vl software.The final model was validated using bootstrap and normalized prediction distribution errors.Results:A one-compartment model with first-order absorption and elimination was developed.The estimated CL/F was 15.1,which was lower than those of children receiving stem cell or kidney transplant reported in the West (16.9-29.3).The weight normalized CL/F was 0.45 (range:0.27-0.70) L.h-1·kg-1.The covariate analysis identified body weight,serum creatinine and concomitant administration of the anabolic steroid stanozolol as individual factors influencing the CL/F of ciclosporin.Conclusion:Our model could be used to optimize the ciclosporin dosing regimen in Chinese children with aplastic anemia.

  18. Bone marrow transplantation for girls with aplastic anemia utilizing modified field of total lymphoid irradiation and cyclophosphamide

    International Nuclear Information System (INIS)

    A preparative regimen for allogeneic bone marrow transplantation, consisting of total lymphoid irradiation (TLI) with 750 cGy and cyclophosphamide (CY), was used in five girls with aplastic anemia. All patients received bone marrow from HLA matched/mixed lymphocyte culture negative siblings. In our regimen the 'inverted Y' field to irradiate the pelvic nodes was modified, which did not include the whole pelvic cavity in an attempt to protect the ovaries from irradiation. Although some of the pelvic nodes was supported not to be irradiated in order to protect the ovaries, engraftment occurred in all five patients including four who had been transfused prior to transplantation. All five are alive from 47 days to 1378 days (median 285 days) after transplantation without tranplantation-associated complications. The calculated dose to the ovaries was sixteen percent of the entire dose of the regimen. Both of the two evaluable patients that had received tranplantation just before or during the puberty are developing normal sex maturity including menstruation. This study suggests that our preparative regimen is effective not only for engraftment of the donor marrow but also for protecting the ovaries from irradiation. (author)

  19. 改良非清髓造血干细胞移植治疗重型再生障碍性贫血%Improved nonmyeloablative allogeneic peripheral blood stem cell transplantation for severe aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    余喆; 葛林阜; 黄宁; 刘希民; 周芳; 解琳娜

    2009-01-01

    Objective To summarize the experience of improved nonmyeloablative hematopoietic stem cell transplantation(NSCT) in the treatment of severe aplastie anemia. Methods Seventeen patients with Severe Aplastic Anemia received NSCT after a nonmyeloablative conditioning.The patients were conditioned with decreased dosage of immunosuppressive agents of CTX and anti-lymphoid cell globulin or anti-thymus gland cell globulins;CsA and MMF were used to prevent the graft-versus-host disease (GVHD) after transplantation. Results 75 % of severe aplastic anemia in patients with type Ⅰ and 60 % of severe aplastic anemia in patients with type Ⅱ achieved rapid hematopoietic reconstitution, with good prognosis and implantation rate with fewer complieations and light symptoms were observed. Conclusion NSCT is an effective treatment of severe aplastic anemia.%目的 总结非清髓性造血干细胞移植(NSCT)治疗两种类型重型再生障碍性贫血(SAA)的临床经验.方法 对17例SAA患者进行NSCT,预处理主要采用小剂量环磷酰胺、抗淋巴细胞球蛋白或抗胸腺细胞球蛋白;移植后采用环孢素、吗替麦考酚酯(商品名:骁悉)预防移植物抗宿主病.结果 9例(75%)SAAⅠ型患者及3例(60%)SAAⅡ型患者获得迅速造血重建、植入率高、并发症少且轻,预后佳.结论 NSCT是治疗SAA的有效措施.

  20. Clinical features and therapeutic response of aplastic anemia patients with or without cytogenetic abnormalities%伴有细胞遗传学异常的再生障碍性贫血患者的临床特征及疗效分析

    Institute of Scientific and Technical Information of China (English)

    李玉龙; 刘禄社; 翟亚萍; 程薇; 张鲁芳; 张茵

    2013-01-01

    Objective To compare clinical features and therapeutic response of patients with aplastic anemia with and without cytogenetic abnormalities.Methods Clinical features of 133 patients with successful chromosomal analysis were retrospectively studied,and therapeutic response between patients with and without cytogenetic abnormalities was compared.Results Cytogenetic abnormalities were found in 9 patients,which included trisomy 8 (4 cases),monosomy 7 (2 cases) and Xq-(1 case),1q-(1 case) and 7q-(1 case).No significant difference was detected between patients with or without cytogenetic abnormalities in terms of age (50 vs.58,P=0.337),sex ratio (male 55.56% vs.62.10%,female 44.44% vs:37.90%,P=0.762),or episode of acute aplastic anemia (44.44% vs.37.10%,P=0.728).Patients with cytogenetic abnormalities had a tendency towards poorer rate of therapeutic response,which was however not significantly different from those without (55.56% vs.79.03%,P=0.116).All of the4 patients with +8 responded to treatment,whilst none of those with-7 or 7q-did.Conclusion No significant difference was found between aplastic anemia patients with or without cytogenetic abnormalities in terms of clinical features and theraputic response.Patients with trisomy 8 seem to have a favorable response towards treatment.%目的 探讨初诊时伴有细胞遗传学异常的再生障碍性贫血(再障)患者相对于遗传学正常患者在临床特征及治疗反应方面的差异.方法 回顾分析133例成功进行细胞遗传学分析的冉障患者,比较有或无遗传学异常的两组患者的临床特征及其对于环孢素联合十一酸睾丸酮的治疗反应的差异.结果 133例再障患者中9例具有细胞遗传学异常,占6.77%,其中8号染色体三体(+8)4例,7号单体(-7)2例,X、1号、7号染色体长臂缺失(Xq-、1q-、7q-)各1例.有细胞遗传学异常与无异常组相比,其年龄(50 vs.58,P=0.337)、性别比例(男55.56%vs.62.10%,女44.44% vs.37

  1. Clinical Observation on Treatment of Chronic Aplastic Anemia by Shengxuening (生血宁) and Cyclosporin A

    Institute of Scientific and Technical Information of China (English)

    ZHANG Xue-zhong; XU Yan-li; JIN Juan; ZHANG Xiu-qun; ZHANG Lei; SU Ai-ling

    2006-01-01

    Objective: To explore the therapy to further elevate the efficacy of the treatment of chronic aplastic anemia (CAA). Methods: Forty-five patients with CCA were assigned into two groups, the 26 paporin A (CsA), and the 19 patients in the control group were treated with androgen alone, with the therapeutic course lasting for over 3 months. Changes of peripheral blood picture, and the colony productivity of burst forming unit-erythroid (BFU-E), colony forming unit-erythroid (CFU-E) and colony forming unit-granulocyte macrophage (CFU-GM) in bone marrow were observed before and after 3 months treatment. The amount of erythrocyte and platelet infusion, frequency of infection, condition of hemorrhage and relevant death were also observed. The follow-up study was conducted for over half a year. Results: The total effective rate in the treated group was 84.6%, which was significantly higher than that in the control group (52.6%, P<0.05).Levels of hemoglobin, reticulocyte, neutrophil and platelet increased after treatment in the treated group, as compared with those before treatment, with significant difference ( P<0.05), and the colony productivity of BFU-E, CFU-E and CFU-GM in bone marrow also got significantly increased ( P<0.01 ), and showed significant difference from those in the control group (P<0.05). Conclusion: Shengxuening-assisting CsA therapy is an effective measure for treatment of CAA.

  2. CLINICAL AND LABORATORY OBSERVATION ON 31 CHILDREN WITH APLASTIC ANEMIA TREATED BY SPATHOLOBUS SUBERECTUS COMPOSITA

    Institute of Scientific and Technical Information of China (English)

    苏尔云; 陈园妹; 史黎青; 陈辉树; 周永列

    2001-01-01

    To investigate the effect of Spatholobus Suberectus Composita (SSC) on bone marrow hematopoiesis in child aplastic anemia (AA).Methods 31 cases of AA children were treated with SSC for 24 months. The pathological changes of bone marrow and the amount of CD34 positive cells before or after treatment were compared. 14 cases of normal volunteers were enrolled as control.Results The overall response rate was 87.1% (27 in 31 patients). The volume of nucleated cell in bone marrow (27.4±9.9vol% before treatment vs 44.6±31.5 vol% after treatment), granulocytes (36.0±9.9% vs 46.2±12.9%), megakaryocytes(3.3±7.2 vs 28.5±40.5 cells in bone marrow sections) and CD34+ cells (0.9±0.5% vs 2.0±0.7%) significantly increased after treatment compared with those before treatment (P<0.01 or P<0.05).Conclusion SSC has stimulative effect, which possibly acts at the level of stem/progenitor cells, on the bone marrow hematopoesis.

  3. Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin

    Directory of Open Access Journals (Sweden)

    de-Medeiros C.R.

    2000-01-01

    Full Text Available Severe aplastic anemia (SAA is probably an immune-mediated disorder, and immunosuppressive therapy is recommended for patients with no available donor for bone marrow transplant. Between October 1984 and November 1987, 25 consecutive children and adolescents with SAA with no HLA-compatible marrow donor received equine antithymocyte globulin (ATG (15 mg kg-1 day-1 for 10 days. The patients were evaluated 6 weeks, 6 months, and 12 months after starting ATG treatment. Thereafter, patients were evaluated yearly until July 1998. Median age was 10 years (range, 1.5-20 years, granulocyte counts on referral ranged from 0.032 to 1.4 x 10(9/l (median 0.256 x 10(9/l, and 12 patients had granulocyte counts <0.2 x 10(9/l. At a median follow-up of 9.6 years (range, 8.6-11.8 years, 10 patients (40% remained alive with good marrow function. No morphologic evidence of hematological clonal disorders has been observed, although two patients probably have acquired clonal chromosomal abnormalities (trisomy 8 and del(6q21, respectively. Responses to ATG were observed between 6 weeks and 6 months from the start of treatment in 60% of evaluable patients. The response rate was not different in patients whose granulocyte count at diagnosis was <0.2 x 10(9/l, or in those who were <10 years of age. This study supports the view that, when compared with supportive measures, ATG is an effective treatment for children or adolescents with SAA. Although these results are inferior to those reported for marrow transplantation or more intensive immunosuppressive regimens, these patients who responded to ATG are long-term survivors with stable peripheral blood counts and a low rate of relapse.

  4. Hematopoietic Stem Cell Regulation by Type I and II Interferons in the Pathogenesis of Acquired Aplastic Anemia.

    Science.gov (United States)

    Smith, Julianne N P; Kanwar, Vikramjit S; MacNamara, Katherine C

    2016-01-01

    Aplastic anemia (AA) occurs when the bone marrow fails to support production of all three lineages of blood cells, which are necessary for tissue oxygenation, infection control, and hemostasis. The etiology of acquired AA is elusive in the vast majority of cases but involves exhaustion of hematopoietic stem cells (HSC), which are usually present in the bone marrow in a dormant state, and are responsible for lifelong production of all cells within the hematopoietic system. This destruction is immune mediated and the role of interferons remains incompletely characterized. Interferon gamma (IFNγ) has been associated with AA and type I IFNs (alpha and beta) are well documented to cause bone marrow aplasia during viral infection. In models of infection and inflammation, IFNγ activates HSCs to differentiate and impairs their ability to self-renew, ultimately leading to HSC exhaustion. Recent evidence demonstrating that IFNγ also impacts the HSC microenvironment or niche, raises new questions regarding how IFNγ impairs HSC function in AA. Immune activation can also elicit type I interferons, which may exert effects both distinct from and overlapping with IFNγ on HSCs. IFNα/β increase HSC proliferation in models of sterile inflammation induced by polyinosinic:polycytidylic acid and lead to BM aplasia during viral infection. Moreover, patients being treated with IFNα exhibit cytopenias, in part due to BM suppression. Herein, we review the current understanding of how interferons contribute to the pathogenesis of acquired AA, and we explore additional potential mechanisms by which interferons directly and indirectly impair HSCs. A comprehensive understanding of how interferons impact hematopoiesis is necessary in order to identify novel therapeutic approaches for treating AA patients. PMID:27621733

  5. A retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemia

    Directory of Open Access Journals (Sweden)

    L.V.M. Ommati

    2009-03-01

    Full Text Available Allogeneic hematopoietic stem cell transplantation (AHSCT is the treatment of choice for young patients with severe aplastic anemia (SAA. The association of antithymocyte globulin (ATG and cyclophosphamide (CY is the most frequently used conditioning regimen for this disease. We performed this retrospective study in order to compare the outcomes of HLA-matched sibling donor AHSCT in 41 patients with SAA receiving cyclophosphamide plus ATG (ATG-CY, N = 17 or cyclophosphamide plus busulfan (BU-CY, N = 24. The substitution of BU for ATG was motivated by the high cost of ATG. There were no differences in the clinical features between the two groups, including age, gender, cytomegalovirus status, ABO match, interval between diagnosis and transplant, and number of total nucleated cells infused. No differences were observed in the time to neutrophil and platelet engraftment, or in the risk of veno-occlusive disease and hemorrhage. However, there was a higher risk of mucositis in the BU-CY group (71 vs 24%, P = 0.004. There were no differences in the incidence of neutrophil and platelet engraftment, acute and chronic graft-versus-host disease, and transplant-related mortality. There was a higher incidence of late rejection in the ATG-CY group (41 vs 4%, P = 0.009. Although the ATG-CY group had a longer follow-up (101 months than the BU-CY group (67 months, P = 0.04, overall survival was similar between the groups (69 vs 58%, respectively, P = 0.32. We conclude that the association BU-CY is a feasible option to the conventional ATG-CY regimen in this population.

  6. Severe Aplastic Anemia following Acute Hepatitis from Toxic Liver Injury: Literature Review and Case Report of a Successful Outcome

    Directory of Open Access Journals (Sweden)

    Kamran Qureshi

    2014-01-01

    Full Text Available Hepatitis associated aplastic anemia (HAAA is a rare syndrome in which severe aplastic anemia (SAA complicates the recovery of acute hepatitis (AH. HAAA is described to occur with AH caused by viral infections and also with idiopathic cases of AH and no clear etiology of liver injury. Clinically, AH can be mild to fulminant and transient to persistent and precedes the onset SAA. It is assumed that immunologic dysregulation following AH leads to the development of SAA. Several observations have been made to elucidate the immune mediated injury mechanisms, ensuing from liver injury and progressing to trigger bone marrow failure with the involvement of activated lymphocytes and severe T-cell imbalance. HAAA has a very poor outcome and often requires bone marrow transplant (BMT. The findings of immune related myeloid injury implied the use of immunosuppressive therapy (IST and led to improved survival from HAAA. We report a case of young male who presented with AH resulting from the intake of muscle building protein supplements and anabolic steroids. The liver injury slowly resolved with supportive care and after 4 months of attack of AH, he developed SAA. He was treated with IST with successful outcome without the need for a BMT.

  7. Anemia in the Preoperative Patient

    OpenAIRE

    Patel, Manish S; Carson, Jeffrey L.

    2009-01-01

    Anemia is commonly encountered in the preoperative patient. With variable etiology, determination of the cause of the anemia can impact perioperative surgical and medical management and outcome. Red blood cell transfusions are often administered during the perioperative time period in patients with preoperative anemia, although evidence to support the optimal transfusion threshold is limited. We review the evaluation of anemia, as well as evidence regarding perioperative blood transfusions. R...

  8. T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia

    DEFF Research Database (Denmark)

    Vries, A.C. de; Langerak, A.W.; Verhaaf, B.;

    2008-01-01

    (Very) severe acquired aplastic anemia ((v)SAA) and myelodysplastic syndrome (MDS) are rare diseases in childhood. (V)SAA is a bone marrow (BM) failure syndrome characterized by immune-mediated destruction of hematopoietic progenitors. MDS is a malignant clonal stem cell disorder, of which...

  9. Variant at position 10,055 in mitochondrial tRNA(Gly) gene has a negative association with aplastic anemia.

    Science.gov (United States)

    Jiang, Zhongxing; Wu, Xinai; Zhu, Yanan

    2016-09-01

    Recently, a growing number of reports had shown the association between mitochondrial DNA (mtDNA) sequence variants and aplastic anemia (AA). Owing to its high mutation rate, mtDNA variant had become biomarker for clinical and molecular diagnosis for AA. However, the relationship between mtDNA variant and AA was largely unknown. In this study, we reanalyzed the possible association between a "pathogenic" mutation A10055G in mt-tRNA(Gly) gene and AA, through the application of bioinformatics tool, we found that this mutation did not alter the secondary structure of tRNA(Gly), the pathogenicity scoring system indicated that the score of this mutation was only two points and belonged to a "neutral polymorphism", suggested that the role of A10055G mutation in clinical expression in AA needed to be further experimentally addressed. PMID:25629498

  10. Primitive Sca-1 Positive Bone Marrow HSC in Mouse Model of Aplastic Anemia: A Comparative Study through Flowcytometric Analysis and Scanning Electron Microscopy

    Directory of Open Access Journals (Sweden)

    Sumanta Chatterjee

    2010-01-01

    Full Text Available Self-renewing Hematopoietic Stem Cells (HSCs are responsible for reconstitution of all blood cell lineages. Sca-1 is the “stem cell antigen” marker used to identify the primitive murine HSC population, the expression of which decreases upon differentiation to other mature cell types. Sca-1+ HSCs maintain the bone marrow stem cell pool throughout the life. Aplastic anemia is a disease considered to involve primary stem cell deficiency and is characterized by severe pancytopenia and a decline in healthy blood cell generation system. Studies conducted in our laboratory revealed that the primitive Sca-1+ BM-HSCs (bone marrow hematopoietic stem cell are significantly affected in experimental Aplastic animals pretreated with chemotherapeutic drugs (Busulfan and Cyclophosphamide and there is increased Caspase-3 activity with consecutive high Annexin-V positivity leading to premature apoptosis in the bone marrow hematopoietic stem cell population in Aplastic condition. The Sca-1bright, that is, “more primitive” BM-HSC population was more affected than the “less primitive” BM-HSC Sca-1dim⁡ population. The decreased cell population and the receptor expression were directly associated with an empty and deranged marrow microenvironment, which is evident from scanning electron microscopy (SEM. The above experimental evidences hint toward the manipulation of receptor expression for the benefit of cytotherapy by primitive stem cell population in Aplastic anemia cases.

  11. Combined transplantation of G-CSF primed allogeneic bone marrow cells and peripheral blood stem cells in treatment of severe aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    黄晓军; 陈育红; 许兰平; 张耀臣; 刘代红; 郭乃榄; 陆道培

    2004-01-01

    @@ The major causes of unsuccessful transplantations for severe aplastic anemia (SAA) are graft-versus-host disease (GVHD), infection, and graft failure.1,2 The latter is particularly associated with SAA in that various methods have been developed to overcome it.Intensification of immunosupression during conditioning and high-dosage stem cell infusion can overcome sensitization to transplant antigens and improve engraftment after transplantation.

  12. 柯微君治疗慢性再生障碍性贫血经验%Ke Weijun's Experience in Treatment of Chronic Aplastic Anemia

    Institute of Scientific and Technical Information of China (English)

    刘晓翔; 高飞; 柯微君

    2015-01-01

    Chronic aplastic anemia is the difficultly - treated disease in blood system. Prof. Ke Wei-jing has accumulated rich experience in the treatment of chronic aplastic anemia. In the paper,the etiology and pathogenesis,syndrome differentiation and medication characteristics were analyzed. Prof. Ke thought that spleen and kidney deficiency and disharmony of yin and yang were the basic pathogenesis of chronic aplastic anemia,heat - toxin - stasis was the causative factor and also the pathological production of chronic aplastic anemia. In the treatment,the basic principle was strengthening the spleen,tonifying the kidney and regulating yin and yang,associated with clearing heat,detoxification,cooling blood and activating blood circulation. The therapeutic effect was very excellent.%慢性再生障碍性贫血是临床上较为难治的血液系统疾病。柯微君老师对慢性再生障碍性贫血的治疗经验丰富。文章介绍了柯老师对慢性再生障碍性贫血的病因病机、辨证分型以及用药特点分析。柯老师认为脾肾两虚、阴阳失调是慢性再生障碍性贫血的基本病机,热毒瘀是慢性再生障碍性贫血的致病因素,也是慢性再生障碍性贫血的病理产物。治疗上以健脾补肾、调补阴阳为本,配合清热解毒、凉血活血之剂,疗效甚佳。

  13. Imbalance of Treg/Th17 cells in patients with aplastic anemia and regulative role of umbilical cord-derived mesenchymal stem cells%再生障碍性贫血患者Treg/Th17细胞失衡及脐带MSCs对其的调节作用

    Institute of Scientific and Technical Information of China (English)

    陈莹; 陈柯材; 刘林

    2013-01-01

    目的 研究Treg/Th17细胞的平衡状态在再生障碍性贫血(aplastic anemia,AA)发病机制中的作用及意义,探讨脐带间充质干细胞(umbilical cord-derived mesenchymal stem cells,UC-MSCs)对AA患者外周血Treg/Th17比率的调节作用.方法 体外分离、培养和鉴定UC-MSCs.流式细胞术(flow cytometry,FCM)检测10例健康对照者、15例AA患者外周血Treg细胞和Th17细胞分别占外周血单个核细胞(peripheral blood mononuclear cells,PBMCs)的百分比,比较Treg/Th17细胞的比率.将AA患者的PBMCs与UC-MSCs共培养72 h,检测AA患者单独培养组和与MSCs共培养组Treg细胞、Th17细胞分别占PBMCs的百分比,比较Treg/Th17比率的变化.结果 经FCM鉴定MSCs表面标记CD90、CD105阳性率≥98%,CD34、CD45阳性率≤1%.AA患者组外周血Treg细胞百分率明显低于健康对照组(P<0.05),Th17细胞百分率明显高于健康对照组(P<0.05),Treg/Th17细胞比率明显低于健康对照组(P<0.05).AA患者的PBMC与UC-MSCs共培养后,Treg细胞百分率明显高于单独培养组(P<0.05),Th17细胞百分率明显低于单独培养组(P<0.05),Treg/Th17细胞比率较单独培养组明显升高(P<0.05).结论 AA患者外周血存在Treg/Th17分化失衡;UC-MSCs可能通过抑制Th17细胞分化,诱导Treg细胞生成/聚集,使得其Treg/Th17的失衡在一定程度上得到恢复.%Objective To determine the role and significance of the balance of Treg/Th17 cells in pathogenesis of aplastic anemia (AA),and to investigate the regulatory effect of umbilical cord-derived mesenchymal stem cells (UC-MSCs) on the ratio of Treg/Th17 cells in patients with AA.Methods UC-MSCs were isolated,cultured and identified in vitro.Flow cytometry (FCM) was used to detect the percentage of Treg cells and Th17 cells in the peripheral blood mononuclear cells (PBMCs) from 10 healthy volunteers and 15 AA patients,respectively by FCM,and the ratio of Treg/Th17 cells was compared.After PBMCs of the

  14. The variation and clinical significance of paroxysmal nocturnal hemoglobinuria clone in patients with aplastic anemia before and after immunosuppressive therapy%再生障碍性贫血免疫抑制治疗后阵发性睡眠性血红蛋白尿症克隆的演变及临床意义

    Institute of Scientific and Technical Information of China (English)

    孙莺心; 朱明清; 何广胜; 王秀丽; 方宝枝; 路丛; 刘真真; 吴倩; 杨永

    2013-01-01

    Objective To evaluate the evolution of paroxysmal nocturnal hemoglobinuria (PNH) clone and its clinical significance before and after immunosuppressive therapy (IST) in patients with aplastic anemia (AA).Methods A total of 186 patients diagnosed as AA were enrolled in this study.Among them,55 patients were diagnosed as severe AA (SAA) and treated with cyclosporine (CsA) plus antithymocyteglobulin (ATG),131 were diagnosed as non SAA (NSAA) and treated with CsA alone.All patients were screened for PNH clone by flow cytometry before treatment and followed up for 18-76 months,with a median time of 22 months.Results Positive PNH clones were detected in 10 SAA (18.9%) patients,significantly more than that of NSAA group [9 patients (7.4%),t =5.041,P =0.025].The proportions of PNH clones in SAA group at 6,12,24 and > 24 months were 13.38%,14.88%,20.00% and 18.85%,respectively,also significantly higher than those of NSAA patients (5.67%,5.31%,5.47% and 9.08%,all P values <0.05).Clinical response rates were comparable in both ATG + CsA or CsA alone groups no matter PNH clone was positive or negative.Conclusions PNH clone are detectable in AA patients either treated with ATG plus CsA or CsA alone,and more significant by ATG plus CsA.Whether PNH clone occurres before or after IST does not affect the therapeutic efficacy.%目的 探索再生障碍性贫血(AA)免疫抑制治疗(IST)后阵发性睡眠性血红蛋白尿症(PNH)克隆变化情况及其临床意义.方法 将2008年1月至2012年2月收治的186例AA患者纳入本研究,其中55例重型AA(SAA)予抗胸腺细胞球蛋白(ATG)联合环孢素A(CsA)治疗,131例非重型AA(NSAA)予CsA治疗.治疗前所有患者进行PNH克隆筛查,治疗后进行随访.中位随访时间22(18 ~76)个月.结果 SAA组10例(18.9%)患者出现PNH克隆,NSAA组9例(7.4%)出现PNH克隆,前者出现PNH克隆比例高于后者(t=5.041,P=0.025),治疗后SAA组在6、12、18、>24

  15. Clinical Evaluation of Anemia in Geriatric Patients - A Cross Sectional Study Conducted At Tertiary Care Hospital

    Directory of Open Access Journals (Sweden)

    Sfurti Mann, Amit Kumar, Shiv Kumar Singh, Surbhi Katyal, Gaurav Chopra, Sanjeev Kumar Varma

    2014-01-01

    Methods: After taking informed written consent, patients were subjected to a detailed history, thorough clinical examination and various relevant investigations including bone marrow examination and radiological means. Result: 42 patients (70% were male and 18 patients (30% were female. Maximum number of patients, 24 (40% were in the age group 65-69 years. Out of which 15 (62.5% were male and 9 (37.5% were female. Conclusion: Among all the patients (irrespective of age groups and types of anemia, ACD was found to be most common (41.67%, followed by IDA (35%, MDS (5%, Megaloblastic anemia (3.34%, myelofibrosis and haemolytic anemia (3.34% each and aplastic anemia (1.67%.

  16. Effect of human bone marrow mesenchymal stem cell on T cell activation in patients with aplastic anemia%人骨髓间充质干细胞对再生障碍性贫血患者T细胞活化的影响

    Institute of Scientific and Technical Information of China (English)

    董毅; 李庆生; 朱太岗; 夏瑞祥

    2008-01-01

    目的 探讨人骨髓间充质干细胞在体外对再生障碍性贫血患者T细胞活化的影响.方法 从人骨髓分离培养间充质干细胞,用尼龙棉柱分离T淋巴细胞,分别以不同数量间充质干细胞加入到植物血凝素刺激的再生障碍性贫血患者T淋巴细胞活化体系中,通过流式细胞仪获取数据,计算CD3+CD25+和CD3+CD38+T细胞的表达率.结果 当间充质干细胞为1×104/孔时,与单独培养的再生障碍性贫血患者T淋巴细胞(对照组)相比,间充质干细胞对再生障碍性贫血患者T淋巴细胞CD25及CD38的表达呈明显抑制作用,差异有统计学意义(P<0.01).当间充质干细胞为1×103/孔时,与对照组相比无统计学意义.结论 间充质干细胞在体外抑制再生障碍性贫血患者T细胞的活化,且这种抑制作用具有数量依赖性.%Objective To observe effect of human bone marrow mesenchymal stem cell (MSC) on T cell activation in patients with aplastic anemia(AA). Methods MSCs were separated with Percoll and cultured in low glucose DMEM. T cells were harvested by using nylon column. MSCs of various concentrations were added to PHA induction T cell activation cultures. The CD25 and CD38 expression rates of CD3+ T cells was analyzed by flow cytometry. Results MSCs were planted in 96 well plates (1×104/well for group A) and coeultured with T cell isolated from peripheral blood of AA patients. Peripheral blood T cell noncocultured with MSC acted as the control group, MSCs inhibit PHA induced the CD25 and CD38 expression of CD3+ T cells in patients with AA. The expression rates were significantly lower than control group (P<0.01). But the expression rates showed no significant difference between the two groups(MSCs , 1×103/well for group B). Conclusion Human bone marrow MSCs inhibit T cell activation in patients with AA in vitro and the inhibitory effects are dependent on the amount of MSCs.

  17. What Causes Anemia?

    Science.gov (United States)

    ... page from the NHLBI on Twitter. What Causes Anemia? The three main causes of anemia are: Blood ... the blood and can lead to anemia. Aplastic Anemia Some infants are born without the ability to ...

  18. Clinical Observation of Compound Tripterygium Particles in Treatment of Chronic Aplastic Anemia%复方雷公藤颗粒治疗慢性再生障碍性贫血临床观察

    Institute of Scientific and Technical Information of China (English)

    邢海燕; 胡灿红

    2012-01-01

    目的:观察复方雷公藤颗粒联合安雄、环孢菌素A治疗慢性再生障碍性贫血的临床疗效.方法:采用复方雷公藤颗粒联合安雄、环孢菌素A治疗慢性再障22例,同时与18例单用安雄、环孢菌素A治疗慢性再生障碍性贫血比较.结果:治疗组总有效率为81.8%,对照组为50.0%,两组比较有显著性差异(P<0.05).治疗组的白细胞、血红蛋白、血小板计数明显高于对照组(P<0.05).结论:复方雷公藤颗粒联合安雄、环孢菌素A治疗慢性再障能起到协同增效作用,加速症状的改善,提高疗效.%Objective: To observe the clinical effect of compound tripterygium particles combined with testosterone undecanoate and cyclosporin A in treatment of chronic aplastic anemia. Methods : In experiment group, there were 22 patients with aplastic anemia treated by compound tripterygium particles combined with testosterone undecanoate and cyrlosporin A. In control group, there were 18 patients treated by estosterone undecanoate and cyclosporin A. Then the clinical effect was compared between the two groups. Results: The total efficiency of experiment group was 81.8%, compared with 50.0% of the control group. The difference was significant ( P<0.05 ). White blood cell, hemoglobin and platelet count of experiment group were significantly higher than those of control group ( P<0.05 ) . Conclusion : Compound tripterygium particles combined with testosterone undecanoate and cyclosporin A can play synergistic effect, accelerate the improvement of symptoms , and improve the curative effect in treatment of chronic aplastic anemia.

  19. Who Is at Risk for Anemia?

    Science.gov (United States)

    ... Aplastic Anemia Hemolytic Anemia Iron-Deficiency Anemia Pernicious Anemia Sickle Cell Disease Send a link to NHLBI to someone ... A family history of inherited anemia, such as sickle cell anemia or thalassemia Rate This Content: NEXT >> Updated: May ...

  20. Anemias.

    Science.gov (United States)

    Broadway-Duren, Jacqueline B; Klaassen, Hillary

    2013-12-01

    Anemias continue to present a challenge to the health care profession. Anemia is defined as a reduction in one or more of the RBC indices. Patients presenting with a mild form of anemia may be asymptomatic; however, in more serious cases the anemia can become life threatening. In many cases the clinical presentation also reflects the underlying cause. Anemia may be attributed to various causes, whereas autoimmune RBC destruction may be attributed to intrinsic and extrinsic factors. Laboratory tests are essential in facilitating early detection and differentiation of anemia.

  1. Improved Outcome of a Reduced Toxicity-Fludarabine, Cyclophosphamide, plus Antithymocyte Globulin Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia: Comparison of 2 Multicenter Prospective Studies.

    Science.gov (United States)

    Kang, Hyoung Jin; Hong, Kyung Taek; Lee, Ji Won; Kim, Hyery; Park, Kyung Duk; Shin, Hee Young; Lee, Soo Hyun; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong Hoe; Lee, Jae Wook; Chung, Nak Gyun; Cho, Bin; Kim, Hack Ki; Koh, Kyung Nam; Im, Ho Joon; Seo, Jong Jin; Jung, Hyun Joo; Park, Jun Eun; Lee, Young Ho; Lim, Young Tak; Lim, Yeon Jung; Kim, Sun Young; Yoo, Eun Sun; Ryu, Kyung Ha; Lee, Jae Hee; Park, Jeong-A; Park, Sang Kyu; Ahn, Hyo Seop

    2016-08-01

    Hematopoietic stem cell transplantation (HSCT) is a curative therapy for severe aplastic anemia (SAA); however, the optimal conditioning regimen for HSCT with an unrelated donor has not yet been defined. A previous study using a fludarabine (FLU), cyclophosphamide (Cy), and antithymocyte globulin (ATG) conditioning regimen (study A: 50 mg/kg Cy once daily i.v. on days -9, -8, -7, and -6; 30 mg/m(2) FLU once daily i.v. on days -5, -4, -3, and -2; and 2.5 mg/kg of ATG once daily i.v. on days -3, -2, and -1) demonstrated successful engraftment (100%) but had a high treatment-related mortality rate (32.1%). Therefore, given that Cy is more toxic than FLU, we performed a new phase II prospective study with a reduced-toxicity regimen (study B: 60 mg/kg Cy once daily i.v. on days -8 and -7; 40 mg/m(2) FLU once daily i.v. on days -6, -5, -4, -3, and -2; and 2.5 mg/kg ATG once daily i.v. on 3 days). Fifty-seven patients were enrolled in studies A (n = 28) and B (n = 29), and donor type hematologic recovery was achieved in all patients in both studies. The overall survival (OS) and event-free survival (EFS) rates of patients in study B was markedly improved compared with those in study A (OS: 96.7% versus 67.9%, respectively, P = .004; EFS: 93.3% versus 64.3%, respectively, P = .008). These data show that a reduced-toxicity conditioning regimen with FLU, Cy, and ATG may be an optimal regimen for SAA patients receiving unrelated donor HSCT. PMID:27090956

  2. Análise da rejeição nos pacientes transplantados por anemia aplástica severa condicionados com ciclofosfamida ou a associação desta ao bussulfano Analysis of rejection in transplanted patients suffering severe aplastic anemia conditioned with cyclophosphamide alone or associated with busulfan

    OpenAIRE

    Lídice C. Lenz e Silva; Ricardo Pasquini

    2005-01-01

    O transplante de medula óssea é um tratamento eficaz para pacientes com anemia aplástica severa (AAS) e é a modalidade terapêutica de escolha para pacientes jovens com doador aparentado HLA idêntico. A rejeição é uma importante complicação do transplante de medula, que, independentemente do tipo de tratamento imunossupressor pré e pós-transplante, ocorre em 55% a 60% dos pacientes. O serviço de TMO da Universidade Federal do Paraná (UFPR) acumula a experiência de 178 casos de AAS transplantad...

  3. Clinical study on viral hepatitis combined with aplastic anemia%病毒性肝炎合并再生障碍性贫血的临床研究

    Institute of Scientific and Technical Information of China (English)

    路遥; 张艳丽; 申戈; 张璐; 王琳; 邱国华; 吴云忠; 杨民; 李明慧

    2011-01-01

    Objective To study the clinical features, outcomes and treatments of viral hepatitis combined with aplastic anemia. Methods25 cases diagnosed as viral hepatitis combined with aplastic anemia in Beijng Ditan Hospital between April 2004 and September 2009 were retrospectively analyzed. In this group of patients aplastic anemia was finally diagnosed by bone marrow aspiration. We collected clinical data of these patients, including a history of liver disease, drug allergies, hospital medication history, laboratory data, and then performed descriptive analysis. Results25 patients with viral hepatitis were diagnosed as complicated with aplastic anemia by histopathological data. Among these patients, 17 were male and 8 were women. Viral hepatitis included: chronic hepatitis B ( 12 cases), chronic hepatitis C (4 cases), acute hepatitis E ( 1 case), hepatitis caused by CMV infection ( 1 case), and unclassified hepatitis (7 cases). Among these patients, 7 were diagnosed as severe hepatitis. Considering previous history, only 3patients had history of short-term interferon therapy before hospitalization, and the remaining patients did not use drug that affects blood system. Treatments were as followings: using colony stimulating factor in 6patients, gamma globulin in 9 patients, glucocorticoids in 3 patients, erythropoietin in 1 patient, only oral drug to raise erythrocytes in 2 patients, red blood cells transfusion in 6 patients, platelets transfusion in 2patients. As for clinical outcomes, 20 patients acquired improved condition and were discharged, 3 patients were discharged voluntarily and 2 patients died of severe hepatitis combined with other complications.Conclusion Main treatments of viral hepatitis combined with aplastic anemia were to treat primary hepatopathy and nucleoside analogue-based antiviral therapy, to provide symptomatic and supportive treatment for blood diseases. Blood diseases would recover simultaneously while liver disease was improved, and the

  4. Incidence of adult aplastic anemia in Shanghai, China%上海市成人再生障碍性贫血发病率调查

    Institute of Scientific and Technical Information of China (English)

    王蔚; 王小钦; 李佩; 林果为

    2011-01-01

    目的 调查上海市成人获得性再生障碍性贫血(AA)发病率,并与20世纪80年代的AA发病率以及国外的AA发病率进行比较,了解其变化趋势.方法 采用回顾性调查的方式对2004至2006年上海市静安区、徐汇区、黄浦区、长宁区、普陀区、杨浦区6个区域的成人新发AA患者进行登记调查,计算这6个区的成人AA发病率情况.结果 上海市6个区内2004年至2006年新诊断成人AA患者共38例,平均年发病率0.33/10万,其中18~34岁、35~59岁和≥60岁人群的年发病率分别为0.40/10万、0.14/10万和0.64/10万,其中重型AA的平均年发病率为0.17/10万.结论 与20世纪80年代相比,上海市成人AA发病率有所下降,但重型AA发病率无明显变化.%Objective To survey the incidence of acquired adult aplastic anemia (AA) in Shanghai, China. Meanwhile, we compared it with the previous data from China in 1986 and other countries in order to explore the trends. Methods Newly diagnosed AA patients were registered in 6 districts (Jingan, Xuhui, Huangpu, Changning, Putuo, Yangpu ) in Shanghai from 2004 to 2006. Then we calculated the crude and age-adjusted incidence of AA according to the population data from Shanghai Statistic Yearbook. Results There were 38 adult patients with acquired AA. The average crude incidence of AA was 0. 33/100 000 from 2004 to 2006. The incidences per 100 000 persons per year were 0. 40, 0. 14and 0. 64 in 18-34, 35-59 and ≥ 60 years, respectively. The rate of severe AA was 0. 17/100 000.Conclusion The incidence of severe AA has no marked change, but the total rate is a little decreased compared with the data from China in 1986.

  5. Successful allogeneic stem cells transplantation in severe aplastic anaemia complicated by dengue fever

    International Nuclear Information System (INIS)

    Aplastic anaemia is characterized by severe compromise of haematopoiesis and hypocellular bone marrow. Haemorrhagic episodes in patients with aplastic anemia occur usually secondary to thrombocytopenia and require frequent support with platelet concentrates and other blood products. Infection with dengue virus (particularly dengue sero type-2 of South Asian genotype) is associated with dengue haemorrhagic fever. Dengue infection further worsens the disease process in patients with aplastic anaemia due to uncontrolled haemorrhagic diathesis and major organ failure, which may prove fatal in these already immunocompromised patients, if not treated in time. Recent epidemics of dengue haemorrhagic fever has not only affected the southern region of our country but also spread to other areas of the country. With this background, we report a case of aplastic anaemia complicated by dengue haemorrhagic fever who achieved successful engraftment after allogeneic stem cell transplantation from sibling brother and is having normal healthy post transplant life. (author)

  6. Study of chronic hemolytic anaemia patients in Rio de Janeiro: prevalence of anti-human parvovirus B19 IgG antibodies and the developement aplastic crises

    Directory of Open Access Journals (Sweden)

    SANT'ANNA Anadayr L.M.

    2002-01-01

    Full Text Available The prevalence of anti-human parvovirus B19 IgG antibodies was determined in sera from 165 chronic hemolytic anemia patients, receiving medical care at Instituto Estadual de Hematologia (IEHE, Rio de Janeiro, during the year of 1994. This sample represents around 10% of the chronic hemolytic anemia patients attending at IEHE. Most of these patients (140 have sickle cell disease. Anti-B19 IgG antibodies were detected in 32.1% of patients. No statistically significant difference (p > 0.05 was seen between IgG antibody prevalence in male (27.8% and female (35.5% patients. Anti-B19 IgG antibodies were more frequent in older (37.6% than younger (28.2% than 20 years old patients, although this difference had no statistical significance (p > 0.05. Anti-B19 IgG antibody prevalence showed that 67.9% of patients enrolled in the study were susceptible to B19 acute infection. With the aim to detect acute B19 infection, patients follow up continued until February 1996. During this period four patients presented transient aplastic crisis due to human parvovirus B19 as confirmed by the detection of specific IgM antibodies. All four patients were younger than 20 years old, and 3 were younger than 10 years old. Three of them were sickle cell disease patients. Three of the four acute B19 infection occurred during 1994 springtime.

  7. Development of acute leukemia in a known case of fanconi anaemia ( aplastic anaemai

    Directory of Open Access Journals (Sweden)

    Preeti Jhaveri

    2013-01-01

    Full Text Available Fanconi anemia is an autosomal recessive disease associated with an abnormal DNA damage. Although Fanconi anemia is well known for its association of Aplastic anemia and characteristic birth defects, leukemia and solid tumors also occur at a high rate in this group of patients. A patient male / 20yrs, known case of Fanconi anemia presented with ulcer over left lower limb. On further evaluation, the patient was found to have pancytopenia and his peripheral smear revealed many atypical blast like cells. So bone marrow study was done which revealed it to be Acute leukemia probably Acute Myeloid leukemia.

  8. [Aplastic crisis due to parvovirus B19 and Epstein-Barr virus in a patient with hereditary spherocytosis].

    Science.gov (United States)

    Leoz Gordillo, I; Pérez Suárez, E

    2015-01-01

    Anemic syndrome in childhood requires a diagnosis and urgent treatment guided by systematic protocols that can avoid unnecessary additional testing. The case of a 4 year-old girl with fatigue and intermittent fever of 7 days duration, accompanied by abdominal pain is presented. She had regular general health status, with mucocutaneous jaundice, a grade III/VI/iv murmur, and painful abdomen with hepatosplenomegaly. The blood analysis showed a hypo-regenerative anemia with increased LDH and indirect bilirubin. The Coombs Test was negative, with spherocytes being observed in the peripheral blood smear. The IgM and IgG were positive for parvovirus B19 IgM and Epstein Barr virus, leading to the diagnosis of aplastic crisis in a patient with hereditary spherocytosis. No specific treatment was required. Under the suspicion of anemic syndrome in emergencies, the ABCDE sequence must be followed. Through the history, physical examination and basic laboratory tests, an initial diagnostic approach can be made. Specific etiological tests should be based on this first study. PMID:24629905

  9. Alleviating anemia and thrombocytopenia in myelofibrosis patients.

    Science.gov (United States)

    Cervantes, Francisco; Correa, Juan-Gonzalo; Hernandez-Boluda, Juan Carlos

    2016-05-01

    Anemia and thrombocytopenia are frequent clinical manifestations of myelofibrosis as well as important prognostic factors of the disease. Concerning the treatment of anemia, the first step should be the correction of reversible contributing factors, such as possible iron, folate and vitamin B12 deficiency. Then, treatment options include erythropoiesis stimulating agents, androgens, immunomodulating drugs, corticosteroids, and splenectomy. Anemia responses may also be observed in some patients treated with JAK inhibitors. However, most patients eventually fail to such therapies and become transfusion dependent. Some of the aforementioned therapies can also improve thrombocytopenia, but the responses are usually observed in patients with moderate platelet count decrease. Allogeneic hematopoietic stem cell transplantation, the only curative treatment of myelofibrosis, can be an alternative for selected patients with cytopenias who are refractory to conventional therapies. However, for the majority of patients, the management of anemia and severe thrombocytopenia remains an unmet need. PMID:26891375

  10. 再生障碍性贫血继发流感病毒感染的危险性研究%Research on danger of aplastic anemia secondary infection with influenza virus

    Institute of Scientific and Technical Information of China (English)

    郭潮潭; 尤金彪; 曹毅; 胡致平; 陈帅帅; 沃恩康; 王怡婷; 杨新燕; 张儒轩

    2015-01-01

    目的 探讨流感病毒感染对再生障碍性(再障)贫血模型小鼠造血功能的影响,以期为临床再障合并流感的研究提供参考.方法 采用环磷酰胺及甲苯法构建小鼠再障模型,观察再障模型小鼠与正常小鼠血红蛋白和血细胞三系的变化,判断造模效果.用微量病毒接种法判断流感病毒对正常小鼠及再障小鼠血细胞及生存的影响.结果 成功建立了小鼠再障模型,再障小鼠的血红蛋白、红细胞、白细胞、血小板计数显著下降,与对照组比较差异均有统计学意义(P<0.05).与未接种病毒的小鼠相比,正常小鼠微量多次接种流感病毒后除发生一过性体重轻度下降外,血细胞三系均无明显变化;而再障小鼠模型接种病毒后的病死率较正常小鼠接种病毒后显著增高.结论 流感病毒感染对正常小鼠的造血功能无明显影响,但可能会导致再障动物病情加重,甚至增加病死率.%Objective To investigate the influence of influenza virus infection on the hematopoietic function of aplastic anemia model mouse,and provide reference for research on clinical aplastic anemia influenza complication.Methods Small mice aplastic anemia model was set up by cyclophosphamide and toluene method.Through observing changes of hemoglobin and blood three series between model mouse and normal mouse to estimate the molding effect.Virus inoculation method was used to estimate the effects of influenza virus on the blood cell and survival of normal and aplastic anemia mouse.Results Aplastic anemia model mouse with chemical method were successfully established.Hemoglobin,red blood cell,white blood cell and blood platelet were reduced obviously,the differences compared with control group had statistical significance (P<0.05).In contrast with uninoculated mouse,normal mouse had no significant change in blood three series after less frequent influenza virus inoculation except for temporary body weight loss

  11. Anemia in patients with diabetes mellitus

    Directory of Open Access Journals (Sweden)

    Dimković Nada

    2007-01-01

    Full Text Available Introduction: Anemia is more common and pronounced in patients with diabetic, than in patients with non-diabetic renal disease. While several factors contribute to its pathogenesis, the failure of the kidney to increase erythropoietin in response to falling hemoglobin appears to be the dominant factor. The most frequent complications of anemia in diabetic patients include decreased quality of life and work capacity and increased cardiovascular morbidity and mortality. Material and Methods: This cross-sectional multicenter study included a total of 539 patients with type I (~20% and type II diabetes (~80% classified into five stages according to the glomerular filtration rate. Results Diabetic nephropathy appears in stage I, and progresses in all patients to the stage V (p=0.045. The presence of anemia progressively increased from stage I to stage V (from 60% to 100%, p=0.008. Only 62% of patients with anemia were treated (mainly with iron and only 3.4% received erythropoietin treatment. Hypertension was present in 90% of patients in stage I and in 100% of patients in stage V nephropathy. The presence of heart failure increased from 0% (stage I to 51% (stage IV, p=0.03. Around 62% of patients were referred to a nephrologist, and according to the logistic regression model, renal failure and presence of anemia were significant predictors of patients' referral to nephrologist. Conclusion: In a primary care setting, anemia is a frequent finding, even in the very beginning of diabetic renal disease. Currently available guidelines for management of anemia are not followed; this may explain high percentage of patients with heart failure in pre-dialysis stage. Early referral to a nephrologist and regular follow-up by an endocrinologist and cardiologist are the best way for the prevention of diabetic complications and comorbidity.

  12. Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia.

    Science.gov (United States)

    Agarwal, M B; Jijina, Farah; Shah, Sandip; Malhotra, Pankaj; Damodar, Sharat; Ross, Cecil

    2015-06-01

    To confirm the safety and efficacy of an indigenous equine antithymocyte globulin (eATG) along with cyclosporine in Indian subjects with acquired aplastic anaemia. Subjects >2 years old with acquired aplastic anaemia were enrolled at six hospitals between April 2011 and February 2013, after approval from respective Ethics Committees. Equine ATG at a dose of 40 mg/kg/day was infused for 4 days. Efficacy analysis defined a priori, was in subjects, who had completed eATG treatment and followed-up on day 90 and/or 180. Complete response (CR) was defined as-transfusion independent, haemoglobin ≥11 g/dL, absolute neutrophil count (ANC) >1.5 10(9)/L and platelet ≥150 10(9)/L; partial response (PR) was transfusion independent, haemoglobin ≥8 g/dL, ANC >0.5 10(9)/L and platelet ≥20 10(9)/L; non responders were transfusion dependent. Lymphocyte subsets (CD 2, 3, 4 and 8) in the blood were tested on days 0 (pre eATG infusion), 3, 5, 7, 14 and 21 after eATG. Of the 30 subjects (two children pneumonia, one was withdrawn after the first dose of eATG due to jaundice and eight were lost to follow-up. The median age was 30 (9-58) years and weight was 57 (26-84) kg. On day 90, 12 of 30 subjects responded (CR 1, PR 11) and 15 of 30 (CR 2, PR 13) on day 180. The most common adverse event was fever related to eATG infusion. There were two serious adverse events (acute renal failure, febrile neutropenia) and both recovered with treatment. There were no unusual adverse events noted during the study period. Blood T lymphocytes showed a mean decrease of 91 % from baseline that recovered by day 21. We conclude that eATG is safe and in combination with cyclosporine showed overall response in 50 % of enrolled subjects. The trial was registered with the clinical trial registry-india (Registration no. CTRI/2012/03/002498). PMID:25825555

  13. Frequency of anemia in chronic psychiatry patients

    Directory of Open Access Journals (Sweden)

    Korkmaz S

    2015-10-01

    Full Text Available Sevda Korkmaz,1 Sevler Yildiz,1 Tuba Korucu,1 Burcu Gundogan,1 Zehra Emine Sunbul,1 Hasan Korkmaz,2 Murad Atmaca1 1Department of Psychiatry, 2Department of Cardiology, Faculty of Medicine, Firat University, Elazig, Turkey Purpose: Anemia could cause psychiatric symptoms such as cognitive function disorders and depression or could deteriorate an existing psychiatric condition when it is untreated. The objective of this study is to scrutinize the frequency of anemia in chronic psychiatric patients and the clinical and sociodemographic factors that could affect this frequency.Methods: All inpatients in our clinic who satisfied the study criteria and received treatment between April 2014 and April 2015 were included in this cross-sectional study. Sociodemographic data for 378 patients included in the study and hemoglobin (Hb and hematocrit values observed during their admission to the hospital were recorded in the forms. Male patients with an Hb level of <13 g/dL and nonpregnant female patients with an Hb level of <12 g/dL were considered as anemic.Findings: Axis 1 diagnoses demonstrated that 172 patients had depressive disorder, 51 patients had bipolar disorder, 54 patients had psychotic disorder, 33 patients had conversion disorder, 19 patients had obsessive-compulsive disorder, 25 patients had generalized anxiety disorder, and 24 patients had other psychiatric conditions. It was also determined that 25.4% of the patients suffered from anemia. Thirty-five percent of females and 10% of males were considered as anemic. The frequency of anemia was the highest among psychotic disorder patients (35%, followed by generalized anxiety disorder patients (32%, and obsessive-compulsive disorder patients (26%. Anemia was diagnosed in 22% of depressive disorder patients, 25% of bipolar disorder patients, and 24% of conversion disorder patients.Results: The prevalence of anemia among chronic psychiatry patients is more frequent than the general population

  14. Therapy of Aplastic Anemia with Autologous Peripheral Mononuclear Cells Treated by IL-2 and GM-CSF in culture:a Long-term Follow-up report on 49 Patients%IL-2/GM-CSF体外处理的自体外周血单个核细胞治疗再生障碍性贫血49例长期随访

    Institute of Scientific and Technical Information of China (English)

    陈玲珍; 陈嘉榆; 余卫; 巫进明; 詹昱; 冯可欣; 杨德懋

    2011-01-01

    本研究回顾分析2001年4月至2007年12月期间采用IL-2和GM-CSF体外处理的外周血单个核细胞治疗再生障碍性贫血(aplastie anemia,AA)的安全性及远期疗效.取自体外周血单个核细胞,在IL-2和GM-CSF作用下培养48小时后进行静脉回输,细胞总剂量为6×106-1×108,每周1次,连用4-22个月.外周血常规检查、骨髓细胞涂片和骨髓活检评价造血恢复,流式细胞术测定输注细胞的组成以及治疗前后T细胞亚群的变化,多聚酶链反应检测外周血T细胞TCRVβ克隆性.结果表明:49例患者中痊愈37例,随访至今无1例出现复发;5例部分缓解,3例明显进步,4例无效,总有效率91.8%(45/49).治疗前外周血T细胞亚群CD4/CD8比例倒置者39例,治疗后31例(79.5%)恢复正常.11例患者行外周血TCRVβ克隆性分析,受抑制的亚群重新得到恢复,出现多克隆的表达图像.未发现晚期克隆性疾病及其它远期不良反应.结论:IL-2和GM-CSF体外处理的外周血单个核细胞疗法疗效肯定,其机制可能与T细胞免疫功能的恢复有关.%This study was purposed to evaluate the long-term outcome and the safety of autologous peripheral blood mononuclear cells(PBMNC) treated by interleukin 2 (IL-2) and granulocyte-macrophage colony stimulating factor(GM-CSF) in the therapy of patients with aplastic anemia (AA). The therapy of 49 patients admittedBG in hospital from April 2001 to December 2007 were analyzed retrospectively. PBMNC were isolated and cultured for 48 hours in presence of IL-2 and GM-CSF. Cells were collected, and 6 × 106 - 1 × 108 PBMNC were intravenously injected weekly for 4 -22 months. Hematopoietic recovery was evaluated by examinations of peripheral blood, bone marrow aspirates and bone marrow biopsy. Flow cytometry was used to assess the peripheral T cell subsets before and after treatment. Polymerase chain reaction was performed to observe the clonal diversity of T cell receptor variable β-chain (TCR

  15. 环孢素A联合司坦唑醇片治疗慢性再生障碍性贫血的临床疗效%Cyclosporin A joint Stanozolol Tablets in Treatment of Chronic Aplastic Anemia Clinical Curative Effect

    Institute of Scientific and Technical Information of China (English)

    尹永玲

    2013-01-01

    Objective:To explore cyclosporin A joint Stanozolol Tablets in the treatment of chronic aplastic anemia clinical curative effect. Methods: 40 cases of chronic aplastic anemia patients were randomly divided into observation group and control group the 20 cases, observation group was given cyclosporin A Stanozolol Tablets combined treatment group, give Testosterone Undecanoate treatment, compared two groups of patients and the clinical effect of when the drug adverse reactions. Results:The observation group of patients with total effective rate was 100%, in the patients in the total effective rate was 75%, the observation group was superior to control group, two groups of comparisons, a statistically significant difference (P<0.05). Conclusions:Cyclosporin A joint Stanozolol Tablets in the treatment of chronic aplastic anemia was obviously better than the clinical effect of Testosterone Undecanoate treatment, safe and effective, no serious adverse reaction, it should be worth clinical application.%  目的:探讨环孢素A联合司坦唑醇片治疗慢性再生障碍性贫血的临床疗效.方法:将40例慢性再生障碍性贫血患者随机分为观察组和对照组各20例,观察组给予环孢素A联合司坦唑醇片治疗,对照组给予十一酸睾酮治疗,比较2组患者的临床效果及用药后的不良反应.结果:观察组患者的总有效率为100%,对照组患者的总有效率为75%,观察组显著优于对照组,2组比较,差异具有统计学意义(P<0.05).结论:环孢素A联合司坦唑醇片治疗慢性再生障碍性贫血的临床效果明显优于十一酸睾酮治疗,且安全有效,无严重不良反应,值得临床推广应用.

  16. Aplastic crisis due to human parvovirus B19 infection in hereditary hemolytic anaemia Crise aplástica devido à infecção por parvovirus humano B19 em anemia hemolítica hereditária

    Directory of Open Access Journals (Sweden)

    R. C. N. Cubel

    1992-10-01

    Full Text Available Specific anti-B19 IgM was demonstrated in sera from three children showing transient aplastic crisis. A two years-old boy living in Rio de Janeiro suffering from sickle-cell anaemia showed the crisis during August, 1990. Two siblings living in Santa Maria, RS, developed aplastic crisis during May, 1991, when they were also diagnosed for hereditary spherocytosis. For a third child from this same family, who first developed aplastic crisis no IgM anti-B19 was detected in her sera.IgM específica anti-B19 foi demonstrada nos soros de três crianças apresentando aplasia transitória de medula. Um menino de dois anos de idade vivendo no Rio de Janeiro e sendo portador de anemia falciforme, apresentou a crise durante Agosto de 1990. Dois irmãos vivendo em Santa Maria - RS, desenvolveram crise de aplasia em Maio de 1991, quando foram também diagnosticados como portadores de microesferocitose. IgM anti-B19 não foi detectada no soro de uma terceira criança, desta mesma família, a qual primeiramente apresentou crise de aplasia.

  17. Immune Hemolytic Anemia in a Patient with Tuberculous Lymphadenitis

    OpenAIRE

    Manjunath Nandennavar; Sanju Cyriac; Krishnakumar; Sagar, T. G.

    2011-01-01

    Anemia in tuberculosis is usually anemia of chronic disease. Severe hemolytic anemia is exceedingly rare in tuberculosis patients. We report a patient diagnosed with tubercular lymphadenitis complicated by Coomb′s positive hemolytic anemia. Patient responded well to antituberculous treatment. Hematological parameters improved after initiation of antituberculosis treatment. To the best of our knowledge, this is the first case from India of an adult patient with tuberculous lymphadenitis presen...

  18. 有机磷农药与再生障碍性贫血发病关系的Meta分析%Meta-analysis of association between organophosphorus pesticides and aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    张骥; 杨土保

    2015-01-01

    目的 评价有机磷农药与再生障碍性贫血发病的关系,为一级预防提供科学依据.方法 检索1990年1月至2014年8月公开发表在中国生物医学文献数据库(CBM)、中国知网(CNKI)、PubMed和EMBASE关于有机磷农药与再生障碍性贫血发病关系的病例对照研究.制定纳入和排除标准,对符合纳入标准的文献进行质量评价,利用Review Manager 5.0软件计算有机磷农药的合并OR值及其95%CI,并对文献的研究人群和有机磷农药使用方式进行亚组分析.结果 最终共纳入9篇文献,5 833例研究对象,其中病例组1 404人,对照组4 429人.结果显示有机磷农药可增加再生障碍性贫血的发病风险(OR=1.97,95%CI:1.60~ 2.44).亚组分析显示亚洲人群再生障碍性贫血的发病风险(OR=2.01,95%CI:1.52~2.66)高于欧美人群(OR=1.93,95%CI:1.39 ~ 2.67);使用单一有机磷类农药(OR=2.15,95%CI:1.60 ~ 2.88)比使用有机磷类农药的混配制剂(OR=1.82,95%CI:1.34 ~ 2.47)更易引发再生障碍性贫血.结论 有机磷农药可能是再生障碍性贫血的危险因素.在日常生活和工农业生产中,减少有机磷农药的暴露,可以预防再生障碍性贫血的发生.%Objective To evaluate the association between organophosphorus pesticides and aplastic anemia,and provide scientific evidence for the primary prevention of aplastic anemia.Methods The published papers of case control studies on the association between organophosphorus pesticides and aplastic anemia from January 1990 to August 2014 were collected from Chinese BioMedical Literature Base (CBM),Chinese National Knowledge Infrastructure (CNKI),PubMed and EMBASE.The papers which met the inclusion criteria were evaluated.The pooled odds ratios (OR) and 95% confidence interval (CI) of organophosphorus pesticides were calculated with software Review Manager 5.0.Subgroup analysis were conducted for different population and different usage of organophosphorus

  19. Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.

    Science.gov (United States)

    Anur, P; Friedman, D N; Sklar, C; Oeffinger, K; Castiel, M; Kearney, J; Singh, B; Prockop, S E; Kernan, N A; Scaradavou, A; Kobos, R; Curran, K; Ruggiero, J; Zakak, N; O'Reilly, R J; Boulad, F

    2016-07-01

    Hematopoietic stem cell transplantation (HSCT) is curative for hematological manifestations of Fanconi anemia (FA). We performed a retrospective analysis of 22 patients with FA and aplastic anemia, myelodysplastic syndrome or acute myelogenous leukemia who underwent a HSCT at Memorial Sloan Kettering Cancer Center and survived at least 1 year post HSCT. Patients underwent either a TBI- (N=18) or busulfan- (N=4) based cytoreduction followed by T-cell-depleted transplants from alternative donors. Twenty patients were alive at time of the study with a 5- and 10-year overall survival of 100 and 84% and no evidence of chronic GvHD. Among the 18 patients receiving a TBI-based regimen, 11 (61%) had persistent hemochromatosis, 4 (22%) developed hypothyroidism, 7 (39%) had insulin resistance and 5 (27%) developed hypertriglyceridemia after transplant. Eleven of 16 evaluable patients (68%), receiving TBI, developed gonadal dysfunction. Two patients who received a TBI-based regimen died of squamous cell carcinoma. One patient developed hemochromatosis, hypothyroidism and gonadal dysfunction after busulfan-based cytoreduction. TBI appears to be a risk factor for malignant and endocrine late effects in the FA host. Multidisciplinary follow-up of patients with FA (including cancer screening) is essential for early detection and management of late complications, and improving long-term outcomes. PMID:26999465

  20. Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization.

    Science.gov (United States)

    Takahashi, Natsuko; Kameoka, Junichi; Takahashi, Naoto; Tamai, Yoshiko; Murai, Kazunori; Honma, Riko; Noji, Hideyoshi; Yokoyama, Hisayuki; Tomiya, Yasuo; Kato, Yuichi; Ishizawa, Kenichi; Ito, Shigeki; Ishida, Yoji; Sawada, Kenichi; Harigae, Hideo

    2016-09-01

    There have been no studies on the distribution of causes of macrocytic anemia with respect to mean corpuscular volume (MCV) cutoff values. We retrospectively investigated the causes of macrocytic anemia (MCV ≥100 fL) among 628 patients who visited the outpatient hematology clinic in Tohoku University Hospital. To ensure data validity, we also analyzed data from 307 patients in eight other hospitals in the Tohoku district. The leading causes of macrocytic anemia (number of patients, %) were myelodysplastic syndromes (121, 19.3 %), suspected bone marrow failure syndromes (BMF; 74, 11.8 %), aplastic anemia (51, 8.1 %), plasma cell dyscrasia (45, 7.2 %), and vitamin B12 deficiency (40, 6.4 %) in Tohoku University Hospital. We made three primary findings as follows. First, the most common cause of macrocytic anemia is BMF. Second, lymphoid and solid malignancies are also common causes of macrocytosis. Third, macrocytic anemia may be classified into three groups: Group 1 (megaloblastic anemia and medications), which can exceed MCV 130 fL; Group 2 (alcoholism/liver disease, BMF, myeloid malignancy, and hemolytic anemia), which can exceed MCV 114 fL; and Group 3 (lymphoid malignancy, chronic renal failure, hypothyroidism, and solid tumors), which does not exceed MCV 114 fL. These conclusions were supported by the results from eight other hospitals. PMID:27352093

  1. [Anemia treatment in peritoneal dialysis patients].

    Science.gov (United States)

    Janković, Nikola; Janković, Mateja

    2009-09-01

    Anemia is highly prevalent among chronic kidney disease (CKD) patients and patients receiving renal replacement therapy. In this paper we will outline the prevention and treatment of anemia in patients treated with peritoneal dialysis (PD). PD patients are less anemic and more sensitive to erythropoesis-stimulating agent (ESA) than their hemodialysis (HD) counterparts and, in general, dosages required for achieving similar hemoglobin levels to those achieved in HD patients are remarkably less. Before starting with ESA treatment we have to evaluate the degree of anemia and excluded other causes which are not connected with CKD and method of treatment. Patient's compliance is crucial for a successful therapy and it can be improved by decreasing frequency of administration of ESA. Since ESAare expensive, "cost-effectivnes" studies represent an important factor in choosing a distinct drug. Subcutaneous administration provides better long-term utilization of ESA in comparison to intravenous administration and is therefore preferred in PD patients. Intraperitoneal administration is not recommended due to poor bioavailability. In some patients we can observe the reduced response to ESA therapy. The definition of reduced response is generally regarded as a failure to achieve target hemoglobin concentration of >11 g/dL. Identification of underlying cause is not always easy but every attempt should be made to investigate every patient with resistance to therapy because some causes are easily corrected. Since 2005 particular ESA drugs have been approved by Croatian Institute for Health Insurance and registered for use in Croatia. For PD patients the ESAcan be prescribed by general practitioner. The list of available drugs is available in the official government newspaper Nardone novine No.27, March 2nd, 2009. PMID:20232548

  2. Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Treatment of Severe Aplastic Anemia%异基因造血干细胞移植治疗重型再生障碍性贫血的疗效研究

    Institute of Scientific and Technical Information of China (English)

    朱玲; 薛梅; 王志东; 闫洪敏; 刘静; 丁丽; 王恒湘

    2011-01-01

    Objective To explore the effectiveness of Allogeneic hematopoietic stem cell transplantation ( allo -HSCT ) in treating severe aplastic anemia ( SAA ).Methods Among the 8 patients, 1 patient received allogeneic peripheral stem cell transplantation from an HLA matched sibling, 4 patients received allogeneic bone marrow and peripheral stem cell transplantation from haploidentical donors ( parents ), 3 patients received unrelated allogeneic peripheral stem cell transplantation.Conditioning regimens included: fludarabine, Cyeclophosphamide, anti - themocyte globulin ( for unrelated and HLA matched sibling donors ); fludarabine, Cyeclophosphamide, busulphan and anti - lymphocyte globulin ( ALG ) /anti - themocyte globulin ( ATG ) ( for haploidentical donors ).For prevention of graft versus host disease ( GVHD ) the patient with HLA matched sibling donor was administered with a combination of immunosuppressive drugs including CSA, short - course MTX while for the patients with haploidentical or unrelated donors, MMF, anti - CD25 monoclonal antibody and ATG were, also employed.Results All the 8 patients achieved hematopoietic reconstitution after transplantation.It took 10 ~ 17 days ( : median: 12.5 days ) for the level of neutrophils to reach 0.5 × 10 /L and 9-25 days ( median: 13.8 days ) for platelets to reach 20 × 10 /L.All the 8 patients became donor chimerism.As for the complications, CMV - related sepsis was found in 5 cases, hemorrhagic cystitis in 3 cases, Grade Ⅰ ~ Ⅲ graf - versus - host disease ( GVHD ) and chronic local GVHD in 2 patients, and central nervous system infection accompanied with pure red aplastic anemia in 1 case.All the patients survived during the follow - up ( range: 9 ~ 38 months; median: 20 months).Conclusion Allo - HSCT is an effective approach for treating patients with SAA.It may be helpful to prolong the survivals of these patients.%目的 探讨异基因造血干细胞移植(allo-HSCT)治疗重型再生障

  3. Prevalence of Anemia in Renal Transplant Patients in Turkey

    Directory of Open Access Journals (Sweden)

    Alparslan MERDİN

    2014-05-01

    Full Text Available OBJECTIVE: Post-transplant anemia is a common complication in renal allograft recipients. The most common causes are impaired graft function, immunosuppressive drugs, and infections. The aim of our study was to further investigate the prevalence of anemia before and after renal transplantation in renal allograft recipients in Turkey. MATERIAL and METHODS: We assessed 464 patients who received a kidney transplant between the years 2010 and 2012. The prevalence of anemia was evaluated before transplantation and at the 3 rd and at 6th months after transplantation. Our study is a retrospective study. RESULTS: The prevalence of anemia at the 6th month after the transplant surgery was 28.8%. The percentage of the patients who did not have anemia prior to the transplant surgery, and who developed anemia after the transplantation was 24.4%. CONCLUSION: Our findings are similar to those found in the literature, and show that anemia is a very common entity after renal transplantation.

  4. ANEMIA IN HEMODIALYSIS PATIENTS: DIABETIC VS NON DIABETIC PATIENTS

    Directory of Open Access Journals (Sweden)

    SH SHAHIDI

    2002-12-01

    Full Text Available Introduction. One of the characteristic signs of uremic syndrome is anemia. One of major factors that affects on severity of anemia in ESRD is underlying diseas. The porpuse of this study is to compaire anemia between diabetic and non diabetic ESRD patients. Methods. In a case control study we compared the mean valuse of Hb, Het, MCV, MCH, MCHC, BUN, Cr and duration of dialysis between diabetic and nondiabetic patients on chronic hemodialyis. some variables (such as age, sex, use of erythropoietin, nonderolone decaonats, folic acid, ferrous sulfate, transfusion and blood loss in recent three months and acquired kidney cysts were matched between cases and controls. Results. Means of Hb were 9±1.3 and 8 ± 1.7 in diabetic and non diabetic patients (P<0.05. Mean corposcular volume in diabetic patients (91±3.1 fl was more higher than non diabetic ones (87.1 ± 8.9 (P < 0.05. Other indices had no differences between two groups (P > 0.05. Discussion. Severity of anemia in patients with diabetic nephropathy is milder that other patients with ESRD. So, Anemia as an indicator of chronocity of renal disease in diabetics is missleading.

  5. Aplastic Anemia & MDS International Foundation

    Science.gov (United States)

    ... Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany ... Island and McDonald Islands Honduras Hong ...

  6. Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology.

    Directory of Open Access Journals (Sweden)

    Zachary Gowanlock

    Full Text Available In many elderly patients with anemia, a specific cause cannot be identified. This study investigates whether erythropoietin levels are inappropriately low in these cases of "anemia of unknown etiology" and whether this trend persists after accounting for confounders.This study includes all anemic patients over 60 years old who had erythropoietin measured between 2005 and 2013 at a single center. Three independent reviewers used defined criteria to assign each patient's anemia to one of ten etiologies: chronic kidney disease, iron deficiency, chronic disease, confirmed myelodysplastic syndrome (MDS, suspected MDS, vitamin B12 deficiency, folate deficiency, anemia of unknown etiology, other etiology, or multifactorial etiology. Iron deficiency anemia served as the comparison group in all analyses. We used linear regression to model the relationship between erythropoietin and the presence of each etiology, sequentially adding terms to the model to account for the hemoglobin concentration, estimated glomerular filtration rate (eGFR and Charlson Comorbidity Index.A total of 570 patients met the inclusion criteria. Linear regression analysis showed that erythropoietin levels in chronic kidney disease, anemia of chronic disease and anemia of unknown etiology were lower by 48%, 46% and 27%, respectively, compared to iron deficiency anemia even after adjusting for hemoglobin, eGFR and comorbidities.We have shown that erythropoietin levels are inappropriately low in anemia of unknown etiology, even after adjusting for confounders. This suggests that decreased erythropoietin production may play a key role in the pathogenesis of anemia of unknown etiology.

  7. A Patient with Microcytic Anemia and Fever

    Directory of Open Access Journals (Sweden)

    Sacha Bhatia

    2006-01-01

    Full Text Available A 62-year-old man with a history of mechanical aortic valve insertion and ascending aorta replacement in 1997 presented to his family doctor in August 2004 with a two-week history of melena after recently returning from a six-month vacation in Mexico. The patient had no other abdominal complaints. He took warfarin but did not take nonsteroidal anti-inflammatory agents, acetylsalicylic acid or alcohol. The patient had no history of liver or peptic ulcer disease. He had lost 7 kg over the past month, but did not complain of fever or night sweats. On physical examination, vital signs were normal, the second heart sound was mechanical, and there were no abnormal findings. Laboratory investigations showed a borderline microcytic anemia (hemoglobin 76 g/L; mean corpuscular volume 79 fL; mean corpuscular hemoglobin concentration 323 g/L, a therapeutic international normalized ratio (2.6 and an elevated creatinine level (112 µmol/L. His stool was positive for occult blood, although the ferritin level was high (623 µg/L. Other routine blood work was normal. The patient was admitted to hospital for investigation of the anemia.

  8. Treatment for intractable anemia with the traditional Chinese medicines Hominis Placenta and Cervi Cornus Colla (deer antler glue

    Directory of Open Access Journals (Sweden)

    Yasuyo Hijikata

    2009-05-01

    Full Text Available Yasuyo Hijikata1, Takashi Kano2, Lu Xi31Toyodo Hijikata Clinic, Osaka, Japan; 2Kano Clinic, Osaka city, Osaka, Japan; 3Traditional Chinese Medicine Institute, Si-chuan Province, ChinaObjective: Intractable anemia, such as aplastic anemia or that presumably associated with chronic herpes virus infections, sometimes require bone marrow transplant. We investigated the use of traditional Chinese medicine (TCM for the treatment of intractable anemia. Method: Placenta Hominis (PH, steam boiled and roasted, and Cervi Cornus Colla (deer antler glue has been used in China for hundreds of years to treat anemia. After consent was obtained, we prescribed these two materials for a 74-year-old female with aplastic anemia and a 26-year-old male with presumably a virus-induced anemia. Concomitant conventional therapy was continued in both patients as prescribed by their respective attending physicians. Conclusion: Conventional therapy with steroid hormones, immunosuppressive drugs, platelet and erythrocyte transfusions were not effective in these patients. In addition, both patients suffered from serious side effects. In two patients, ingestion of Placenta Hominis and Cervi Cornus Colla with TCM prescriptions increased the platelet and enhanced the hemoglobin concentration in several months of therapy accompanied by a dramatic improvement in quality of life. The addition to conventional therapy of PH and Cervi Cornus Colla, the latter of which is very easy to obtain, may be one of the potentially advantageous choices in case of otherwise intractable anemia.Keywords: placenta, antler glue, Cervi Cornus Colla, anemia, aplastic anemia

  9. [Case report: hookworm infection in a patient with severe anemia].

    Science.gov (United States)

    Yilmaz, Hasan; Taş Cengiz, Zeynep; Ciçek, Mutalip; Dülger, Ahmet Cumhur

    2009-01-01

    In this study, a patient who was hospitalized with a severe anemia in the Internal Medicine Clinic of the Health Research and Application Hospital of Yüzüncü Yil University for one week is presented. The patient had fatigue, paleness and dizziness for one month and approximately 12 kg weight lost for four mounts previous to admission.. Severe iron deficiency anemia was diagnosed in the patient by laboratory analyses. Because there were no hematologic factors associated with severe anemia, the stool examination was also performed. In the Parasitology Laboratory, stool microscopy of the patient revealed numerous ova of hookworm. General condition of the patient well improved with anti-parasitic and anti-anemia treatment. It was concluded that patients with iron deficiency anemia diagnosed in health centers should be also examined for the intestinal parasitic diseases encountered rarely, and physicians should consider non-endemic parasitic diseases in their provinces.

  10. Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia

    Directory of Open Access Journals (Sweden)

    Gao C

    2014-04-01

    Full Text Available Chong Gao, Li Li, Baoan Chen, Huihui Song, Jian Cheng, Xiaoping Zhang, Yunyu SunDepartment of Hematology and Oncology, Key Department of Jiangsu Medicine, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People’s Republic of ChinaBackground: The purpose of this study was to evaluate the clinical outcomes of transfusion-associated iron overload in patients with chronic refractory anemia.Methods: Clinical manifestations, main organ function, results of computed tomography (CT, endocrine evaluation, and serum ferritin levels were analyzed retrospectively in 13 patients who were transfusion-dependent for more than 1 year (receiving >50 units of red blood cells to determine the degree of iron overload and efficacy of iron-chelating therapy.Results: Serum ferritin levels increased to 1,830–5,740 ng/mL in all patients. Ten patients had abnormal liver function. The CT Hounsfield units in the liver increased significantly in eleven patients, and were proportional to their serum ferritin levels. Skin pigmentation, liver dysfunction, and endocrine dysfunction were observed in nine patients with serum ferritin >3,500 ng/mL, eight of whom have since died. Interestingly, serum ferritin levels did not decrease significantly in nine transfusion-dependent patients who had received 15–60 days of iron-chelating therapy.Conclusion: Transfusion-dependent patients may progress to secondary iron overload with organ impairment, which may be fatal in those who are heavily iron-overloaded. The CT Hounsfield unit is a sensitive indicator of iron overload in the liver. Iron chelation therapy should be initiated when serum ferritin is >1,000 ng/mL and continued until it is <1,000 ng/mL in transfusional iron-overloaded patients.Keywords: anemia, aplastic, iron overload, myelodysplastic syndromes

  11. The significance of hematopoietic cell genetic instability in aplastic anemia%再生障碍性贫血骨髓造血细胞遗传不稳定性的意义

    Institute of Scientific and Technical Information of China (English)

    张丽红; 刘强; 储榆林; 张凤奎; 王慧君; 张莉; 周康; 杨栋林; 阎嶂松; 李洪强; 刘庆国; 齐军元

    2010-01-01

    目的 评价再生障碍性贫血(AA)患者骨髓造血细胞遗传不稳定性,探讨其对患者免疫抑制治疗(IST)的影响和在晚期克隆性血液学异常发生中的意义.方法 采用彗星试验检测AA患者骨髓造血细胞遗传不稳定性,分析其与反映骨髓造血衰竭参数的相关性,评价遗传不稳定对IST近期疗效的影响及IST对骨髓细胞遗传不稳定性的影响.结果 AA患者骨髓造血细胞彗星参数尾矩(TM)、Olive尾矩(OTM)、彗星细胞率(Comet%)均明显高于对照组(P值均0.05);比较Comet%0.05);IST治疗对SAA患者彗星参数无明显影响,获得部分治疗反应者Comet%、TM、OTM以及获得完全治疗反应者Comet%均较治疗前明显降低.2例SAA患者在发生克隆性细胞遗传学异常前彗星参数均明显增高.结论 遗传不稳定性增高与骨髓造血衰竭可能是AA同一病理生理机制导致的不同表现形式;治疗前造血细胞遗传不稳定性对SAA患者IST近期疗效无影响;IST可能减轻获得治疗反应者骨髓造血细胞遗传不稳定.%Objective To evaluate bone marrow hematopoietic cells genetic instability (BMHCGI) in patients with aplastic anemia(AA) and to explore its influence on immunosupressive therapy for AA and significance on late clonal hematologic disorders.Methods Genetic instability of bone marrow mononuclear cells (BMMNC) was measured by Comet assay.The relationship between bone marrow failure parameters and genetic instability results was evaluated.The reciprocity of genetic instability and treatment responses to im-munosuppressive therapy (IST) was investigated.Results Comet assay parameters [tail moment (TM) , ol-ive TM(OTM), comet % ] of AA patients were significantly higher than that of control group (P0.05).For the treatment response rate at six months after IST there was no statistical difference between comet cells of<21.64% and of ≥21.64% , and so did between OTM<1.58 and 1.58 in SAA patients.IST had no effect on SAA

  12. Hookworm Anemia in a Peritoneal Dialysis Patient in China.

    Science.gov (United States)

    Wu, Fuquan; Xu, Ying; Xia, Min; Ying, Guanghui; Shou, Zhangfei

    2016-06-01

    Hookworm infections as well as other intestinal nematodiases are endemic in China. In this case, a 70-year-old male showed symptoms of chest tightness, shortness of breath, and both lower extremities edema. The diagnostic result was chronic renal insufficiency, chronic kidney disease (5th stage), and renal anemia at first. Then, he received treatment with traditional drugs. However, this treatment did not help to alleviate the symptoms of the patient significantly. The results of gastroendoscopy showed hookworms in the duodenum, also confirmed by pathology examination. Anemia was markedly ameliorated after eliminating the parasites. The results mentioned above suggested that ancylostomiasis was the leading causes of anemia in this patient, and the etiology of anemia in uremic patients should be systematically considered. Especially when anemia could not be cured by regular treatments, rare diseases should be investigated. PMID:27417086

  13. An Etiologic Profile of Anemia in 405 Geriatric Patients

    Directory of Open Access Journals (Sweden)

    Tabea Geisel

    2014-01-01

    Full Text Available Background. Anemia is a common condition in the elderly and a significant risk factor for increased morbidity and mortality, reducing not only functional capacity and mobility but also quality of life. Currently, few data are available regarding anemia in hospitalized geriatric patients. Our retrospective study investigated epidemiology and causes of anemia in 405 hospitalized geriatric patients. Methods. Data analysis was performed using laboratory parameters determined during routine hospital admission procedures (hemoglobin, ferritin, transferrin saturation, C-reactive protein, vitamin B12, folic acid, and creatinine in addition to medical history and demographics. Results. Anemia affected approximately two-thirds of subjects. Of 386 patients with recorded hemoglobin values, 66.3% were anemic according to WHO criteria, mostly (85.1% in a mild form. Anemia was primarily due to iron deficiency (65%, frequently due to underlying chronic infection (62.1%, or of mixed etiology involving a combination of chronic disease and iron deficiency, with absolute iron deficiency playing a comparatively minor role. Conclusion. Greater awareness of anemia in the elderly is warranted due to its high prevalence and negative effect on outcomes, hospitalization duration, and mortality. Geriatric patients should be routinely screened for anemia and etiological causes of anemia individually assessed to allow timely initiation of appropriate therapy.

  14. Human parvovirus B19-induced aplastic crisis in an adult patient with hereditary spherocytosis: a case report and review of the literature

    OpenAIRE

    Kobayashi, Yujin; Hatta, Yoshihiro; Ishiwatari, Yusaku; Kanno, Hitoshi; Takei, Masami

    2014-01-01

    Background Although there are several case reports of human parvovirus B19 infection in patients with hereditary spherocytosis, no systematic reviews of adult patients with hereditary spherocytosis with human parvovirus B19 infection have been published as clinical case reports. In this study, we report a case of aplastic crisis due to human parvovirus B19 infection in an adult patient with hereditary spherocytosis. Case presentation A 33-year-old woman with hereditary spherocytosis and galls...

  15. Anemia

    Science.gov (United States)

    ... Physician October 01, 2002, http://www.aafp.org/afp/20021001/1217.html) Normocytic Anemia by JR Brill, ... Physician November 15, 2000, http://www.aafp.org/afp/20001115/2255.html) Written by familydoctor.org editorial ...

  16. Anemia and functional capacity in elderly Brazilian hospitalized patients.

    Science.gov (United States)

    Bosco, Raquel de Macedo; Assis, Elisa Priscila Souza; Pinheiro, Renata Rosseti; Queiroz, Luiza Cristina Viana de; Pereira, Leani S M; Antunes, Carlos Maurício Figueiredo

    2013-07-01

    This study evaluated the association between anemia and physical functional capacity in a cross-sectional population-based sample of 709 hospitalized elderly patients aged 60 years and over admitted to the Madre Teresa Hospital, Belo Horizonte, State of Minas Gerais, Brazil. The Mann-Whitney or "t" test, and chi-square or Fisher exact test were used for quantitative and categorical variables, respectively, and hierarchical binary logistic regression was used to identify significant predictors. The presence of anemia was found in 30% of participants and was significantly associated with decreased functionality according to the two measures which were used - ADL (activities of daily living) and IADL (instrumental activities of daily living). Anemia was also independently associated with older age. The results of this study demonstrate a strong association between the presence of anemia and lower levels of functional capacity. Further investigations are needed to assess the impact of anemia treatment on the functionality and independence of older people.

  17. Effectiveness and Safety of Astragalus Injection for Aplastic Anemia:A Systematic Review%黄芪注射液治疗再生障碍性贫血疗效和安全性的系统评价

    Institute of Scientific and Technical Information of China (English)

    晁荣; 席亚明; 靳蕊蕊

    2011-01-01

    目的 系统评价黄芪注射液+雄激素与雄激素单用比较治疗再生障碍性贫血(再障)的疗效和安全性.方法 计算机检索Cochrane Library(2011年第3期)、PubMed (1966 ~ 2011.3)、EMbase (1974 ~ 2011.3)、CNKI (1994 ~ 2011.3)、VIP (1989~2011.3)和万方(1997 ~ 2011.3)数据库等,按照纳入排除标准选择文献、提取资料和进行质量评价后,采用RevMan 5.0.24软件进行Meta分析.结果 共纳入7个随机对照试验,合计518例患者.Meta分析结果显示:黄芪注射液+雄激素治疗组的总有效率优于单用雄激素组,其差异有统计学意义[OR=3.12,95%CI (2.09,4.66),P<0.000 01];治疗组与对照组的骨髓增生升级程度相当,其差异无统计学意义[OR= 1.93,95%CI (0.85,4.38),P=0.11];治疗组的不良反应明显少于对照组,其差异亦有统计学意义[OR=0.30,95%CI (0.12,0.76),P=0.01].结论 黄芪注射液+雄激素治疗再障的有效率高于单用雄激素,且不良反应少.但由于纳入研究样本量小且质量较低,上述结论尚需更多高质量的研究来加以证实.%Objective To assess the clinical effectiveness and safety of astragalus injection plus androgen versus androgen alone for patients with aplastic anemia (AA). Methods Such databases as The Cochrane Library (Issue 3, 2011), PubMed (1966 to March 2011), Embase (1974 to March 2011), CNKI (1994 to March 2011), VIP (1989 to March 2011) and Wanfang Data (1997 to March 2011) were searched to include the randomized controlled trails (RCTs) according to the inclusive and exclusive criteria. The data were extracted, the quality was assessed, and meta-analysis was conducted by using Revman5.0.24 software. Results Seven RCTs involving 518 patients with AA were included. The meta-analysis showed that the astragalus plus androgen treatment group was superior to the androgen alone group in the total effective rate with significant difference (OR=3.12, 95%CI 2.09 to 4.66, P<0.000 01); the adverse events

  18. Stroke in a Patient with Sickle Cell Anemia

    OpenAIRE

    Caridade, S; Machado, A.; Ferreira, C.

    2007-01-01

    Stroke in patients with sickle cell anemia is multifactorial but occurs mainly by 2 mechanisms: occlusive arteriopathy and obliteration of small vessels with plugs of sickle cells. The high individual risk can be assessed by simple and well-defined strategies such as ultrasounds with transcranial and cervical Doppler Ultrasonography. The authors report the clinical case of a 25 year-old black female patient with sickle cell anemia, who was admitted with right hemiparesis. Cerebral MRI sho...

  19. Aplastic anaemia with microfilaria in marrow aspirate

    OpenAIRE

    Narender Tejwnai; Seema Tyagi; Jasmita Dass

    2012-01-01

    Wuchereria bancrofti is endemic in many parts of of south east asia including india. The parasite is reported previously in many aspirate cytology smears, however its rare to find this parasite in bone marrow aspirate smear and even rare is it association with aplastic anemia. We report here a case presenting with symptoms related to bone marrow failure and incidentally detected to have microfilaria of Wuchereria bancrofti. The case is reported because of this rare association.<...

  20. Aplastic anaemia with microfilaria in marrow aspirate

    OpenAIRE

    Narender Tejwnai; Seema Tyagi; Jasmita Dass

    2012-01-01

    Wuchereria bancrofti is endemic in many parts of of south east asia including india. The parasite is reported previously in many aspirate cytology smears, however its rare to find this parasite in bone marrow aspirate smear and even rare is it association with aplastic anemia. We report here a case presenting with symptoms related to bone marrow failure and incidentally detected to have microfilaria of Wuchereria bancrofti. The case is reported because of this rare association.

  1. Iron deficiency anemia: online methods of patient education

    Directory of Open Access Journals (Sweden)

    Doiniţa Crişan

    2011-06-01

    Full Text Available The authors present some of the most important online patient education methods in English on iron deficiency anemia (easy-to-read articles, information leaflets, easy-to-understand fact sheets, newsletters, patient page, glossaries, frequently asked questions, quizzes, forums, blogs, and patient stories.

  2. 含盐酸二甲双胍联合方案治疗再生障碍性贫血的短期疗效观察%Observations on the short-term therapeutic effects of combined therapy with metformin hydrochloride for aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    卢学春; 李松威; 脱帅; 张峰; 脱朝伟; 姚善谦; 范利; 杨波; 迟小华; 蔡力力; 于睿莉; 刘洋; 刘丽宏; 李炳军; 吴晓雄

    2012-01-01

    目的 采用临床生物信息学方法筛选治疗再生障碍性贫血(AA)的新型药物并评估其临床疗效.方法 首先建立AA的人类全基因组表达谱,与药物基因组学数据库进行相似性分析,筛选可能有效的药物.纳入难治性AA患者[接受过免疫抑制剂和(或)雄激素治疗时间超过6个月无效]作为研究对象评估疗效,6个月后评估临床疗效和不良反应.结果 临床生物信息学筛选结果显示盐酸二甲双胍可能对AA有治疗作用.纳入43例难治性AA患者(其中15例为重型AA),采用包含盐酸二甲双胍、环孢素A(CsA)和司坦唑醇的联合方案进行治疗,结果显示:27例输血依赖患者在治疗6个月后全部(100%)停止输血;40例贫血患者中,37例(92.5%)血红蛋白完全恢复正常;30例血小板低于20×109/L的患者中,28例(93.3%)升至50×109/L以上;35例白细胞低于2.5×109/L的患者中,31例(88.6%)升至3.5×109/L以上.40例贫血患者中,1例出现肾功能异常,停用环孢素A后恢复正常;18例出现转氨酶升高,加用保肝药物并减少司坦唑醇用量后恢复正常.所有患者均未出现低血糖反应.结论 盐酸二甲双胍、环孢素A和司坦唑醇联合方案治疗难治性AA有效.%Objective This paper aims to screen and select new drugs with potential in the treatment of aplastic anemia, and to evaluate their clinical efficacy through clinical bioinformatics methods. Methods First, we established genome expression profiles of aplastic anemia (AA) patients, and conducted similarity analyses with the pharmacogenomics database to screen and select drugs with possible efficacy. Intractable AA patients who received immunosuppressors and/or androgen for more than six months showing no clinical efficacy were included for the study to evaluate therapeutic effects of the therapeutic regime for thestudy. Clinical efficacy and adverse effects were evaluated after six months. Results The clinical bioinformatics

  3. 父母供者外周血单倍体移植治疗儿童难治性重型再生障碍性贫血%Parental haploidentical peripheral blood stem cell transplantation for treatment of children with refractory severe aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    万鼎铭; 陈晓娜; 曹伟杰; 邢海洲; 何海燕; 柳飞; 陈诗彧; 庞雨晴

    2015-01-01

    BACKGROUND:For pediatric patients with aplastic anemia in China, it is difficult to find human leucocyte antigen-matched sibling donors that are mostly replaced by parental donors. OBJECTIVE:To retrospectively analyze the clinical efficacy and safety of parental haploidentical peripheral blood hematopoietic stem cel transplantation in children with relapsed and refractory severe aplastic anemia. METHODS:Seventeen children with relapsed and refractory severe aplastic anemia who had no matched sibling or unrelated donor and failed to respond to immunosuppressive therapy were subjected to parental haploidentical peripheral blood hematopoietic stem cel transplantation. A conditioning regimen of fludarabine+cyclophosphamide+rabbit anti-human thymocyte immunoglobulin antibody and the triple therapy of methotrexate, cyclosporine A and mycophenolate mofetil were applied to prevent graft-versus-host disease. RESULTS AND CONCLUSION: (1) Of the 17 children, 16 cases (94%) reached hematopoietic reconstitution, and the median time of neutrophils≥ 0.5×109/L and platelets≥ 20×109/L was 13 (11-15) days and 17 (12-28) days, respectively. (2) Incidence of acute graft-versus-host disease was 47% (8 of 17 cases), including 29% (5/17) of grades I-II and 18% (3/17) of grades III-IV. Incidence of chronic graft-versus-host disease was 41% (7/17). (3) With a median folow-up duration of 268 (43-753) days, the overal survival rate was 70.6% (12/17). Five dead cases (29%) belonged to transplantation-related death, including one case of fungal skin infections, one case of graft-versus-host disease, three cases of severe lung infection. No relapse case was reported. These findings indicate that if there are no matched sibling or unrelated donors and the immunosuppression effect is poor, parental haploidentical peripheral blood hematopoietic stem cel transplantation is a safe and effective salvage treatment for children with relapsed and refractory severe aplastic anemia.%移

  4. Treatment of Anemia in Patients with Heart Disease: A Clinical Practice Guideline

    Science.gov (United States)

    ... of Internal Medicine Summaries for Patients Treatment of Anemia in Patients With Heart Disease: A Clinical Practice ... Physicians The full report is titled “Treatment of Anemia in Patients With Heart Disease: A Clinical Practice ...

  5. Anemia and Blood Transfusions in Critically Ill Patients

    Directory of Open Access Journals (Sweden)

    M. Kamran Athar

    2012-01-01

    Full Text Available Anemia is common in critically ill patients. As a consequence packed red blood cell (PRBC transfusions are frequent in the critically ill. Over the past two decades a growing body of literature has emerged, linking PRBC transfusion to infections, immunosuppression, organ dysfunction, and a higher mortality rate. However, despite growing evidence that risk of PRBC transfusion outweighs its benefit, significant numbers of critically ill patients still receive PRBC transfusion during their intensive care unit (ICU stay. In this paper, we summarize the current literature concerning the impact of anemia on outcomes in critically ill patients and the potential complications of PRBC transfusions.

  6. 复方雷公藤颗粒对再障小鼠骨髓T细胞亚群的影响%Effect of Compound Tripterygium Granule on Bone Marrow T Cell Subsets in Mice Aplastic Anemia Model

    Institute of Scientific and Technical Information of China (English)

    邢海燕; 胡春萍; 蔡雪婷; 胡灿红; 霍介格; 曹鹏; 王志刚

    2012-01-01

    目的:观察复方雷公藤颗粒对再生障碍性贫血(简称再障)小鼠的疗效及对骨髓CD4+,CD8+,CD4+/CD8+T淋巴细胞表达的影响.方法:建立再障小鼠模型,分为5组,正常组及模型组小鼠(给予同体积的生理盐水ig),复方雷公藤低、高剂量组(分别为生药10.63,13.29 g·kg-1,ig)、十一酸睾酮(22 mg·kg-1,ig),连续给药35 d,取骨髓单个核细胞培养24 h后,流式细胞术检测CD4+,CD8+,CD4 +/CD8+T淋巴细胞的表达水平.结果:模型组CD4+,CD8+,CD4 +/CD8+各指标均较正常组下降,其中CD4+,CD4 +/CD8+T淋巴细胞明显低于正常组(P<0.05);十一酸睾酮组与模型组相比,CD4+,CD8+均有所下降,但CD4 +/CD8+T细胞较之上升,但统计学均无明显差异,复方雷公藤颗粒低、高剂量组与模型组相比,CD4+,CD8+,CD4+/CD8+均升高,其中CD4+,CD4+/CD8+升高有统计学意义(P<0.05),与十一酸睾酮组相比差异有统计学意义(P<0.05).结论:复方雷公藤颗粒能调节骨髓T细胞的异常状态,恢复T细胞及其亚群之间的平衡,促进骨髓造血功能的恢复.%Objective: To observe the effect of Tripterygium granule on expression of bone marrow CD4+/CD8 + T-lymphocytes in mice aplastic anemia model. Method: A mouse model of aplastic anemia was established and divided into five groups, normal group and model group ( fed with normal saline) , compound Tripterygium granule group (10.63, 13.29 g·kg-1, ig) , testosterone undecanoate group (22 mg·kg-1, ig). After continuous administration of 35 d, bone marrow mononuclear cells were separated and cultured for 24 h. Expression levels of CD4 + , CD8 + , CD4 + /CD8 + T cells were analyzed by flow cytometry. Result: Compared with the normal group, amount of CD4 + , CD8 + , CD4 + /CD8 + T cells was decreased in model group, which of CD4 + , CD4 + /CD8 + T cells were significantly lower than the normal group ( P < 0. 05 ) , CD4 + and CD8 + were decreased, while CD4+ /CD8+ was increased in testosterone undecanoate

  7. Iron deficiency anemia in patients with inflammatory bowel disease

    Directory of Open Access Journals (Sweden)

    Goldberg ND

    2013-06-01

    Full Text Available Neil D Goldberg Emeritus Chief of Gastroenterology, University of Maryland St. Joseph Medical Center, Towson, MD, USA Abstract: Iron deficiency anemia is the most common form of anemia worldwide, caused by poor iron intake, chronic blood loss, or impaired absorption. Patients with inflammatory bowel disease (IBD are increasingly likely to have iron deficiency anemia, with an estimated prevalence of 36%–76%. Detection of iron deficiency is problematic as outward signs and symptoms are not always present. Iron deficiency can have a significant impact on a patient's quality of life, necessitating prompt management and treatment. Effective treatment includes identifying and treating the underlying cause and initiating iron replacement therapy with either oral or intravenous iron. Numerous formulations for oral iron are available, with ferrous fumarate, sulfate, and gluconate being the most commonly prescribed. Available intravenous formulations include iron dextran, iron sucrose, ferric gluconate, and ferumoxytol. Low-molecular weight iron dextran and iron sucrose have been shown to be safe, efficacious, and effective in a host of gastrointestinal disorders. Ferumoxytol is the newest US Food and Drug Administration-approved intravenous iron therapy, indicated for iron deficiency anemia in adults with chronic kidney disease. Ferumoxytol is also being investigated in Phase 3 studies for the treatment of iron deficiency anemia in patients without chronic kidney disease, including subgroups with IBD. A review of the efficacy and safety of iron replacement in IBD, therapeutic considerations, and recommendations for the practicing gastroenterologist are presented. Keywords: anemia, inflammatory bowel disease, intravenous iron, iron deficiency, oral iron, therapy

  8. Cytogenetic profile of aplastic anaemia in Indian children

    Directory of Open Access Journals (Sweden)

    Vineeta Gupta

    2013-01-01

    Interpretation & conclusions: Five (11.9% patients with acquired aplastic anaemia had chromosomal abnormalities. Trisomy was found to be the commonest abnormality. Cytogenetic abnormalities may be significant in acquired aplastic anaemia although further studies on a large sample are required to confirm the findings.

  9. Anemia and functional capacity in elderly Brazilian hospitalized patients

    Directory of Open Access Journals (Sweden)

    Raquel de Macedo Bosco

    2013-07-01

    Full Text Available This study evaluated the association between anemia and physical functional capacity in a cross-sectional population-based sample of 709 hospitalized elderly patients aged 60 years and over admitted to the Madre Teresa Hospital, Belo Horizonte, State of Minas Gerais, Brazil. The Mann-Whitney or "t" test, and chi-square or Fisher exact test were used for quantitative and categorical variables, respectively, and hierarchical binary logistic regression was used to identify significant predictors. The presence of anemia was found in 30% of participants and was significantly associated with decreased functionality according to the two measures which were used - ADL (activities of daily living and IADL (instrumental activities of daily living. Anemia was also independently associated with older age. The results of this study demonstrate a strong association between the presence of anemia and lower levels of functional capacity. Further investigations are needed to assess the impact of anemia treatment on the functionality and independence of older people.

  10. Estimation of serum concentration of parvovirus B19 DNA by PCR in patients with chronic anemia

    DEFF Research Database (Denmark)

    Hornsleth, A.; Carlsen, K. M.; Christensen, Laurids Siig;

    1994-01-01

    Parvovirus B19 DNA was detected in serum samples from 10 out of 42 patients with chronic anaemia, the majority of whom suffered from aplastic anaemia, haemolytic anaemia, pure red cell anaemia or myelodysplastic syndrome. Nested PCR methods with sensitivities of 0.005-0.05 fg DNA were developed...

  11. Prevalence of anemia in predialysis chronic kidney disease patients

    Directory of Open Access Journals (Sweden)

    FAM Shaheen

    2011-01-01

    Full Text Available To evaluate the prevalence of anemia in a large cohort that comprises patients in different stages of chronic kidney disease (CKD in the kingdom of Saudi Arabia (KSA, we conducted a multi-center cross-sectional study of a cohort of CKD patients who have not started dialysis. The study patients were recruited from the nephrology clinics in 11 different medical centers distributed all over the regions of the KSA. For the estimated glomerular filtration rate (GFR, we used the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI equation. There were 250 study patients who fulfilled the criteria for the study. The patients were stratified according to their GFR as follows: stage 1: 19 patients, stage 2: 35 patients, stage 3: 67 patients, stage 4: 68 patients, and stage 5: 61 patients. The composite of proteinuria and abnormal imaging in stages 1 and 2 was satisfied in 100% of the cases. The prevalence of anemia was elevated for the hemoglobin levels below 12 g/dL (the level at which the evaluation of anemia in CKD should be initiated in the different stages of CKD, that is, 42%, 33%, 48%, 71%, and 82% in the stages from 1 to 5, respectively. The prevalence was also elevated for the hemoglobin levels below 11 g/dL (the minimum hemoglobin level at which therapy should be initiated with erythropoietin, that is, 21%, 17%, 31%, 49%, and 72%, respectively for stages from 1 to 5. In conclusion, we found a large prevalence of anemia among the CKD population in Saudi Arabia, and the burden of patients who require treatment with erythropoietin is considerably large. However, the response to therapy will not require large doses according to the availability of long-acting erythropoiesis stimulating agents, which will render the therapy more convenient and less expensive.

  12. 68例儿童重型再生障碍性贫血强化免疫抑制治疗的疗效分析%Clinical Analysis of the Efficacy of Intensive Immunosuppressive Therapy in 68 Children With Severe Aplastic Anemia

    Institute of Scientific and Technical Information of China (English)

    陈纯; 李迎飞; 方建培; 薛红漫; 周敦华; 黄科; 徐宏贵; 郭海霞; 黄绍良

    2009-01-01

    IST亚组及其无反应IST亚组患儿治疗6个月后,有效率分别为76.9%(10/13)和45.6%(5/11),两亚组比较,差异有显著意义(P<0 05).G-CSF反应IST亚组患儿总有效率(92.3%,12 /13)较无反应IST亚组(54.5%,6/11)高,且差异有显著意义(P<0.05).结论 强化免疫抑制治疗重型再生障碍性贫血的疗效明显优于单用环孢菌素A. 强化免疫抑制治疗前,对粒细胞集落刺激因子有反应的患儿,强化免疫抑制治疗的预后相对较好.%children with severe aplastic anemia is better than that of cyclosporine A therapy only. Children with severe aplastic anemia who responded well to granulocyte colony stimulating factor had a better prognosis in the intensive immunosuppressive therapy.

  13. Individualized model discovery: the case of anemia patients.

    Science.gov (United States)

    Akabua, Elom; Inanc, Tamer; Gaweda, Adam; Brier, Michael E; Kim, Seongho; Zurada, Jacek M

    2015-01-01

    The universal sequel to chronic kidney condition (CKD) is anemia. Patients of anemia have kidneys that are incapable of performing certain basic functions such as sensing of oxygen levels to secrete erythropoietin when red blood cell counts are low. Under such conditions, external administration of human recombinant erythropoietin (EPO) is administered as alternative to improve conditions of CKD patients by increasing their hemoglobin (Hb) levels to a given therapeutic range. Presently, EPO dosing strategies extensively depend on packet inserts and on "average" responses to the medication from previous patients. Clearly dosage strategies based on these approaches are, at best, nonoptimal to EPO medication and potentially dangerous to patients that do not adhere to the notion of expected "average" response. In this work, a technique called semi-blind robust identification is provided to uniquely identify models of the individual patients of anemia based on their actual Hb responses and EPO administration. Using the a priori information and the measured input-output data of the individual patients, the procedure identifies a unique model consisting of a nominal model and the associated model uncertainty for the patients. By incorporating the effects of unknown system initial conditions, considerably small measurement samples can be used in the modeling process. PMID:25459523

  14. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease

    DEFF Research Database (Denmark)

    Evstatiev, Rayko; Alexeeva, Olga; Bokemeyer, Bernd;

    2013-01-01

    Iron-deficiency anemia is the most common systemic complication of inflammatory bowel diseases (IBD). Iron-deficiency anemia recurs frequently and rapidly after iron-replacement therapy in patients with IBD. We performed a randomized, placebo-controlled trial to determine if administration...... of ferric carboxymaltose (FCM) prevents anemia in patients with IBD and low levels of serum ferritin....

  15. Enhanced eryptosis contributes to anemia in lung cancer patients

    Science.gov (United States)

    Bissinger, Rosi; Schumacher, Carla; Qadri, Syed M.; Honisch, Sabina; Malik, Abaid; Götz, Friedrich; Kopp, Hans-Georg; Lang, Florian

    2016-01-01

    Objectives Anemia is a common complication of malignancy, which could result from either compromised erythropoiesis or decreased lifespan of circulating erythrocytes. Premature suicidal erythrocyte death, characterized by cell shrinkage and phosphatidylserine (PS) externalization, decreases erythrocyte lifespan and could thus cause anemia. Here, we explored whether accelerated eryptosis participates in the pathophysiology of anemia associated with lung cancer (LC) and its treatment. Methods Erythrocytes were drawn from healthy volunteers and LC patients with and without cytostatic treatment. PS exposure (annexin V-binding), cell volume (forward scatter), cytosolic Ca2+ (Fluo3 fluorescence), reactive oxygen species (ROS) production (DCFDA fluorescence) and ceramide formation (anti-ceramide antibody) were determined by flow cytometry. Results Hemoglobin concentration and hematocrit were significantly lower in LC patients as compared to healthy controls, even though reticulocyte number was higher in LC (3.0±0.6%) than in controls (1.4±0.2%). The percentage of PS-exposing erythrocytes was significantly higher in LC patients with (1.4±0.1%) and without (1.2±0.3%) cytostatic treatment as compared to healthy controls (0.6±0.1%). Erythrocyte ROS production and ceramide abundance, but not Fluo3 fluorescence, were significantly higher in freshly drawn erythrocytes from LC patients than in freshly drawn erythrocytes from healthy controls. PS exposure of erythrocytes drawn from healthy volunteers was significantly more pronounced following incubation in plasma from LC patients than following incubation in plasma from healthy controls. Conclusion Anemia in LC patients with and without cytostatic treatment is paralleled by increased eryptosis, which is triggered, at least in part, by increased oxidative stress and ceramide formation. PMID:26872376

  16. Anemia and mortality in heart failure patients - A systematic review and meta-analysis

    NARCIS (Netherlands)

    Groenveld, Hessel F.; Januzzi, James L.; Damman, Kevin; van Wijngaarden, Jan; Hillege, Hans L.; van Veldhuisen, Dirk J.; van der Meer, Peter

    2008-01-01

    Objectives The aim of this study was to assess the effect of anemia on mortality in chronic heart failure (CHF). Background Anemia is frequently observed in patients with CHF, and evidence suggests that anemia might be associated with an increased mortality. Methods A systematic literature search in

  17. Study on the therapeutic effects of 2SZAPXRO on aplastic anemia in a mouse model induced by busulfan%2SZA PXRO治疗小鼠经白消安诱导的再生障碍性贫血模型的效果评价

    Institute of Scientific and Technical Information of China (English)

    易翠林; 郝苗; 韩丽丽; 王玉林

    2015-01-01

    2SZAPXRO是一种以海参、牡蛎及枸杞为原料,应用细胞平衡液(BalanCell)技术制备的复合提取液,富含海参黏多糖、海参皂苷、多肽、氨基酸、牛磺酸、多种微量元素和维生素等多种生物活性成分。从中医学角度,该提取液具有补肾益精、滋阴养血的功效。用白消安诱导小鼠,建立再生障碍性贫血动物模型。对再生障碍性贫血小鼠进行口服2SZAPXRO给药治疗,同时设立正常小鼠对照组(未经白消安造模)和无药物治疗组(对白消安造模小鼠不进行2SZAPXRO给药治疗)。结果表明:2SZAPXRO复合提取液对小鼠再生障碍性贫血具有显著的治疗效果。%2SZAPXRO is an elaborate extraction of sea cucumber ,oyster and Chinese wolfberry by the technique of “BalanCell” ,with various enriched biologically active components ,including mucopoly-saccharides ,polypeptide ,amino acid ,taurine and diverse trace elements and vitamins .From the view of TCM theory ,2SZAPXRO should be of kidney tonifying and blood replenishing . In this study ,aplastic anemia was established in mice by administration of busulfan for the in vivo effect e-valuation of 2SZAPXRO on aplastic anemia ,which was administered to mice orally .Meanwhile , normal control group and non-therapeutic group were set .The results indicated that 2SZAPXRO ex-hibits excellent in v ivo effects on aplastic anemia in a mouse model .

  18. 基于文本挖掘技术分析西药和中成药治疗再生障碍性贫血的规律%Rules of treating aplastic anemia with Western medicines and Chinese patent medicines based on text mining technique

    Institute of Scientific and Technical Information of China (English)

    郭洪涛; 吕爱平; 张志华; 郑光; 姜淼

    2012-01-01

    Objective To explore the rules of treating aplastic anemia with Western medicines and Chinese patent medicines by applying text mining technique. Methods The relevant literature about treating aplastic anemia were collected from Chinese Medical Current Contents ( CMCC) and a Access database was established. The data were treated with SQL platform and the administration rules of Western medicines and Chinese patent medicines were analyzed combining artificial noise reduction. Results Stanozolol, cyclosporin A, antithymocyte globulin ( ATG ) , cyclophosphamide and antilymphocyte globulin (ALG) were Western medications with high-frequency in the literature, and Fufang Zaofan Wan and Zaizhang Shengxue Pian were Chinese patent medicines with high-frequency. Conclusion The frequency in literature reports showed the administration rules of Western medicines and Chinese patent medicines in the treatment of aplastic anemia by applying text mining technique. The integrative administration of Western medicines and Chinese patent medicines is worth studying further.%目的 利用文本挖掘技术探索西药、中成药治疗再生障碍性贫血的规律.方法 在中国生物医学文献数据库中收集治疗再生障碍性贫血的相关文献,建立Access数据库,运用SQL数据平台处理数据,并结合人工降噪,分析西药、中成药的用药规律.结果 司坦唑醇、环孢素A、抗胸腺细胞球蛋白、环磷酰胺、抗淋巴细胞球蛋白等为文献中出现的高频西药,复方皂矾丸、再障生血片等为文献中出现的高频中成药.结论 利用文本挖掘的方法,从文献报告频数方面呈现了西药、中成药治疗再生障碍性贫血的用药规律,尤其是西药、中成药联合应用还值得进一步研究.

  19. Study on the therapeutic effects of 2SZAPXRO on aplastic anemia in a mouse model induced by busulfan%2SZA PXRO治疗小鼠经白消安诱导的再生障碍性贫血模型的效果评价

    Institute of Scientific and Technical Information of China (English)

    易翠林; 郝苗; 韩丽丽; 王玉林

    2015-01-01

    2SZAPXRO is an elaborate extraction of sea cucumber ,oyster and Chinese wolfberry by the technique of “BalanCell” ,with various enriched biologically active components ,including mucopoly-saccharides ,polypeptide ,amino acid ,taurine and diverse trace elements and vitamins .From the view of TCM theory ,2SZAPXRO should be of kidney tonifying and blood replenishing . In this study ,aplastic anemia was established in mice by administration of busulfan for the in vivo effect e-valuation of 2SZAPXRO on aplastic anemia ,which was administered to mice orally .Meanwhile , normal control group and non-therapeutic group were set .The results indicated that 2SZAPXRO ex-hibits excellent in v ivo effects on aplastic anemia in a mouse model .%2SZAPXRO是一种以海参、牡蛎及枸杞为原料,应用细胞平衡液(BalanCell)技术制备的复合提取液,富含海参黏多糖、海参皂苷、多肽、氨基酸、牛磺酸、多种微量元素和维生素等多种生物活性成分。从中医学角度,该提取液具有补肾益精、滋阴养血的功效。用白消安诱导小鼠,建立再生障碍性贫血动物模型。对再生障碍性贫血小鼠进行口服2SZAPXRO给药治疗,同时设立正常小鼠对照组(未经白消安造模)和无药物治疗组(对白消安造模小鼠不进行2SZAPXRO给药治疗)。结果表明:2SZAPXRO复合提取液对小鼠再生障碍性贫血具有显著的治疗效果。

  20. The 1957 MRC report on leukaemia and aplastic anaemia in patients irradiated for ankylosing spondylitis

    Energy Technology Data Exchange (ETDEWEB)

    Smith, Peter G [London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT (United Kingdom)

    2007-12-15

    The estimation of the carcinogenic effects of exposure to low doses of ionizing radiation has depended primarily on extrapolation from effects seen in two populations exposed to relatively high doses-the survivors of the atomic bomb explosions in Japan and patients treated in the UK with x-rays for the arthritic condition ankylosing spondylitis. The study of the leukaemia risk in over 14000 irradiated spondylitis patients was completed in an astonishingly short period of time in the mid-1950s. The full report of the original study has been difficult to access because it was not published in a journal but only as a Special Report of the UK Medical Research Council. To mark 50 years since this publication this full report is reproduced in this issue of the Journal. This accompanying review describes the background to the study, the principal findings and the further follow-up of the population that documented the risks of cancers in addition to leukaemia associated with the x-ray treatment. The architects of the study were a radiobiologist, Michael Court-Brown, and an epidemiologist, Richard Doll. Their very productive study of the leukaemia risk among spondylitics spawned a lifelong collaboration including further seminal studies of the carcinogenic effects of radiation exposure, which are also summarised in the review. (review)

  1. The 1957 MRC report on leukaemia and aplastic anaemia in patients irradiated for ankylosing spondylitis

    International Nuclear Information System (INIS)

    The estimation of the carcinogenic effects of exposure to low doses of ionizing radiation has depended primarily on extrapolation from effects seen in two populations exposed to relatively high doses-the survivors of the atomic bomb explosions in Japan and patients treated in the UK with x-rays for the arthritic condition ankylosing spondylitis. The study of the leukaemia risk in over 14000 irradiated spondylitis patients was completed in an astonishingly short period of time in the mid-1950s. The full report of the original study has been difficult to access because it was not published in a journal but only as a Special Report of the UK Medical Research Council. To mark 50 years since this publication this full report is reproduced in this issue of the Journal. This accompanying review describes the background to the study, the principal findings and the further follow-up of the population that documented the risks of cancers in addition to leukaemia associated with the x-ray treatment. The architects of the study were a radiobiologist, Michael Court-Brown, and an epidemiologist, Richard Doll. Their very productive study of the leukaemia risk among spondylitics spawned a lifelong collaboration including further seminal studies of the carcinogenic effects of radiation exposure, which are also summarised in the review. (review)

  2. About hematopoietic properties of peripheral blood lymphocytes RNA from patients with polycythemia vera and healthy donors

    Directory of Open Access Journals (Sweden)

    A. G. Babaeva

    2015-06-01

    Full Text Available Total RNA isolated from peripheral blood lymphocytes of donor and patient with polycythemia, stimulates hematopoiesis in rats with toxic aplastic anemia due to benzene administration. Total RNA of lymphocytes from polycythemia patient has a more pronounced effect on the erythroid, myeloid and megakaryocytic hematopoiesis comparing to total RNA from donor lymphocytes. The greatest stimulatory effectof RNA observed after 21 days from the start of experiment. Total RNA of lymphocytes from polycythemia patient largely activates erythropoiesis promoting restoration of reticulocyte count in animals with aplastic anemia.

  3. About hematopoietic properties of peripheral blood lymphocytes RNA from patients with polycythemia vera and healthy donors

    Directory of Open Access Journals (Sweden)

    A. G. Babaeva

    2015-01-01

    Full Text Available Total RNA isolated from peripheral blood lymphocytes of donor and patient with polycythemia, stimulates hematopoiesis in rats with toxic aplastic anemia due to benzene administration. Total RNA of lymphocytes from polycythemia patient has a more pronounced effect on the erythroid, myeloid and megakaryocytic hematopoiesis comparing to total RNA from donor lymphocytes. The greatest stimulatory effectof RNA observed after 21 days from the start of experiment. Total RNA of lymphocytes from polycythemia patient largely activates erythropoiesis promoting restoration of reticulocyte count in animals with aplastic anemia.

  4. Anesthesia for a patient with Fanconi anemia for developmental dislocation of the hip: a case report

    Directory of Open Access Journals (Sweden)

    Zafer Dogan

    2014-06-01

    Full Text Available Fanconi anemia is a rare autosomal recessive inherited bone marrow failure syndrome with congenital and hematological abnormalities. Literature regarding the anesthetic management in these patients is limited. A management of a developmental dislocation of the hip was described in a patient with fanconi anemia. Because of the heterogeneous nature, a patient with fanconi anemia should be established thorough preoperative evaluation in order to diagnose on clinical features. In conclusion, we preferred caudal anesthesia in this patient with fanconi anemia without thrombocytopenia, because of avoiding from N2O, reducing amount of anesthetic, existing microcephaly, hypothyroidism and elevated liver enzymes, providing postoperative analgesia, and reducing amount of analgesic used postoperatively.

  5. Mouse models of Fanconi anemia

    Energy Technology Data Exchange (ETDEWEB)

    Parmar, Kalindi; D' Andrea, Alan [Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115 (United States); Niedernhofer, Laura J., E-mail: niedernhoferl@upmc.edu [Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine and Cancer Institute, 5117 Centre Avenue, Hillman Cancer Center, Research Pavilion 2.6, Pittsburgh, PA 15213-1863 (United States)

    2009-07-31

    Fanconi anemia is a rare inherited disease characterized by congenital anomalies, growth retardation, aplastic anemia and an increased risk of acute myeloid leukemia and squamous cell carcinomas. The disease is caused by mutation in genes encoding proteins required for the Fanconi anemia pathway, a response mechanism to replicative stress, including that caused by genotoxins that cause DNA interstrand crosslinks. Defects in the Fanconi anemia pathway lead to genomic instability and apoptosis of proliferating cells. To date, 13 complementation groups of Fanconi anemia were identified. Five of these genes have been deleted or mutated in the mouse, as well as a sixth key regulatory gene, to create mouse models of Fanconi anemia. This review summarizes the phenotype of each of the Fanconi anemia mouse models and highlights how genetic and interventional studies using the strains have yielded novel insight into therapeutic strategies for Fanconi anemia and into how the Fanconi anemia pathway protects against genomic instability.

  6. Parvovirose e anemia acentuada em paciente imunocompetente Parvovirus and severe anemia in an immunocompetent patient

    Directory of Open Access Journals (Sweden)

    Juliana Annete Damasceno

    2012-04-01

    Full Text Available Paciente de 16 anos, sexo masculino, com vírus da imunodeficiência humana (HIV negativo e sem doença hematológica prévia, desenvolveu anemia acentuada devido à infecção por parvovírus B19. A doença apresentou evolução bifásica, com acalmia clínica e retorno dos sintomas após 15 dias. Ao exame físico, apresentava-se descorado e febril, sem adeno e organomegalias, com sinais de insuficiência cardíaca. O aspirado de medula óssea mostrava megaloblastos com nucléolos aberrantes e, na histologia, foram observadas células gigantes com nucleolação aberrante e presença do corpúsculo de inclusão nuclear típico da parvovirose. O exame de imuno-histoquímica mostrou positividade para anticorpo específico para parvovírus. A sorologia comprovou a infecção.A 16-year-old human immunodeficiency virus (HIV negative male patient without hematological disease developed acute anemia due to parvovirus B19 infection. The disease showed a biphasic evolution: clinical remission and return of symptoms after 15 days. Physical examination revealed paleness and fever, neither adeno nor organomegalies, and signs of heart failure. The bone marrow aspiration showed megaloblasts with aberrant nucleoli. As far as histology is concerned, giant cells with aberrant nucleoli and the presence of intranuclear inclusions typical of Parvoviruses were observed. Immunohistochemistry revealed positivity for specific Parvovirus antibody. Serology confirmed parvovirus B19 infection.

  7. Treatment of childhood aplastic anemia with antithymocyte globulin, management of side effects and long-term follow-up%抗胸腺细胞球蛋白治疗儿童再生障碍性贫血的临床研究

    Institute of Scientific and Technical Information of China (English)

    傅晓燕; 谢晓恬; 蒋莎义; 石苇; 邵越霞

    2011-01-01

    Objective To evaluate the efficacy of antithymocyte globulin (ATG) based immunosupression therapy for childhood aplastic anemia, to reduce the adverse effects and to observe the long-term outcome. Method Thirty-five children with aplastic anemia (AA) were enrolled in this study.Six of the cases had very severe AA (VSAA), 11 had severe AA (SAA)-Ⅰ, 8 had SAA-Ⅱ and 10 had moderate AA (MAA). All these patients were treated with ATG plus Cyclosporin A (CSA). The following measures were taken during the ATG therapy: infection of the patients had been controlled before ATG treatment. Comprehensive anti-allergic measures were implemented. Close attention was paid to the hemorrhage related with platelet reduction caused by ATG and severe infection of the patients. Result Shortly after the ATG usage, all the patients had a significant decrease of absolute peripheral lymphoblast count by more than 60 percent. With a mean follow-up time of 28 months, the total effective rate was 77.14% ( 27/35), significant response rate was 57.14%(20/35). There was no significant difference among VSAA, SAA and MAA groups in the response rate. Adverse reactions included the following:① 48.6% (17/35) patients presented mild anaphylactoid reaction during the first day of ATG treatment; ②42.9%(15/35) cases presented serum sickness 5-11 days after the last dose of ATG with a mean duration of 3. 6 days, all the patients were cured effectively with methylprednisolone; ③25.7% (9/35)patient's peripheral blood platelet count was reduced, might be caused by ATG, to below 10 × 109/L, but no patient had severe hemorrhagic complication after platelet transfusion was performed; ④22.9% ( 8/35 ) of patients got infection within a month after ATG therapy, including 3 cases with clinical septicemia, all the 3 cases recovered after antibiotics treatment. There was no ATG treatment-related death in this series. Conclusion ATG is a very effective therapy for children with SAA and MAA

  8. Qualitative assessment of red blood cell parameters for signs of anemia in patients with chronic periodontitis

    OpenAIRE

    Khan, Nubesh S.; Luke, Roji; Soman, Rino Roopak; Krishna, Praveen M.; Safar, Iqbal P.; Swaminathan, Senthil Kumar

    2015-01-01

    Aim: Anemia of chronic disease is defined as anemia occurring in chronic infections and inflammatory conditions that is not caused by marrow deficiencies or other diseases and in the presence of adequate iron stores and vitamins. The present case control study was aimed to assess the red blood cell parameters for signs of anemia in patients with mild, moderate, and severe chronic periodontitis. Materials and Methods: A simple random sampling method was used to select 80 healthy male patients,...

  9. Anemia in Patients With Diabetic Foot Ulcer: Prevalence, Clinical Characteristics, and Outcome.

    Science.gov (United States)

    Chuan, Fengning; Zhang, Min; Yao, Yang; Tian, Wenqing; He, Xiaoqun; Zhou, Bo

    2016-09-01

    The aim of this study was to describe the characteristics of diabetic foot ulcer (DFU) patients with anemia and assess the relationship between anemia and DFU outcome. A retrospective cohort study was conducted on patients with DFU who attended our hospital from May 2007 to September 2014. All of the variables in the DFU patients with and without anemia were compared. In this study, 353 subjects were included, anemia was present in 236 patients (66.9%). These patients were significantly male, more likely to be a smoker, had a lower level of serum albumin and worse kidney function, more likely to use at least 2 types of antibiotics and had a worse perfusion of the lower limb, a larger and deeper ulcer and a more severe infection. A multivariate analysis showed that male sex, lower serum albumin, and worse kidney function were independent predictors of anemia in DFU patients. Additionally, in multivariate models, anemia was one of the variables that was most significantly associated with adverse outcomes and with similar findings for secondary outcomes. Receiver operating characteristic analysis determined a hemoglobin cutoff of 12.3 g/dL (females) and 12.1 g/dL (males) to identify a high-risk population of DFU patients who would have adverse outcomes. So anemia is common in patients with DFU. Although typically mild or moderate, anemia has been associated with substantial morbidity and mortality in patients with DFU. PMID:27440798

  10. Microcytic hypochromic anemia patients with thalassemia : Genotyping approach

    Directory of Open Access Journals (Sweden)

    Rahim Fakher

    2009-03-01

    Full Text Available Background: Microcytic hypochromic anemia is a common condition in clinical practice, and alpha-thalassemia has to be considered as a differential diagnosis. Aims: This study was conducted to evaluate the frequency of α-gene, β-gene and hemoglobin variant numbers in subjects with microcytic hypochromic anemia. Setting And Designs: Population-based case-control study in the Iranian population. Materials And Methods: A total of 340 subjects from southwest part of Iran were studied in the Research Center of Thalassemia and Hemoglobinopathies (RCTH, Iran. Genotyping for known a- and b-gene mutations was done with gap-PCR and ARMS. In cases of some rare mutations, the genotyping was done with the help of other techniques such as RFLP and ARMS-PCR. Statistical Analysis: Statistical analysis was carried out by SPSS 11.5 and an independent-sample t test. Results: Out of the total 340 individuals, 325 individuals were evaluated to have microcytic hypochromic anemia based on initial hematological parameters such as MCV< 80 fl; MCH < 27 pg; the remaining 15 patients were diagnosed with no definite etiology. The overall frequency of -α3.7 deletion in 325 individuals was 20.3%. The most frequent mutations were IVS II-I, CD 36/37 and IVS I-110 with frequencies of 6.31%, 5.27% and 1.64%, respectively. Only, there was a significant difference between beta-thalassemia trait and beta-thalassemia major with regard to MCV (P < 0.05 and MCH (P < 0.05 indices, and also MCH index between beta-thalassemia trait and Hb variants (P < 0.05. Conclusion: Molecular genotyping provides a rapid and reliable method for identification of common, rare and unknown a- and b-gene mutations, which help to diagnose unexplained microcytosis and thus prevent unnecessary iron supplementation.

  11. The Effects of Anemia on Pregnancy Outcome in Patients with Pyelonephritis

    Directory of Open Access Journals (Sweden)

    Sarah K. Dotters-Katz

    2013-01-01

    Full Text Available Objective. Pyelonephritis is a common infectious morbidity of pregnancy. Though anemia is commonly associated with pyelonephritis, there are little data describing the effect of pyelonephritis with anemia on pregnancy outcomes. The purpose of this study was to further assess the association of anemia with infectious morbidity and pregnancy complications among women with pyelonephritis. Study Design. We conducted a retrospective cohort study of pregnant women admitted to Duke University Hospital between July 2006 and May 2012 with pyelonephritis. Demographic, laboratory, and clinical data from the subject’s pregnancy and hospitalizations were analyzed. Patients with pyelonephritis and anemia (a hematocrit < 32 were compared to those without anemia. Descriptive statistics were used to compare the two groups. Results. 114 pregnant women were admitted with pyelonephritis and 45 (39.5% had anemia on admission. There was no significant difference in age, race, preexisting medical conditions, or urine bacterial species between patients with anemia and those without. Women with anemia were more likely to deliver preterm (OR 3.3 (95% CI 1.07, 11.4, . When controlling for race and history of preterm delivery, women with anemia continued to have increased odds of preterm birth (OR 6.0, CI 1.4, 35, . Conclusion. Women with pyelonephritis and anemia are at increased risk for preterm delivery.

  12. Erythrokinetics: quantitative measurements of red cell production and destruction in normal subjects and patients with anemia.

    Science.gov (United States)

    Giblett, Eloise R; Coleman, Daniel H; Pirzio-Biroli, Giacomo; Donohue, Dennis M; Motulsky, Arno G; Finch, Clement A

    2016-03-17

    To study erythropoiesis and anemia, one must have a firm foundation of indices that accurately measure red blood cell production and destruction. This paper, authored by hematology legends Arno G. Motulsky and Clement A. Finch, provides that foundation. Using methods that would not be approved in today's environment, the authors studied a cohort of normal healthy patients and an equal number of patients with different forms of anemia. The results confirm a reciprocal model of red cell production and destruction, show that anemia can be the result of either underproduction (a regenerative anemia or ineffective erythropoiesis) or increased destruction, and define parameters for distinguishing these 2 possibilities that are still widely used today.

  13. Anti-erythropoietin receptor antibodies in systemic lupus erythematosus patients with anemia.

    Science.gov (United States)

    Luo, X-Y; Yang, M-H; Peng, Ping; Wu, L-J; Liu, Q-S; Chen, L; Tang, Z; Liu, N-T; Zeng, X-F; Liu, Y; Yuan, G-H

    2013-02-01

    Anemia is a common hematologic abnormality in systemic lupus erythematosus (SLE). An inadequate erythropoietin (EPO) response in SLE patients with anemia has been described that may be due to the presence of antibodies to EPO in SLE patients. However, whether anemia in patients with SLE is related to antibodies to EPO receptor (EPOR) has not yet been investigated. We enlisted 169 consecutive patients with SLE and 45 normal individuals to investigate the existence and importance of circulating autoantibodies to EPOR in sera from patients with SLE. In all patients with SLE, the disease activity was evaluated by using the SLE disease activity index SLEDAI. Anti-EPOR antibodies were detected by using an enzyme-linked immunosorbent assay (ELISA). A higher frequency of anti-EPOR antibodies was observed in SLE patients than in healthy controls (18.3% vs 2.2%, p = 0.007). Moreover, anti-EPOR antibodies were detected in 22 of 69 (31.9%) SLE patients with anemia and in only nine of 100 (9.0%, p antibodies exhibited more severe anemia and often presented as microcytic anemia (p = 0.001). Finally, anti-EPOR antibodies seemed more likely to occur in patients with rash (p = 0.008), lower levels of C(3) component (p = 0.01), higher titer of anti-dsDNA antibodies (p antibodies might play a vital role in SLE patients developing anemia because of the higher incidence of antibodies to EPOR found in SLE patients with anemia. Thus, there might be clinical value in detecting anti-EPOR antibodies in SLE patients with anemia. Therefore, the pathologic role of the antibodies in inducing anemia needs to be established in future studies.

  14. Managing anemia and blood loss in elective gynecologic surgery patients.

    Science.gov (United States)

    Rock, W A; Meeks, G R

    2001-05-01

    Hysterectomy is the second-most-common surgical procedure among premenopausal women. The conditions that lead to the need for a hysterectomy often are accompanied by chronic blood loss that can lead to anemia. Moreover, hysterectomy and myomectomy may result in significant blood loss, which exacerbates the anemia. The presence of fatigue associated with anemia has a substantially negative impact on quality of life and the ability to perform activities of daily living. Options for alleviating perioperative anemia include minimizing surgical blood loss, blood transfusion, supplementation with hematinics, such as iron and folic acid, and treatment with recombinant human erythropoietin. Treating preoperative anemia is expected to help correct anemia prior to surgery and may have a positive impact on anemia-related symptoms and surgical outcomes.

  15. Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy

    International Nuclear Information System (INIS)

    To describe the prevalence and management of anemia in cancer patients. This cross-sectional, observational survey was conducted in Italy and Austria. Centers prespecified one day, during a 4-month enrollment window, to report specific data collected during normal clinical practice for patients with non-myeloid tumors attending for chemotherapy (±radiotherapy) treatment. The primary endpoint was the prevalence of anemia as determined using a prespecified algorithm: hemoglobin (Hb) ≤10 g/dL on/within 3 days prior to visit; ongoing anemia treatment; physician diagnosis of anemia, together with ≥1 anemia symptom. Between November 18, 2010 and March 18, 2011, data for 1412 patients were collected (Italy n = 1130; Austria n = 282). Most patients (n = 1136; 80%) had solid tumors; 809 (57%) had received ≤3 chemotherapy cycles. The prevalence of anemia was 32% (95% confidence interval: 29.4%–34.2%); 196 patients (14%) were deemed anemic based on Hb ≤10 g/dL, 131 (9%) on ongoing anemia treatment, and 121 (9%) on physician diagnosis/anemia symptom. Overall, 1153 patients (82%) had Hb data; mean (standard deviation [SD]) Hb levels were 11.7 (1.7) g/dL. In total, 456 patients (32%) had anemia symptoms: fatigue (n = 392; 28%), depression (n = 122; 9%), and dyspnea (n = 107; 8%) were most common. Fifty-one patients (4%) had had their current chemotherapy cycle delayed due to anemia. On visit day, or ≤28 days prior, 91 (6%), 188 (13%), and 81 patients (6%) had evidence of whole blood/red blood cell transfusion, erythropoiesis-stimulating agent use, or iron use, respectively. On the prespecified study day, one-third of patients with non-myeloid tumors undergoing chemotherapy were found to be anemic and 13% had evidence of erythropoiesis-stimulating agent use then or in the 28 days prior

  16. Cornual pregnancy in a patient suffering from sickle cell anemia

    Directory of Open Access Journals (Sweden)

    Onilda Labrada Silva

    2015-10-01

    Full Text Available Nowadays, ectopic pregnancy is a pathological entity of great incidence, which is increased, among other things, by each time earlier sexual relations. Cornual pregnancy is as a result of the implantation of the blastocyte within the segment of the fallopian tube that goes into the uterus wall or between the tubal ostium and the proximal portion of the isthmus. This is a case of a cornual pregnancy in which the use of ultrasonography played an essential role for its diagnosis, since it is about a patient suffering from sickle cell anemia, where it was not possible to clinically eliminate the possibility of an occlusive vessel crisis as the cause of abdominal pain. Subtotal hysterectomy of the right tube was performed. The patient’s evolution is satisfactory.

  17. Management of Antiviral Induced Anemia in HCV Infected Patients

    Directory of Open Access Journals (Sweden)

    Mitra Ranjbar

    2005-03-01

    Full Text Available IntroductionHepatitis C virus (HCV infection affects more than 170 million people worldwide(1,2. Approximately 80% of patients with acute infection will subsequently develop chronic disease, and an estimated 20% to 30% will develop cirrhosis and hepatocellular carcinoma(3. The maost effective therapeutic regimen for chronic hepatitis C is the combination of pegylated interferon alpha and ribavirin, which yields a sustained virologic response (SVR in up to 56% of patients(4, 5. However, combination therapy is also associated with significant adverse events and is contraindicated in certain patient populations. Development of side effects, particularly hematologic ones, may result in suboptimal dosing or discontinuation of therapy that can reduce the likelihood of SVR.IncidenceIn clinical trials, significant anemia (hemoglobin 10.6 mg/kg/d is 65% compared with a rate of 50% for those receiving peginterferon alfa-2b plus ribavirin at dosages of 10.6 mg/kg/d or less.It has been shown that SVR rates are significantly higher in patients who receive more than 80% of their full interferon alfa-2b plus ribavirin doses for more than 80% of the time for more than 80% of the intended duration of therapy(14. In the Hepatitis C Long-term Treatment Against Cirrhosis (HALT-C trial, a trial involving patients who were previous nonresponders to or relapsers after therapy, reduction of ribavirin dose from> 80% to 10.6 mg/kg/d. The standard-of-care management of ribavirin induced anemia has been dose reduction to 600 mg/d when the hemoglobin level decreases to =2g/dL decrease inhemoglobinduring any 4-weektreatment period 12g/dL despite 4weeks at reduceddose Recombinant human erythropoietin therapy in the HCV-infected patient who becomes anemic during antiviral therapy represents an alternative to ribavirin dose reduction or discontinuation. Erythropoietin is mainly produced by the kidney in adults in response to tissue hypoxia, and it increases the number of

  18. Prevalence of Anemia and Its Impact on Mortality and Hospitalization Rate in Predialysis Patients

    NARCIS (Netherlands)

    Voormolen, N.; Grootendorst, D. C.; Urlings, T. A. J.; Boeschoten, E. W.; Sijpkens, Y. W.; Huisman, R. M.; Krediet, R. T.; Dekker, F. W.

    2010-01-01

    Background/Aim: Anemia is associated with increased mortality and morbidity in both early and very late stages of chronic kidney disease (CKD). The aim of this study was to assess whether anemia is a risk factor for mortality or hospitalization in CKD stage 4-5 predialysis patients not yet on dialys

  19. Chromosomal instability in patients with Fanconi anemia from Serbia

    Directory of Open Access Journals (Sweden)

    Ćirković Sanja

    2014-01-01

    Full Text Available Background/Aim. Fanconi anemia (FA is a rare hereditary disease in a heterogeneous group of syndromes, so-called chromosome breakage disorders. Specific hypersensitivity of its cells to chemical agents, such as diepoxybutane (DEB, was used as a part of screening among patients with clinical suspicion of FA. The aim of this study was to determine chromosomal instability in patients with FA symptoms in Serbia. Methods. A total of 70 patients with phenotypic symptoms of FA, diagnosed at the Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade and University Children’s Hospital, Belgrade from February 2004 to September 2011, were included in this study. Cytogenetic instability analysis was performed on untreated and DEBtreated 72 h-cultures of peripheral blood. Results. Ten patients in the group of 70 suspected of FA, showed increased DEB induced chromosome breakage and were classified into the FA group. The range of DEB induced aberrant cells percentages in the FA group was from 32% to 82%. DEB sensitivity of 58 tested patients were bellow FA values (range: 0-6% (non-FA group, with no overlapping. The remaining two patients showed borderline sensitivity (borderline FA group - FA*, comparing to the healthy controls. Conclusion. This study revealed 10 patients with FA on the basis of cytogenetic analysis of DEB induced chromosome aberrations. Our results are in consistency with those from the literature. Early and precise diagnosis of FA is very important in further treatment of these patients, considering its cancer prone and lethal effects. [Projekat Ministarstva nauke Republike Srbije, br. 173046

  20. Autoimmune hemolytic anemia in a patient with Malaria

    Directory of Open Access Journals (Sweden)

    Rajesh Sonani

    2013-01-01

    Full Text Available Autoimmune Hemolytic Anemia (AIHA, a very infrequent condition which represents a group of disorders in which presence of autoantibodies directed against self-antigens leads to shortened red cell survival. Till date, a very few cases of AIHA in Malaria patients are reported worldwide but still AIHA should be considered a relatively rare cause of anemia in malaria. A 20 year male presented with intermittent fever since seven days and yellowish discoloration of urine and sclera since 5 days. He was transfused three units of blood at a private clinic before one month. On examination, pallor, icterus and spelnomegaly were present. Hemoglobin (Hb was 3.2 gm% and peripheral smear revealed ring forms of both Plasmodium vivax and Plasmodium falciparum. Serum LDH and Serum billirubin (Indirect and Direct were high. This patient′s blood group was B +ve with positive autocontrol. Indirect Antiglobulin Test (IAT, antibody screening and antibody identification were pan-positive with reaction strength of +4 against each cell. Direct Antiglobulin Test was +4 positive anti IgG and negative with anti C3. He was treated with Artesunate and methylprednisone. Least incompatible, saline washed O Neg and B neg red cells were transfused on the 2 nd day of starting treatment. Hb was raised to 6.1 gm% on 4 th day. Patient was discharged on 9th day with Hb 7.0 gm% with oral tapering dose of steroids. In the above case, patient was suffering from high grade malarial parasitemia with co-existing autoimmune RBC destruction by IgG auto-antibodies which led to sudden drop in Hb and rise in serum LDH and indirect billirubin. Least incompatible packed red cells along with antimalarials and steroids led to clinical improvement. So far, one case report each from India, Korea, Canada and Germany and one case series report of three cases from India have been reported. Under-reporting or rarity of this phenomenon may be accountable for this.

  1. Role of Anemia in Home Oxygen Therapy in Chronic Obstructive Pulmonary Disease Patients.

    Science.gov (United States)

    Copur, Ahmet Sinan; Fulambarker, Ashok; Molnar, Janos; Nadeem, Rashid; McCormack, Charles; Ganesh, Aarthi; Kheir, Fayez; Hamon, Sara

    2015-01-01

    Anemia is a known comorbidity found in chronic obstructive pulmonary disease (COPD) patients. Hypoxemia is common and basically due to ventilation/perfusion (V/Q) mismatch in COPD. Anemia, by decreasing arterial oxygen content, may be a contributing factor for decreased delivery of oxygen to tissues. The objective of this study is to determine if anemia is a factor in qualifying COPD patients for home oxygen therapy. The study was designed as a retrospective, cross-sectional, observational chart review. Patients who were referred for home oxygen therapy evaluation were selected from the computerized patient record system. Demographic data, oxygen saturation at rest and during exercise, pulmonary function test results, hemoglobin level, medications, reason for anemia, comorbid diseases, and smoking status were recorded. The χ tests, independent sample t tests, and logistic regression were used for statistical analysis. Only 356 of total 478 patient referrals had a diagnosis of COPD over a 2-year period. Although 39 of them were excluded, 317 patients were included in the study. The overall rate of anemia was 38% in all COPD patients. Anemia was found significantly more frequent in COPD patients on home oxygen therapy (46%) than those not on home oxygen therapy (18.5%) (P Chronic Obstructive Lung Disease class, smoking status, hemoglobin level, hematocrit, percent of forced expiratory volume in first second, forced expiratory volume in first second/forced vital capacity, residual volume/total lung volume, percent of carbon monoxide diffusion capacity were significantly different between home oxygen therapy and those not on home oxygen therapy (P anemia remained a strong predictor for long-term oxygen therapy use in COPD patients after adjusting for other significant parameters. Anemic COPD patients are more hypoxic especially during exercise than those who are not anemic. We conclude that anemia is a contributing factor in qualifying COPD patients for home oxygen

  2. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010–2013

    Directory of Open Access Journals (Sweden)

    Xu H

    2016-04-01

    Full Text Available Hairong Xu,1 Lanfang Xu,2 John H Page,1 Kim Cannavale,2 Olivia Sattayapiwat,2 Roberto Rodriguez,3 Chun Chao2 1Center for Observational Research, Amgen Inc., Thousand Oaks, CA, USA; 2Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA; 3Department of Hematology Oncology, Los Angeles Medical Center, Kaiser Permanente Southern California, Psadena, CA, USA Purpose: The purpose of this study was to evaluate and characterize the risk of anemia during the course of chemotherapy among patients with five common types of solid tumors. Patients and methods: Patients diagnosed with incident cancers of breast, lung, colon/rectum, stomach, and ovary who received chemotherapy were identified from Kaiser Permanente Southern California Health Plan (2010–2012. All clinical data were collected from the health plan’s electronic medical records. Incidence proportions of patients developing anemia and 95% confidence intervals were calculated overall and by anemia severity and type, as well as by stage at cancer diagnosis, and by chemotherapy regimen and cycle. Results: A total of 4,426 patients who received chemotherapy were included. Across cancers, 3,962 (89.5% patients developed anemia during the course of chemotherapy (normocytic 85%, macrocytic 10%, microcytic 5%; normochromic 47%, hyperchromic 44%, hypochromic 9%. The anemia grades were distributed as follows: 58% were grade 1, 34% grade 2, 8% grade 3, and <1% grade 4. The incidence of grade 2+ anemia ranged from 26.3% in colorectal cancer patients to 59.2% in ovarian cancer patients. Incidence of grade 2+ anemia increased from 29% in stage I to 49% in stage IV. Incidence of grade 2+ anemia varied from 18.2% in breast cancer patients treated with cyclophosphamide + docetaxel regimen to 59.7% in patients with ovarian cancer receiving carboplatin + paclitaxel regimen. Conclusion: The incidence of moderate-to-severe anemia (hemoglobin <10 g/dL remained considerably

  3. Haptoglobin gene polymorphisms and interleukin-6 and -8 levels in patients with sickle cell anemia

    Directory of Open Access Journals (Sweden)

    Bruna Spinella Pierrot-Gallo

    2015-10-01

    Full Text Available BACKGROUND: Haptoglobin genotypes, and interleukin-6 and -8 participate in the pathophysiology of sickle cell anemia. The expression of cytokines is regulated by genetic mechanisms however the effect of haptoglobin polymorphisms on these cytokines is not fully understood. This study aimed to compare the frequency of haptoglobin genotypes and the interleukin-6 and -8 concentrations in sickle cell anemia patients and controls to investigate the association between haptoglobin genotypes and cytokine levels.METHODS: Sixty sickle cell anemia patients and 74 healthy individuals were analyzed. Haptoglobin genotypes were determined by multiplex polymerase chain reaction, and the interleukin-6 and -8 levels by enzyme linked immunosorbent assay. The association between haptoglobin genotypes and cytokines was investigated by statistical tests.RESULTS:Hp2-1 was the most common genotype in both the cases and controls while Hp1-1 was less frequent among sickle cell anemia patients. Interleukin-6 and -8 levels were higher in patients than controls (p-value 0.05. A similar trend was observed among the controls.CONCLUSION: Although, levels of interleukin-6 and -8 were higher in the sickle cell anemia patients, they appeared not to be related to the haptoglobin genotypes. Further investigations are necessary to identify factors responsible for increased secretion of the interleukin-6 and -8 pro-inflammatory cytokines in patients with sickle cell anemia.

  4. Anemia and iron homeostasis in a cohort of HIV-infected patients in Indonesia

    Directory of Open Access Journals (Sweden)

    Jusuf Hadi

    2011-08-01

    Full Text Available Abstract Background Anemia is a common clinical finding in HIV-infected patients and iron deficiency or redistribution may contribute to the development of low hemoglobin levels. Iron overload is associated with a poor prognosis in HIV and Hepatitis C virus infections. Iron redistribution may be caused by inflammation but possibly also by hepatitis C co-infection. We examined the prevalence of anemia and its relation to mortality in a cohort of HIV patients in a setting where injecting drug use (IDU is a main mode of HIV transmission, and measured serum ferritin and sTfR, in relation to anemia, inflammation, stage of HIV disease, ART and HCV infection. Methods Patient characteristics, ART history and iron parameters were recorded from adult HIV patients presenting between September 2007 and August 2009 in the referral hospital for West Java, Indonesia. Kaplan-Meier estimates and Cox's regression were used to assess factors affecting survival. Logistic regression was used to identity parameters associated with high ferritin concentrations. Results Anemia was found in 49.6% of 611 ART-naïve patients, with mild (Hb 10.5 - 12.99 g/dL for men; and 10.5 - 11.99 g/dL for women anemia in 62.0%, and moderate to severe anemia (Hb Conclusion HIV-associated anemia is common among HIV-infected patients in Indonesia and strongly related to mortality. High ferritin with low sTfR levels suggest that iron redistribution and low erythropoietic activity, rather than iron deficiency, contribute to anemia. Serum ferritin and sTfR should be used cautiously to assess iron status in patients with advanced HIV infection.

  5. 猪抗淋巴细胞免疫球蛋白联合环孢素治疗重型再生障碍性贫血疗效观察%Therapeutic effect of porcine anti- human lymphocyte globulin combined with cyclosporine A therapy on severe aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    王春生

    2012-01-01

    目的 探讨猪抗淋巴细胞免疫球蛋白与环孢素联合应用于治疗重型再生障碍性贫血(再障)的临床疗效及临床转归.方法 50例重型再障患者作为研究资料,治疗组给予猪抗淋巴细胞免疫球蛋白与环孢素联合治疗,对照组给予猪抗淋巴细胞免疫球蛋白治疗,观察并对比两组患者疗效、起效时间以及不良反应.结果 治疗组总有效率明显高于治疗组,基本治愈率、明显缓解率以及有所改善率均高于对照组.经过治疗后两组患者白细胞(WBC)、血红蛋白(HGB)以及血小板(PLT)均明显升高,但治疗后治疗组WBC、HGB以及PLT均明显高于对照组.治疗组平均起效时间、牙龈增生出现例数明显高于对照组,另出现5例手颤,3例继发性糖尿病,而对照组未发现此类不良反应.结论 猪抗淋巴细胞免疫球蛋白与环孢素联合应用于治疗重型再障疗效优于单用猪抗淋巴细胞免疫球蛋白治疗,但不良反应较单用猪抗淋巴细胞免疫球蛋白治疗更多,可以推荐应用,如何防治并发症仍值得思考.%Objective To investigate the clinical efficacy of porcine anti -human lymphocyte globulin combined with cyclosporine A in treatment of severe aplastic anemia (SAA). Methods Fifty SAA patients were included in the study. The treatment group received the porcine anti -human lymphocyte globulin combined with cyclosporine A therapy, while the control group received only porcine anti - human lymphocyte globulin therapy. The efficacy, onset time, and adverse events were observed and compared between the two groups. Results The overall efficacy rate, basic cure rate, and apparent remission rate were significantly higher in the treatment group than in the control group. After treatment, white blood cells (WBC), hemoglobin (HGB), and platelets (PLT) were significantly increased in both groups, but significantly higher in the treatment group than in the control group. The average onset time and

  6. Nutritional status, hospitalization and mortality among patients with sickle cell anemia in Tanzania

    OpenAIRE

    Cox, S.E.; Makani, J.; Fulford, A J; Komba, A. N.; Soka, D; Williams, T.N.; Newton, C R; Marsh, K.; Prentice, A M

    2011-01-01

    BackgroundReduced growth is common in children with sickle cell anemia, but few data exist on associations with long-term clinical course. Our objective was to determine the prevalence of malnutrition at enrolment into a hospital-based cohort and whether poor nutritional status predicted morbidity and mortality within an urban cohort of Tanzanian sickle cell anemia patients.Design and MethodsAnthropometry was conducted at enrolment into the sickle cell anemia cohort (n = 1,618; ages 0.5-48 ye...

  7. 妊娠合并慢性再生障碍性贫血并发子痫前期的危险因素分析%Analysis the risk factors of pregnancy complicated with chronic aplastic anemia and pre-eclampsia

    Institute of Scientific and Technical Information of China (English)

    谭大勇

    2013-01-01

      目的探讨影响妊娠合并慢性再生障碍性贫血并发子痫前期的相关危险因素,为妊娠合并慢性再生障碍性贫血并发子痫前期的预防提供帮助。方法选择并分析我院2007年5月-2012年12月住院合妊娠合并慢性再生障碍性贫血27例的临床资料,统计分析其年龄、首诊孕期、出血倾向、再障的严重程度、白细胞0.05)。结论妊娠合并慢性再生障碍性贫血并发子痫前期受到多种因素影响,血红蛋白0.05). Conclusion Pregnancy complicated with chronic aplastic anemia and pre-eclampsia may affected by many factors, but the <60g/L hemoglobin, platelet <10×109/L is the major related Risk factors.

  8. Anemia and Blood Transfusion in Patients with Isolated Traumatic Brain Injury

    Science.gov (United States)

    Al-Dorzi, Hasan M.; Al-Humaid, Waleed; Tamim, Hani M.; Haddad, Samir; Aljabbary, Ahmad; Arifi, Abdulaziz; Arabi, Yaseen M.

    2015-01-01

    Rationale. By reducing cerebral oxygen delivery, anemia may aggravate traumatic brain injury (TBI) secondary insult. This study evaluated the impact of anemia and blood transfusion on TBI outcomes. Methods. This was a retrospective cohort study of adult patients with isolated TBI at a tertiary-care intensive care unit from 1/1/2000 to 31/12/2011. Daily hemoglobin level and packed red blood cell (PRBC) transfusion were recorded. Patients with hemoglobin < 10 g/dL during ICU stay (anemic group) were compared with other patients. Results. Anemia was present on admission in two (2%) patients and developed in 48% during the first week with hemoglobin < 7 g/dL occurring in 3.0%. Anemic patients had higher admission Injury Severity Score and underwent more craniotomy (50% versus 13%, p < 0.001). Forty percent of them received PRBC transfusion (2.8 ± 1.5 units per patient, median pretransfusion hemoglobin = 8.8 g/dL). Higher hospital mortality was associated with anemia (25% versus 6% for nonanemic patients, p = 0.01) and PRBC transfusion (38% versus 9% for nontransfused patients, p = 0.003). On multivariate analysis, only PRBC transfusion independently predicted hospital mortality (odds ratio: 6.8; 95% confidence interval: 1.1–42.3). Conclusions. Anemia occurred frequently after isolated TBI, but only PRBC transfusion independently predicted mortality. PMID:26605080

  9. Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients

    OpenAIRE

    Hamid Nasri

    2013-01-01

    Currently many patients with chronic renal failure have profited from the use of erythropoietin to correct anemia (1,2). In chronic kidney disease, anemia is believed to be a surrogate index for tissue hypoxia that continues preexisting renal tissue injury (1-3). Erythropoietin is an essential glycoprotein that accelerates red blood cell maturation from erythroid progenitors and facilitates erythropoiesis. It is a 30.4 kD glycoprotein and class I cytokine containing 165 amino acids (3,4). App...

  10. Haptoglobin gene polymorphisms and interleukin-6 and -8 levels in patients with sickle cell anemia

    OpenAIRE

    Bruna Spinella Pierrot-Gallo; Perla Vicari; Sandra Satiko Matsuda; Samuel Ademola Adegoke; Grazielle Mecabo; Maria Stella Figueiredo

    2015-01-01

    BACKGROUND: Haptoglobin genotypes, and interleukin-6 and -8 participate in the pathophysiology of sickle cell anemia. The expression of cytokines is regulated by genetic mechanisms however the effect of haptoglobin polymorphisms on these cytokines is not fully understood. This study aimed to compare the frequency of haptoglobin genotypes and the interleukin-6 and -8 concentrations in sickle cell anemia patients and controls to investigate the association between haptoglobin genotypes and cyto...

  11. Distinct Roles of Urinary Liver-Type Fatty Acid-Binding Protein in Non-Diabetic Patients with Anemia

    OpenAIRE

    Naohiko Imai; Takashi Yasuda; Atsuko Kamijo-Ikemori; Yugo Shibagaki; Kenjiro Kimura

    2015-01-01

    Background Various stresses including ischemia are known to up-regulate renal L-FABP gene expression and increase the urinary excretion of L-FABP. In diabetic patients with anemia, the urinary excretion of L-FABP is significantly increased. We studied the clinical significance of urinary L-FABP and its relationship with anemia in non-diabetic patients. Subjects and Methods A total of 156 patients were studied in this retrospective cross-sectional analysis. The associations between anemia and ...

  12. Prevalence and severity of anemia in pediatric hemodialysis patients, a single center study

    Directory of Open Access Journals (Sweden)

    Afshin Azhir

    2006-12-01

    Full Text Available BACKGROUNDS: This study was conducted to determine the prevalence and severity of anemia in children and adolescents on chronic hemodialysis, and to identify independent predictors of anemia in children on hemodialysis. METHODS: This cross-sectional study was performed between September 2005 and January 2006. The study population consisted of 25 patients aged 7−20 years on chronic hemodialysis from pediatric hemodialysis centers in Isfahan. RESULTS: A total of 22 (88% patients had hemoglobin levels of <11 g/dL (anemic and 12 patients (48% had hemoglobin levels of <8 g/dL (severe anemia. The mean age of these patients was 15.5 ± 3.7 years. Mean time on chronic dialysis was 20.44 ± 15.25 months. Anemia was more common and more severe among children who were on dialysis for less than 6 months. There was an inverse relationship between the severity of anemia and duration of hemodialysis (P = 0.019, r = – 0.465. Nearly all patients were treated with erythropoietin, Children with more severe anemia received slightly higher dose of erythropoietin (P = 0.09, r = 0.202. There was a significant difference between serum albumin values in anemic patients and patients without anemia (P = 0.023. There was a correlation between serum albumin and hemoglobin level (r = 0.511, P = 0.01. Intact PTH levels were >200 pg/ml in 16 patients (66% and >400 pg/ml in 9 patients (37. 5%. There was a reverse correlation between intact PTH level >200 pg/ml and hemoglobin level (r = -0.505, P = 0.046. CONCLUSIONS: The prevalence of anemia in hemodialysis children in Isfahan appears to be higher than that reported in the other studies in spite of extensive use of rHuEPO and iron supplementation. We found this to be especially true for patients new on hemodialysis (less than 6 months and in those with low albumin and severe hyperparathyroidism. KEY WORDS: Hemodialysis, anemia, children.

  13. Analysis of risk factors for preeclampsia in pregnancies complicated with chronic aplastic anemia%妊娠合并慢性再生障碍性贫血患者并发子痫前期的危险因素分析

    Institute of Scientific and Technical Information of China (English)

    张超; 尹璐瑶; 梁梅英; 王山米; 张晓红; 王建六

    2012-01-01

    Objective To investigate the risk factors for preeclampsia (PE) in pregnancies complicated with chronic aplastic anemia ( CAA ) by analyzing the obstetric management and pregnancy outcome.Methods Retrospectively review the clinical data including the obstetric management,the laboratory findings and the pregnancy outcome of 41 pregnant women complicated with CAA,all of whom were hospitalized in Peking University People's Hospital from May 2002 to February 2011.Multiple logistic regression was used to explore the risk factors associated with PE.Results ( 1 ) Twenty-eight patients were diagnosed before conception while 13 were diagnosed during gestation.Eleven patients including all the 7 who were categorized as severe CAA presented with mild bleeding in the third trimester.( 2 ) The medians of white blood cell counts,hemoglobin concentrations and platelet counts were 5.0 × 109/L,66.0 g/L and 12.0 × 109/L respectively.(3) The obstetric management consisted of strict assessment, intensive surveillance and follow-up,appropriate supportive measures,timely recognition of complications,and delivery when necessary.Twenty-one patients received supportive transfusions.Ten patients developed PE,all of whom were diagnosed as severe PE( SPE).Twelve patients suffered postpartum hemorrhage,and 3 of them had blood loss more than 1000 mL All were conservatively treated in success.(4) The median gestational age of delivery was 37 weeks.Sixteen cases delivered before 37 weeks and 5 delivered before 34 weeks.Two patients developed SPE at 29 weeks and 30 weeks respectively,and both of the neonates died for severe asphyxia.The birth weight of the live neonates ranged from 1500 to 3660 g.(5) The postpartum follow-up period ranged from 6 months to 7 years.Thirty-three patients got improvement without dependence on transfusions.Four achieved no remission and still needed intermittent transfusions.Four were lost in followup.(6) Significant differences were found in the bleeding tendency

  14. Serum zinc levels in patients with iron deficiency anemia and its association with symptoms of iron deficiency anemia.

    Science.gov (United States)

    Kelkitli, Engin; Ozturk, Nurinnisa; Aslan, Nevin Alayvaz; Kilic-Baygutalp, Nurcan; Bayraktutan, Zafer; Kurt, Nezahat; Bakan, Nuri; Bakan, Ebubekir

    2016-04-01

    Iron deficiency anemia (IDA) is a major public health problem especially in underdeveloped and developing countries. Zinc is the co-factor of several enzymes and plays a role in iron metabolism, so zinc deficiency is associated with IDA. In this study, it was aimed to investigate the relationship of symptoms of IDA and zinc deficiency in adult IDA patients. The study included 43 IDA patients and 43 healthy control subjects. All patients were asked to provide a detailed history and were subjected to a physical examination. The hematological parameters evaluated included hemoglobin (Hb); hematocrit (Ht); red blood cell (erythrocyte) count (RBC); and red cell indices mean corpuscular volume (MCV), mean corpuscular hemoglobin (МСН), mean corpuscular hemoglobin concentration (МСНС), and red cell distribution width (RDW). Anemia was defined according to the criteria defined by the World Health Organization (WHO). Serum zinc levels were measured in the flame unit of atomic absorption spectrophotometer. Symptoms attributed to iron deficiency or depletion, defined as fatigue, cardiopulmonary symptoms, mental manifestations, epithelial manifestations, and neuromuscular symptoms, were also recorded and categorized. Serum zinc levels were lower in anemic patients (103.51 ± 34.64 μ/dL) than in the control subjects (256.92 ± 88.54 μ/dL; zinc level zinc level > 100 μ/dL. When the serum zinc level was compared with pica, no statistically significant correlation was found (p = 0.742). Zinc is a trace element that functions in several processes in the body, and zinc deficiency aggravates IDA symptoms. Measurement of zinc levels and supplementation if necessary should be considered for IDA patients.

  15. Role of Anemia in Home Oxygen Therapy in Chronic Obstructive Pulmonary Disease Patients.

    Science.gov (United States)

    Copur, Ahmet Sinan; Fulambarker, Ashok; Molnar, Janos; Nadeem, Rashid; McCormack, Charles; Ganesh, Aarthi; Kheir, Fayez; Hamon, Sara

    2015-01-01

    Anemia is a known comorbidity found in chronic obstructive pulmonary disease (COPD) patients. Hypoxemia is common and basically due to ventilation/perfusion (V/Q) mismatch in COPD. Anemia, by decreasing arterial oxygen content, may be a contributing factor for decreased delivery of oxygen to tissues. The objective of this study is to determine if anemia is a factor in qualifying COPD patients for home oxygen therapy. The study was designed as a retrospective, cross-sectional, observational chart review. Patients who were referred for home oxygen therapy evaluation were selected from the computerized patient record system. Demographic data, oxygen saturation at rest and during exercise, pulmonary function test results, hemoglobin level, medications, reason for anemia, comorbid diseases, and smoking status were recorded. The χ tests, independent sample t tests, and logistic regression were used for statistical analysis. Only 356 of total 478 patient referrals had a diagnosis of COPD over a 2-year period. Although 39 of them were excluded, 317 patients were included in the study. The overall rate of anemia was 38% in all COPD patients. Anemia was found significantly more frequent in COPD patients on home oxygen therapy (46%) than those not on home oxygen therapy (18.5%) (P < 0.0001). Mean saturation of peripheral oxygen values were significantly lower in anemic COPD patients both at rest and during exercise (P < 0.0001). Also, in COPD patients, age, Global Initiative for Chronic Obstructive Lung Disease class, smoking status, hemoglobin level, hematocrit, percent of forced expiratory volume in first second, forced expiratory volume in first second/forced vital capacity, residual volume/total lung volume, percent of carbon monoxide diffusion capacity were significantly different between home oxygen therapy and those not on home oxygen therapy (P < 0.05). Multivariate logistic regression showed that anemia remained a strong predictor for long-term oxygen therapy use in

  16. Pathogenesis of chronic aplastic anemia suffering from kidney yin deficiency through the maternal genetics%从母系遗传研究肾阴虚型慢性再生障碍性贫血的发病机制

    Institute of Scientific and Technical Information of China (English)

    崔兴; 张文静; 蔡治国; 徐瑞荣; 刘菲; 王敬毅; 刘奎

    2012-01-01

    BACKGROUND: Several laboratories have reported unexpectedly large number of mitochondrial mutations in leukemia. But the direct relations hip between mitochondrial mutations and chronic a plastic anemia (CAA) has not studied yet. OBJECTIVE: To study the mitochondrial mutations of CAAsuffered from kidneyyin deficiency and kidney yang deficiency.andCAA suffered from kidney yin deficiency in order to further study the pathogenesis of CAA.METHODS: The bone marrow and the oral epithelium were obtained from 10 patients with CAA suffered from kidney yindeficiency and 5 patients with CAA suffered from kidney yang deficiency. DNA was extracted and underwent the entireRESULT SAND CONCLUSION: The entire sequencing of mitochondrial DNA in CAA suffer from kidney yin deficiency showed that the mutations were occurrence in the areas that closely related with mitochondrial oxidative respiratory chain, it included themutations in CAA suffered from kidney yang deficiency were not obvious. We are led to conclude that mitochondrial gene mutation can change the expression of respiratory chain enzyme complex in CAA patients, which results in energy metabolismimpairment may participate in the physiological and athology processes of hem atopoietic failure,Functional impairment of mitochondrial respiration chain induced by gene mutation may be an important reason of hematopoietic failure in CAA.And this change is closely related to maternal inheritance and kidney yin deficiency.%背景:多项研究表明恶性血液病可以出现线粒体的突变,但尚未有关于慢性再生障碍性贫血中线粒体变化的研究.目的:研究肾阴虚和肾阳虚型慢性再生障碍性贫血患者线粒体突变情况,探讨母系遗传的本质--线粒体与肾阴虚型慢性再障发生、发展的关系,以期进一步研究慢性再障的发病机制.方法:收集10例诊断明确的肾阴虚型5例肾阳虚型慢性再生障碍性贫血患者骨髓和口腔黏膜上皮,提取DNA,进行线粒

  17. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation : insights from the RE-LY trial

    NARCIS (Netherlands)

    Westenbrink, B. D.; Alings, M.; Connolly, S. J.; Eikelboom, J.; Ezekowitz, M. D.; Oldgren, J.; Yang, S.; Pongue, J.; Yusuf, S.; Wallentin, L.; van Gilst, W. H.

    2015-01-01

    BackgroundAnemia may predispose to thromboembolic events or bleeding in anticoagulated patients with atrial fibrillation (AF). ObjectivesTo investigate whether anemia is associated with thromboembolic events and bleeding in patients with AF. Patients and methodsWe retrospectively analyzed the RE-LY

  18. [Kirlianography used to treat patients who are suffering from iron-deficiency anemia with gastroenterological pathology].

    Science.gov (United States)

    Pesotskaia, L A; Evstigneev, I V; Bobrova, E A; Malyĭ, V P; Kapshuchenko, O N; Viazovskaia, V N

    2012-12-01

    The data given below show the efficiency of the therapy of the patients suffering from iron-deficiency anemia with gastroenterological pathology and helicobacter infection. The indicators of red blood of the patients from the group where they had been treated with medicine containing iron and antihelicobacterial therapy had a tendency to be higher with a prolonged compensation of anemia in comparison with the group of the patients who had not had antibacterial therapy. Finger kirliandiagnostics was offered as an express-method to identify a possible infection. The feature of a high probability of infection is intoxication in gastroduodenal zone, abdomen area and a colon. PMID:23786012

  19. Health-related quality of life and anemia in hospitalized patients with heart failure

    NARCIS (Netherlands)

    Kraai, I. H.; Luttik, M. L. A.; Johansson, P.; De Jong, R. M.; Van Veldhuisen, D. J.; Hillege, H. L.; Jaarsma, T.

    2012-01-01

    Background: Anemia is a serious and highly prevalent co-morbidity in chronic heart failure (HF) patients. Its influence on health-related quality of life (HR-QoL) has rarely been studied, and no data is available regarding the role it plays in hospitalized HF patients. Methods: Baseline data from th

  20. 非清髓性无关供者脐血移植与同胞供者骨髓移植治疗再生障碍性贫血的比较%Clinical comparision of non-myeloablative stem cell transplantation from related bone marrow vs unrelated umbilical cord blood for severe aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    李庆山; 毛平; 王顺清; 莫文健; 张玉平; 应逸

    2008-01-01

    目的 对非清髓性无关供者脐血移植与同胞供者骨髓移植治疗重型再生障碍性贫血(SAA)的临床效果进行评价和比较.方法 回顾性分析15例SAA患者进行非清髓性造血干细胞移植的临床资料,根据造血干细胞(HSC)来源的不同,将患者分为骨髓移植组(BMT组;6例)和脐血移植组(UCBT组;9例).对两组患者术后的外周血象、骨髓象、细胞嵌合体状态、移植物抗宿主病(GVHD)以及存活率等长期随访结果进行了统计学分析.结果 BMT组和UCBT组造血干细胞植入率分别为100%和66.7%,两组比较,差异有统计学意义(P<0.05).UCBT组移植后大多数形成了供、受者型细胞混合嵌合体,BMT组大多数形成了供者型完全嵌合体.BMT组血象恢复正常的中位时间为25 d、UCBT组为120 d,BMT组骨髓象恢复正常的中位时间为25 d,UCBT组为150 d.BMT组慢性GVHD的表现以肝功能异常为主,而UCBT组则以皮疹为主.UCBT组术后早期感染率为33.3%,BMT组为16.7%.结论 非清髓性无关供者脐血移植和同胞供者骨髓移植均可成功治疗SAA;但与BMT比较,UCBT的造血功能恢复较慢、血型转变少而延迟、早期感染率较高、而慢性GVHD的程度却较轻.%Objective To compare and evaluate the clinical effectiveness of non-myeloablative stem cell transplantation from related donor vs unrelated umbilical cord blood(UCB)for patients with severe aplastic anemia(SAA). Methods The clinical data of 15 patients with SAA were retrospectively analyzed. According to the sources of hematopoietic stem cells,patients were divided into bone marrow transplantation(BMT)group(n=6) and UCB transplantation(UCBT) group(n=9)and both of them subjected to nonmyeloablative stem cell transplantation. Long-term follow-up results including peripheral blood,bone marrow,chimerism status,graft-versus-host disease(GVHD),and survival rate were analyzed statistically. Results There was different engraftment rate between BMT

  1. The relationship of telomere and telomerase activity with outcome of aplastic anemia after immunesu pysessive therapy%端粒及端粒酶与再生障碍性贫血免疫抑制治疗疗效的关系

    Institute of Scientific and Technical Information of China (English)

    宋佳音; 邝丽萍; 王洋; 李勇华; 吴九龙; 张航; 李力; 王耀春; 蒋祖军

    2013-01-01

    Objective To observe the changes of telomere length and telomerase activity in patients with aplastic anemia (AA),and relationship with immunosuppressive therapy (IST) efficacy,to explore the pathogenesis of AA and the role of telomere length in evaluating immunosuppressive therapy efficacy.Method 71 cases of AA patients between September 2010 and March 2013 were enrolled into this study.3 ml peripheral blood specimens from this cohort of patients were collected to test the telomere length in peripheral blood mononuclear cell (PBMNC) with flow-FISH and detect telomerase activity with TRAP-PCR-ELISA method.Results Telomere length and age showed negative correlation (b=-0.387,P=0.001) in normal control,NSAA and SAA + VSAA groups,telomere length became shorter with the growth of age,and normal control group telomere length decreased along with the age growth slightly greater than the other two groups (NSAA,SAA+VSAA).Besides the effect of age on telomere length,(30.957±4.502) (29.510±5.911) no significant difference was observed between NSAA and SAA+VSAA groups (P=0.573),and NSAA,SAA+VSAA groups were significantly shorter than normal control group (51.086± 10.844) (P<0.01).Telomere length in NR group (25.357±4.848) was significantly lower than normal control group (51.086± 10.844) (P=0.005),telomere length in CR (32.808±4.685)/PR groups (30.334±4.464) compared with normal control group had no significant difference (P=0.517,P=0.254).Telomere length below 29.21% obviously decreased outcomes of IST.Telomerase activity had significant difference (x2=20.385,P<0.01).The telomerase activity had no significant difference interms of age and gender in three groups,multiple comparison found that telomerase activities in SAA + VSAA (0.324± 0.178) (P<0.01),and NSAA (0.234± 0.175)groups (P=0.002) were significantly higher than normal control group (0.107±0.083).Conclusion Telomere length of PBMNC in AA patients was significantly shortened than normal control group

  2. The correlation of anemia and contrast-induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention

    Institute of Scientific and Technical Information of China (English)

    刘远辉

    2014-01-01

    Objective To investigate the correlation of anemia and contrast-induced nephropathy(CIN)in patients with chronic kidney disease(CKD)undergoing percutaneous coronary intervention(PCI).Methods A total of 292 patients with CKD undergoing PCI admitted to Guangdong General Hospital from October 2010 to December 2012were consecutively enrolled in this study.Anemia was

  3. Increased radiosensitivity of a subpopulation ot T-lymphocyte progenitors from patients with Fanconi's anemia

    International Nuclear Information System (INIS)

    In vitro radiation survival of peripheral blood T lymphocytes was studied in 15 clinically normal adults and 4 patients with Fanconi's anemia. Tritiated thymidine incorporation in a whole blood lymphocyte stimulation test (LST) and a newly developed whole blood T-lymphocyte colony assay were used to measure lymphocyte blastogenesis and colony formation in response to phytohemagglutinin (PHA) or concanavalin-A (Con-A) stimulation. Lymphocyte colony formation was found to be consistently more sensitive than the LST for detection of low-level radiation effects using both normal cells and lymphocytes from Fanconi's anemia patients. Lymphocytes from patients with Fanconi's anemia were significantly more sensitive to in vitro x-irradiation than lymphocytes from clinically normal individuals as measured by their ability to divide when stimulated by PHA in the LST (patients, D37 . 198 R; normals, D37 . 309 R, p . 0.057) and colony formation assay (patients, D37 . 53 R; normals, D37 . 109 R, p . 0.016). No significant difference in the radiosensitivity of the Con-A response was observed between the two groups. The PHA-responsive T-lymphocyte subpopulation in Fanconi's anemia patients appears to be intrinsically defective. The nature of this defect, significance in the disease process, and relevancy of these findings to the establishment of radiation protection standards are discussed

  4. [Peripheral blood monocyte hepcidin in patients with multiple myeloma is associated with anemia of chronic disease].

    Science.gov (United States)

    Han, Xiao; Zhou, Dao-Bin; Duan, Ming-Hui; Wang, Xuan; Zhang, Jie-Ping; Zhao, Yong-Qiang; Shen, Ti; Wu, Yong-Ji

    2013-04-01

    Disorders of iron utilization caused by abnormal elevation of hepcidin levels are the main mechanism of anemia of chronic disease. Hepcidin is mainly produced by the liver. Recently it has been found that monocytes are another source of hepcidin. The increased hepcidin in serum and urine of multiple myeloma patients may be one cause of anemia of chronic disease (ACD). However it is unclear whether the peripheral blood monocyte hepcidin is involved in the pathogenesis of anemia of chronic disease. This study was purposed to investigate the role of monocyte hepcidin in multiple myeloma patients with anemia of chronic disease. The clinical data and peripheral venous blood of multiple myeloma patients were collected.Serum concentration of IL-6 and TNF-α was detected by ELISA. Peripheral blood monocytes were isolated by CD14(+) magnetic beads. Hepcidin, IL-6 and TNF-α mRNA of monocytes were detected by real time quantitative PCR. The results showed that the expression level of monocyte hepcidin mRNA in myeloma patients was higher than that in normal controls. In untreated patients, the expression level of monocyte hepcidin mRNA was negatively correlated with hemoglobin, and positively correlated with serum ferritin and IL-6 levels, but unrelated with TNF-α levels.It is concluded that the increased monocyte hepcidin levels in multiple myeloma patients may play an etiologic role in ACD.

  5. Púrpura trombocitopênica e anemia hemolítica auto-imune em pacientes internados com lúpus eritematoso sistêmico juvenil Trombocytopenic purpura and autoimmune hemolytic anemia in hospitalized patients with juvenile systemic lupus erythematosus

    Directory of Open Access Journals (Sweden)

    Jochebed Kyoung Kim

    2007-02-01

    esplenectomia. CONCLUSÕES: o CHE isolado foi uma manifestação grave em pacientes internados com LESJ, habitualmente associado a uma doença ativa e sistêmica.OBJECTIVE: to evaluate the hematological involvement (HI in hospitalized patients with juvenile systemic lupus erythematosus (JSLE. METHODS: from 1994 to 2005, 195 admissions occurred in 77 JSLE patients (American College of Rheumatology criteria and were followed by the Pediatric Rheumatology Unit of the Instituto da Criança - University of São Paulo. These admissions were evaluated according to the presence of HI at onset or during the evolution of the disease: autoimmune hemolytic anemia (AHA or thrombocytopenic purpura. All patients performed at least two complete blood counts. AHA was defined by a fall in hemoglobin levels (beyond 2 g/dl, reticulocytosis, increase in lactate dehydrogenase (LDH and indirect bilirubin levels, and a positive Coombs test. The hematologic manifestations associated with infection, neoplasia and aplastic anemia were excluded. RESULTS: HI occurred in 14 patients (18.9%, with 15 admissions. Among these patients, 11 were female, 7 had trombocytopenic purpura, 5 AHA and 2 Evans syndrome. HI as onset and single manifestation of JSLE was observed in three patients. All the patients with trombocytopenic purpura presented cutaneous bleeding (petechia and/or ecchymosis. All had disease activity and simultaneously presented other manifestations of JSLE, particularly nephritis and vasculitis. Initially, all patients received pulsetherapy with methylprednisolone and prednisone later. In three patients the treatment aimed predominantly the control of hematologic manifestations, with intravenous gammaglobulin. The most used immunossupressive therapies were intravenous cyclophosphamide, cyclosporine and azathioprine. One patient died of central nervous system bleeding. No patient needed splenectomy. CONCLUSIONS: isolated HI was a severe manifestation in hospitalized patients with JSLE, generally

  6. Frequency of red cell, leukocytic and platelet alloantibodies in patients with hematological diseases

    OpenAIRE

    N. V. Mineeva; S. V. Gavrovskaya; I. I. Krobinets; I. A. Pashkova; N. N. Bodrova; E. A. Sysoeva

    2013-01-01

    History of multiple transfusions in patients with hematological diseases increases the likelihood of immunization to donor blood cells antigensand immunological complications development. Incidence of alloantibodies development in this patients was assessed in this work. Alloantibodies detection was performed in patients with aplastic anemia, acute leukemia, chronic lymphocytic leukemia, and autoimmune thrombocytopenia. 9696 patients were included in this study. Frequency of alloantibodies to...

  7. THE PREVALENCE OF CELIAC DISEASE IN PATIENTS WITH IRON-DEFICIENCY ANEMIA IN CENTER AND SOUTH AREA OF IRAN

    Directory of Open Access Journals (Sweden)

    Mahmud BAGHBANIAN

    2015-12-01

    Full Text Available Background - Celiac disease is an immune-mediated enteropathy due to a permanent sensitivity to gluten in genetically susceptible people. Iron-deficiency anemia is the most widely experienced anemia in humans. Iron-deficiency anemia additionally is a common extra intestinal manifestation of celiac disease. Objective - To investigate correlation between tTg levels and histological alterations and then to determine the prevalence of celiac disease in Center and South area patients of Iran with iron deficiency anemia. Methods - A total of 402 patients aged 12-78 years who presented with iron-deficiency anemia were included in this study. Hemoglobin, mean corpuscular volume and serum ferritin were determined. Venous blood samples for anti-tissue transglutaminase antibody immunoglobuline A and G were obtained from these patients. Upper gastrointestinal endoscopy was recommended to patients who had positive serology. Results - Of 402 patients with iron-deficiency anemia, 42 (10.4% had positive serology for celiac disease. The small intestine biopsy of all patients with positive serology showed pathological changes (Marsh I, II & III. There was not significant difference in the mean hemoglobin level between iron-deficiency anemia patients with celiac disease and without celiac disease, duodenal biopsy results did not show significant relationship between the severity of pathological changes and levels of anti-tTG IgG (P -value: 0/869 but significant relationship was discovered between pathological changes and levels of anti-tTG IgA (P -value: 0/004. Conclusion - Screening of celiac disease by anti-tissue transglutaminase antibody should be completed as a routine investigation in patients with iron-deficiency anemia. Also physicians must consider celiac disease as a possible reason of anemia in all patients with iron deficiency anemia.

  8. Recovery from anemia in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation--prevalence, predictors and clinical outcome

    DEFF Research Database (Denmark)

    De Backer, Ole; Arnous, Samer; Lønborg, Jacob;

    2014-01-01

    -recovery, while blood transfusion (OR 0.31, P = 0.038) and chronic kidney disease (CKD, OR 0.33, P = 0.043) were identified as negative predictors at, respectively, one and two years after TAVI. When compared to patients without baseline anemia, those anemic patients with Hb-recovery had a similar functional......INTRODUCTION: Preoperative anemia is common in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) and has been linked to a poorer outcome--including a higher 1-year mortality. The aim of this study was to investigate the impact of successful TAVI...... on baseline anemia. METHODS: A total of 253 patients who survived at least 1 year following TAVI were included in this study. The prevalence, predictors and clinical outcome of hemoglobin (Hb)-recovery were assessed. RESULTS: The prevalence of baseline anemia was 49% (n = 124)--recovery from anemia occurred...

  9. Increasing peripheral blood neutrophils after G-CSF treatment is a predictor of early response to immunosuppressive therapy in severe aplastic anemia%G-CSF治疗后中性粒细胞反应预测重型再生障碍性贫血免疫抑制治疗早期疗效

    Institute of Scientific and Technical Information of China (English)

    武志洁; 杨文睿; 张莉; 井丽萍; 周康; 李洋; 彭广新; 叶蕾; 李园

    2014-01-01

    Objective To testify whether absolute neutrophil count (ANC) response to preimmunosuppressive-therapy (pre-IST) granulocyte-stimulating factor (G-CSF) treatment could predict early response to IST in severe aplastic anemia (SAA).Methods Clinical data and hematologic response of 125 SAA patients treated with antithymocyte globulin (r-ATG) combined with cyclosporine were retrospectively analyzed.Correlation of ANC response to pre-IST G-CSF treatment and early response to IST were statistically analyzed,and receiver operating characteristic (ROC) curve was used to estimate the value of increased ANC (Δ ANC) in predicting early IST response.Results The hematologic response (HR) rate to IST in ANC reponded patients was significantly higher than non-responded group (3-month HR 49.0% vs 28.9%,P=0.023; 6-month HR 61.2% vs 40.8%,P=0.026).With ΔANC≥0.5× 109/L as cutoff level,the best point to predict early IST response was 10 days after G-CSF (d 10).Response of ANC to pre-IST G-CSF treatment at d 10 was among the independent factors of predicting 3-month (P=0.004),but not for 6-month response to IST.The overall 5-year survival rate was 92.8% and 69.5% in ANC responded and non-responed groups,respectively (P=0.025).Conclusion Responding to pre-IST G-CSF treatment reflected the residual bone marrow hematopoiesis,and could act as a convenient and practical predictor to early IST response as well as long-term survival in SAA.%目的 探讨重型/极重型再生障碍性贫血(SAA/VSAA)患者免疫抑制治疗(IST)前应用G-CSF治疗后的中性粒细胞反应(ANC反应)对于IST早期疗效的预测价值.方法 回顾性分析2005年9月至2011年11月行IST的SAA/VSAA共125例患者资料,对IST前应用G-CSF治疗后的ANC反应与IST近期疗效进行相关性分析,绘制G-CSF治疗后ANC增高程度(ΔANC)预测IST疗效的ROC曲线.结果 G-CSF治疗后ANC反应组IST后3个月(49.0%对28.9%,P=0.023)及6个月(61.2%对40.8%,P=0.026)血液学反

  10. Impacts of parathyroidectomy on renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism.

    Science.gov (United States)

    Chen, Chen; Wu, Hua; Zhong, Lin; Wang, Xin; Xing, Zhuang-Jie; Gao, Bi-Hu

    2015-01-01

    The aim of this study was to investigate the impacts of parathyroidectomy (PTX) towards the renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism (SHPT). 32 patients, enrolled into the blood purification center of our hospital for the hemodialysis treatment, were collected and divided into the PTX group and the non-PTX group, with 16 patients in each group. The changes of relevant indicators such as immunoreactive parathyroid hormone (iPTH), anemia and nutrition were observed before, 1-, 3-, 6-month after the treatment. The contents of iPTH, Ca, P and Ca × P of the PTX group decreased rapidly 1 month after the surgery; while Hb and Hct increased significantly from the 1st postoperative month; the dosage of EPO was significantly reduced 3-month after the surgery; the content of Alb gradually increased from the 3(rd) postoperative month; the content of TG decreased significantly from the 6(th) postoperative month; while the contents of BMI and TSF increased significantly from the 6(th) postoperative month, which exhibited the statistically significant differences when compared with the preoperative and the non-PTX group (P anemia and nutritional status; SHPT was the important factor that would affect the renal anemia and malnutrition; PTX could reduce the amount of EPO, and reduce the economic burden of patients.

  11. Clostridium Perfringens Infection in a Febrile Patient with Severe Hemolytic Anemia

    OpenAIRE

    Hashiba, Masamitsu; Tomino, Atsutoshi; Takenaka, Nobuyoshi; Hattori, Tomonori; Kano, Hideki; Tsuda, Masanobu; Takeyama, Naoshi

    2016-01-01

    Patient: Male, 82 Final Diagnosis: Clostridium perfringens infection Symptoms: Anemia • fever • shock Medication: — Clinical Procedure: Antimicrobial chemotherapy Specialty: Infectious Diseases Objective: Rare disease Background: Clostridium perfringens (C. perfringens) can cause various infections, including gas gangrene, crepitant cellulitis, and fasciitis. While C. perfringens sepsis is uncommon, it is often rapidly fatal because the alpha toxin of this bacterium induces massive intravascu...

  12. Anemia in Elderly Koreans

    OpenAIRE

    Lee, Jong Hwa

    2011-01-01

    Recently, the geriatric population in Korea has grown to comprise approximately 10% of the total population, and anemia has become a significant problem among elderly patients. Many elderly patients have anemia due to nutritional deficiency, chronic inflammation, or comorbid diseases; however, in a significant fraction of the patients with anemia, the cause remains obscure. Anemia of any degree is recognized as a significant independent contributor to morbidity and mortality in elderly patien...

  13. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.

    Directory of Open Access Journals (Sweden)

    Sheeja M Krishnan

    Full Text Available The current standard of care for hepatitis C virus (HCV infection - combination therapy with pegylated interferon and ribavirin - elicits sustained responses in only ∼50% of the patients treated. No alternatives exist for patients who do not respond to combination therapy. Addition of ribavirin substantially improves response rates to interferon and lowers relapse rates following the cessation of therapy, suggesting that increasing ribavirin exposure may further improve treatment response. A key limitation, however, is the toxic side-effect of ribavirin, hemolytic anemia, which often necessitates a reduction of ribavirin dosage and compromises treatment response. Maximizing treatment response thus requires striking a balance between the antiviral and hemolytic activities of ribavirin. Current models of viral kinetics describe the enhancement of treatment response due to ribavirin. Ribavirin-induced anemia, however, remains poorly understood and precludes rational optimization of combination therapy. Here, we develop a new mathematical model of the population dynamics of erythrocytes that quantitatively describes ribavirin-induced anemia in HCV patients. Based on the assumption that ribavirin accumulation decreases erythrocyte lifespan in a dose-dependent manner, model predictions capture several independent experimental observations of the accumulation of ribavirin in erythrocytes and the resulting decline of hemoglobin in HCV patients undergoing combination therapy, estimate the reduced erythrocyte lifespan during therapy, and describe inter-patient variations in the severity of ribavirin-induced anemia. Further, model predictions estimate the threshold ribavirin exposure beyond which anemia becomes intolerable and suggest guidelines for the usage of growth hormones, such as erythropoietin, that stimulate erythrocyte production and avert the reduction of ribavirin dosage, thereby improving treatment response. Our model thus facilitates, in

  14. Anemia in patients on combined androgen block therapy for prostate cancer

    Institute of Scientific and Technical Information of China (English)

    Li-XinQian; Li-XinHua; Hong-FeiWu; Yuan-GengSui; Shuang-GuanCheng; WeiZhang,JieLi; Xin-RuWang

    2004-01-01

    Aim: To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer. Methods: One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1,2,3,6,9 and 12 months of therapy. Results: The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05). Conclusion: Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia. (Asian J Androl 2004 Dec;6: 383-384)

  15. Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients

    NARCIS (Netherlands)

    Kleijn, Lennaert; Westenbrink, B. Daan; van Deursen, Vincent M.; Damman, Kevin; de Boer, Rudolf A.; Hillege, Hans; van Veldhuisen, Dirk J.; Voors, Adriaan A.; van der Meer, Peter

    2014-01-01

    Background Anemia is frequently observed in patients with cardiovascular disease. Multiple factors have been associated with anemia, but the role of hemodynamics is largely unknown. Therefore, we investigated the association between hemoglobin (Hb) levels, hemodynamics and outcome in a broad spectru

  16. T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

    Science.gov (United States)

    2015-10-05

    Acute Myelogenous Leukemia; Lymphoid Leukemia; Chronic Myelogenous Leukemia; Malignant Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia; Myeloproliferative Disorder; Anemia, Aplastic; Myelodysplastic Syndromes

  17. Risk Factors of anemia in head and neck cancer patients undergoing chemotherapy with high-dose cisplatin

    Directory of Open Access Journals (Sweden)

    Johan Kurnianda

    2008-12-01

    Full Text Available Cisplatin is well-known for its effectiveness against cancer, as well as its toxicity to human tissues. Of several documented side effects, anemia was reported to have significant association with decreased quality of life. This study was conducted to investigate development of cisplatin-induced anemia, and to identify independent factors contributing to anemia. Clinical data from head and neck cancer patients treated with high-dose cisplatin between December 2002 and December 2005 were obtained in this study. Incidence and risk factors of anemia were assessed in a model including age, sex, baseline hemoglobin level, baseline creatinine clearance, and occurrence of distant metastases. Multivariate logistic regression was used to define independent predictors of anemia. Among 86 eligible patients, 26 (30.2% developed anemia, defined as Hb level lower than 11 g/dL. Age > 55 years old (RR = 2.2, 95% CI, 1.2-4.0, female sex (RR = 2.0, 95% CI, 1.2-3.8, baseline Hb ≤ 13 g/dL (RR = 4.2, 95% CI, 1.9-9.4 and baseline CrCl < 50 mL/min (RR = 2.9, 95% CI, 1.7-5.1 were significantly correlated with incidence of anemia (P < 0.05. In multivariate analysis, baseline Hb and baseline CrCl were identified as independent risk factors for anemia. However, considerable confounding was observed in baseline CrCl after stratified by age (aRR = 2.2, 95% CI, 1.1-4.7. Thus, baseline Hb level was the strongest predictor of anemia. The findings suggested that baseline Hb and CrCl were useful to recognize cisplatin-treated patients at risk for anemia who might benefits from preventive measures. (Med J Indones 2008; 17: 248-54Keywords: anemia, cisplatin, chemotherapy, hemoglobin, creatinine clearance

  18. Parvovirus B19 infection in Tunisian patients with sickle-cell anemia and acute erythroblastopenia

    Directory of Open Access Journals (Sweden)

    Zili Mohamed

    2007-10-01

    Full Text Available Abstract Background Human parvovirus B19 is the etiologic agent of erythema infectiosum in children. It is also associated with other clinical manifestations in different target groups. Patients with chronic hemolytic anemia are at high risk of developing acute erythroblastopenia following infection by the virus. They usually become highly viremic and pose an increased risk of virus transmission. Close monitoring of such high risk groups is required for epidemiologic surveillance and disease prevention activities. Here we report a molecular epidemiological study on B19 virus infection in Tunisian patients with chronic hemolytic anemia. Methods This study was conducted on 92 young chronic hemolytic anemia patients who attended the same ward at the National Bone Marrow Transplantation Center of Tunis and 46 controls from a different hospital. Screening for IgM and IgG anti-B19 antibodies was performed using commercially available enzyme immunoassays and B19 DNA was detected by nested PCR in the overlapping VP1/VP2 region. DNA was sequenced using dideoxy-terminator cycle sequencing technology. Results Anti-parvovirus B19 IgG antibodies were detected in 26 of 46 sickle-cell anemia patients, 18 of 46 β-thalassemia and 7 of 46 controls. Anti-parvovirus B19 IgM antibodies were detected only in 4 of the sickle-cell anemia patients: two siblings and two unrelated who presented with acute erythroblastopenia at the time of blood collection for this study and had no history of past transfusion. B19 DNA was detected only in sera of these four patients and the corresponding 288 bp nested DNA amplicons were sequenced. The sequences obtained were all identical and phylogenetic analysis showed that they belonged to a new B19 virus strain of Genotype1. Conclusion A new parvovirus B19 strain of genotype1 was detected in four Tunisian patients with sickle-cell anemia. Virus transmission appeared to be nosocomial and resulted in acute erythroblastopenia in the four

  19. Assessment of Enalapril Effect on Inducing Anemia In Non-Azotemic Diabetic Patients

    Directory of Open Access Journals (Sweden)

    S Seyrafian

    2005-01-01

    Full Text Available Background: Angiotensin converting enzyme inhibitors (ACEIs are known to induce anemia following renal transplantation, dialysis and in renal failure patients. It seems that ACEIs cause anemia via inhibition of erythropoietin synthesis or inhibiting normal proliferation of early erythroid progenitors, which are normally stimulated by angiotensin converting enzyme. There are few reports on how ACEIs induce anemia in non-azotemic diabetic patients. We studied the effect of enalapril on inducing anemia in non-azotemic diabetic patients. Methods: This study included 94 diabetic non-azotemic patients (serum creatinine (sCr ?1.5 mg/dl by jaffe reaction. Patients were divided into two groups, the first; with clinical proteinuria (P+ having a 24 hour urine protein ?300 mg or positive urine dipstick for protein, at least on two of three times tested, with an interval of 1 month and the second group without any signs of clinical proteinuria (P- . Only 32 patients completed the course of study; 17 as P+ and 15 as P-. Patients in both groups received 10 mg enalapril daily; and every 3 months, the dose was doubled until the dose of 40 mg/day was reached, unless any side effects emerged. Hemoglobin concentration (Hb, sCr and serum potassium (K+ were also checked regularly. Data were analyzed using t-Student test, paired t test, and chi-square test. A p value < 0.05 was considered as significant. Results: Both groups of patients were matched from the standpoint of age and sex. The average baseline sCr in P+ and P- groups were 0.8 ± 0.19 mg/dl and 0.8 ± 0.18 mg/dl respectively.( p = 0.97 After the study was completed, the average baseline sCr rose to 0.99±0.19 and 0.92±0.22 mg/dl in P+ and P- groups respectively. In P+ group, mean Hb was 14.1 ±1.30 g/dl and 13.9 ± 0.99g/dl before and after the study respectively.(p = 0.28 The same parameter for the P- group was measured as 14.1±1.00 and 12.9±3.30 before and after the study respectively

  20. Efficacy,safety and tolerance of continuous erythropoietin receptor activator intravenous administration on anemia correction in dialysis patients with chronic renal anemia

    Institute of Scientific and Technical Information of China (English)

    钱家麒

    2013-01-01

    Objective To evaluate the efficacy,safety and toler-ance of continuous erythropoietin receptor activator(CE-RA) once every 2 weeks intravenous injection on anemia correction in dialysis patients compared to Epoetin-β(EPO-β) administration. Methods An open label,

  1. Treatment of solitary gastric carcinoid tumor by endoscopic polypectomy in a patient with pernicious anemia

    Institute of Scientific and Technical Information of China (English)

    Gurhan Kadikoylu; Irfan Yavasoglu; Vahit Yukselen; Esra Ozkara; Zahit Bolaman

    2006-01-01

    Type T gastric carcinoid tumors result from hypergastrinemia in 1%-7% of patients with pernicious anemia. We diagnosed pernicious anemia in a 48-year-old female patient with complaint of fatigue for three months.She had no gastrointestinal symptoms. Endoscopic examination ot the upper gastrointestinal tract revealed atrophic gastritis and a polypoid lesion in the corpus of 3-4 mm in size. Endoscopic polypectomy was performed.Histopathological examination of the specimen revealed positive chromogranin A and synaptophysin stainings compatible with the diagnosis of a carcinoid tumor. Serum gastrin level was increased, urinary 5-hydroxyindoleacetic acid was within the normal range.There was no other symptom, sign, or laboratory finding of a carcinoid syndrome in the patient. No metastasis was found with indium-111 octreotide scan, computed tomographies of abdomen and thorax. Type Ⅰ gastric carcinoid tumors are only rarely solitary and patients with tumors < 1 cm in size may benefit from endoscopic polypectomy.

  2. Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city

    Directory of Open Access Journals (Sweden)

    Rose A Ugiagbe

    2011-01-01

    Full Text Available Background: Hepatotoxicity is a relevant adverse effect of highly active antiretroviral Treatment owing to its frequency, and it can cause interruption of therapy, hepatitis, and death. There is dearth of information on hepatotoxicity arising from highly active antiretroviral therapy (HAART in anemic patients. Anemia is the most common symptom in human immunodeficiency virus (HIV/acquired immunodeficiency syndrome. We studied the effect of anemia on hepatotoxicity in HIV patients who were about to start HAART, attending clinic, or in the medical wards. Materials and Methods: This was a prospective study in which patients were recruited consecutively and followed up for 24 weeks. Results: In all, 84 patients were recruited and 42 were enrolled as controls. The mean ages of the cases and controls were 35.2΁9.9 and 35.5΁9.0 years, respectively. The age range of the cases was 18-68 years with a median age of 31.5 years, whereas the mean age of the controls was 20-57 years with a median age of 33.5 years. There was no difference (t=0.197, df=124, and P=0.844. There were 61 females (72.6% and 23 males (27.4% in the cases, whereas in the controls, there were 34 females (81.0% and 8 males (19.0%. Among the cases, 30 (35.7% were anemic, while 54 (64.3% were not anemic. Six (20% of the anemic patients had hepatotoxicity, and 9 (16.7% of the patients with normal packed cell volume had hepatotoxicity. Among the controls, all 42 (100% patients had normal packed cell volume. Four (9.5% of the patients had hepatotoxicity. There was no association between hepatotoxicity and anemia (χ2 =3.243, df=2, P=0.198. Conclusion: Anemia did not affect hepatotoxicity of HAART in this study.

  3. Mild hemorheological changes induced by a moderate endurance exercise in patients with sickle cell anemia

    OpenAIRE

    Balayssac-Siransy, Edwige; Connes, Philippe; Tuo, Nalourgo; Danho, Clotaire; Diaw, Mor; Sanogo, Ibrahima; Hardy-Dessources, Marie-Dominique; Samb, Abdoulaye; Ballas, Samir K.; Bogui, Pascal

    2011-01-01

    Abstract The levels and duration of physical activity that can be considered as completely safe in patients with sickle cell anemia (SCA) is unknown. The present study compared the hemorheological and hematological profile, cell density distribution and basic biochemistry between a group of 17 patients with SCA and 21 healthy subjects before and after a 20 min duration submaximal cycling exercise at the same absolute workload. Blood was sampled at rest and 3 min after the end of ex...

  4. Relation between Anemia and Vulnerable Coronary Plaque Components in Patients with Acute Coronary Syndrome: Virtual Histology-Intravascular Ultrasound Analysis

    OpenAIRE

    Hong, Young Joon; Jeong, Myung Ho; Choi, Yun Ha; Song, Jin A; Kim, Dong Han; Lee, Ki Hong; Yamanaka, Futoshi; Lee, Min Goo; Park, Keun Ho; Sim, Doo Sun; Yoon, Nam Sik; Yoon, Hyun Ju; Kim, Kye Hun; Park, Hyung Wook; Kim, Ju Han

    2012-01-01

    The aim of the present study was to evaluate the plaque components and the predictors of thin-cap fibroatheroma (TCFA) in anemic patients with acute coronary syndrome using virtual histology-intravascular ultrasound (VH-IVUS). Anemia was defined according to criteria of the World Health Organization, (i.e. , hemoglobin levels < 13 g/dL in men and < 12 g/dL in women) and we compared VH-IVUS findings between anemia group (171 patients, 260 lesions) and non-anemia group (569 patients, 881 lesion...

  5. Hepcidin-Induced Iron Deficiency Is Related to Transient Anemia and Hypoferremia in Kawasaki Disease Patients.

    Science.gov (United States)

    Huang, Ying-Hsien; Kuo, Ho-Chang; Huang, Fu-Chen; Yu, Hong-Ren; Hsieh, Kai-Sheng; Yang, Ya-Ling; Sheen, Jiunn-Ming; Li, Sung-Chou; Kuo, Hsing-Chun

    2016-01-01

    Kawasaki disease (KD) is a type of systemic vasculitis that primarily affects children under the age of five years old. For sufferers of KD, intravenous immunoglobulin (IVIG) has been found to successfully diminish the occurrence of coronary artery lesions. Anemia is commonly found in KD patients, and we have shown that in appropriately elevated hepcidin levels are related to decreased hemoglobin levels in these patients. In this study, we investigated the time period of anemia and iron metabolism during different stages of KD. A total of 100 patients with KD and 20 control subjects were enrolled in this study for red blood cell and hemoglobin analysis. Furthermore, plasma, urine hepcidin, and plasma IL-6 levels were evaluated using enzyme-linked immunosorbent assay in 20 KD patients and controls. Changes in hemoglobin, plasma iron levels, and total iron binding capacity (TIBC) were also measured in patients with KD. Hemoglobin, iron levels, and TIBC were lower (p hepcidin levels (both p hepcidin levels were positively and significantly correlated with urine hepcidin levels (p hepcidin and hemoglobin levels significantly decreased (both p hepcidin induces transient anemia and hypoferremia during KD's acute inflammatory phase. PMID:27187366

  6. Prevalence and Severity of Anemia in Pediatric Hemodialysis Patients; A Single Center Study

    Directory of Open Access Journals (Sweden)

    Alaleh Ghasari

    2007-04-01

    Full Text Available Objective: To determine the prevalence and severity of anemia in children and adolescents on chronic hemodialysis and to identify independent predictor for anemia in children on hemodialysis. Material & Methods: A cross sectional study was performed between September 2005 and January 2006. The study population consisted of 25 patients aged 7−20 years on chronic hemodialysis from pediatric hemodialysis centers in Isfahan, Iran. Findings: A total of 22 (82% patients had hemoglobin level of 200 pg/ml in 16 patients (66% and >400 pg/ml in 9 patients (37.5%. There was a reverse correlation between PTH level>200 pg/ml and hemoglobin level (r=-0.505, P=0.046. Conclusion: The prevalence of anemia in children on hemodialysis in Isfahan appears to be higher than that reported in the other studies in spite of extensive use of rHuEPO and iron supplementation. We found this to be especially true for patients new on hemodialysis (less than 6 months, low albumin and severe hyperparathyroidism.

  7. Distinct roles of urinary liver-type fatty acid-binding protein in non-diabetic patients with anemia.

    Directory of Open Access Journals (Sweden)

    Naohiko Imai

    Full Text Available Various stresses including ischemia are known to up-regulate renal L-FABP gene expression and increase the urinary excretion of L-FABP. In diabetic patients with anemia, the urinary excretion of L-FABP is significantly increased. We studied the clinical significance of urinary L-FABP and its relationship with anemia in non-diabetic patients.A total of 156 patients were studied in this retrospective cross-sectional analysis. The associations between anemia and urinary L-FABP levels, and the predictors of urinary L-FABP levels in non-diabetic patients were evaluated.Urinary L-FABP levels were significantly higher in patients with anemia compared to those in patients without anemia. Similarly, the urinary L-FABP levels were significantly higher in patients with albuminuria compared to those in patients without albuminuria. Urinary L-FABP levels correlated with urinary albumin-to-creatinine ratios, estimated glomerular filtration rates, body mass index, and hemoglobin levels. Multivariate linear regression analysis determined that hemoglobin levels (β = -0.249, P = 0.001 and urinary albumin-to-creatinine ratios (β = 0.349, P < 0.001 were significant predictors of urinary L-FABP levels.Urinary L-FABP is strongly associated with anemia in non-diabetic patients.

  8. Variabilidade da frequência cardíaca em pacientes com anemia ferropriva Variabilidad de la frecuencia cardiaca en pacientes con anemia ferropriva Heart rate variability in patients with iron deficiency anemia

    Directory of Open Access Journals (Sweden)

    Mustafa Tuncer

    2009-05-01

    with increased cardiac risk factor in several conditions. The iron status of an individual may play an important role in cardiovascular health. OBJECTIVE: To evaluate heart rate variability in patients with iron deficiency anemia. METHODS: Twenty-three patients with iron deficiency anemia (mean hemoglobin (Hb 8.6±2.2 g/dl and 10 healthy people (mean Hb 13.9±1.2 g/dl were assessed with 24-hour ambulatory Holter recordings during in hospital course having limited physical activity. RESULTS: Although mean heart rate was significantly higher in patients with anemia, there was no significant difference regarding HRV parameters compared to the healthy group. CONCLUSION: There was no significant difference in HRV parameters between patients with iron deficiency anemia with limited physical activity and healthy ambulatory people.

  9. [Hospital-acquired anemia and decrease of hemoglobin levels in hospitalized patients].

    Science.gov (United States)

    Gianserra, Carina V; Agüero, Andrés P; Chapelet, Adrián G; Paradiso, Bruno; Spanevello, Valeria A; Del Pino, María A

    2011-01-01

    It is common to observe the development of anemia in hospitalized patients, especially in critical cases. Few studies have evaluated its prevalence and associated factors in patients in the general ward. The purpose of this study is to determine the prevalence, characteristics and associated clinical factors of hospital-acquired anemia and the drop of hemoglobin concentration in hospitalized patients. This is a cross-sectional, prospective and descriptive study. A total of 192 consecutive in-patients in the general ward were studied. Associated risk factors to the drop in hemoglobin by ≥ 2g/dl were analyzed; 139 patients (72.4%) presented anemia; 89 of them (46.4%) had it at admission and 50 (26%) developed hospital-acquired anemia, 47 out of 192 showed a drop in hemoglobin ≥ 2 g/dl(24.48%). They also presented lower values of hematocrite and hemoglobin at discharge (p = 0.01), parenteral hydration at a higher volume (p = 0.01), and lengthier hospitalizations (p = 0.0001). In the univariate analysis, the following variables were statistically significant risk factors: leukocytosis ≥ 11000 mm3 (OR; IC95%: 2,02; 1.03-4; p = 0.01), hospitalization days ≥ 7 (OR; IC95%:3.39; 1.62-7.09; p = 0.0006), parenteral hydration ≥ 1500 ml/day (OR; IC95%: 2.47; 1.06-6.4; p = 0.01), central venous access (OR; IC95%:10.29; 1.75-108.07; p = 0.003) and hospital-acquired anemia (OR; IC95%: 7.06; 3.41-15.83; p = 0.00000004). In the multivariate analysis, the following variables were independent predictive factors of the hemoglobin decrease = 2 g/dl: leukocytosis ≥ 11000 mm3 (OR; IC95%: 2.45; 1.14-5,27; p = 0.02), hospitalization days ≥ 7 (OR; IC95%:5.15; 2.19-12.07; p = 0.0002), parenteral hydration ≥ 1500 ml/day (OR; IC95%: 2.95; 1.13-7.72; p = 0.02), central venous access (OR; IC95%:8.82; 1.37-56.82; p = 0.02). Hospital-acquired anemia has a high prevalence. Lengthier stays, presence of leukocytosis, parenteral hydration and central venous access placement are

  10. Effect of different methods of haematopoietic stem cell transplantation for the treatment of severe aplastic anemia%不同的造血干细胞移植方式对重型再生障碍性贫血治疗效果的影响

    Institute of Scientific and Technical Information of China (English)

    戚永磊; 许多荣; 王顺清; 邹外一; 李娟

    2012-01-01

    transplantation (Allo-PBSCT) , allogeneic bone marrow transplantation (Allo-BMT) and Allo-PBSCT plus Allo-BMT for the treatment of severe aplastic anemia (SAA). Methods; Thirty^seven patients with SAA received HLA-matched sibling donor stem cell transplantation ( n = 11, Allo-PBSCT group, n =14, Allo-BMT group, n = 12, Allo-PBSCT plus BMT group). The mean time of reconsitution of neutrophils (Neu) and platelets (Pit) , short tandem repeats (STR) in detecting the engratment, the incidence of infection with agranulocytosis , and graft versus host diseases (GvHD)were observed.The three-year incidence of graft failure(GF),mortality and disease -tree survival(DFS) after transplantation were also investigated.Results; The mean time of reconsitution of Neu was (13. 5 ± 2. 3) days.(21. 2 ±3. 5) days and (14. 7 ±2. 4) days in Allo-PBSCT group, Allo-PBSCT plus BMT group and Allo-BMT group respectively.Significant differences were observed between the front two groups and the latter group(P<0.05).The mean time of reconsitution of Pit was (24 ±4) days.(22±5) days and (23 ±5)days respectively in Allo-PBSCT group, Allo-PBSCT plus BMT group and Allo-BMT group respectively No statistical difference among the three groups.Full donor chimerism was confirmed in all 37 patients at post-tranplant day28. The incidence of infection with agranulocytosis of Allo -PBSCT group and Allo-PBSCT plus BMT group was 9% and 17% respectively and were lower obviously than that in Allo -BMT group which was 57% and there were statistical differences between the front two groups and the latter group( P < 0. 05 ).The incidence of GvHD of Allo -PBSCT group was 36% and no GvHD happened in Allo-BMT group and Allo-PBSCT plus BMT group and the statistical differences between the front group and the latter groups was positive respectively(P <0. 05). The three-year incidence of GF, mortality and DFS in PBSCT group was 36. 3%, 9. 0% and 63. 6% respectively.All patients in Allo-PBSCT plus BMT group and Allo-BMT group

  11. Anemia and Immunosuppressive Regimen in Renal Transplanted Patients: Single-Center Retrospective Study.

    Science.gov (United States)

    Carta, P; Bigazzi, B; Buti, E; Antognoli, G; Di Maria, L; Caroti, L; Minetti, E E

    2016-03-01

    We compared retrospectively the level of hemoglobin and the percentage of patients with anemia among 59 kidney transplant recipients receiving everolimus, cyclosporine, and corticosteroids and 128 treated with cyclosporine, mycophenolic acid, and corticosteroids. We also compared age at the time of transplantation, sex and ferritine, serum creatinine, creatinine clearance, folic acid, cyanocobalamine levels, use od recombinant erythropoietin, mean corpuscolar volume at the last ambulatory control. Statistical analysis included Student t test, χ(2) test, and logistic regression. The analysis was performed using SPSS software. We observed no difference in terms of hemoglobin levels in patients treated with everolimus (12.9 ± 1.6 vs 12.7 ± 1.5 g/dL). Anemia (defined as hemoglobin erythropoietin) was found in 49% and 45% of patients in the 2 groups respectively (P = .6). The other parameters evaluated were similar except for the mean corpuscular volume, which was significantly lower in the everolimus group. In the multivariate analysis only serum creatinine and estimated glomerular filtration rate influenced the level of hemoglobin. We observed no differences in terms of development of anemia in renal transplanted patients treated with everolimus-based regimen. PMID:27109950

  12. Anemia del paciente crítico y quirúrgico: tratamiento con hierro intravenoso Anemia in critically ill and surgical patient: treatment with intravenous iron

    Directory of Open Access Journals (Sweden)

    M.ª Cortés-Berdonces

    2012-02-01

    Full Text Available Introducción: La anemia es la anomalía hematológica y analítica más frecuente entre los pacientes críticos y quirúrgicos. Habitualmente se trata con transfusión de sangre alogénica (TSA, la cuál está relacionada con aumento de la morbimortalidad, por lo que se plantea la búsqueda de alternativas para el tratamiento de la anemia grave. Objetivos: Valorar la posible utilidad de la terapia con hierro intravenoso en pacientes con enfermedad crítica o quirúrgica que presentan anemia. Métodos: Revisión de los trabajos publicados con hierro intravenoso en este tipo de pacientes. Búsqueda en la base de datos Medline (www.ncvi.nlm.nih.gov y búsqueda manual. Resultado y discusión: El tratamiento con hierro intravenoso no es suficiente para tratar la anemia del paciente crítico. Su asociación a eritropoyetina sí puede tener un efecto sobre la tasa de transfusiones aunque no se ha demostrado que mejore la morbimortalidad ni la estancia hospitalaria. En cirugía digestiva o traumatológica no hay evidencia que apoye el tratamiento sistemático pericirugía con hierro intravenoso, pudiendo encontrarse beneficio cuando se utiliza junto con eritropoyetina. La utilización de hierro intravenoso solo o asociado a EPO en el postoperatorio no ha demostrado ser útil para una corrección rápida de la anemia, disminuir la estancia hospitalaria ni disminuir la mortalidad.Background: Anemia is a common condition among surgical and critically ill patients and it is usually treated with allogenic blood transfusion (ABT. As ABT is associated with increased morbidity and mortality, alternative therapies for anemia in these patients are actively investigated. Objectives: To asses the potential usefulness of intravenous iron therapy in critically-ill or surgical patients with anemia. Methods: Review of published papers with intravenous iron in these patients. Bibliographical search on database Medline (www.ncvi.nlm.nih.gov. Results and discussion

  13. Comparative study of intravenous iron sucrose versus ferric carboxymaltose for the treatment of iron deficiency anemia in postpartum patients

    Directory of Open Access Journals (Sweden)

    Kishorkumar Vitthal Hol

    2015-06-01

    Conclusions: Fixed dose iron sucrose and ferric carboxymaltose are equally effective and safe for the treatment of iron deficiency anemia in postpartum patients. [Int J Reprod Contracept Obstet Gynecol 2015; 4(3.000: 669-673

  14. Screening of aplastic anaemia-related genes in bone marrow CD4+ T cells by suppressive subtractive hybridization

    Institute of Scientific and Technical Information of China (English)

    ZHENG Miao; LIU Wen-li; FU Jin-rong; SUN Han-ying; ZHOU Jian-feng; XU Hui-zhen

    2007-01-01

    Background CD4+ T cells play a crucial role in the pathogenesis of aplastic anaemia. However, the mechanisms of over-proliferation, activation, infiltration of bone marrow and damage to haematopoietic cells of CD4+ T cells in aplastic anaemia are unclear. Therefore, we screened differentially expressed genes of bone marrow CD4+ T cells of aplastic anaemia patients and normal donors by suppressive subtractive hybridization to investigate the pathogenesis of aplastic anaemia.Methods The bone marrow mononuclear cells of a first visit aplastic anaemia patient and a healthy donor of the same age and sex were isolated using lymphocyte separating medium by density gradient centrifugation. With the patients as "tester" and donor as "driver", their CD4+T cells were separated with magnetic bead sorting and a cDNA library established by suppressive subtractive hybridization. Then 15 of the resulting subtracted cDNA clones were randomly selected for DNA sequencing and homological analysis. With semiquantitative RT-PCR, bone marrow samples from 20 patients with aplastic anaemia and 20 healthy donors assessed the expression levels of differentially expressed genes from SSH library.Results PCR detected 89 clones in the library containing an inserted fragment of 100 bp to 700 bp. Among 15 sequenced clones, 12 were known genes including 3 repeated genes. Compared with normal donors, there were 9/12 genes over-expressed in bone marrow CD4+T cells of patients with aplastic anaemia. The effects of these genes included protein synthesis, biology oxidation, signal transduction, proliferative regulation and cell migration. Not all these genes had been reported in the mechanisms of haematopoietic damage mediated by CD4+ T cells in aplastic anaemia.Conclusions Screening and cloning genes, which regulate functions of CD4+ T cells, are helpful in elucidating the mechanisms of over proliferation, activation, infiltrating bone marrow and damaging haematopoietic cells of CD4+ T cells in

  15. Relationship Between Blood Concentrations of Hepcidin and Anemia Severity, Mycobacterial Burden, and Mortality Among Patients With HIV-Associated Tuberculosis

    OpenAIRE

    Kerkhoff, AD; Meintjes, G.; Burton, R; Vogt, M.; Wood, R.; Lawn, SD

    2015-01-01

    Background Anemia is very common in patients with human immunodeficiency virus (HIV)–associated tuberculosis, and hepcidin may be key in mediating this. We explored the relationship between blood hepcidin concentrations and anemia severity, mycobacterial burden and mortality in patients with HIV-associated tuberculosis. Methods Consecutive unselected HIV-infected adults in South Africa were systematically investigated for tuberculosis. Three groups were studied: 116 hospitalized inpatients wi...

  16. Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study

    Science.gov (United States)

    Loutradis, Charalampos; Skodra, Alexandra; Georgianos, Panagiotis; Tolika, Panagiota; Alexandrou, Dimitris; Avdelidou, Afroditi; Sarafidis, Pantelis A

    2016-01-01

    AIM: To compare anemia prevalence between matched chronic kidney disease (CKD) patients with and without diabetes mellitus (DM) and to assess factors associated with anemia development. METHODS: This is a nested case-control study of 184 type-2 diabetic and 184 non-diabetic CKD patients from a prospectively assembled database of a Nephrology outpatient clinic, matched for gender, age and estimated glomerular filtration rate (eGFR). Prevalence of anemia (hemoglobin: Men: < 13 g/dL, women: < 12 g/dL and/or use of recombinant erythropoietin) was examined in comparison, in the total population and by CKD Stage. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with anemia. RESULTS: The total prevalence of anemia was higher in diabetics (47.8% vs 33.2%, P = 0.004). Accordingly, prevalence was higher in diabetics in CKD Stage 3 (53.5% vs 33.1%, P < 0.001) and particularly in Stage 3a (60.4% vs 26.4%, P < 0.001), whereas it was non-significantly higher in Stage 4 (61.3% vs 48.4%; P = 0.307). Serum ferritin was higher in diabetics in total and in CKD stages, while serum iron was similar between groups. In multivariate analyses, DM (OR = 2.206, 95%CI: 1.196-4.069), CKD Stages 3a, 3b, 4 (Stage 4: OR = 12.169, 95%CI: 3.783-39.147) and serum iron (OR = 0.976, 95%CI: 0.968-0.985 per mg/dL increase) were independently associated with anemia. CONCLUSION: Prevalence of anemia progressively increases with advancing stages of CKD and is higher in diabetic than matched non-diabetic CKD patients and diabetes is independently associated with anemia occurrence. Detection and treatment of anemia in diabetic CKD patients should be performed earlier than non-diabetic counterparts. PMID:27458564

  17. Detection of Parvovirus B19 Infection in Thalasemic Patients in Isfahan Province, Iran

    OpenAIRE

    Nikoozad, Razieh; Mahzounieh, Mohammad Reza; Ghorani, Mohammad Reza

    2015-01-01

    Background: Parvovirus B19, a member of the Erythrovirus genus of Parvoviridae family, causes various clinical illnesses including infectious erythema, arthropathy, hydrops fetalis or congenital anemia, and transient aplastic crises. The B19 virus can be transmitted through respiratory secretions, blood products, and blood transfusion. Objectives: The aim of this study was to detect the B19 virus in thalassemia patients in Isfahan, Iran. Patients and Methods: The prevalence of parvovirus B19 ...

  18. About hematopoietic properties of peripheral blood lymphocytes RNA from patients with polycythemia vera and healthy donors

    OpenAIRE

    A. G. Babaeva; N. M. Gevorkyan; Tishevskaya, N. V.; L. L. Golovkina; Yu. O. Muratova; A. A. Ragimov

    2015-01-01

    Total RNA isolated from peripheral blood lymphocytes of donor and patient with polycythemia, stimulates hematopoiesis in rats with toxic aplastic anemia due to benzene administration. Total RNA of lymphocytes from polycythemia patient has a more pronounced effect on the erythroid, myeloid and megakaryocytic hematopoiesis comparing to total RNA from donor lymphocytes. The greatest stimulatory effectof RNA observed after 21 days from the start of experiment. Total RNA of lymphocytes from polycy...

  19. Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients

    Directory of Open Access Journals (Sweden)

    Amir-Hooshang Mohammadpour

    2014-01-01

    Full Text Available Use of recombinant human erythropoietin (rh-Epo improves hemoglobin (Hgb in 90-95% of the cases of anemia of chronic kidney disease (CKD. However, it is known that pro-inflammatory cytokines such as interferon-gamma (IFN-γ, tumor necrosis factor-alfa (TNF-α and interleukin-1 (IL-1 suppress erythropoiesis, resulting in inadequate response to rh-Epo. Pentoxifylline has been shown to have modulatory effects on the immune system. This prospec-tive study to evaluate the effect of pentoxyphylline on erythropoeisis was performed on 15 (eight males, seven females clinically stable patients who had been on hemodialysis for at least six months with anemia (Hgb of <10.7 g/dL unresponsive to rh-Epo despite high doses. They were treated with 400 mg pentoxifylline tablets once daily for 12 weeks. Hgb increased after one and two months of drug administration, but significant changes were observed in eight (53% patients after three months (P <0.05. Our study illustrates a probable new use for an old medicine. Three months treatment with pentoxifylline was seen to increase Hgb significantly in rh-Epo-resistant patients. More prospective studies with a larger sample size are needed to determine the inhi-bitory role of cytokines on hematopoiesis and exploring new drugs or new drug indications to overcome anemia in advanced renal failure.

  20. Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia.

    Directory of Open Access Journals (Sweden)

    Clarisse Lopes de Castro Lobo

    Full Text Available This study was a prospective cross-sectional cohort study of 125 patients with sickle cell anemia (SS between the ages of 16 to 60 years. Enrolled patients were followed-up prospectively for 15 months. Demographic, clinical, hematological and routine biochemical data were obtained on all patients. Six-minute walk test and Doppler Echocardiography were performed on all patients. A tricuspid regurgitant jet velocity (TRJV 3.0 m/sec, severe. Patients with abnormal TRJV were significantly older and more anemic, had significantly higher lactate dehydrogenase (LDH levels, reticulocyte count and incidence of death. The logistic multimodal model implemented for the 125 patients indicated that age was the covariate that influenced the outcome of normal or abnormal TRJV with a cutoff age of thirty-two years. The survival rate for the group of patients with creatinine (Cr > 1.0 mg/dL was lower than the group with Cr ≤ 1 and normal TRJV. A coefficient matrix showed that the LDH values were weakly correlated with the reticulocyte count but strongly correlated with hemoglobin suggesting that the TRJV values were not correlated with the hemolytic rate but with anemia. Ten patients died during the follow-up of whom 7 had TRJV > 2.5 m/sec. Acute chest syndrome was the most common cause of death followed by sepsis. In conclusion, this study shows that patients with SS older than thirty-two years with high LDH, elevated TRJV, severe anemia and Cr > 1 have poor prognosis and may be at risk of having pulmonary hypertension and should undergo RHC.

  1. Bed bugs reproductive life cycle in the clothes of a patient suffering from Alzheimer's disease results in iron deficiency anemia.

    Science.gov (United States)

    Sabou, Marcela; Imperiale, Delphine Gallo; Andrès, Emmanuel; Abou-Bacar, Ahmed; Foeglé, Jacinthe; Lavigne, Thierry; Kaltenbach, Georges; Candolfi, Ermanno

    2013-01-01

    We report the case of an 82-year-old patient, hospitalized for malaise. Her clothes were infested by numerous insects and the entomological analysis identified them as being Cimex lectularius (bed bugs). The history of the patient highlighted severe cognitive impairment. The biological assessment initially showed a profound microcytic, aregenerative, iron deficiency anemia. A vitamin B12 deficiency due to pernicious anemia (positive intrinsic factor antibodies) was also highlighted, but this was not enough to explain the anemia without macrocytosis. Laboratory tests, endoscopy and a CT scan eliminated a tumor etiology responsible for occult bleeding. The patient had a mild itchy rash which was linked to the massive colonization by the bed bugs. The C. lectularius bite is most often considered benign because it is not a vector of infectious agents. Far from trivial, a massive human colonization by bed bugs may cause such a hematic depletion that severe microcytic anemia may result. PMID:23673315

  2. Endoscopic investigation in non-iron deficiency anemia: a cost to the health system without patient benefit

    Science.gov (United States)

    Mogilevski, Tamara; Smith, Rebecca; Johnson, Douglas; Charles, Patrick G. P.; Churilov, Leonid; Vaughan, Rhys; Ma, Ronald; Testro, Adam

    2016-01-01

    Background and aims: The indication for endoscopy to investigate anemia of causes other than iron deficiency is not clear. Increasing numbers of endoscopic procedures for anemia raises concerns about costs to the health system, waiting times, and patient safety. The primary aim of this study was to determine the diagnostic yield of endoscopy in patients referred to undergo investigation for anemia. Secondary aims were to identify additional factors enabling the risk stratification of those likely to benefit from endoscopic investigation, and to undertake a cost analysis of performing endoscopy in this group of patients. Methods: We performed a retrospective review of endoscopy referrals for the investigation of anemia over a 12-month period at a single center. The patients were divided into three groups: those who had true iron deficiency anemia (IDA), tissue iron deficiency without anemia (TIDWA), or anemia of other cause (AOC). Outcome measures included finding a lesion responsible for the anemia and a significant change of management as a result of endoscopy. A costing analysis was performed with an activity-based costing method. Results: We identified 283 patients who underwent endoscopy to investigate anemia. A likely cause of anemia was found in 31 of 150 patients with IDA (21 %) and 0 patients in the other categories (P < 0.001). A change of management was observed in 35 patients with IDA (23 %), 1 of 14 patients with TIDWA (7.14 %), and 8 of 119 patients with AOC (6.7 %) (P < 0.001). The cost of a single colonoscopy or gastroscopy was approximated to be $ 2209. Conclusions: Endoscopic investigation for non-IDA comes at a significant cost to our institution, equating to a minimum of $ 293 797 per annum in extra costs, and does not result in a change of management in the majority of patients. No additional factors could be established to identify patients who might be more likely to benefit from endoscopic investigation. The endoscopic

  3. Cold agglutinin disease (CADwith autoimmune haemolytic anaemia: a case report of a coronary artery disease patient Doença por aglutininas a frio (DAC com anemia hemolítica auto-imune: relato de caso de um coronariopata

    Directory of Open Access Journals (Sweden)

    Leandro A. Barbosa

    2008-02-01

    Full Text Available Cold agglutinin disease (CAD with autoimmune haemolytic anemia is characterized by the production of harmful cold autoantibodies associated with increased red cell destruction during exposure to cold. The treatment of CAD is very difficult and a great effort is required to obtain therapeutic success. Cyclophosphamide is a potent immunosuppressive agent which is widely used in all bone marrow transplantation conditioning regimens for patients with acquired severe aplastic anemia. In this report, we describe the case of a coronary artery disease patient with severe CAD, but without lymphoproliferative disease, in which general measures and immunosuppressive therapies were adopted, there by avoiding blood transfusions.A doença por aglutininas a frio (CAD cursando com anemia hemolítica auto-imune (AHAI é decorrente da produção de autoanticorpos que reagem muito bem a baixas temperaturas, dirigidos contra hemácias autólogas. A habilidade desses anticorpos em destruir as hemácias encontra-se diretamente relacionada à sua capacidade em fixar complemento durante a exposição do paciente a baixas temperaturas. A AHAI por anticorpos frios pode ser idiopática - ausência de doença de base - ou secundária, geralmente associada a desordens linfoproliferativas de células B ou determinados processos infecciosos. A hemólise é intravascular, através de aglutininas da classe IgM, com teste direto da antiglobulina humana positivo para complemento. O tratamento da CAD é difícil, exigindo um esforço contínuo, necessário para se obter sucesso terapêutico. A ciclofosfamida é um agente imunossupressor potente, amplamente utilizado em transplantes de medula óssea, particularmente nos portadores de anemia aplástica. Descrevemos o caso de um coronariopata portador de CAD severa, cuja exploração diagnóstica excluiu doença linfoproliferativa. Adotamos medidas gerais de suporte e terapia imunossupressora, coibindo o uso de hemotransfusões.

  4. Management of anemia in patients undergoing curative radiotherapy. Erythropoietin, transfusions, or better nothing?

    Energy Technology Data Exchange (ETDEWEB)

    Dunst, J. [Dept. of Radiotherapy, Martin Luther Univ. Halle-Wittenberg, Halle (Germany)

    2004-11-01

    Background and results: anemia is a well-known risk factor for decreased local control and survival in patients undergoing curative radiotherapy. There is clear evidence from recent clinical investigations that anemia is an independent risk factor and hemoglobin (Hb) levels during radiotherapy are important (and not pretreatment Hb levels). The most likely explanation for the prognostic impact is the association with tumor hypoxia. An ''optimal'' Hb range with regard to tumor oxygenation seems to exist, and Hb levels < 11 g/dl and > {proportional_to}15 g/dl impair tumor oxygenation but have (over a broader range) no significant impact on normal tissue oxygenation. There is some evidence from retrospective and prospective studies that the response to radiotherapy and the prognosis, especially in cervical cancers, might be improved if the Hb levels during radiotherapy can be maintained in the optimal range, either by transfusions or by erythropoietin. The effect of any antianemic therapy should be analyzed according to whether or not treatment was successful with regard to achieving optimal Hb levels during irradiation. Erythropoietin is probably more effective in steadily increasing and stabilizing Hb levels, but bears the risk of overcorrection of Hb levels. The clinical relevance of erythropoietin receptors on tumor cells remains questionable. Conclusions: treatment of anemia with the objective of improving local control and survival in radiotherapy patients is probably more difficult and sophisticated than coping with symptoms of anemia or improving quality of life. Nevertheless, the potential of antianemic treatment is high on the basis of experimental and clinical data, and further clinical trials are warranted. (orig.)

  5. Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hypeferritinemia

    Directory of Open Access Journals (Sweden)

    Shahrbanoo Keyhanian

    2008-01-01

    Full Text Available Hemodialysis (HD patients with functional iron deficiency (FID often develop resistance to recombinant human erythropoietin (Epo. The contributory role of chronic infla-mmation and oxidative stress in its pathogenesis is poorly understood. We assessed the effect of vitamin C, an antioxidant, on Epo-hyporesponsive anemia in hemodialysis patients with un-explained hyperferritinemia levels. Thirty-one of 132 with Hb < 11 g/dL were prospectively fo-llowed up after exclusion of reasons for Epo hyporesponsiveness. Patients were randomly divided into two groups: 15 patients received standard care and 300 mg of intravenous vitamin C with each dialysis session (group 1 and 15 patients received standard care (group 2. After 3 months, Hb and transferrin saturation levels significantly increased in group 1 but not in group 2 (p < 0.05%. Hemoglobin content in reticulocyte and serum ferritin decreased significantly in group 1 but not in control group. In conclusion, hemodialysis patients with refractory anemia and ade-quate iron stores, vitamin C improved responsiveness to Epo by augmenting iron mobilization and possibly via antioxidant effect.

  6. Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis

    Directory of Open Access Journals (Sweden)

    Jiannong Liu

    2009-04-01

    Full Text Available Jiannong Liu1, Haifeng Guo1, David Gilbertson1, Robert Foley1,2, Allan Collins1,21Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN, USA; 2Department of Medicine, University of Minnesota, Minneapolis, MN, USAAbstract: Most end-stage renal disease (ESRD patients begin renal replacement therapy with hemoglobin levels below the recommended US National Kidney Foundation Dialysis Outcomes Quality Initiative Guidelines lower level of 110 g/L. Although most patients eventually reach this target, the time required varies substantially. This study aimed to determine whether length of time with below-target hemoglobin levels after dialysis initiation is associated with medical costs, and if so, whether intermediate factors underlie the associations. US patients initiating dialysis in 2002 were studied using the Centers for Medicare and Medicaid Services ESRD database. Anemia persistence (time in months with hemoglobin below 110 g/L was determined in a six-month entry period, and outcomes were assessed in the subsequent six-month follow-up period. The structural equation modeling technique was used to evaluate associations between persistent anemia and medical costs and to determine intermediate factors for these associations. The study included 28,985 patients. Mean per-patient-per-month medical cost was $6267 (standard deviation $5713 in the six-month follow-up period. Each additional month with hemoglobin below 110 g/L was associated with an 8.9% increment in medical cost. The increased cost was associated with increased erythropoietin use and blood transfusions, and increased rates of hospitalization and vascular access procedures in the follow-up period. Keywords: anemia persistency, end-stage renal disease, medical costs, structural equation modeling

  7. Effects of erythropoiesis-stimulating agents on heart failure patients with anemia: a meta-analysis

    Science.gov (United States)

    Zhang, Pei; Zhang, Yaheng; Yan, Junqiang; Dong, Pingshuan; Wang, Yanyu; Niu, Xiaowei

    2016-01-01

    Introduction Heart failure (HF) is always complicated with anemia and is associated with bad prognosis in this patient population. Several studies have assessed the potential role of erythropoietin-stimulating agent (ESA) in improving cardiac function and reducing the number of hospitalizations in anemic patients with HF. Aim We performed a meta-analysis to assess the potential role of ESA in the treatment of anemic patients with HF. Material and methods A literature and Medline search was performed to identify studies with control groups that examined the efficacy of ESA therapy in patients with HF and anemia. Results A total of 11 studies were included (n = 3044 subjects) in the final analysis. Compared to placebo, ESA therapy was associated with increased hemoglobin levels (1.89 g/dl; 95% CI: 1.64–2.14, p < 0.00001), increased left ventricular ejection fraction (LVEF) to 6.88 (95% CI: 0.49–13.28, p = 0.03), decreased B-type natriuretic protein (–272.20; 95% CI: (–444.52)–(–99.89), p = 0.002), improvement in New York Heart Association functional class to –0.33 mean difference (95% CI: (–0.44)–(–0.23), p < 0.00001), and decreased hospitalization (OR = 0.61, 95% CI: 0.39–0.94, p = 0.02). There was no significant between-group difference in all-cause mortality (OR = 0.78, 95% CI: 0.51–1.21, p = 0.27). Conclusions The treatment of anemia with ESA therapy did not reduce the rate of all-cause mortality among patients with heart failure, but ESA therapy made a potential important contribution to patients’ symptomatic improvement. PMID:27625688

  8. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose

    Directory of Open Access Journals (Sweden)

    Carlos Walter SOBRADO

    2015-12-01

    Full Text Available Objectives - Anemia is the most common hematological alteration in patients with Crohn's disease, and is frequently related to intestinal inflammatory activity. Its cause is multifactorial and mostly associated with absolute iron deficiency (iron deficiency anemia and/or functional iron deficiency (inflammation anemia or anemia of chronic disease. It may also be identified through other causes, such as folic acid or vitamin B12 deficiency and secondary to adverse effects from medications (salicylic derivatives and immunosuppressive drugs. In the present study, patients with active Crohn's disease and anemia were evaluated and treated with intravenous ferric carboxymaltose. We discuss the therapeutic schemes (doses, safety, results and improvement of quality of life. Methods - In the present prospective study, 10 consecutive patients with Crohn's disease, with moderate to severe activity, with anemia (Hb: 6.7 to 10 g/dL, who were attended between March 2014 and March 2015, were evaluated. Six (60% were men and four were women, all with moderate or severe anemia (hemoglobin <10 g/dL. They were treated with a maximum of three intravenous infusions of 1000 mg of ferric carboxymaltose, of at least 15 minutes in duration. It was also sought to correlate the inflammatory Crohn's disease activity degree (measured using the Crohn's Disease Activity Index, CDAI and C-reactive protein level with the severity of anemia. The primary outcome was an increase in Hb of ≥2 g/dL and the secondary outcome was the normalization of anemia (Hb ≥12 g/dL for women and ≥13 g/dL for men and the improvement in quality of life seen 12 weeks after the last application of carboxymaltose. Results - Among the 10 patients studied, parenteral iron supplementation was administered in three cases during hospitalization and the others received this on an outpatient basis. The total iron dose ranged from 1,000 to 2,000 mg, with an average of 1,650 mg. Crohn's disease activity

  9. Significance of assess the iron reserves of severe renal anemia patients before and after blood transfusion

    Institute of Scientific and Technical Information of China (English)

    Gui-Fen Zhang

    2015-01-01

    Objective:To study the significance of evaluating hemoglobin and iron reserves in the severe renal anemia patient before and after blood transfusion, to guide clinical treatment.Methods:Simple randomly selected 120 patients in phase 5 of chronic renal failure from the department of nephrology, who are regular dialysis with severe renal anemia, according to the situation of iron reserves before blood transfusion, patients will be divided into its reserves of iron deficiency and iron overload group and normal group, and the three groups were divided into 1 U and 2 U group. Comparing the change of different unit quantity of hemoglobin, serum iron, iron, protein and total iron binding force before and after blood transfusion and variation is compared between groups.Results: Three groups of patients with 1U blood transfusion ,Hemoglobin, serum iron and ferritin, total iron binding force, transferrin saturation are higher before a blood transfusion,The differences were statistically significant; before and after blood transfusion hemoglobin, serum iron and ferritin, total iron binding force, transferrin saturation change in 1 U group normal iron reserves compared with Insufficient iron reserves 1 U group has no statistically significant difference, iron overload 1 U group before and after blood transfusion hemoglobin, serum iron and ferritin, total iron binding force, transferrin saturation change significantly greater than Insufficient iron reserves 1 U group and 1U with normal iron reserves group, the differences were statistically significant; Three groups of patients blood transfusion after 2 U, hemoglobin, serum iron and ferritin, total iron binding force, transferrin saturation were higher before a blood transfusion, differences were statistically significant; iron overload 2 U group before and after blood transfusion hemoglobin, serum iron and ferritin, total iron binding force, transferrin saturation change significantly greater than Insufficient iron reserves 2

  10. Gluten sensitive enteropathy in patients with iron deficiency anemia of unknown origin

    Institute of Scientific and Technical Information of China (English)

    Farhad Zamani; Mehdi Mohamadnejad; Ramin Shakeri; Afsaneh Amiri; Safa Najafi; Seyed Meysam Alimohamadi; Seyed Mohamad Tavangar; Ardeshir Ghavamzadeh; Reza Malekzadeh

    2008-01-01

    AIM:To determine the prevalence of gluten sensitive enteropathy (GSE) in a large group of patients with iron deficiency anemia (IDA) of obscure origin.METHODS:In this cross-sectional study,patients with IDA of obscure origin were screened for GSE.Antiendomysial antibody (EMA) and tissue transglutaminase antibody (tTG) levels were evaluated and duodenal biopsies were taken and scored according to the Marsh classification.The diagnosis of GSE was based on a positive serological test and abnormal duodenal histology.Gluten free diet (GFD) was advised for all the GSE patients.RESULTS:Of the 4120 IDA patients referred to our Hematology departments,206 (95 male) patients were found to have IDA of obscure origin.Thirty out of 206 patients (14.6%) had GSE.The mean age of GSE patients was 34.6±17.03 (range 10-72 years).The female to male ratio was 1,3:1.Sixteen patients had Marsh 3,12 had Marsh 2,and 2 had Marsh 1 lesions.The severity of anemia was in parallel with the severity of duodenal lesions.Twenty-two GSE patients (73.3%) had no gastrointestinal symptoms.Fourteen GSE patients who adhered to GFD without receiving iron supplementation agreed to undergo follow up visits.After 6 mo of GFD,their mean hemoglobin levels (Hb) increased from 9.9 ±1.6 to 12.8 ± 1.0 g/dL (P<0.01).Interestingly,in 6 out of 14 patients who had Marsh 1/2 lesions (e.g.no villous atrophy) on duodenal biopsy,mean Hb increased from 11.0 ± 1.1 to 13.1 ±1.0 g/dL (P<0.01) while they did not receive any iron supplementation.CONCLUSION:There is a high prevalence (e.g.14.6%) of GSE in patients with IDA of obscure origin.Gluten free diet can improve anemia in GSE patients who have mild duodenal lesions without villous atrophy.

  11. Aplastic

    Science.gov (United States)

    Stedman's Online Medical Dictionary. Wolters Kluwer Health, Inc. 2009. Lippincott Williams & Wilkins. Accessed May 29, 2014. Dorland's Online Medical Dictionary. Elsevier. 2013. Accessed May 29, 2014.

  12. Reactivity of patients with maintenance hemodialysis to erythropoietin in the treatment of renal anemia.

    Science.gov (United States)

    Hu, J P; Cheng, X; Xu, X F; Yu, G J; Luo, F; Zhang, G S; Yang, N; Shen, P; Yan, X Y

    2016-01-01

    To explore the reactivity of patients with renal anemia (MHD) to erythropoietin (EPO) in maintenance hemodialysis (HD), 31 patients were enrolled in this study. According to the level of serum ferritin (SF), they were divided into two groups; one group received treatment using recombinant human erythropoietin (rHuEPO) and the other group was given iron sucrose. Taking terminal EPO dosage, terminal erythropoietin resistance index (ERI) and rate of change of ERI (ΔERII) as target indexes, the influence of SF level on dosage of EPO was evaluated after usage conditions of relevant substances in a 3-month period. The results revealed that differences of dialysis age, albumin (ALB), blood calcium, initial and terminal SF, variable quantity of hemoglobin (Hb), terminal EPO and ERI between two groups had statistical significance. Furthermore, SF level and terminal EPO (r = -0.37, P < 0. 05) as well as SF level and terminal ERI (r = - 0.39, P <0.05) were negatively correlated. Difference of terminal ERI between the two groups had statistical significance. It can therefore be summarized that supplementing an iron agent intravenously to maintain SF level between 500 ng/ml and 1200 ng/ml may improve reactivity of patients with MHD to EPO. In addition, rHuEPO therapy in treating anemia of patients with MHD has the same effect with intravenous drug delivery, less side effects and is easy to administer. PMID:27358145

  13. The impact of short daily hemodialysis on anemia and the quality of life in Chinese patients.

    Science.gov (United States)

    Jiang, J L; Ren, W; Song, J; Sun, Q L; Xiao, X Y; Diao, X Z; Huang, Y H; Lan, L; Wang, P; Hu, Z

    2013-07-01

    Anemia is a frequent complication in hemodialysis patients. Compared to conventional hemodialysis (CHD), short daily hemodialysis (sDHD) has been reported to be effective in many countries except China. The aim of the present study was to determine whether sDHD could improve anemia and quality of life (QOL) for Chinese outpatients with end-stage renal disease. Twenty-seven patients (16 males/11 females) were converted from CHD to sDHD. All laboratory values were measured before conversion (baseline), at 3 months after conversion (sDHD1), and at 6 months after conversion (sDHD2). The patient's QOL was evaluated at baseline and 6 months after conversion using the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Hemoglobin concentration increased significantly from 107.4 ± 7.9 g/L at baseline to 114.4 ± 6.8 g/L (Phemodialysis patients compared to CHD. A possible mechanism for improvement of clinical outcomes may be optimized management of uremia associated with the higher efficiency of sDHD.

  14. 兔抗人胸腺细胞免疫球蛋白治疗重型再生障碍性贫血25例疗效分析%The therapeutic effects of Antithymocyte globulin to treat children with severe aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    李玉玲; 薛惠良

    2011-01-01

    Objective To evaluate the effects and side effects of Antithymocyte globulin (ATG)to treat children with severe aplastic anemia (SAA). Methods The therapeutic effects of 25 children with SAA treated by Antithymocyte globulin were analyzed retrospectively from 2004 to 2009. Peripheral hemogram, long-term clone change and infection were observed after treatment for more than 6 months.Results ATG were effective in 17 children (68%). Among them, five (20%) cases were nearly cured, three (12%) got remission and nine (36%) got improved. Eight (32%) cases had no response to ATG treatment. Among them, two (8%) cases were cured after receiving allogeneic hematopoietic stem cell transplantation and two (8%) died because of infection after 6 months. One (4%) case had a clone change into MDS. One case (4%) got rash, fever and joint pain and two cases (8%) got laryngeal edema during ATG infusion. Some children had serum reaction in two weeks after ATG infusion. Conclusion The effective rate of ATG was 68%. The side effects of ATG included rash, fever and joint pain. Laryngeal edema was rare. Corticosteroid hormone should be considered to prevent allergic and serum reactions during ATG treatment.%目的 探讨使用兔抗人胸腺细胞免疫球蛋白(ATG)治疗重型再生障碍性贫血(SAA)的疗效及毒副反应.方法 回顾性分析2004-2009年共25例SAA患儿应用ATG+环孢素A+雄激素治疗后随访半年以上的疗效.观察患儿血象变化、远期克隆性改变、感染.结果 ATG治疗半年后25例患儿中17例(68%)有效,其中5例(20%)基本治愈,3例(12%)缓解,9例(36%)明显进步,8例(32%)无效中2例(8%)行异基因造血干细胞移植后治愈,2例(8%)半年后因感染死亡.随访期间1例SAA-II型发生远期克隆性改变转变为MDS.1例患儿在输注ATG过程中出现皮疹、发烧、关节痛;2例出现喉头水肿;输注后2周内患儿出现血清病反应,表现为皮疹、发热、关节痛.第1周7例,第2

  15. An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients.

    Science.gov (United States)

    Barbieri, Carlo; Molina, Manuel; Ponce, Pedro; Tothova, Monika; Cattinelli, Isabella; Ion Titapiccolo, Jasmine; Mari, Flavio; Amato, Claudia; Leipold, Frank; Wehmeyer, Wolfgang; Stuard, Stefano; Stopper, Andrea; Canaud, Bernard

    2016-08-01

    Managing anemia in hemodialysis patients can be challenging because of competing therapeutic targets and individual variability. Because therapy recommendations provided by a decision support system can benefit both patients and doctors, we evaluated the impact of an artificial intelligence decision support system, the Anemia Control Model (ACM), on anemia outcomes. Based on patient profiles, the ACM was built to recommend suitable erythropoietic-stimulating agent doses. Our retrospective study consisted of a 12-month control phase (standard anemia care), followed by a 12-month observation phase (ACM-guided care) encompassing 752 patients undergoing hemodialysis therapy in 3 NephroCare clinics located in separate countries. The percentage of hemoglobin values on target, the median darbepoetin dose, and individual hemoglobin fluctuation (estimated from the intrapatient hemoglobin standard deviation) were deemed primary outcomes. In the observation phase, median darbepoetin consumption significantly decreased from 0.63 to 0.46 μg/kg/month, whereas on-target hemoglobin values significantly increased from 70.6% to 76.6%, reaching 83.2% when the ACM suggestions were implemented. Moreover, ACM introduction led to a significant decrease in hemoglobin fluctuation (intrapatient standard deviation decreased from 0.95 g/dl to 0.83 g/dl). Thus, ACM support helped improve anemia outcomes of hemodialysis patients, minimizing erythropoietic-stimulating agent use with the potential to reduce the cost of treatment.

  16. An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients.

    Science.gov (United States)

    Barbieri, Carlo; Molina, Manuel; Ponce, Pedro; Tothova, Monika; Cattinelli, Isabella; Ion Titapiccolo, Jasmine; Mari, Flavio; Amato, Claudia; Leipold, Frank; Wehmeyer, Wolfgang; Stuard, Stefano; Stopper, Andrea; Canaud, Bernard

    2016-08-01

    Managing anemia in hemodialysis patients can be challenging because of competing therapeutic targets and individual variability. Because therapy recommendations provided by a decision support system can benefit both patients and doctors, we evaluated the impact of an artificial intelligence decision support system, the Anemia Control Model (ACM), on anemia outcomes. Based on patient profiles, the ACM was built to recommend suitable erythropoietic-stimulating agent doses. Our retrospective study consisted of a 12-month control phase (standard anemia care), followed by a 12-month observation phase (ACM-guided care) encompassing 752 patients undergoing hemodialysis therapy in 3 NephroCare clinics located in separate countries. The percentage of hemoglobin values on target, the median darbepoetin dose, and individual hemoglobin fluctuation (estimated from the intrapatient hemoglobin standard deviation) were deemed primary outcomes. In the observation phase, median darbepoetin consumption significantly decreased from 0.63 to 0.46 μg/kg/month, whereas on-target hemoglobin values significantly increased from 70.6% to 76.6%, reaching 83.2% when the ACM suggestions were implemented. Moreover, ACM introduction led to a significant decrease in hemoglobin fluctuation (intrapatient standard deviation decreased from 0.95 g/dl to 0.83 g/dl). Thus, ACM support helped improve anemia outcomes of hemodialysis patients, minimizing erythropoietic-stimulating agent use with the potential to reduce the cost of treatment. PMID:27262365

  17. Management of dental extraction in a female patient with fanconi anemia.

    Directory of Open Access Journals (Sweden)

    Andre Peisker

    2014-10-01

    Full Text Available Oral surgery in patients with bleeding disorders is associated with a high risk of bleeding during and after surgery. This article is aimed to present the case of an eight-year-old girl suffering from severe Fanconi anemia with pancytopenia who underwent a dental extraction. The hemostatic effect of local administration of tranexamic acid in combination with a primary suture seems to be extremely helpful in order to reduce the necessity of blood products and the risk of postoperative bleeding.

  18. Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose

    Directory of Open Access Journals (Sweden)

    Toblli JE

    2014-12-01

    Full Text Available Jorge Eduardo Toblli, Margarita Angerosa Nephrology Section, Department of Internal Medicine, Hospital Alemán, School of Medicine, University of Buenos Aires, Argentina Abstract: With the challenge of optimizing iron delivery, new intravenous (iv iron–carbohydrate complexes have been developed in the last few years. A good example of these new compounds is ferric carboxymaltose (FCM, which has recently been approved by the US Food and Drug Administration for the treatment of iron deficiency anemia in adult patients who are intolerant to oral iron or present an unsatisfactory response to oral iron, and in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD. FCM is a robust and stable complex similar to ferritin, which minimizes the release of labile iron during administration, allowing higher doses to be administered in a single application and with a favorable cost-effective rate. Cumulative information from randomized, controlled, multicenter trials on a diverse range of indications, including patients with chronic heart failure, postpartum anemia/abnormal uterine bleeding, inflammatory bowel disease, NDD-CKD, and those undergoing hemodialysis, supports the efficacy of FCM for iron replacement in patients with iron deficiency and iron-deficiency anemia. Furthermore, as FCM is a dextran-free iron–carbohydrate complex (which has a very low risk for hypersensitivity reactions with a small proportion of the reported adverse effects in a large number of subjects who received FCM, it may be considered a safe drug. Therefore, FCM appears as an interesting option to apply high doses of iron as a single infusion in a few minutes in order to obtain the quick replacement of iron stores. The present review on FCM summarizes diverse aspects such as pharmacology characteristics and analyzes trials on the efficacy/safety of FCM versus oral iron and different iv iron compounds in multiple clinical scenarios. Additionally, the

  19. Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece

    Directory of Open Access Journals (Sweden)

    Fragoulakis V

    2012-05-01

    Full Text Available Vassilis Fragoulakis1, Georgia Kourlaba1, Dimitris Goumenos2, Manousos Konstantoulakis3, Nikolaos Maniadakis11Department of Health Services Management, National School of Public Health, Athens, 2Department of Medicine University Hospital of Patras, Patras, 3Department of Medicine, Athens Medical School, Athens, GreecePurpose: To conduct an economic evaluation comparing Ferinject® (ferric carboxymaltose [FCM] with Venofer® (iron sucrose [IS] and CosmoFer® (low-molecular-weight iron dextran [LMWID] in the management of iron deficiency anemia in Greece.Patients and methods: A cost-minimization analysis was conducted since there are no clear data indicating that one of these regimens is superior to the others in terms of efficacy. Main data inputs were based on bibliography and validated by clinicians. The economic evaluation was conducted for inpatients (ie, surgical patients or patients hospitalized due to a disease related to chronic or acute blood loss and outpatients (eg, nondialysis chronic kidney disease patients, separately. Analysis was carried out from a National Health Service (NHS perspective and also from a patient perspective. Total cost treatment reflects the cost of drugs, the cost of all resources expended in patient management such as the cost of disposables for each infusion, the monitoring costs during infusion (salaries of personnel, other hospital expenses, the cost for management of adverse events, the productivity loss, and the traveling cost for patients.Results: In the case of outpatients, the mean total cost per patient in the FCM arm was €198.6, in the IS arm €627.7, and in the LMWID arm, €510.5. For inpatients the mean total cost was estimated at €189.2 for FCM while it was €419.9 and €228.8 for IS and LMWID, respectively. Budget impact analysis for a typical Greek hospital with 100 patients revealed that the total cost of FCM (inpatients analysis was 113% and 15.4% lower against their comparators. In an

  20. Anemia intrahospitalaria y descenso de hemoglobina en pacientes internados Hospital-acquired anemia and decrease of hemoglobin levels in hospitalized patients

    Directory of Open Access Journals (Sweden)

    Carina V. Gianserra

    2011-06-01

    estadía hospitalaria prolongada, la presencia de leucocitosis, la hidratación parenteral y colocación de acceso venoso central fueron factores predictivos de descenso de hemoglobina = 2 g/dl.It is common to observe the development of anemia in hospitalized patients, especially in critical cases. Few studies have evaluated its prevalence and associated factors in patients in the general ward. The purpose of this study is to determine the prevalence, characteristics and associated clinical factors of hospital-acquired anemia and the drop of hemoglobin concentration in hospitalized patients. This is a cross-sectional, prospective and descriptive study. A total of 192 consecutive in-patients in the general ward were studied. Associated risk factors to the drop in hemoglobin by = 2g/dl were analyzed; 139 patients (72.4% presented anemia; 89 of them (46.4% had it at admission and 50 (26% developed hospital-acquired anemia, 47 out of 192 showed a drop in hemoglobin = 2 g/dl(24.48%. They also presented lower values of hematocrite and hemoglobin at discharge (p = 0.01, parenteral hydration at a higher volume (p = 0.01, and lengthier hospitalizations (p = 0.0001. In the univariate analysis, the following variables were statistically significant risk factors: leukocytosis = 11 000 mm³ (OR; IC95%: 2,02; 1.03-4; p = 0.01, hospitalization days = 7 (OR; IC95%:3.39; 1.62-7.09; p = 0.0006, parenteral hydration = 1500 ml/day (OR; IC95%: 2.47; 1.06-6.4; p = 0.01, central venous access (OR; IC95%:10.29; 1.75-108.07; p = 0.003 and hospital-acquired anemia (OR; IC95%: 7.06; 3.41-15.83; p = 0.00000004. In the multivariate analysis, the following variables were independent predictive factors of the hemoglobin decrease = 2 g/dl: leukocytosis = 11 000 mm³ (OR; IC95%: 2.45; 1.14-5,27; p = 0.02, hospitalization days = 7 (OR; IC95%:5.15; 2.19-12.07; p = 0.0002, parenteral hydration = 1500 ml/day (OR; IC95%: 2.95; 1.13-7.72; p = 0.02, central venous access (OR; IC95%:8.82; 1.37-56.82; p = 0

  1. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease.

    Science.gov (United States)

    Kim, Sun Moon; Kim, Kyeong Min; Kwon, Soon Kil; Kim, Hye-Young

    2016-01-01

    Anemia is common in patients with advanced chronic kidney disease (CKD). Though erythropoiesis-stimulating agents (ESAs) have been strongly endorsed in guidelines, it is of particular financial interest. Recently, the reimbursement of ESAs in non-dialytic patients was started by the Korean National Health Insurance System. Thus, we investigated the impact of the reimbursement of ESAs on the anemia care in non-dialytic CKD patients. Medical records of patients with advanced CKD (estimated GFR <30 mL/min/1.73 m(2)) were reviewed. Use of ESAs, blood transfusion, and hemoglobin concentrations were analyzed from one year prior to reimbursement to three years following. We used multivariable modified Poisson regression to estimate the utilization prevalence ratio (PRs). A total of 1,791 medical records were analyzed. The proportion of patients receiving ESAs increased from 14.8% before reimbursement to a peak 33.6% in 1 yr after reimbursement; thereafter, ESA use decreased to 22.4% in 3 yr after reimbursement (compared with baseline; PR, 2.19 [95% CI, 1.40-3.42]). In patients with Hb <10 g/dL, the proportion of receiving ESAs increased from 32.1% before reimbursement to 66.7% in 3 yr after reimbursement (compared with baseline; PR, 2.04 [95% CI, 1.25-3.32]). Mean hemoglobin concentrations were 10.06±1.54 g/dL before reimbursement and increased to 10.78±1.51 g/dL in 3 yr after the reimbursement change (P=0.001). However, the requirement of blood transfusion was not changed over time. With the reimbursement of ESAs, the advanced CKD patients were more likely to be treated with ESAs, and the hemoglobin concentrations increased.

  2. Hereditary Spherocytosis Unmasked by Human Parvovirus B19 Induced Aplastic Crisis in a Family

    Directory of Open Access Journals (Sweden)

    Samin Alavi

    2015-09-01

    Full Text Available Human parvovirus (HPV B19 induced aplastic crisis in a family leading to the diagnosis of hereditary spherocytosis (HS is a very rare condition being barely reported in the literature. We herein report a 4-year-old girl, her brother, and their mother who all presented with progressive pallor and jaundice after a febrile illness. The HPV B19 was diagnosed using polymerase chain reaction (PCR and positive serology for specific anti-HPV B19 IgM. They were further diagnosed with having HS. The clinical importance of this report is that in the case of an abrupt onset of unexplained severe anemia and jaundice, one should consider underlying hemolytic anemias mostly hereditary spherocytosis complicated by HPV B19 aplastic crisis. Herein, we report the occurrence of this condition, simultaneously in three members of a family. The distinguished feature of this report is that all affected family members developed some degrees of transient pancytopenia, not only anemia, all simultaneously in the course of their disease.

  3. Hereditary Spherocytosis Unmasked by Human Parvovirus B19 Induced Aplastic Crisis in a Family.

    Science.gov (United States)

    Alavi, Samin; Arabi, Nahid; Yazdi, Mohammad Kaji; Arzanian, Mohammad Taghi; Zohrehbandian, Farahnaz

    2015-09-01

    Human parvovirus (HPV) B19 induced aplastic crisis in a family leading to the diagnosis of hereditary spherocytosis (HS) is a very rare condition being barely reported in the literature. We herein report a 4-year-old girl, her brother, and their mother who all presented with progressive pallor and jaundice after a febrile illness. The HPV B19 was diagnosed using polymerase chain reaction (PCR) and positive serology for specific anti-HPV B19 IgM. They were further diagnosed with having HS. The clinical importance of this report is that in the case of an abrupt onset of unexplained severe anemia and jaundice, one should consider underlying hemolytic anemias mostly hereditary spherocytosis complicated by HPV B19 aplastic crisis. Herein, we report the occurrence of this condition, simultaneously in three members of a family. The distinguished feature of this report is that all affected family members developed some degrees of transient pancytopenia, not only anemia, all simultaneously in the course of their disease. PMID:26379354

  4. [Analysis of clinical characteristics in 45 cases of Diamond-Blackfan anemia].

    Science.gov (United States)

    Chen, Yu-Mei; Ruan, Min; Wang, Ya-Qin; Zou, Yao; Zhang, Li; Liu, Tian-Feng; Zhu, Xiao-Fan

    2012-06-01

    In order to explore the diagnosis and therapy of Diamond Blackfan anemia (DBA), the clinical data of 45 cases of DBA admitted in our hospital from February 1994 to July 2011 were analyzed retrospectively. The clinical characteristics, results of laboratory examination, treatment reaction and outcome of disease were investigated. The results indicated that out of 45 children diagnosed as DBA, 14 cases (31.1%) had short stature and physical malformation. All patients had anemia with reticulocytopenia. Thirty-four patients (75.6%) had mean corpuscular volume. Eleven patients (24.4%) had macrocytic anemia. Bone marrow examination showed a marked erythroid hypoplasia in all patients. Out of 29 cases tested for fetal hemoglobin (HbF), 13 cases (44.8%) had high level of HbF. Erythroid colony-forming unit of bone marrow was tested in 25 patients, among them 12 patients (48%) showed normal plasia, 13 (52%) showed hypoplasia. The erythropoietin (EPO) levels of 17 patients were elevated. Karyotypes were examined in 28 patients, and showed all normal. The treatment was based on corticosteroids and Cyclosporine A. Thirty patients had good response to corticosteroid therapy, and 10 of them obtained a sustained corticosteroid-induced remission. Twenty cases discontinued corticosteroid therapy after remission, as a result, 15 cases (75%) relapsed, moreover all the relapsed cases still had good response to corticosteroid. Two relapsed patients suffered from aplastic anemia, one of them died of therapy failure. Six patients were unresponsive to corticosteroid, 1 of which achieved remission with cyclosporine A and the others continued to receive regular transfusions. 3 patients received iron chelation therapy. It is concluded that the clinical characteristics, complete blood count, bone marrow smear, HbF level and EPO level are useful to make a diagnosis of DBA. Most patients have a good response to corticosteroid therapy, but relapse rate is high when drug was discontinued. Patients

  5. Impact of hepcidin, interleukin 6, and other inflammatory markers with respect to erythropoietin on anemia in chronic hemodialysis patients

    Directory of Open Access Journals (Sweden)

    Ihab A. Ibrahim

    2014-01-01

    Conclusion Serum hepcidin levels were associated with iron status and inflammation in maintenance hemodialysis patients, and the high hepcidin serum levels, found in hemodialysis (HD patients, are dependent on the magnitude of the inflammatory process and on recombinant human erythropoietin doses. Hepcidin and its regulatory pathways are potential therapeutic targets, which could lead to effective treatment of anemia in chronic hemodialysis.

  6. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia

    DEFF Research Database (Denmark)

    McMurray, John J V; Uno, Hajime; Jarolim, Petr;

    2011-01-01

    This study aims to examine predictors of cardiovascular mortality and morbidity in patients with chronic kidney disease (CKD). Individuals with the triad of diabetes, CKD, and anemia represent a significant proportion of patients with cardiovascular disease and are at particularly high risk...

  7. Effects of sodium ferrous chlorophyll treatment on anemia of hemodialysis patients and relevant biochemical parameters.

    Science.gov (United States)

    Xu, X F; Hu, J P; Cheng, X; Yu, G J; Luo, F; Zhang, G S; Yang, N; Shen, P

    2016-01-01

    This study explores the effects of sodium ferrous chlorophyll treatment on the anemia of maintenance hemodialysis (MHD) patients, as well as the relevant biochemical parameters. We selected 72 patients who had received regular MHD treatment two or three times a week for more than 3 months in the Hospital of Traditional Chinese Medicine of Zhengzhou City of Henan Province from March 2014 to March 2016. They were equally divided into a treatment group and a control group. Haemoglobin (HB) and hematocrit (HCT) of the treatment group increased significantly after treatment (p 0.05). Albumin (ALB) dosage of the treatment group increased after treatment (p 0.05). ALB level of the treatment group increased more significantly than in the control group (p MHD patients and their quality of life. PMID:27049084

  8. TXRF analysis of multielements in serum of patients with sickle cell anemia (SCA) by synchrotron radiation

    International Nuclear Information System (INIS)

    The determination of trace elements levels in physiological fluids is of considerable interest in clinical chemistry. Since it has been established these levels in human serum can be utilized as indicators for several pathological conditions, diagnosis and treatment of various diseases. In this work, trace elements were analyzed in serum of patients with sickle cell anemia (SCA) by total reflection X-ray fluorescence using synchrotron radiation (SRTXRF). Sickle cell Anemia is a blood disorder that affects hemoglobin, the protein found in red blood cells that help carry oxygen throughout the body. SCA occurs when a person inherits two abnormal genes (one from each parent) that cause their red blood cells to change shape. These irregular-shaped blood cells die prematurely, resulting in a chronic shortage of red blood cells. We studied forty-three patients (15 males and 28 females) aged 18 to 50 years, suffering SCA and Sixty healthy volunteers (41 males and 19 females) aged 18 to 60 years. All the serum samples had been collected of people who live in the urban area of Rio de Janeiro City/Brazil. The measurements were performed at the X-ray fluorescence beam line at Brazilian National Synchrotron Light Laboratory (LNLS), in Campinas, Sao Paulo using a polychromatic beam. It was possible to determine the concentrations of the following elements: P, S, Cl, K, Ca, Cu, Zn, Br and Rb. (author)

  9. TXRF analysis of multielements in serum of patients with sickle cell anemia (SCA) by synchrotron radiation

    Energy Technology Data Exchange (ETDEWEB)

    Canellas, Catarine G.L.; Jesus, Edgar F.O. de; Anjos, Marcelino J.; Lopes, Ricardo T., E-mail: catarine@lin.ufrj.b, E-mail: edgar@lin.ufrj.b, E-mail: marcelin@lin.ufrj.b, E-mail: ricardo@lin.ufrj.b [Federal University of Rio de Janeiro (UFRJ), RJ (Brazil). COPPE Technology Center. Nuclear Instrumentation Lab.; Carvalho, Silvia M.F., E-mail: silvia@hemorio.rj.gov.b [State Institute of Hematology Arthur de Siqueira Cavalcanti (HEMORIO), Rio de Janeiro, RJ (Brazil)

    2009-07-01

    The determination of trace elements levels in physiological fluids is of considerable interest in clinical chemistry. Since it has been established these levels in human serum can be utilized as indicators for several pathological conditions, diagnosis and treatment of various diseases. In this work, trace elements were analyzed in serum of patients with sickle cell anemia (SCA) by total reflection X-ray fluorescence using synchrotron radiation (SRTXRF). Sickle cell Anemia is a blood disorder that affects hemoglobin, the protein found in red blood cells that help carry oxygen throughout the body. SCA occurs when a person inherits two abnormal genes (one from each parent) that cause their red blood cells to change shape. These irregular-shaped blood cells die prematurely, resulting in a chronic shortage of red blood cells. We studied forty-three patients (15 males and 28 females) aged 18 to 50 years, suffering SCA and Sixty healthy volunteers (41 males and 19 females) aged 18 to 60 years. All the serum samples had been collected of people who live in the urban area of Rio de Janeiro City/Brazil. The measurements were performed at the X-ray fluorescence beam line at Brazilian National Synchrotron Light Laboratory (LNLS), in Campinas, Sao Paulo using a polychromatic beam. It was possible to determine the concentrations of the following elements: P, S, Cl, K, Ca, Cu, Zn, Br and Rb. (author)

  10. Clinico hematological profile and outcome of anemia in children at tertiary care hospital, Karimnagar, Telangana, India

    Directory of Open Access Journals (Sweden)

    Srinivas Madoori

    2015-12-01

    Results: In present study out of 316 cases, 173 were males and 143 were females. It was found that 58% of children were anemic due to iron deficiency anemia, 27 % were having sickle cell disorder, 9 % were having Thalassemia, and 5 % with megaloblastic anemia and 2% with aplastic anemia. Conclusions: Besides haematological investigations for typing of anemia, Haemoglobin electrophoresis establishes the disease in haemoglobinopathies. Adequate health and healthy nutritional habits and prescription of Iron supplements are of great importance in prevention and management of anemia in children assisted by public health services. [Int J Res Med Sci 2015; 3(12.000: 3567-3571

  11. Fanconi anemia - learning from children

    Directory of Open Access Journals (Sweden)

    Johanna Svahn

    2011-06-01

    Full Text Available Fanconi Anemia (FA is a rare autosomic recessive and X-linked disease with chromosomal instability after exposure to crosslinking agents as the hallmark. Clinical features of FA are somatic malformations, progressive bone marrow failure and cancer proneness, however there is wide clinical heterogeneity. The symptom most frequently and early associated with morbidity and mortality is progressive pancytopenia in the first decade of life although acute myelogenous leukemia (AML or myelodysplastic syndrome (MDS can appear before aplastic anemia. Squamous cell carcinoma (SCC of the head-neck, intestinal or genital tract has a very high incidence in FA and can appear at young age. This paper will focus on treatment of bone marrow failure in FA.

  12. Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

    Science.gov (United States)

    2016-05-13

    Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Fanconi Anemia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Secondary Myelodysplastic Syndromes; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

  13. A COMPARATIVE STUDY OF INJECTABLE IRON-SUCROSE VERSUS ORAL IRON IN POSTPARTUM MODERATE ANEMIA PATIENTS

    Directory of Open Access Journals (Sweden)

    Patange

    2014-03-01

    Full Text Available BACKGROUND: Postpartum anemia can develop after delivery because of unforeseen medical problems during and after delivery which could complicate a mother’s ability to properly care for her newborn child. The current treatment for postpartum anemia is oral iron supplementation but this treatment has been associated with gastrointestinal side effects. Alternative treatment includes blood transfusions and intravenous iron therapy. Since blood transfusions are very costly, intravenous iron treatments have become more popular. OBJECTIVES: The objective of this study was to evaluate the hematological parameters and to compare the efficacy and safety of postpartum moderate anemic patients while being treated with IV iron sucrose and oral ferrous sulphate. METHODS: A randomized comparative prospective clinical study was conducted in our hospital. In this study 100 women with postpartum anemia with hemoglobin (Hb between 6 to 8 gm. percent after 24 hours postpartum were randomized into two groups. Group A consisted of 50 women who received 100 mg of IV iron sucrose on alternate day for 3 days along with 0.5mg of folic acid. Group B consisted of 50 women who received two tablets of ferrous sulphate 200mg twice daily for 30 days. RESULTS: Significant rise in Hb level was seen on day 7.14and 30 with IV iron as compared to oral iron. Mean rise in Hb level was 4.1 gm. % with IV iron as compared to 3.4 gm. % with oral iron on day 30 of treatment with P value less than 0.0001 which was significant. Mean rise in PCV level was 12.22% with IV iron and 10.46% with oral iron on day 30. Mean rise in MCV was 12.65u3 with IV iron and 7.9u3 with oral iron. Mean rise in MCH was 5.86pg with IV iron and 3.31pg with oral iron. Mean rise in MCHC was 5.52% with IV iron and 4.17% with oral iron. Mean rise in serum iron was 24.09ug/dl with IV iron and 18.95ug/dl with oral iron. TIBC levels drop by 185.14ug/dl with IV iron and 168.94Ug/dl with oral iron on day 30. CONCLUSION

  14. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.

    Science.gov (United States)

    Silverberg, D S; Iaina, A; Peer, G; Kaplan, E; Levi, B A; Frank, N; Steinbruch, S; Blum, M

    1996-02-01

    Iron deficiency may develop in hemodialysis patients, especially when erythropoietin is given. The role of iron deficiency in the anemia of predialysis chronic renal failure (CRF), however, is much less clear. We have intravenously (IV) administered iron as ferric saccharate in a total dose of 200 mg elemental iron monthly for 5 months to 33 CRF patients who remained anemic despite oral iron supplementation and who had no laboratory signs of iron overload. None was receiving erythropoietin therapy. In 22 of the patients there was an increase in the hematocrit values by the end of the study. These patients were considered responders to intravenous iron (IV Fe) therapy. In 11 patients the iron administration was not associated with improvement of the anemia (nonresponders). Before onset of the IV Fe therapy there were no differences between the responders and nonresponders with regard to degree of anemia, serum ferritin, iron saturation, renal function, or blood pressure. One additional patient was excluded from the study because of a mild reaction during an IV test dose before the study. No worsening of kidney function and no other side effects were noted. In four patients (three responders and one nonresponder) the control of blood pressure necessitated antihypertensive drug therapy adjustment. In conclusion, IV Fe supplementation in two thirds of anemic CRF patients not receiving dialysis resulted in a significant improvement of the anemia, thus avoiding the necessity of erythropoietin or blood administration. This could be achieved by increasing the plasma ferritin levels to 200 to 400 microns/L and/or increasing the iron saturation to 25% to 35%. Intravenous ferric saccharate appears to be a safe and effective method of administering iron for the correction of anemia in CRF patients not receiving dialysis.

  15. Spleen in sickle cell anemia: comparative studies of Nigerian and U.S. patients.

    Science.gov (United States)

    Adekile, A D; McKie, K M; Adeodu, O O; Sulzer, A J; Liu, J S; McKie, V C; Kutlar, F; Ramachandran, M; Kaine, W; Akenzua, G I

    1993-03-01

    Anecdotal reports have attributed persistent splenomegaly in African sickle cell anemia (SS) patients to the effects of malaria. However, no comparative studies of patients in malarial and nonmalarial regions have been conducted, and few studies of malaria antibody titers have been reported. In the present study, age- and sex-matched Nigerian patients (n = 310), while it was found only in 8% of U.S. patients (n = 100) from Georgia. There was significant linear correlation between spleen size and Hb levels and with serum immunoglobulins in the Nigerian group. However, serum complement levels (C3 and C4) were not affected by spleen size. In both groups, patients with splenomegaly had fewer circulating pitted red cells than their counterparts without splenomegaly. The mean +/- SE of IgG-specific malaria antibody titer among the Nigerian patients without palpable spleens was 9,386 +/- 2,036; 9,334 +/- 2,980 in those with spleens between 1 and 5 cm, 16,201 +/- 4,502 in those with spleens between 6 and 10 cm, and 22,445 +/- 8,456 in those with spleens above 10 cm. Coexistent alpha-thalassemia did not influence the prevalence of splenomegaly among the Nigerian SS patients. This study provides additional evidence that malaria plays a significant role in the persistence of splenomegaly in African patients. PMID:8438905

  16. Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation.

    Science.gov (United States)

    Barnum, Jessie L; Petryk, Anna; Zhang, Lei; DeFor, Todd E; Baker, K Scott; Steinberger, Julia; Nathan, Brandon; Wagner, John E; MacMillan, Margaret L

    2016-08-01

    A number of endocrinopathies have been described after hematopoietic cell transplantation (HCT), but data are limited in patients with Fanconi anemia (FA). We report several endocrine-based disorders in a cohort of 44 patients with FA after HCT compared with both 74 patients who received HCT for hematologic malignancies and with 275 healthy controls. Endocrinopathies assessed included hypothyroidism, hypogonadism, short stature, dyslipidemia, insulin resistance, abnormalities in body composition, and bone health. Most (86%) patients with FA had at least 1 endocrinopathy, with 11% having 3 or more. Hypothyroidism was seen in 57%, hypogonadism in 27%, short stature in 50%, and reduced total body and lumbar spine bone mineral density (BMD) (height adjusted Z-score android/gynoid ratio by dual energy X-ray absorptiometry. Hypothyroidism, short stature, and reduced total body BMD were more prevalent in patients with FA compared with patients with hematologic malignancies. We recommend an assessment before transplantation and close follow-up afterwards to ensure proper clinical management. Future studies should continue to explore the impact of HCT on endocrinopathies in FA patients.

  17. [The frequency and development of tissue iron deficiency in 6 iron deficiency anemia patients with plummer-vinson syndrome].

    Science.gov (United States)

    Uchida, T; Matsuno, M; Ide, M; Kawachi, Y

    1998-11-01

    The physical signs of tissue iron deficiency include smooth and red tongue, angular stomatitis, koilonychia, and pica. The incidence of these conditions is unknown in Japan. We evaluated the frequency and development of tissue iron deficiency in 353 patients with iron deficiency anemia. The frequency of tissue iron deficiency was 6.8%; papillary atrophy of the tongue, 5.4%; abnormal nails, 5.4%; angular stomatitis, 1.1%; Plummer-Vinson syndrome, 1.7%; and pica, 0.06%. These findings were compared with the date collected by Wintrobe and Beveridge. The development and incidence of tissue iron deficiency correlated significantly with the severity of iron deficiency anemia.

  18. Anemia (For Parents)

    Science.gov (United States)

    ... Story" 5 Things to Know About Zika & Pregnancy Anemia KidsHealth > For Parents > Anemia Print A A A ... With Anemia Preventing Anemia en español Anemia About Anemia Anemia, one of the more common blood disorders, ...

  19. Erythroblast transferrin receptors and transferrin kinetics in iron deficiency and various anemias

    Energy Technology Data Exchange (ETDEWEB)

    Muta, K.; Nishimura, J.; Ideguchi, H.; Umemura, T.; Ibayashi, H.

    1987-06-01

    To clarify the role of transferrin receptors in cases of altered iron metabolism in clinical pathological conditions, we studied: number of binding sites; affinity; and recycling kinetics of transferrin receptors on human erythroblasts. Since transferrin receptors are mainly present on erythroblasts, the number of surface transferrin receptors was determined by assay of binding of /sup 125/I-transferrin and the percentage of erythroblasts in bone marrow mononuclear cells. The number of binding sites on erythroblasts from patients with an iron deficiency anemia was significantly greater than in normal subjects. Among those with an aplastic anemia, hemolytic anemia, myelodysplastic syndrome, and polycythemia vera compared to normal subjects, there were no considerable differences in the numbers of binding sites. The dissociation constants (Kd) were measured using Scatchard analysis. The apparent Kd was unchanged (about 10 nmol/L) in patients and normal subjects. The kinetics of endocytosis and exocytosis of /sup 125/I-transferrin, examined by acid treatment, revealed no variations in recycling kinetics among the patients and normal subjects. These data suggest that iron uptake is regulated by modulation of the number of surface transferrin receptors, thereby reflecting the iron demand of the erythroblast.

  20. [Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy].

    Science.gov (United States)

    Altinbaş, Akif; Ozkaya, Gülşen; Büyükaşik, Yahya; Unal, Serhat

    2007-07-01

    Anemia, which may develop due to direct effect of the virus or indirect effect of zidovudine a widely used antiviral agent for the treatment, is not an uncommon complication in human immundeficiency virus (HIV) infections. In this report, a 26 years old male HIV positive patient who developed rapid anemia in the HAART (Highly active anti-retroviral therapy) protocol including zidovudine, was presented. The patient has been followed since May 2003 without anti-retroviral therapy. He was diagnosed as alpha-thalassemia trait, because of the low mean red blood cell volume (MCV), high red blood cell count and living in an Mediterranian country. However, no treatment for thalassemia had been given in this period, since the other laboratory findings [hemoglobin, hematocrit, red cell distribution width index (RDWI), iron and iron binding capacity, transferrin saturation and ferritin levels] were normal. During the follow-up of patient, HAART protocol with zidovudine, lamivudine and indinavir, was started depending on the findings of low CD4+ T-cell count (443/mm3) and high HIV serum load (1,330,000 copies/ml). In the second month of the therapy the hemoglobin level decreased to 12.9 gr/dL, and then to 9.9 gr/dL in the fourth month, while it was 14.5 gr/dL before anti-retroviral therapy. Although the patient had no hemolysis findings, and his serum folic acid level was normal, folbiol treatment was initiated with the possibility of the presence of folic acid deficiency at cellular level. Anemia resolved with folic acid replacement without discontinuation of zidovudine or a reduction in dosage. It was thought that the presence of alpha-thalassemia co-morbidity has facilitated the development of anti-retroviral-induced anemia in this patient. As a result, it is concluded that thalassemia should be considered in the differential diagnosis of anemia in HIV positive patients, especially for the ones from Mediterranian countries.

  1. Correction of anemia in multiple myeloma patients by erythropoiesis-stimulating agents

    Directory of Open Access Journals (Sweden)

    N. A. Romanenko

    2014-07-01

    Full Text Available In this paper analysis of anemia correction efficacy in multiple myeloma patients was shown. Patients (n = 68 treated with epoetin alfa (recombinant erythropoietin (rEPO 150 IU/kg subcutaneously three times per week (no more 20 weeks were included in the study group. Patients who did not receive erythropoiesis-stimulating therapy were included in the control group (n = 31. Patients in both groups received at least 3 courses of chemotherapy and continued to receive anticancer treatment during follow-up. Baseline hemoglobin level was 5.3 g/dl – 10.0 g/dl. The increase in hemoglobin level to normal range (≥ 12.0 g/dl during ≤ 20 weeks was considered as positive therapy response. Positive response rate was higher in patients received epoetin alfa comparing with control group (64.7 % and 25.8 %, respectively; p < 0.05. Transfusion dependence persisted in 6 from 19 study patients who received RBC transfusions along with rEPO therapy (31.6 %, whereas in 5 from 9 control group patients (55.6 %. In epoetin alfa group significant increase in reticulocytes count at 2–3 weeks of therapywas revealed: from 27.3 × 109/l to 64.9 × 109/l (in patients with positive response and from 13.3 × 109/l to 25.1 × 109/l (in patients without response. Changes in the reticulocytes count in the control group were not revealed. Thus in patients with positive response reticulocytes level significantly increased to 3 weeks of therapy compared with negative response patients (37.6 × 109/l versus 11.8 × 109/l, respectively; p < 0,05, it can be used as prognostic factors of rEPO response.

  2. The Comparison of Serum Vitamin D Level in Patients with Iron Deficiency Anemia and Minor Thalassemia

    OpenAIRE

    Royani, S. (MSc); Alijanpor, S. (BSc); Shirbaghaei, Z. (BSc); Khorasaninejad, R. (BSc); Roshandel, GH. (MSc); Ayatollahi, AA. (MD); Joshaghani, HR. (PhD)

    2013-01-01

    Background and Objective: Of the most common hypochromic microcytic anemia are iron deficiency anemia and minor thalassemia, which are common in Iran and their differential diagnosis is extremely important. The level of 25-hydroxy vitamin D is the indication of vitamin D blood status. The aim of this study was to compare serum levels of vitamin D in people with minor thalassemia and iron deficiency anemia with healthy subjects in order to investigate the relationship between vitamin D deficie...

  3. Immune thrombocytopenia in two unrelated Fanconi anemia patients – a mere coincidence?

    Directory of Open Access Journals (Sweden)

    Anna eKarastaneva

    2015-06-01

    Full Text Available Thrombocytopenia and pancytopenia, occurring in patients with Fanconi anemia (FA, are interpreted either as progression to bone marrow failure or as developing myelodysplasia. On the other hand, immune thrombocytopenia (ITP represents an acquired and often self-limiting benign hematologic disorder, associated with peripheral, immune-mediated, platelet destruction requiring different management modalities than those used in congenital bone marrow failure syndromes, including FA. Here we describe the clinical course of two independent FA patients with atypical - namely immune - thrombocytopenia. While in one patient belonging to complementation group FA-A, the ITP started at 17 months of age and showed a chronically persisting course with severe purpura, responding well to intravenous immunoglobulins (IVIG and later also danazol, a synthetic androgen, the other patient (of complementation group FA-D2 had a self-limiting course that resolved after one administration of IVIG. No cytogenetic aberrations or bone marrow abnormalities other than FA-typical mild dysplasia were detected. Our data show that acute and chronic ITP may occur in FA patients and impose individual diagnostic and therapeutic challenges in this rare congenital bone marrow failure / tumor predisposition syndrome. The management and a potential context of immune pathogenesis with the underlying marrow disorder are discussed.

  4. Risk of cancer in patients with iron deficiency anemia: a nationwide population-based study.

    Directory of Open Access Journals (Sweden)

    Ning Hung

    Full Text Available This study evaluated the risk of cancer among patients with iron deficiency anemia (IDA by using a nationwide population-based data set.Patients newly diagnosed with IDA and without antecedent cancer between 2000 and 2010 were recruited from the Taiwan National Health Insurance Research Database. The standardized incidence ratios (SIRs of cancer types among patients with IDA were calculated.Patients with IDA exhibited an increased overall cancer risk (SIR: 2.15. Subgroup analysis showed that patients of both sexes and in all age groups had an increased SIR. After we excluded patients diagnosed with cancer within the first and first 5 years of IDA diagnosis, the SIRs remained significantly elevated at 1.43 and 1.30, respectively. In addition, the risks of pancreatic (SIR: 2.31, kidney (SIR: 2.23, liver (SIR: 1.94, and bladder cancers (SIR: 1.74 remained significantly increased after exclusion of patients diagnosed with cancer within 5 years after IDA diagnosis.The overall cancer risk was significantly elevated among patients with IDA. After we excluded patients diagnosed with IDA and cancer within 1 and 5 years, the SIRs remained significantly elevated compared with those of the general population. The increased risk of cancer was not confined to gastrointestinal cancer when the SIRs of pancreatic, kidney, liver, and bladder cancers significantly increased after exclusion of patients diagnosed with IDA and cancer within the first 5 years. This finding may be caused by immune activities altered by IDA. Further study is necessary to determine the association between IDA and cancer risk.

  5. 抗胸腺细胞免疫球蛋白治疗儿童再生障碍性贫血的不良反应相关因素及疗效相关性研究%Adverse reactions management of Antithymocyte Globulin in treatment of childhood with aplastic anemia

    Institute of Scientific and Technical Information of China (English)

    李福兴; 石苇; 乔晓红; 周晓迅; 何薇; 谢晓恬

    2016-01-01

    目的:归纳抗胸腺细胞免疫球蛋白(ATG)免疫抑制治疗儿童再生障碍性贫血(AA)不良反应防治对策,评价不良反应与疗效的关系,分析不良反应发生的相关因素。方法采用ATG联合环孢菌素A(CsA)联合免疫抑制疗法(CIS)治疗儿童再生障碍性贫血共61例,其中使用美国(Genzyme公司)R- ATG 31例,使用德国(Fresenius公司)R- ATG 30例。采取不良反应综合防治措施,比较两种ATG不良反应发生率,分析不良反应与疗效关系,分析不良反应的相关因素。结果 Fresenius- ATG相关类过敏反应、血清病、感染和需加输血小板等不良反应发生率分别为40.00%(12例)、43.30%(13例)、16.70%(5例)和23.33%(7例);Genzyme- ATG相关类过敏反应、血清病、感染和需加输血小板等不良反应发生率分别为35.48%(11例)、35.48%(11例)、9.70%(3例)和29.03%(9例),两种制剂ATG不良反应发生率差异无统计学意义(>0.05)。不良反应的发生与否疗效比较差异无统计学意义,不良反应发生率在不同年龄,性别和疾病分型中差异无统计学意义。经综合防治,所有不良反应均得以及时控制,无治疗相关死亡。结论 ATG联合CsA治疗儿童再生障碍性贫血安全有效,综合防治措施可有效防治不良反应。Fresenius- ATG和Genzyme- ATG治疗儿童再生障碍性贫血不良反应发生率相当;不良反应的发生并不影响ATG治疗效果;不同年龄、性别及疾病严重程度与不良反应发生无直接相关性。%Objective To summarize the adverse reactions of rabbit antithymocyte globulin in treatment of chil-dren with aplastic anemia. Methods 61 children with AA treated with ATG and CsA in our department were ana-lyzed, 31 of them received (Genzyme) R-ATG and CsA, the other 30 received Fresenius-ATG and CsA therapy, comprehensive measures were used to prevent and control ATG

  6. Treatment of severe aplastic anemia with intensified immunosuppressive therapy and two different regimens with recombinant human granulocyte colony-stimulating factor: a retrospective study based on long-term follow-up%强化免疫抑制疗法联合不同方案G-CSF治疗重型再生障碍性贫血患者的长期随访研究

    Institute of Scientific and Technical Information of China (English)

    李英梅; 李星鑫; 葛美丽; 施均; 钱林生; 王建祥; 郑以州

    2010-01-01

    目的 比较强化免疫抑制疗法(IIST)联合两种不同方案重组人粒细胞集落刺激因子(rhG-CSF)治疗重型再生障碍性贫血(SAA)患者的有效性和安全性.方法 回顾性分析1994年3月至2007年12月lIST联合rhG-CSF治疗的176例SAA患者资料.方案A:96例患者IIST后1个月始用rhG-CSF,300μg/次,每周3次、2次、1次各用1个月;方案B:80例患者IIST前始用rhG-CSF 5μg·kg-1·d-1,直至造血功能出现恢复.比较两组的治疗反应、感染相关死亡率和克隆性演变发生率.结果 ①B组患者早期治疗反应率(67.5%)显著高于A组(37.5%)(P<0.01),且其获早期治疗反应时间明显提前.B组患者IIST后4个月内感染相关死亡率(6.3%)显著低于A组(16.7%)(P=0.034).B组患者4年总体生存率[(77.7±4.9)%]显著高于A组[(57.2±5.1)%](P=0.006).②IIST后4个月无效的难治性SAA患者,A组者停用rhG-CSF,B组者继续应用,两组12个月疗效、感染相关死亡率及总体生存率差异均无统计学意义(P值分别为0.066、0.296、0.288),但B组患者转化为骨髓增生异常综合征/急性髓系白血病(MDS/AML)风险显著增高.③多因素分析发现疾病严重程度(RR=1.922,P=0.010)、是否有早期治疗反应(RR=5.749,P<0.01)为独立预后影响因素,且SAA转化为MDS/AML仅与rhG-CSF疗程相关(RR=1.004,P=0.017).结论 早期足量应用rhG-CSF联合IIST有助于造血功能恢复,并降低其感染相关死亡率,但延长rhG-CSF疗程并不能进一步提高难治性SAA患者的远期疗效,且增加其转化为MDS/AML的危险性.%Objective To compare the efficacy and safety of two different regimens with recombinant human granulocyte colony-stimulating factor (rhG-CSF) combined with intensified immunosuppressive therapy (IIST) in severe aplastic anemia (SAA). Methods Retrospectively analyzed 176 SAA treated with IIST and rhG-CSF in our hospital from March 1994 to December 2007. Regimen A (Group A, n =96) , rhG-CSF 300 (μg/d was initiated on day 31

  7. Safety of Pegfilgrastim (Neulasta in Patients with Sickle Cell Trait/Anemia

    Directory of Open Access Journals (Sweden)

    Pashtoon Murtaza Kasi

    2013-01-01

    Full Text Available Pegfilgrastim (Neulasta is a recombinant filgrastim (human granulocyte colony-stimulating factor (G-CSF attached to a polyethylene glycol (PEG molecule and is given as part of chemotherapy regimens that are associated with significant myelosuppression and risk for febrile neutropenia. Prescribing information available on manufacturer’s website for the drug warns us about possible severe sickle cell crises related to the medication but does not report the actual incidence or the use in patients with sickle cell trait. Caution is advised when using it in patients with sickle cell disease. Here we present a case of a Caucasian female with known sickle cell trait (SCT with no prior complications who developed a presumed sickle cell crisis after getting Neulasta, as a part of the chemotherapy regimen used to treat her breast cancer. Based on our literature review, this appears to be the first case report of a patient with SCT developing a sickle cell crisis with the pegylated form of recombinant filgrastim. Given the dearth of literature regarding the use of G-CSF and its related pegylated forms in patients with sickle cell anemia and sickle cell trait, a discussion of potential mechanisms and review of current literature and guidelines is also presented.

  8. Anemia and the risk of contrast-induced nephropathy in patients with renal insufficiency undergoing contrast-enhanced MDCT

    Energy Technology Data Exchange (ETDEWEB)

    Murakami, Ryusuke, E-mail: rywakana@nms.ac.jp; Kumita, Shin-ichiro; Hayashi, Hiromitsu; Sugizaki, Ken-ichi; Okazaki, Emi; Kiriyama, Tomonari; Hakozaki, Kenta; Tani, Hitomi; Miki, Izumi; Takeda, Minako

    2013-10-01

    Purpose: The purpose of this study was to assess the effect of anemia on the incidence of contrast-induced nephropathy (CIN) in patients with renal impairment undergoing MDCT. Materials and methods: Institutional review board approval was waived for this retrospective review of 843 patients with stable renal insufficiency (eGFR between 15 and 60 mL/min) who had undergone contrast-enhanced MDCT. Baseline hematocrit and hemoglobin values were measured. Serum creatinine (SCr) was assessed at the baseline and at 48–72 h after contrast administration. Results: The overall incidence of CIN in the patient population with renal insufficiency was 6.9%. CIN developed in 7.8% (54 of 695) of anemic patients, and in 2.8% (4 of 148) of non-anemic patients (P = .027). After adjustment for confounders, low hemoglobin and low hematocrit values remained independent predictors of CIN (odds ratio 4.6, 95% CI 1.0–20.5, P = .046). Conclusions: Anemia is associated with a higher incidence of CIN in patients with renal insufficiency. Anemia is a potentially modifiable risk factor for CIN, and has an unfavorable impact on prognosis in patients with renal insufficiency undergoing contrast-enhanced MDCT.

  9. Evaluation of Macrocytic Anemias.

    Science.gov (United States)

    Green, Ralph; Dwyre, Denis M

    2015-10-01

    Macrocytic anemia, defined as a mean cell volume (MCV) ≥100 fL in adults, has a narrow differential diagnosis that requires evaluation of the peripheral blood smear as well as additional laboratory testing taken in conjunction with clinical information that includes patient history and physical examination findings. This review is an update on the approach to a patient with macrocytic anemia with attention paid to the differentiation of megaloblastic and non-megaloblastic macrocytic anemias. Critical to the determination of the diagnosis is the judicious use of laboratory testing and the evaluation of those findings in conjunction with the patient medical, surgical, and medication history. PMID:26404440

  10. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders

    DEFF Research Database (Denmark)

    Markvardsen, L H; Christiansen, Ingelise; Harbo, T;

    2014-01-01

    High dose intravenous immunoglobulin (IVIG) is an established treatment for various neuromuscular disorders. Recently, cases of hemolytic anemia following IVIG have been observed. The objective of this study was to determine the extent of anemia and hemolysis after IVIG and its relationship...

  11. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.

    Science.gov (United States)

    Salim, Ozan; Toptas, Tayfur; Avsar, Esin; Yucel, Orhan Kemal; Ozturk, Erman; Ferhanoglu, Burhan; Geduk, Ayfer; Mehtap, Ozgur; Tombak, Anil; Tiftik, Eyup Naci; Deveci, Burak; Kurtoglu, Erdal; Kara, Osman; Atagunduz, Isik Kaygusuz; Tuglular, Tulin Firatli; Undar, Levent

    2016-06-01

    The present study aimed to compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndrome (MDS). A total of 88 patients diagnosed with refractory anemia with excess blast (RAEB) treated with azacitidine (n=57) or decitabine (n=31) were evaluated. Comparisons between azacitidine and decitabine groups were performed in the whole cohort, and in a 1:1 propensity score-matched cohort in order to reduce the simple selection bias. Patients who received azacitidine or decitabine had comparable overall response rates in both the unmatched (49.1% vs. 64.5%, p=0.166) and the propensity-matched cohorts (52% vs. 68%, p=0.248). The cumulative incidence of AML transformation at one year was comparable between azacitidine and decitabine in the unmatched (24.0% vs. 31.3%, p=0.26) and in the propensity-matched cohorts (18.7% vs. 31.5%, p=0.11). There was no difference in terms of transfusion requirement, febrile neutropenia episodes or the need for antifungal use during the treatment cycles in the propensity-matched cohort. The median overall survival was 20.4 months for azacitidine and 16.8 months for decitabine (p=0.59). Finally, we found that at least a four-cycle treatment with any HMA was a favorable factor. In conclusion, both azacitidine and decitabine have similar efficacy and toxicity profiles in the treatment of MDS-RAEB.

  12. Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial

    OpenAIRE

    Abbas Norouzi Javidan; Heshmatollah Shahbazian; Amirhossein Emami; Mir Saeed Yekaninejad; Hassan Emami-Razavi; Masoumeh Farhadkhani; Ahmad Ahmadzadeh; Fazel Gorjipour

    2014-01-01

    Recombinant human erythropoietin (rHuEPO) is available for correcting anemia. PDpoetin, a new brand of rHuEPO, has been certified by Food and Drug Department of Ministry of Health and Medical Education of Iran for clinical use in patients with chronic kidney disease. We conducted this post-marketing survey to further evaluate the safety and efficacy of PDpoetin for management of anemia in patients on maintenance hemodialysis. Patients from 4 centers in Iran were enrolled for this multicenter,...

  13. A novel mutation of ribosomal protein S10 gene in a Japanese patient with diamond-Blackfan anemia.

    Science.gov (United States)

    Yazaki, Makoto; Kamei, Michi; Ito, Yasuhiko; Konno, Yuki; Wang, Runan; Toki, Tsutomu; Ito, Etsuro

    2012-05-01

    Diamond-Blackfan anemia (DBA) is an inherited bone marrow disease. The condition is characterized by anemia that usually presents during infancy or early childhood and congenital malformation. Several reports show that DBA is associated with mutations in the ribosomal protein (RP) genes, RPS19, RPS24, RPS17, RPL35A, RPL5, RPL11, and RPS7. Recently, 5 and 12 patients with mutations in RPS10 and RPS26, respectively, were identified in a cohort of 117 DBA probands. Therefore, we screened the DBA patients who were negative for mutations in these DBA genes for mutations in RPS10 and RPS26. The present case report describes the identification of the first Japanese DBA patient with a novel mutation in RPS10.

  14. Treatment of anemia with darbepoetin alfa in systolic heart failure

    DEFF Research Database (Denmark)

    Swedberg, Karl; Young, James B; Anand, Inder S;

    2013-01-01

    Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia....

  15. Hemolytic anemia

    Science.gov (United States)

    ... Jager U, Lechner K. Autoimmune hemolytic anemia. In: Hoffman R, Benz EJ Jr, Silberstein LE, et al, ... Price EA, Schrier SS. Extrinsic nonimmune hemolytic anemias. In: Hoffman R, Benz EJ Jr, Silberstein LE, et al, ...

  16. Plasmodium falciparum Merozoite Surface Protein-1 Polymorphisms among Asymptomatic Sickle Cell Anemia Patients in Nigeria.

    Science.gov (United States)

    Bamidele Abiodun, Iwalokun; Oluwadun, Afolabi; Olugbenga Ayoola, Aina; Senapon Olusola, Iwalokun

    2016-01-01

    Asymptomatic malaria (ASM) has been implicated in the development of hemolytic crisis in infected sickle cell anemia (SCA) patients worldwide. This study surveyed steady state SCA Nigerian patients for ASM to investigate the influence of malaria prevention behaviors and age on parasitaemia and multiplicity of infection (MOI). A total of 78 steady SCA patients aged 5 - 27 years on routine care at three health facilities in Lagos were investigated for ASM by light microscopy and PCR with a multiplicity of infection determined by genotyping block 2 of merozoite surface protein 1 (msp1) gene of Plasmodium falciparum (P. falciparum). Use of malaria prevention measures was captured using a semi-structured questionnaire. The prevalence rates of ASM (due to Pf only) by microscopy and PCR were found to be 27.3% and 47.4% respectively (P < 0.05) with a Mean + SEM parasite density of 2238.4 + 464.3 parasites/uL. Five distinct msp1 genotypes [K1 (2), MAD20 (2), RO33 (1)] were detected and significant (P<0.05) disparity in allele frequencies (K1, 91.8%, MAD20, 32.4%; RO33, 18.9%) was found. The overall MOI was 1.43 and 37.8% of infections were polyclonal (P<0.05). ASM was associated with non-use of preventive measures and occurred in 62.1% of SCA patients aged < 10y with lower MOI of 1.3 compared to 38.1% in older patients with a higher MOI of 1.5 (P<0.05). We conclude that PCR improved the diagnosis of ASM among Nigerian SCA patients with infections being of low complexity and associated with non-use of preventive interventions and R033 msp1 allele selection. PMID:26853290

  17. Plasmodium falciparum Merozoite Surface Protein-1 Polymorphisms among Asymptomatic Sickle Cell Anemia Patients in Nigeria

    Directory of Open Access Journals (Sweden)

    Iwalokun Bamidele Abiodun

    2016-01-01

    Full Text Available Asymptomatic malaria (ASM has been implicated in the development of hemolytic crisis in infected sickle cell anemia (SCA patients worldwide. This study surveyed steady state SCA Nigerian patients for ASM to investigate the influence of malaria prevention behaviors and age on parasitaemia and multiplicity of infection (MOI. A total of 78 steady SCA patients aged 5 – 27 years on routine care at three health facilities in Lagos were investigated for ASM by light microscopy and PCR with a multiplicity of infection determined by genotyping block 2 of merozoite surface protein 1 (msp1 gene of Plasmodium falciparum (P. falciparum. Use of malaria prevention measures was captured using a semi-structured questionnaire. The prevalence rates of ASM (due to Pf only by microscopy and PCR were found to be 27.3% and 47.4% respectively (P < 0.05 with a Mean + SEM parasite density of 2238.4 + 464.3 parasites/uL. Five distinct msp1 genotypes [K1 (2, MAD20 (2, RO33 (1] were detected and significant (P<0.05 disparity in allele frequencies (K1, 91.8%, MAD20, 32.4%; RO33, 18.9% was found. The overall MOI was 1.43 and 37.8% of infections were polyclonal (P<0.05. ASM was associated with non-use of preventive measures and occurred in 62.1% of SCA patients aged < 10y with lower MOI of 1.3 compared to 38.1% in older patients with a higher MOI of 1.5 (P<0.05. We conclude that PCR improved the diagnosis of ASM among Nigerian SCA patients with infections being of low complexity and associated with non-use of preventive interventions and R033 msp1 allele selection.

  18. Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.

    Science.gov (United States)

    Bandeira, Izabel C J; Rocha, Lillianne B S; Barbosa, Maritza C; Elias, Darcielle B D; Querioz, José A N; Freitas, Max Vitor Carioca; Gonçalves, Romélia P

    2014-02-01

    The chronic inflammatory state in sickle cell anemia (SCA) is associated with several factors such as the following: endothelial damage; increased production of reactive oxygen species; hemolysis; increased expression of adhesion molecules by leukocytes, erythrocytes, and platelets; and increased production of proinflammatory cytokines. Genetic characteristics affecting the clinical severity of SCA include variations in the hemoglobin F (HbF) level, coexistence of alpha-thalassemia, and the haplotype associated with the HbS gene. The different haplotypes of SCA are Bantu, Benin, Senegal, Cameroon, and Arab-Indian. These haplotypes are associated with ethnic groups and also based on the geographical origin. Studies have shown that the Bantu haplotype is associated with higher incidence of clinical complications than the other haplotypes and is therefore considered to have the worst prognosis. This study aimed to evaluate the profile of the proinflammatory cytokines interleukin-6, tumor necrosis factor-α, and interleukin-17 in patients with SCA and also to assess the haplotypes associated with beta globin cluster S (HBB(*)S). We analyzed a total of 62 patients who had SCA and had been treated with hydroxyurea; they had received a dose ranging between 15 and 25 (20.0±0.6)mg/kg/day for 6-60 (18±3.4)months; their data were compared with those for 30 normal individuals. The presence of HbS was detected and the haplotypes of the beta S gene cluster were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Our study demonstrated that SCA patients have increased inflammatory profile when compared to the healthy individuals. Further, analysis of the association between the haplotypes and inflammatory profile showed that the levels of IL-6 and TNF-α were greater in subjects with the Bantu/Bantu haplotype than in subjects with the Benin/Benin haplotype. The Bantu/Benin haplotype individuals had lower levels of cytokines than those with

  19. Spontaneous liver rupture in a patient with peliosis hepatis:A case report

    Institute of Scientific and Technical Information of China (English)

    Sun-Keun Choi; Jun-Shuo Jin; Soon-Gu Cho; Suk-Jin Choi; Chul-Soo Kim; Yun-Mee Choe; Keon-Young Lee

    2009-01-01

    Peliosis hepatis is a rare pathological entity and may cause fatal hepatic hemorrhage and liver failure.Here, we present a young male patient with aplastic anemia, who had received long-term treatment with oxymetholone.The patient suffered from sudden onset of intra-abdominal hemorrhage with profuse hemoperitoneum.The patient was treated successfully with a right hemihepatectomy and is in good health after 13 postoperative months.We suggest that peliosis hepatis be considered in patients with hepatic parenchymal hematoma, especially in patients under prolonged synthetic anabolic steroid medication.The possibility of a potentially life-threatening complication of massive intra-abdominal bleeding should also be considered.

  20. Single-center open-label randomized study of anemia management improvement in ESRD patients with secondary hyperparathyroidism

    Directory of Open Access Journals (Sweden)

    Bellasi Antonio

    2016-04-01

    Full Text Available Whether anemia and mineral bone abnormalities (chronic kidney disease–mineral bone disorder [CKD-MBD] are associated still remains to be elucidated. Both anemia and CKD-MBD have been associated with adverse cardiovascular outcome and poor quality of life. However, recent evidence suggests that use of large doses of erythropoietin-stimulating agents (ESAs to correct hemoglobin (Hb may be detrimental in CKD. The Optimal Anemia Treatment in End Stage Renal Disease (ESRD (Optimal ESRD Treatment study will assess whether lowering of parathyroid hormone (PTH is associated with a reduction in ESA consumption. The Optimal ESRD Treatment study is a pilot single-center open-label study with blinded end point (a prospective randomized open blinded end-point [PROBE] design enrolling 50 patients on maintenance dialysis. Eligible patients with intact PTH (iPTH 300-540 pg/mL and Hb 10-11.5 g/dL will be randomized 1:1 to strict PTH control (150-300 pg/mL versus standard care (PTH range 300-540 pg/mL. Available drugs for CKD-MBD and anemia treatment will be managed by the attending physician to maintain the desired levels of PTH (according to study arm allocation and Hb (10-11.5 g/dL. Echocardiographic data for cardiac structure and function as well as arterial stiffness will be assessed at study inception and completion. The Optimal ESRD Treatment study should shed light on the complicated interplay of anemia and CKD-MBD and on the feasibility of clinical trials in this domain. The study results are expected in the spring of 2017.

  1. Basic conditions for radioimmunoassay of erythropoietin, and plasma levels of erythropoietin in normal subjects and anemic patients

    Energy Technology Data Exchange (ETDEWEB)

    Mizoguchi, Hideaki; Ohta, Kazuo; Suzuki, Toshiaki; Murakami, Akihiko; Ueda, Masatsugu; Sasaki, Ryuzou; Chiba, Hideo

    1987-02-01

    We have developed a specific and sensitive radioimmunoassay for erythropoietin. The sensitivity of our assay is 0.5 mU or 5 mU/ml and is sufficient to detect normal plasma erythropoietin levels. The mean plasma erythropoietin titer of normal Japanese with our radioimmunoassay was found to be 21.9 +- 12.0 mU/ml (n = 199). The validity of the method was further confirmed by the observations that the plasma erythropoietin titers were inversely related to hemoglobin levels in patients with nonuremic anemias, lower in uremic patients than in patients with nonuremic anemias with similar hemoglobin levels, markedly elevated in patients with aplastic anemia and pure red cell aplasia, and in a low normal range in patients with polycythemia vera.

  2. Efeitos da pentoxifilina na anemia resistente à eritropoetina em pacientes sob hemodiálise Pentoxifylline effects on the resistant anemia to erythropoietin in hemodialysis patients

    Directory of Open Access Journals (Sweden)

    Sandra A. Antunes

    2008-08-01

    ímos que, em nossa amostra, não obtivemos benefícios com o uso da pentoxifilina. Porém, certamente se fazem necessários estudos mais amplos e controlados para que se possa chegar a conclusões que norteiem a indicação clínica desta droga como coadjuvante da EPO.Anemia in end stage renal disease occurs due to the reduction in the production of erythropoietin caused by the decrease in functional renal mass. Erythropoietin has been indicated in the treatment of anemia however, about 5% of patients are resistant to this treatment. In erythropoietin resistance, it is necessary to increase the dosage to more than 12000 U/Kg/weekly, but even so the hematocrit target, which should remain between 33 and 36%, is not reached. Pro-inflammatory cytokines are significantly associated to resistance to erythropoietin treatment and so pentoxifylline is used to inhibit the production of these pro-inflammatory cytokines. This study was carried out with hemodialysis patients at the Ribamar Vaz Institute of Nephrology - in the Santa Casa de Misericórdia Hospital of Maceió. Patients with diagnoses of resistance to erythropoietin received 400mg VO pentoxifylline after hemodialysis over a period of six months. The hematocrit and C-reactive protein (CRP concentrations were analyzed three times: in the first month, at the end of three months (12 patients and at the end of six months (7 patients. The mean CRP of the 12 patients in the first month was 5.65 and in the third month it was 2.58. However, in the sixth month, with the 7 patients remaining in the protocol, it was 4.55. No significant differences were observed. The final average hematocrit concentration of the patients was 28.74%. The average hematocrit concentration, in the six-month evaluation that preceded the project, was 26.22%. Statistically-relevant differences were not observed in the 12 patients followed up for 3 months or in the 7 that concluded the study. No correlations between the levels of CRP and hematocrit

  3. Genotyping of fanconi anemia patients by whole exome sequencing: advantages and challenges.

    Directory of Open Access Journals (Sweden)

    Kerstin Knies

    Full Text Available Fanconi anemia (FA is a rare genomic instability syndrome. Disease-causing are biallelic mutations in any one of at least 15 genes encoding members of the FA/BRCA pathway of DNA-interstrand crosslink repair. Patients are diagnosed based upon phenotypical manifestations and the diagnosis of FA is confirmed by the hypersensitivity of cells to DNA interstrand crosslinking agents. Customary molecular diagnostics has become increasingly cumbersome, time-consuming and expensive the more FA genes have been identified. We performed Whole Exome Sequencing (WES in four FA patients in order to investigate the potential of this method for FA genotyping. In search of an optimal WES methodology we explored different enrichment and sequencing techniques. In each case we were able to identify the pathogenic mutations so that WES provided both, complementation group assignment and mutation detection in a single approach. The mutations included homozygous and heterozygous single base pair substitutions and a two-base-pair duplication in FANCJ, -D1, or -D2. Different WES strategies had no critical influence on the individual outcome. However, database errors and in particular pseudogenes impose obstacles that may prevent correct data perception and interpretation, and thus cause pitfalls. With these difficulties in mind, our results show that WES is a valuable tool for the molecular diagnosis of FA and a sufficiently safe technique, capable of engaging increasingly in competition with classical genetic approaches.

  4. Phase 1 study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia.

    Directory of Open Access Journals (Sweden)

    Ted Wun

    Full Text Available BACKGROUND: Sickle cell anemia is an inherited disorder of hemoglobin that leads to a variety of acute and chronic complications. Abnormal cellular adhesion, mediated in part by selectins, has been implicated in the pathophysiology of the vaso-occlusion seen in sickle cell anemia, and selectin inhibition was able to restore blood flow in a mouse model of sickle cell disease. METHODS: We performed a Phase 1 study of the selectin inhibitor GMI 1070 in patients with sickle cell anemia. Fifteen patients who were clinically stable received GMI 1070 in two infusions. RESULTS: The drug was well tolerated without significant adverse events. There was a modest increase in total peripheral white blood cell count without clinical symptoms. Plasma concentrations were well-described by a two-compartment model with an elimination T1/2 of 7.7 hours and CLr of 19.6 mL/hour/kg. Computer-assisted intravital microscopy showed transient increases in red blood cell velocity in 3 of the 4 patients studied. CONCLUSIONS: GMI 1070 was safe in stable patients with sickle cell anemia, and there was suggestion of increased blood flow in a subset of patients. At some time points between 4 and 48 hours after treatment with GMI 1070, there were significant decreases in biomarkers of endothelial activation (sE-selectin, sP-selectin, sICAM, leukocyte activation (MAC-1, LFA-1, PM aggregates and the coagulation cascade (tissue factor, thrombin-antithrombin complexes. Development of GMI 1070 for the treatment of acute vaso-occlusive crisis is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov NCT00911495.

  5. Evaluation of microalbuminuria in relation to asymptomatic bacteruria in Nigerian patients with sickle cell anemia

    Directory of Open Access Journals (Sweden)

    B A Iwalokun

    2012-01-01

    Full Text Available Studies have identified microalbuminuria (MA and asymptomatic bacteruria (ASB as co-morbid factors in sickle cell anemia (SCA. However, the relationship between these comorbid factors remains unclear and data are lacking for Nigerian patients. This study determined the prevalence of MA and ASB in a cohort of patients with SCA in a steady state, in Lagos, Nigeria. Early morning mid-stream urine samples were collected in sterile bottles from 103 patients comprising 48 males and 55 females with a mean age of 10.4 years. Aerobic culture and colony count of organisms was done using conventional methods. Serum creatinine and hematological indices, including irreversibly sickled cells (ISC, were also assayed. Of the 103 urine samples screened, 23 (22.3% had albuminuria (ALB, and consisted of nine males and 14 females (P > 0.05; 16.5% of the cases had MA (P 0.05. The prevalence of confirmed ASB was 14.6%, with females accounting for 14 of 19 probable ASB cases (P <0.05. Univariate regression analysis demonstrated a significant (P <0.05 association between age at onset of MA, hemoglobin level, reticulocyte count, ISC and occurrence of ASB, but with only ISC evolving as an independent predictor. Twenty-eight bacterial isolates predominated by Escherichia coli (39.3%; P <0.05, of whom 89.3% were multi-drug resistant, were recovered from the ASB urine samples. In conclusion, both MA and ASB are common in Nigerian SCA patients, with the former occurring from the first decade of life.

  6. Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders

    OpenAIRE

    Strauss, William

    2016-01-01

    David C Ford,1 Naomi V Dahl,2 William E Strauss,2 Charles F Barish,3 David J Hetzel,4 Kristine Bernard,2 Zhu Li,2 Lee F Allen,2 1Toronto Digestive Disease Associates, Inc, Vaughan Endoscopy Clinic, Vaughan, ON, Canada; 2AMAG Pharmaceuticals, Inc, Waltham, MA, 3Wake Gastroenterology, Wake Research Associates, Raleigh, NC, USA; 4Department of Gastroenterology, Royal Adelaide Hospital, Adelaide, SA, Australia Introduction: Iron deficiency anemia (IDA) is common in patients with gastrointestinal...

  7. Frequency distribution of sickle cell anemia, sickle cell trait and sickle/beta-thalassemia among anemic patients in Saudi Arabia

    OpenAIRE

    Elsayid, Mohieldin; Al-Shehri, Mohammed Jahman; Alkulaibi, Yasser Abdullah; Alanazi, Abdullah; Qureshi, Shoeb

    2015-01-01

    Background: Notwithstanding, the growing incidence of sickle cell hemoglobinopathies (SCH) such as sickle cell anemia (SCA) or sickle cell disease, sickle/beta-thalassemia; the exact prevalence remains obscure in Saudi Arabia. Hence, this study is an attempt to determine the frequency of SCA and sickle cell trait (SCT) among all anemic patients with SCH treated at the King Abdul-Aziz Medical City (KAMC), Riyadh, Saudi Arabia. Furthermore, the hemoglobin (Hb) S and other Hb patterns (Hb AS and...

  8. Bed bugs reproductive life cycle in the clothes of a patient suffering from Alzheimer’s disease results in iron deficiency anemia

    OpenAIRE

    Sabou, Marcela; Gallo Imperiale, Delphine; Andrès, Emmanuel; Abou-Bacar, Ahmed; Foeglé, Jacinthe; Lavigne, Thierry; Kaltenbach, Georges; Candolfi, Ermanno

    2013-01-01

    We report the case of an 82-year-old patient, hospitalized for malaise. Her clothes were infested by numerous insects and the entomological analysis identified them as being Cimex lectularius (bed bugs). The history of the patient highlighted severe cognitive impairment. The biological assessment initially showed a profound microcytic, aregenerative, iron deficiency anemia. A vitamin B12 deficiency due to pernicious anemia (positive intrinsic factor antibodies) was also highlighted, but this ...

  9. Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study.

    Science.gov (United States)

    Garlo, Katherine; Williams, Deanna; Lucas, Lee; Wong, Rocket; Botler, Joel; Abramson, Stuart; Parker, Mark G

    2015-06-01

    The aim of this study was to examine the relationship of severe anemia to hospital readmission and length of stay (LOS) in patients with chronic kidney disease (CKD) stage 3-5. Compared with the general population, patients with moderate CKD have a higher hospital readmission rate and LOS. Anemia in patients with moderate CKD is associated with higher morbidity and mortality. The influence of anemia on hospital outcomes in patients with moderate CKD has not been characterized.We conducted a retrospective cohort study at Maine Medical Center, a 606-bed academic tertiary care hospital. Patients with CKD stages 3-5 and not on dialysis admitted during February 2013 to January 2014 were eligible. Patients with end stage renal disease on hemodialysis or peritoneal dialysis, kidney transplant, acute kidney injury, gastrointestinal bleeding, active malignancy, pregnancy, and surgery were excluded. The cohort was split into severe anemia (hemoglobin ≤9  g/dL) versus a comparison group (hemoglobin >9 g /dL), and examined for differences in 30-day hospital readmission and LOS.In this study, the data of 1141 patients were included, out of which 156 (13.7%) had severe anemia (mean hemoglobin 8.1 g/dL, SD 0.8). Severe anemia was associated with increased hospital LOS (mean 6.4 (SD 6.0) days vs mean 4.5 (SD 4.0) days, P anemia are at risk for increased hospital LOS. Interventions targeting this high-risk population, including outpatient management of anemia, may benefit patient care and save costs through improved hospital outcomes.

  10. HEMOGLOBIN PRODUCTION FACTORS IN THE HUMAN LIVER : ANEMIAS, HYPOPROTEINEMIA, CIRRHOSIS, PIGMENT ABNORMALITIES, AND PREGANCY.

    Science.gov (United States)

    Whipple, G H; Robscheit-Robbins, F S

    1942-09-01

    Human liver tissue has been assayed to determine the amount of hemoglobin production factors in normal and abnormal states. Standardized dogs made anemic by blood removal have been used in this biological assay. Normal animal liver as control is rated as 100 per cent. Normal human liver tissue as compared with the normal animal control contains more of these hemoglobin production factors-a biological assay ratio of 120 to 160 per cent. Infections, acute and chronic, do not appear to modify these values, the concentration of hemoglobin-producing factors falling within the normal range. Pernicious anemia and aplastic anemia both show large liver stores of hemoglobin-producing factors-a biological assay ratio of 200 to 240 per cent. Therapy in pernicious anemia reduces these liver stores as new red cells are formed. Secondary anemia presents a low normal or subnormal liver store of hemoglobin-producing factors-an assay of 60 to 130 per cent. Hemochromatosis, erythroblastic anemia, and hemolytic icterus in spite of large iron deposits in the liver usually show a biological assay which is normal or close to normal. Polycythemia shows low reserve stores of hemoglobin-producing factors. Leukemias present a wide range of values discussed above. Hypoproteinemia almost always is associated with low reserve stores of hemoglobin-producing factors in the liver-biological assays of 60 to 80 per cent. Hypoproteinemia means a depletion of body protein reserve stores including the labile protein liver reserves-a strong indication that the prehemoglobin material (or globin) is related to these liver stores. Pregnancy, eclampsia, and lactation all may present subnormal liver stores of hemoglobin-producing factors. Exhaustion of protein stores lowers the barrier to infection and renders the liver very susceptible to many toxic substances. It should not be difficult to correct hypoproteinemia under these conditions and thus relieve the patient of a real hazard.

  11. A COMPARATIVE STUDY OF INJECTABLE IRON-SUCROSE VERSUS ORAL IRON IN POSTPARTUM MODERATE ANEMIA PATIENTS

    OpenAIRE

    Patange; Viral Kashyap

    2014-01-01

    BACKGROUND: Postpartum anemia can develop after delivery because of unforeseen medical problems during and after delivery which could complicate a mother’s ability to properly care for her newborn child. The current treatment for postpartum anemia is oral iron supplementation but this treatment has been associated with gastrointestinal side effects. Alternative treatment includes blood transfusions and intravenous iron therapy. Since blood transfusions are very costly, int...

  12. Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia.

    Science.gov (United States)

    Arroyo-Ávila, Mariangelí; Fred-Jiménez, Ruth M; Vilá, Luis M

    2015-01-01

    Rituximab is an anti-CD20 monoclonal antibody that has been used to treat several complications of systemic lupus erythematosus (SLE) including nephritis, cerebritis, and hematological disorders. Neutropenia is among the adverse events associated with rituximab; this usually occurs several weeks after therapy. However, early-onset neutropenia has been reported only in a few cases. Herein, we describe a 36-year-old Hispanic SLE woman who developed severe early-onset neutropenia (0.3 × 10(9)/L) after the second weekly rituximab infusion (375 mg/m(2) weekly × 4) given for nephritis and hemolytic anemia. She also had early-onset thrombocytopenia after rituximab therapy. Both hematological disorders resolved 12 days after the fourth and final dose. This case, together with few others, suggests that early-onset neutropenia may occur during rituximab therapy. Even though rituximab-induced neutropenia seems to be transient, it may predispose SLE patients to severe complications such as infections. PMID:25767732

  13. Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia

    Directory of Open Access Journals (Sweden)

    Mariangelí Arroyo-Ávila

    2015-01-01

    Full Text Available Rituximab is an anti-CD20 monoclonal antibody that has been used to treat several complications of systemic lupus erythematosus (SLE including nephritis, cerebritis, and hematological disorders. Neutropenia is among the adverse events associated with rituximab; this usually occurs several weeks after therapy. However, early-onset neutropenia has been reported only in a few cases. Herein, we describe a 36-year-old Hispanic SLE woman who developed severe early-onset neutropenia (0.3 × 109/L after the second weekly rituximab infusion (375 mg/m2 weekly × 4 given for nephritis and hemolytic anemia. She also had early-onset thrombocytopenia after rituximab therapy. Both hematological disorders resolved 12 days after the fourth and final dose. This case, together with few others, suggests that early-onset neutropenia may occur during rituximab therapy. Even though rituximab-induced neutropenia seems to be transient, it may predispose SLE patients to severe complications such as infections.

  14. Relationship of anemia with clinicolaboratory measures of inflammation activity in patients with rheumatoid arthritis

    Directory of Open Access Journals (Sweden)

    A E Sizikov

    2007-01-01

    Full Text Available Objective. To study relationship of anemic syndrome with inflammation activity measures in pts with rheumatoid arthritis (RA. Material and methods. 177 pts with RA fulfilled 1987 ACR criteria were included. 132 from them had anemia at the examination. Results were processed with complex of descriptive, structural and multivariate statistics. Results. Close relationship of RA clinical features with erythropoiesis disturbances clinically manifesting with anemia development was proved. Critical hemoglobin level (<113 g/1 was determined at which pathological processes in erythron leading to the development of anemia begin significantly influence severity of immunopathological rheumatoid process. Diapasons of disease activity measures were revealed associated with anemia presence or absence in pts with RA. Diagnostic value of studied measures diapasons for prognosis of anemia development in RA was determined. Conclusion. The results of the study allow developing criteria for prognosis of anemia appearance in RA pts with normal blood concentration of hemoglobin. Such method could help to reveal early disturbances of erythron and improve RA treatment schemes with erythropoiesis modulating drugs.

  15. Clinical analysis on 28 cases of primary sjogren's syndrome complicated with anemia%原发性干燥综合征并发贫血28例临床研究

    Institute of Scientific and Technical Information of China (English)

    章赛芜; 武洵

    2013-01-01

    Objective:To observe the clinical features of primary sjogren's syndrome (pSS) with anemia. Method: Collect the clinical data of primary sjogren's syndrome with anemia from 28 patients,and analyze the types of a-nemia and its correlation with autoantibody in these patients. Result:28(44%) out of 64 pSS patients were primary sjogren's syndrome with anemia,of which 18(64%) were anemia of chronic disease (ACD),3(10%) were iron deficiency anemia(IDA) ,3( 10%) were autoimmune hemolytic anemia (AIHA),2(7%) were megaloblastic anemia (MA) and other 2(7%)cases were (aplastic anemia) A A. Patients with positive ANA,anti-SSA,anti-SSB antibody were more common in pSS with immunity anemia( AIHA, AA) ,P<0. 05. Conclusion: ACD was the most common type of anemia in pSS complicated with anemia;There was some kind of inherent association between the disorder of immune function and anemia.%目的:观察原发性干燥综合征(pSS)并发贫血的特征.方法:回顾性分析28例pSS并发贫血患者临床资料,并对贫血的类型及与自身抗体相关性进行分析.结果:pSS并发贫血占所有住院pSS患者的44%.其中慢性病贫血(ACD) 18例(64.%),缺铁性贫血(IDA)3例(10%),巨幼红细胞性贫血(MA)2例(7%),自身免疫性溶血性贫血(AIHA)3例(10%),再生障碍性贫血(AA)2例(7%).ANA、抗SSA、SSB抗体阳性在pSS伴免疫性贫血(AIHA,AA)中更常见(P<0.05).结论:pSS并发贫血以ACD最多见;免疫功能紊乱与贫血存在内在的关联.

  16. Prevalence of anemia and its impact on mortality in patients with acute exacerbation of chronic obstructive pulmonary disease in a developing country setting.

    Science.gov (United States)

    Rahimi-Rad, Mohammad Hossein; Sadighi, Tannaz; Rabieepour, Masomeh; Dinparast, Reza; RahimiRad, Shagayegh

    2015-01-01

    Chronic Obstructive Pulmonary Disease (COPD) is going to be the third most common cause of death worldwide. The natural course of COPD is interrupted by acute exacerbations (AECOPD) with an overall mortality rate of 10%. Anemia is a well-known independent predictor of mortality in several chronic diseases. Little is known about the impact of anemia on mortality in AECOPD. The aims of this study were to determine the prevalence of anemia in AECOPD patients and its impact on mortality in a developing country setting. We retrospectively studied 200 hospitalized patients with AECOPD (100 died in hospital and 100 survived) in Imam Khomeini teaching hospital, Urmia, Iran. Prevalence of anemia between deceased and surviving patients compared by using x-square test. Mean admission day Hb and Hct level were compared between the two groups by using Student t-test. Anemia was defined according to WHO criteria: Hbanemia was significantly higher in patients who died in hospital compared to those who survived (72% vs. 49%, p=0.001 and OR=2.68). The mean ±SD Hb level was 11.5±2.7 g/dl among deceased patients vs. 13.0±2.0 g/dl among survivors (p valueAnemia was common in AECOPD patients in this developing country setting and was significantly associated with in hospital mortality.

  17. Microcytic hypochromic anemia: Should high performance liquid chromatography be used routinely for screening anemic and antenatal patients?

    Directory of Open Access Journals (Sweden)

    Joseph Philip

    2013-01-01

    Full Text Available Background: Hemoglobinopathies are the most common inherited red cell disorders worldwide. Identification of these disorders is immensely important epidemiologically and for improved management protocols. Aim and Objectives: Our aim was to determine the prevalence of hemoglobinopathies in patients with microcytic hypochromic anemia and to assess the suitability of using high performance liquid chromatography (HPLC routinely for screening antenatal cases and patients with anemia. Materials and Methods: A total of 4335 cases received from Mar 2007 to Nov 2011 were studied for various hemoglobinopathies and variants on BIO RAD ′VARIANT′ analyzer. Results: Of the 4335 cases studied, 2119 were antenatal cases, 1710 patients with other disorders and 506 family studies. Of these, 688 cases displayed abnormal hemoglobin fractions on HPLC of which 140 were antenatal women. There were 455 cases of β thalassemia trait, 24 β thalassemia major, 20 thalassemia inter-media, 54 sickle cell trait, fivesickle cell disease, 21 double heterozygous β thalassemia-sickle cell trait, nineand 4 Hb D- Punjab heterozygous and homozygous respectively, three Hb D β Thalassemia trait, 20 and 37 Hb E homozygous and heterozygous respectively, three Hb E β Thalassemia trait and four cases of Hb Q India. Twenty nine adults had isolated HbF elevation. Conclusion: Our study found a high prevalence (15.8% of hemoglobinopathies amongst microcytic hypochromic anemia and antenatal cases. An accurate diagnosis helps in preventing unnecessary iron loading. Screening all antenatal cases with anemia helps in timely antenatal counseling, thus preventing the psychological trauma of bearing a transfusion dependent child for life.

  18. Importance of anemia laboratory indexes in diagnosis and treatment of patients with anemia%贫血的实验室指标在贫血患者诊断治疗中的重要性

    Institute of Scientific and Technical Information of China (English)

    李琼芬; 张芸蕾

    2015-01-01

    Objective: To study importance of anemia laboratory indexes in diagnosis and treatment of anemia. Methods:4330 cases of anemia were selected, the ratio of male to female patients and anemia type were statistically analyzed. The levels of ser-um ferritin, folic acid and vitamin B12 were analyzed. Results:Among the 4 330 cases, there were 2 254 male patients and 2 076 fe-male patients. Among the male patients, there were 208 cases with microcytic hypochromic anemia, and 194 cases with macrocytic a-nemia;while among the female patients, there were 302 cases with microcytic hypochromic anemia, and 77 cases with macrocytic ane-mia. The serological examination showed that:among the patients with macrocytic anemia, the percentage of vitamin B12 decrease was lower with the ratio of male to female patients of being close to 1:3, but the percentage of folic acid decrease was greater with the ratio of being close to 1. 2:1;among the patients with microcytic anemia, the ratio of male to female patients was close to 2:3; among the patients with microcytic hypochromic anemia, the percentage of serum ferritin combined with folic acid and/or vitamin B12 decrease was 5%. Among 781 cases with macrocytic anemia ﹢microcytic hypochromic anemia, the patients in the departments of oncology and hematology, infection, pediatrics, obstetrics, gastroenterology, and gynecology were more and accounted for 19. 2%, 11. 78%, 10. 50%, 9. 73%, 8. 71% and 7. 94%, respectively. The ratio of male to female patients with microcytic hypochromic anemia was a-bout 3:2, and that of patients with macrocytic anemia was about 2. 5:1. Conclusions:Serum ferritin decrease is an imperative basis in the diagnosis of iron deficiency anemia, and serum ferritin decrease combined with folic acid or vitamin B12 decrease indicates micro-cytic hypochromic anemia. The detection of folic acid and vitamin B12 is a requisite basis in the diagnosis of megaloblastic anemia.%目的::探讨贫血的实验室指标在贫

  19. Anemia of Chronic Liver Diseases

    Energy Technology Data Exchange (ETDEWEB)

    Shin, Hyun Chung; Lee, Jhung Sang; Koh, Chang Soon; Lee, Mun Ho [Seoul National University College of Medicine, Seoul (Korea, Republic of)

    1971-09-15

    The pathogenetic mechanisms of anemia in patients with chronic liver disease were observed. Seventeen patients with moderate to advanced hepatic diseases were studied by various methods. Only patients without previous blood loss were included : 14 had cirrhosis, 2 had active chronic hepatitis, and one had inferior vena cava obstruction with associated liver cirrhosis. The followings were the results: 1. The anemia based on red blood cell count, Hb., and Ht. was found in 76.5-78.6% of the patients. 2. Red cell indices indicated that normo-macrocytic and normochromic anemia was present is the majority of the patients. 3. No evidence of megaloblastic anemia was found on the basis of the morphological examinations. 4. Serum iron, TIBC, % saturation and iron content in the bone marrow indicated that iron deficiency anemia was present in about half of the patients. 5. In the view of the erythrocyte dynamics, primary increase in the red cell destruction was ascribed to the cause of the anemia. 6. Decrease in the red cell survival time was not correlated with MCV, % saturation and S.L. ratio. Also, hemoglobin level was not correlated with MCV, % saturation and T{sub 50} Cr. Therefore, multiple causes may be involved in the pathogenesis of the anemia. 7. Anemia as determined by the red cell volume was found in only 60% of the patients. It may be possible that hemodilutional anemia is present.

  20. Fatores de risco para aloimunização em pacientes com anemia falciforme Risk factors for alloimmunization in patients with sickle cell anemia

    Directory of Open Access Journals (Sweden)

    Patrícía Costa Alves Pinto

    2011-12-01

    Full Text Available OBJETIVO: Determinar a imunofenotipagem eritrocitária em doadores de sangue e em pacientes com anemia falciforme (SS atendidos no Hemocentro de Alagoas e descrever a frequência e os fatores associados à aloimunização eritrocitária. MÉTODOS: Estudo transversal com 102 pacientes SS e 100 doadores de sangue. Realizou-se a fenotipagem eritrocitária, teste de Coombs Direto e Indireto e detecção de anticorpos irregulares por painel de hemácias fenotipadas. Os dados foram comparados por meio do teste de Mann-Whitney, qui-quadrado ou teste exato de Fisher. Para análise dos fatores associados à aloimunização utilizou-se a regressão logística univariada e múltipla. RESULTADOS: Os antígenos mais frequentes entre os pacientes e os doadores foram c, e, M, s, JK(a. Observaram-se diferenças significativas entre as frequências dos fenótipos dos pacientes e dos doadores em relação aos antígenos s, FY(a e JK(b. Dos 79 pacientes transfundidos, 10 (12,7% apresentaram Coombs Indireto positivo. Detectaram-se 13 aloanticorpos, sete do sistema Rh, dois do Kell e quatro não identificados. Os fatores associados à aloimunização foram o intervalo de tempo entre a última transfusão e a data do teste e ter recebido mais de dez transfusões de hemácias. Receber mais de dez transfusões representou uma chance 16,39 (IC 95%: 2,23-120,59 vezes maior de ser aloimunizado, em comparação aos que receberam menos que dez. CONCLUSÃO: A prevalência de aloimunização nos pacientes SS foi 12,7%, sendo 70% dos anticorpos encontrados pertencentes a grupos sanguíneos Rh e Kell. Este estudo mostra a importância da fenotipagem eritrocitária em doadores e receptores para diminuir o risco de aloimunização.OBJECTIVE: To determine erythrocyte phenotyping in blood donors and patients with sickle cell anemia (SS treated at Hemocentro of Alagoas and describe the frequency and factors associated with erythrocyte alloimmunization. METHODS: Cross-sectional study

  1. Bilateral macular haemorrhages secondary to hepatitis-associated aplastic anaemia, treated with Nd:YAG laser posterior hyaloidotomy.

    Science.gov (United States)

    Ranganath, Akshatha; Mariatos, George; Thakur, Shakti

    2011-01-01

    Hepatitis-associated aplastic anaemia (HAAA) is an uncommon but distinct variant of aplastic anaemia in which pancytopenia and bone marrow failure appears 2-3 months after an acute attack of hepatitis. Although bilateral vision loss may rarely be the initial presentation of aplastic anaemia, no such report is known in HAAA. Here the authors report such a case presenting with large premacular subhyaloid haemorrhages secondary to severe anaemia and thrombocytopenia. Anaemic hypoxic damage to the vessel wall together with increased cardiac output and low platelet counts are interacting causal factors in the development of bleeding. Though these haemorrhages are benign and usually improve spontaneously, the presence of blood may cause permanent macular changes before it resolves. Posterior hyaloidotomy enabled rapid resolution of premacular subhyaloid haemorrhage thereby restoring vision and preventing need for vitreo-retinal surgery. These patients should be advised to refrain from valsalva manoeuvres, ocular rubbing and vigorous exercise to prevent ocular morbidity. PMID:22674943

  2. Darbepoetin Use for the Treatment of Anemia in Hemodialysis Patients in Saudi Arabia

    Directory of Open Access Journals (Sweden)

    Shaheen Faissal

    2006-01-01

    Full Text Available Erythropoietin replacing proteins have improved patient outcomes and quality of life. Darbepoetin has a 3-fold longer half-life than recombinant human erythropoietin (rHuEPO. In this study, we investigate the efficacy and safety of the conversion of stable hemodialysis patients from the current short-acting r-HuEPO (EPO alfa or beta to the long-acting darbepoetin. In addition, we verified the appropriateness of the current ratio of conversion of the short acting to the long-acting erythropoietin in an open label prospective multi-center study. The study design included 12 weeks darbepoetin administration. The conversion ratio was 200 IU of short acting r-HuEPO to 1 microgram of darbepoetin. We adjusted the dose of darbepoetin to maintain hemoglobin levels between 110-120 g/L. There were 33 patients who satisfied the entry criteria. The study was conducted from January-June, 2005. The study patients included 18 men and 15 women, the mean age was 50.4 ± 12.3 years and the mean duration on HD was 323 ± 51.9 days. There was a significant decrease in the mean dose of darbepoetin from 37.3 ± 12.9 ug/week at week 1 of the study to 20.8 ± 16.6 ug/week by the end of week 12 (p< 0.00003 while the hemoglobin level was maintained within the previously defined range. The initial conversion ratio from short-acting erythropoietin to darbepoetin was 200 IU to 1 microgram. However, at the end of week 12, the mean dose of darbepoetin decreased to an equivalent conversion ratio to 361 IU: 1 microgram. This may reflect great savings in the cost of treatment. Our experience with darbepoetin reveals that darbepoetin is effective and safe for the treatment of anemia in hemodialysis patients and has a more convenient dosing schedule than short-acting erythropoietin. The darbepoetin dosage decreases over time and savings are expected to greater with darbepoetin more than with short-acting erythropoietin with time.

  3. Association of Increased Serum Leptin with Ameliorated Anemia and Malnutrition in Stage 5 Chronic Kidney Disease Patients after Parathyroidectomy.

    Science.gov (United States)

    Jiang, Yao; Zhang, Jingjing; Yuan, Yanggang; Zha, Xiaoming; Xing, Changying; Shen, Chong; Shen, Zhixiang; Qin, Chao; Zeng, Ming; Yang, Guang; Mao, Huijuan; Zhang, Bo; Yu, Xiangbao; Sun, Bin; Ouyang, Chun; Xu, Xueqiang; Ge, Yifei; Wang, Jing; Zhang, Lina; Cheng, Chen; Yin, Caixia; Zhang, Jing; Chen, Huimin; Ma, Haoyang; Wang, Ningning

    2016-01-01

    Leptin is an adipokine that regulates various metabolism, but its association with secondary hyperparathyroidism (SHPT), a clinical manifestation of chronic kidney disease-mineral and bone disorder (CKD-MBD), remains obscure. Parathyroidectomy (PTX) is recommended for severe SHPT patients. Here, the associations between circulating leptin and clinical characteristics in CKD patients were investigated. Effects of PTX on leptin production were analyzed in vivo and in vitro. Controls and CKD patients had approximate serum leptin levels in that a larger proportion of CKD patients with body mass index (BMI) leptin was related to anemia, albumin, and bone metabolism disorders in CKD patients. Lower intact parathyroid hormone (PTH) was related with higher leptin in PTX patients group. Severe SHPT inhibited uremia-enhanced leptin production in 3T3-L1 adipocytes, which was attenuated after PTX. High levels of PTH were found to reduce Akt phosphorylation and leptin production in vitro but high levels of calcium and phosphorus were not. Successful PTX was found to improve anemia and malnutrition in severe SHPT patients, and this was correlated with increased circulating leptin levels via up-regulated Akt signaling in adipocytes. These findings indicated the therapeutic potential of leptin and related target pathway for improving survival and quality of life in CKD. PMID:27307101

  4. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

    OpenAIRE

    Ávila-Albuerne Yisel; Casanova-Kutsareva Yuri; Lagarde-Ampudia Marcia; Hernández-Montero Tairí; Valenzuela-Silva Carmen M; Porrero-Martín Pedro J; García-García Idrian; Casanova-González Martha; Pérez-Oliva Jorge F; Vargas-Batista Alicia; Bobillo-López Hailen; Herrera-Valdés Raúl; López-Saura Pedro A

    2005-01-01

    Abstract Background Recombinant human erythropoietin (EPO) is used for the treatment of last stage renal anemia. A new EPO preparation was obtained in Cuba in order to make this treatment fully nationally available. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of two recombinant EPO formulations in patients with anemia due to end-stage renal disease on hemodialysis. Methods A parallel, randomized, double blind study was performed. A single 10...

  5. Sequence change in the HS2-LCR and Gg-globin gene promoter region of sickle cell anemia patients

    Directory of Open Access Journals (Sweden)

    E.V. Adorno

    2008-02-01

    Full Text Available The fetal hemoglobin (HbF levels and ßS-globin gene haplotypes of 125 sickle cell anemia patients from Brazil were investigated. We sequenced the Gg- and Ag-globin gene promoters and the DNase I-2 hypersensitive sites in the locus control regions (HS2-LCR of patients with HbF level disparities as compared to their ßS haplotypes. Sixty-four (51.2% patients had CAR/Ben genotype; 36 (28.8% Ben/Ben; 18 (14.4% CAR/CAR; 2 (1.6% CAR/Atypical; 2 (1.6% Ben/Cam; 1 (0.8% CAR/Cam; 1 (0.8% CAR/Arab-Indian, and 1 (0.8% Sen/Atypical. The HS2-LCR sequence analyses demonstrated a c.-10.677G>A change in patients with the Ben haplotype and high HbF levels. The Gg gene promoter sequence analyses showed a c.-157T>C substitution shared by all patients, and a c.-222_-225del related to the Cam haplotype. These results identify new polymorphisms in the HS2-LCR and Gg-globin gene promoter. Further studies are required to determine the correlation between HbF synthesis and the clinical profile of sickle cell anemia patients.

  6. New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia.

    Science.gov (United States)

    D'Alcamo, Elena; Agrigento, V; Pitrolo, L; Sclafani, S; Barone, R; Calvaruso, G; Buffa, V; Maggio, A

    2016-06-01

    Congenital dyserythropoietic anemia type I is an autosomal recessive disorder associated with macrocytic anemia, ineffective erythropoiesis, iron overloading and characterized by abnormal chromatin ultrastructure in erythroblasts such as internuclear chromatin bridges, spongy heterochromatin and invagination of the nuclear membrane. A 58-year-old Causasian man with chronic hemolytic anemia, heterozygous for β (+) -globin IVS1, nt110 G>A mutation (causing abnormal alpha:beta globin chain ratio) showed clinical, laboratory and hematological features suggesting diagnosis of CDA1. Sequence analysis of CDA-related genes revealed compound heterozygosity for two novel mutations in the CDAN1 gene: a frameshift mutation 3367 del 4 (TTAG) in exon 25 and a missense mutation c.1811 G>T in exon 11 causing an aminoacid change from glycine to valine at codon 565 (G565V). One of the propositus' brothers showed the same gene mutations. As the CDA1 can mimic thalassemia, a frequent misdiagnosis is possible especially in countries where the prevalence of thalassemia is high. A strong clinical suspicion in patients who do not reveal a clear genetic basis for presumed thalassemia may help clinch the correct diagnosis. PMID:27408412

  7. Alpha thalassemia protects sickle cell anemia patients from macro-albuminuria through its effects on red blood cell rheological properties.

    Science.gov (United States)

    Lamarre, Yann; Romana, Marc; Lemonne, Nathalie; Hardy-Dessources, Marie-Dominique; Tarer, Vanessa; Mougenel, Danielle; Waltz, Xavier; Tressières, Benoît; Lalanne-Mistrih, Marie-Laure; Etienne-Julan, Maryse; Connes, Philippe

    2014-01-01

    While chronic hemolysis has been suspected to be involved in the development of glomerulopathy in patients with sickle cell anemia (SCA), no study focused on the implications of blood rheology. Ninety-six adults with SCA at steady state were included in the present cross-sectional study. Three categories were defined: normo-albuminuria (NORMO, n = 41), micro-albuminuria (MICRO, n = 23) and macro-albuminuria (MACRO, n = 32). Blood was sampled to measure hematological and hemorheological parameters, and genomic DNA extraction was performed to detect the presence of α-thalassemia. The prevalence of α-thalassemia was lower in the MACRO group compared with the two other groups. Anemia was more severe in the MACRO compared with the NORMO group leading the former group to exhibit decreased blood viscosity. Red blood cell deformability was lower and red blood cell aggregates strength was greater in the MACRO compared to the two other groups, and this was directly attributed to the lower frequency of α-thalassemia in the former group. Our results show the protective role of α-thalassemia against the development of sickle cell glomerulopathy, and strongly suggest that this protection is mediated through the decrease of anemia, the increase of RBC deformability and the lowering of the RBC aggregates strength.

  8. Correlation between the Lactate Dehydrogenase Levels with Laboratory Variables in the Clinical Severity of Sickle Cell Anemia in Congolese Patients.

    Directory of Open Access Journals (Sweden)

    Tite Minga Mikobi

    Full Text Available Sickle cell anemia is an inflammatory disease and is characterized by chronic hemolysis. We sought to evaluate the association of lactate dehydrogenase levels with specific clinical phenotypes and laboratory variables in patients with sickle cell anemia.The present cross-sectional study was conducted in Sickle Cell Centre of Yolo in Kinshasa, the Democratic Republic of Congo. Two hundred and eleven patients with Sickle Cell Anemia in steady state were recruited. Seventy-four participants with normal Hb (Hb-AA were selected as a control group.The average rates of hemoglobin, hematocrit, and red blood cells tended to be significantly lower in subjects with Hb-SS (p<0.001. The average rates of white blood cells, platelets, reticulocytes and serum LDH were significantly higher in subjects with Hb-SS (p<0.001. The average rates of Hb, HbF, hematocrit and red blood cells of Hb-SS patients with asymptomatic clinical phenotype were significantly higher than those of the two other phenotypes. However, the average rates of white blood cells, platelets, reticulocytes, and LDH of Hb-SS patients with the severe clinical phenotype are higher than those of two other clinical phenotypes. Significant correlations were observed between Hb and white blood cell in severe clinical phenotype (r3 = -0.37 * between Hb and red blood cells in the three phenotypes (r1 = 0.69 * r2 * = 0.69, r3 = 0.83 *, and finally between Hb and reticulocytes in the asymptomatic clinical phenotype and severe clinical phenotype (r1 = -0.50 * r3 = 0.45 *. A significant increase in LDH was observed in patients with leg ulcer, cholelithiasis and aseptic necrosis of the femoral head.The increase in serum LDH is accompanied by changes in hematological parameters. In our midst, serum LDH may be considered as an indicator of the severity of the disease.

  9. Correlation between the Lactate Dehydrogenase Levels with Laboratory Variables in the Clinical Severity of Sickle Cell Anemia in Congolese Patients

    Science.gov (United States)

    Mikobi, Tite Minga; Lukusa Tshilobo, Prosper; Aloni, Michel Ntetani; Mvumbi Lelo, Georges; Akilimali, Pierre Zalagile; Muyembe-Tamfum, Jean Jacques; Race, Valérie; Matthijs, Gert; Mbuyi Mwamba, Jean Marie

    2015-01-01

    Background Sickle cell anemia is an inflammatory disease and is characterized by chronic hemolysis. We sought to evaluate the association of lactate dehydrogenase levels with specific clinical phenotypes and laboratory variables in patients with sickle cell anemia. Methods The present cross-sectional study was conducted in Sickle Cell Centre of Yolo in Kinshasa, the Democratic Republic of Congo. Two hundred and eleven patients with Sickle Cell Anemia in steady state were recruited. Seventy-four participants with normal Hb (Hb-AA) were selected as a control group. Results The average rates of hemoglobin, hematocrit, and red blood cells tended to be significantly lower in subjects with Hb-SS (p<0.001). The average rates of white blood cells, platelets, reticulocytes and serum LDH were significantly higher in subjects with Hb-SS (p<0.001). The average rates of Hb, HbF, hematocrit and red blood cells of Hb-SS patients with asymptomatic clinical phenotype were significantly higher than those of the two other phenotypes. However, the average rates of white blood cells, platelets, reticulocytes, and LDH of Hb-SS patients with the severe clinical phenotype are higher than those of two other clinical phenotypes. Significant correlations were observed between Hb and white blood cell in severe clinical phenotype (r3 = -0.37 *) between Hb and red blood cells in the three phenotypes (r1 = 0.69 * r2 * = 0.69, r3 = 0.83 *), and finally between Hb and reticulocytes in the asymptomatic clinical phenotype and severe clinical phenotype (r1 = -0.50 * r3 = 0.45 *). A significant increase in LDH was observed in patients with leg ulcer, cholelithiasis and aseptic necrosis of the femoral head. Conclusion The increase in serum LDH is accompanied by changes in hematological parameters. In our midst, serum LDH may be considered as an indicator of the severity of the disease. PMID:25946088

  10. Pregnancy Complications: Anemia

    Science.gov (United States)

    ... Close X Home > Complications & Loss > Pregnancy complications > Anemia Anemia E-mail to a friend Please fill in ... anemia at a prenatal care visit . What causes anemia? Usually, a woman becomes anemic (has anemia) because ...

  11. Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia

    Directory of Open Access Journals (Sweden)

    Songul Serefhanoglu, Yahya Buyukasik, Hakan Emmungil, Nilgun Sayinalp, Ibrahim Celalettin Haznedaroglu, Hakan Goker, Salih Aksu, Osman Ilhami Ozcebe

    2011-01-01

    Full Text Available Iron deficiency anemia (IDA is a frequent disorder. Also, it may be a sign of underlying serious diseases. Iron deficiency points to an occult or frank bleeding lesion when occurred in men or postmenopausal women. In this study, we aimed to evaluate the diagnostic yield of endoscopy in patients with IDA and to define predictive factors of gastrointestinal (GI lesions causing IDA. Ninety-one patients (77 women, 14 men; mean age: 43 years who were decided to have esophago-duodenoscopy and/or colonoscopy for iron deficiency anemia were interviewed and responded to a questionnaire that included clinical and biochemical variables. The endoscopic findings were recorded as GI lesions causing IDA or not causing IDA. Endoscopy revealed a source of IDA in 18.6 % of cases. The risk factors for finding GI lesions causing IDA were as follows: male gender (p= 0.004, advanced age (> 50 years (p= 0.010, weight loss (over 20% of total body weight lost in last 6 month (p= 0.020, chronic diarrhea (p= 0.006, change of bowel habits (p= 0.043, epigastric tenderness (p= 0.037, raised carcinoembryonic antigen (CEA level (normal range: 0-7 ng/mL (p= 0.039, < 10 gr/dl hemoglobin (Hb level (p=0.054. None of these risk factors had been present in 21 (23% women younger than 51 years. In this group, no patient had any GI lesion likely to cause IDA (negative predictive value= 100%. In multivariate analysis, advanced age (p=0.017, male gender (p< 0.01 and weight lost (p=0.012 found that associated with GI lesions in all patients. It may be an appropriate clinical approach to consider these risk factors when deciding for gastrointestinal endoscopic evaluation in iron deficiency anemia.

  12. O uso intravenoso de sacarato de hidróxido de ferro III em pacientes com anemia ferropriva Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia

    Directory of Open Access Journals (Sweden)

    Rodolfo Delfini Cançado

    2005-12-01

    Full Text Available OBJETIVO: Avaliar a eficácia do uso intravenoso de sacarato de hidróxido de ferro III no tratamento de pacientes adultos com anemia ferropriva que não obtiveram resposta satisfatória à terapia com ferro oral. MÉTODOS: No período de janeiro de 2003 a janeiro de 2004, estudamos 25 pacientes com anemia ferropriva que apresentaram intolerância e/ou resposta inadequada ao tratamento com ferro por via oral e/ou valor de hemoglobina OBJECTIVE: To evaluate the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia lacking satisfactory response to oral iron therapy. METHODS: Between January 2003 and January 2004, 25 patients with iron deficiency anemia who presented intolerance or inadequate response to iron oral therapy, or hemoglobin level < 7 g/dl were studied. The main laboratory tests performed were: complete blood cell count, reticulocyte count, serum iron, total iron-binding capacity, serum ferritin. Patients received a weekly dose of 200 mg of iron diluted in 250 mL of 0.9% sodium chloride solution administered intravenously for 30 minutes. Treatment continued until a hemoglobin level = 12 g/dL for women and = 13 g/dL for men were obtained or until full administration of the total dose of parenteral iron recommended for each patient. RESULTS: Edian age of the patients studied was 45 years (ages ranging from 31 to 70. Nineteen out of 25 patients (76% were women. The most common cause of iron deficiency anemia was abnormal uterine bleeding observed in 68% of the female patients (13 out of 19 and partial gastrectomy observed in 67% of the male patients (4 out of 6. Seventeen (68% patients were included in this study because they did not respond to oral iron therapy, 24% (6 out of 25 showed intolerance to oral iron and 8% (2 out of 25 presented hemoglobin level < 7 g/dl. Correction of anemia was obtained in 12 out of 19 female patients (63% and in 5 out of 6 male patients (83%. The mean

  13. Sickle cell anemia and α-thalassemia: a modulating factor in homozygous HbS/S patients in Oman.

    Science.gov (United States)

    Hassan, S M; Al Muslahi, M; Al Riyami, M; Bakker, E; Harteveld, C L; Giordano, P C

    2014-01-01

    We report the general phenotype severity and the hematological presentation in a cohort of 125 sickle cell anemia (SCA) patients with identical homozygous HbS/S genotype and categorized by identical β(S) haplotype, both with and without alpha thalassemia. No clear general phenotype correlation was found when patients were compared regardless of the haplotype but overall, patients with homozygous alpha thalassemia (α-/α-) had the highest Hb, HCT, RBC and the lowest MCV, MCH and MCHC levels. When patients with identical haplotype were compared, the mildest hematological and clinical conditions were observed in patients of the Asian/Asian haplotype, also known as Arab-Indian haplotype, and carriers of α-thalassemia, suggesting an additional ameliorating effect of alpha thalassemia. In conclusion, our results show that alpha thalassemia improves the hematological conditions but amelioration of the general disease severity is only noticed when compared in cohorts of the same haplotype. PMID:25266642

  14. Factors Affecting Successful use of Erythropoietin in the Treatment of Anemia in Patients on Hemodialysis: Experience in Hajjah Region, Yemen

    Directory of Open Access Journals (Sweden)

    AL-Rohani Muhamed

    2001-01-01

    Full Text Available The use of recombinant human erythropoietin (rHuEpo became an essential part of the treatment of anemia in patients with end stage renal failure (ESRF. Our experience at the Hajjah region, Yemen, confirms that the use of rHuEpo significantly increases the level of hemoglobin (HB and hematocrit (Hct, improves work tolerance and overall quality of life of patients on hemodialysis. The observable improvement occurred in 87.5% of patients. The most prominent factors that caused deterioration in the increment of HB and Hct were infection with malaria and chronic infection. Failure of patients′ compliance, largely due to lack of education, was another important factor effecting the results. Many of our patients did not understand the importance of diet and drug regime. It is very important to spend more time on educating such patients.

  15. 老年贫血517例的临床分析%Clinical Analysis of 517 Cases with Senile Anemia

    Institute of Scientific and Technical Information of China (English)

    李晓莉

    2015-01-01

    目的:探讨老年人贫血的原因及种类特点。方法回顾性分析517例临床确诊的老年贫血患者的临床资料。结果老年贫血的种类前三位分别是缺铁性贫血161例(31.1%),慢病性贫血76例(14.7%),巨细胞性贫血74例(14.3%),骨髓增生异常综合征48例(9.3%),再生障碍性贫血46例(8.9%),自身免疫性溶血性贫血46例(8.9%),淋巴瘤35例(6.8%),白血病31例(6.0%)。结论老年人贫血病因复杂,很大程度上影响到老年人生活质量,同时也影响到老年人基础疾病的预后,因此防治老年贫血应引起临床工作者的高度重视。%Objective To Discuss on the causes and characteristics types of elderly. Methods Retrospective analysis clinical data of 517 cases elderly anemia clinical y diagnosed. Results The first three type of anemia in the elderly are iron deficiency anemia(161 cases, 31.1%), anemia of chronic disease (76 cases, 14.7%), sickle cel anemia (74 cases,14.3%) respectively, myelodysplastic syndrome was 48 cases ( 9.3%), aplastic anemia was 46 cases (8.9%), autoimmune hemolytic anemia anemia was 46 cases (8.9%), lymphoma was 35 cases (6.7%), leukemia was 31 patients(6.0%). Conclusion The complex etiology of anemia in the elderly, to a great extent af ect the quality of life of the elderly, at the same time, anemia af ects the elderly based disease prognosis, Thus the prevention of anemia in the elderly should be paid high at ention.

  16. Clinical Analysis of 517 Cases with Senile Anemia%老年贫血517例的临床分析

    Institute of Scientific and Technical Information of China (English)

    李晓莉

    2015-01-01

    Objective To Discuss on the causes and characteristics types of elderly. Methods Retrospective analysis clinical data of 517 cases elderly anemia clinical y diagnosed. Results The first three type of anemia in the elderly are iron deficiency anemia(161 cases, 31.1%), anemia of chronic disease (76 cases, 14.7%), sickle cel anemia (74 cases,14.3%) respectively, myelodysplastic syndrome was 48 cases ( 9.3%), aplastic anemia was 46 cases (8.9%), autoimmune hemolytic anemia anemia was 46 cases (8.9%), lymphoma was 35 cases (6.7%), leukemia was 31 patients(6.0%). Conclusion The complex etiology of anemia in the elderly, to a great extent af ect the quality of life of the elderly, at the same time, anemia af ects the elderly based disease prognosis, Thus the prevention of anemia in the elderly should be paid high at ention.%目的:探讨老年人贫血的原因及种类特点。方法回顾性分析517例临床确诊的老年贫血患者的临床资料。结果老年贫血的种类前三位分别是缺铁性贫血161例(31.1%),慢病性贫血76例(14.7%),巨细胞性贫血74例(14.3%),骨髓增生异常综合征48例(9.3%),再生障碍性贫血46例(8.9%),自身免疫性溶血性贫血46例(8.9%),淋巴瘤35例(6.8%),白血病31例(6.0%)。结论老年人贫血病因复杂,很大程度上影响到老年人生活质量,同时也影响到老年人基础疾病的预后,因此防治老年贫血应引起临床工作者的高度重视。

  17. Evaluation of the Relationship of Hepcidin Levels with Anemia and Inflammatory Markers in Patients on Peritoneal Dialysis: A Controlled Study

    Directory of Open Access Journals (Sweden)

    Zeki AYDIN

    2012-01-01

    Full Text Available OBJECTIVE: Hepcidin, a small peptide hormone synthesized in the liver, plays a central role in the regulation of iron metabolism. In addition, it acts as an intermediary in body defense and inflammation. Our aim in this study was to investigate the relationship of hepsidin levels with inflammation and iron indices in patients on peritoneal dialysis (PD.MATERIAL and METHODS: Nondiabetic PD patients were involved. Primary kidney disease, biochemical parameters, complete blood count, iron, total iron binding capacity (TIBC, ferritin, high sensitive C-reactive protein (hsCRP, fibrinogen, parathormone, interleukin (IL-6 and hepcidin levels were recorded as well as demographic parameters.RESULTS: Twenty-one PD patients (mean age 47.7±12.1 years and 17 healthy volunteers (mean age 54.0±7.2 years were involved. HepCidin levels were higher in the PD group (148.2±35.0 vs. 93.8±21.9; p<0.001. There was a positive correlation of hepcidin with urea, creatinine, phosphorus, ferritin, fibrinogen, IL-6 and parathormone; and a negative correlation with albumin, transaminases, calcium, TIBC, GFR, hemoglobin and hematocrit levels.CONCLUSION: Hepcidin levels increase with deepening anemia and show a positive correlation with inflammatory markers. Theurapeutic interventions regarding the effects of hepcidin on inflammatory status may play a role in the treatment of anemia due to inflammation. It may be beneficial to measure hepcidin levels together with ferritin, especially in patients with functional iron defficiency.

  18. Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

    Science.gov (United States)

    2016-10-03

    Chronic Kidney Disease; Acute Myeloid Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Chronic Myelogenous Leukemia (CML); Chronic Lymphocytic Leukemia (CLL); Non-Hodgkin's Lymphoma (NHL); Hodgkin Disease; Multiple Myeloma; Myelodysplastic Syndrome (MDS); Aplastic Anemia; AL Amyloidosis; Diamond Blackfan Anemia; Myelofibrosis; Myeloproliferative Disease; Sickle Cell Anemia; Autoimmune Diseases; Thalassemia

  19. In vivo correlation between MR imaging signal intensity values and serum ferritin levels in patients with Cooley anemia

    International Nuclear Information System (INIS)

    In 12 patients with Cooley anemia, serum ferritin levels (SFe) were correlated with MR spin-echo 0.5-T signal intensity values (SIV) from T1-weighted images of liver, bone marrow, skeletal muscle, and myocardium as standardized to fat. The SIV of liver decreased logarithmically with increasing SFe (r = .84). The SIV of marrow decreased with a less well-defined logarithmic relationship with increasing SFe (r = .66). There was no relationship to SIV of muscle with increasing SFe. The SIV of myocardial areas scored with increasing degrees of abnormality on thallium scan showed a decrease in SIV as correlated with increasing functional cardiac abnormality

  20. Thiamine– Responsive Megaloblastic Anemia Syndrome

    Directory of Open Access Journals (Sweden)

    F Motavaselian

    2009-01-01

    Full Text Available Thiamine Responsive megaloblastic anemia in DIDMOA (Wolfram syndrome has an autosomal- recessive mode of inheritance . Megaloblastic anemia and sideroblastic anemia is accompanied by diabetes insipidus (DI, diabetes mellitus (DM ,optic atrophy (OA and deafness (D. Neutropenia and thrombocytopenia are also present. We report a 7 month old girl with congenital macrocytic anemia; a rare clinical feature of Wolfram,s syndrome with increased plasma levels of blood glucose, both of which dramatically responded to administration of thiamine in large doses . The patient also had neurosensorial deafness, but no improvement was observed in the deafness. We presented the case because thiamine-responsive megaloblastic anemia is a rare clinical presentation of Wolfram syndrome and after institution of treatment with thiamine, the anemia and hyperglycemia returned to normal.

  1. Understanding anemia of chronic disease.

    Science.gov (United States)

    Fraenkel, Paula G

    2015-01-01

    The anemia of chronic disease is an old disease concept, but contemporary research in the role of proinflammatory cytokines and iron biology has shed new light on the pathophysiology of the condition. Recent epidemiologic studies have connected the anemia of chronic disease with critical illness, obesity, aging, and kidney failure, as well as with the well-established associations of cancer, chronic infection, and autoimmune disease. Functional iron deficiency, mediated principally by the interaction of interleukin-6, the iron regulatory hormone hepcidin, and the iron exporter ferroportin, is a major contributor to the anemia of chronic disease. Although anemia is associated with adverse outcomes, experimental models suggest that iron sequestration is desirable in the setting of severe infection. Experimental therapeutic approaches targeting interleukin-6 or the ferroportin-hepcidin axis have shown efficacy in reversing anemia in either animal models or human patients, although these agents have not yet been approved for the treatment of the anemia of chronic disease.

  2. Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis

    Directory of Open Access Journals (Sweden)

    Kaushik T

    2013-11-01

    Full Text Available Tarun Kaushik, Muhammad Magdi YaqoobBarts Health NHS Trust, William Harvey Research Unit, London, UKAbstract: Peginesatide is the newest erythropoietin-stimulating agent (ESA in the quest for the ideal treatment of anemia in chronic kidney disease (CKD patients. Reduced frequency of administration along with a possibly lower cost as a result of simpler manufacturing techniques compared with other available agents makes peginesatide a highly desirable product in the competitive ESA market. Peginesatide is noninferior to the other ESAs, and has a good safety profile in patients on hemodialysis. The higher rates of adverse cardiovascular events reported in CKD patients not on dialysis in the recent Phase III studies require further, better planned, studies. Peginesatide had to be withdrawn from the market in the US after some reports of hypersensitivity reactions to the drug. This is a setback, but the scientific advances gained as a result of this product development can be used to develop other, newer products.Keywords: anemia, hemodialysis, chronic kidney disease, peginesatide

  3. Pyrexia in a Patient with Megaloblastic Anemia: A Case Report and Literature Review

    Directory of Open Access Journals (Sweden)

    Kevin Manuel

    2013-06-01

    Full Text Available Deficiency of vitamin B12 and/or folic acid as a cause of pyrexia, though known, is rarely reported in literature. We aimed to report a case in a 51 year old woman, who presented with fever and pancytopenia and was diagnosed to have megaloblastic anemia secondary to vitamin B12 and folate deficiency. The pyrexia subsided following the intramuscular injection of vitamin B12 and oral folic acid administration. All the other infective, inflammatory/autoimmune, endocrine causes of pyrexia were excluded by appropriate investigations. Therefore, we suggest that all physicians be aware of megaloblastic anemia as a treatable cause of pyrexia in order to avoid unnecessary costly investigations and antibiotic usage.

  4. Ferumoxytol versus placebo in iron deficiency anemia: efficacy, safety, and quality of life in patients with gastrointestinal disorders

    Science.gov (United States)

    Ford, David C; Dahl, Naomi V; Strauss, William E; Barish, Charles F; Hetzel, David J; Bernard, Kristine; Li, Zhu; Allen, Lee F

    2016-01-01

    Introduction Iron deficiency anemia (IDA) is common in patients with gastrointestinal (GI) disorders and can adversely affect quality of life. Oral iron is poorly tolerated in many patients with GI disorders. Ferumoxytol is approved for the intravenous treatment of IDA in patients with chronic kidney disease. This study aimed to evaluate the efficacy and safety of ferumoxytol in patients with IDA and concomitant GI disorders. Patients and methods This analysis included 231 patients with IDA and GI disorders from a Phase III, randomized, double-blind, placebo-controlled trial evaluating ferumoxytol (510 mg ×2) versus placebo in patients who had failed or were intolerant of oral iron therapy. The primary study end point was the proportion of patients achieving a ≥20 g/L increase in hemoglobin (Hgb) from baseline to Week 5. Other end points included mean change in Hgb, proportion of patients achieving Hgb ≥120 g/L, mean change in transferrin saturation, and patient-reported outcomes (PROs). Results Significantly more patients with IDA receiving ferumoxytol achieved a ≥20 g/L increase in Hgb versus placebo (82.1% vs 1.7%, respectively; Piron therapy. PMID:27468245

  5. Anemia and survival in human immunodeficiency virus

    DEFF Research Database (Denmark)

    Lundgren, Jens Dilling; Mocroft, Amanda

    2003-01-01

    The prospective, multicenter cohort study EuroSIDA has previously reported on predictors and outcomes of anemia in patients infected with human immunodeficiency virus. In a Cox proportional-hazards model with serial measures of CD4+ cell count, plasma viral load, and degrees of anemia fitted...... as time-dependent variables, the relative hazard of death increased markedly for patients with anemia versus no anemia. A clinical scoring system was developed and validated for patients receiving highly active antiretroviral therapy using the most recent laboratory measures. Mild and severe anemia were...... independently (Panemia. The mechanisms underlying why hemoglobin is such a strong prognostic...

  6. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype.

    Science.gov (United States)

    da Silva Rocha, Lilianne Brito; Dias Elias, Darcielle Bruna; Barbosa, Maritza Cavalcante; Bandeira, Izabel Cristina Justino; Gonçalves, Romélia Pinheiro

    2012-12-12

    Hydroxyurea (HU) is the primary pharmacologic agent for preventing the complications and improving the quality of life of sickle cell anemia (SCA) patients. Although HU has been associated with an increased risk of leukemia in some patients with myeloproliferative disorders, the mutagenic and carcinogenic potential of HU has not been established. This study used the alkaline comet assay to investigate DNA damage in peripheral blood leukocytes from 41 individuals with SCA treated with HU (SCAHU) and from 26 normal individuals. The presence of HbS and the analysis of the haplotypes of the beta S gene cluster were done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The damage index (DI) in the SCAHU group was significantly higher than in controls (p20kg/m(2). No significant influence of mean HU dose was observed on DI (p=0.950). However, individuals who received a mean HU dose≥20mg/kg showed a higher DI than those who received less. Furthermore, an association was observed between DI damage and HBB*S gene haplotypes. DI values for the Bantu/Bantu haplotype was greater when compared to the Benin/Benin haplotype; and the Bantu/Benin haplotype had a DI lower than the Bantu/Bantu haplotype and greater than the Benin/Benin haplotype. Our results show that DNA damage in sickle cell anemia is associated not only with treatment with HU but also with genotype. PMID:22918118

  7. Megaloblastic anemia in Japan

    Directory of Open Access Journals (Sweden)

    Taguchi,Hirokuni

    1978-08-01

    Full Text Available Since 1903, 744 cases of megaloblastic anemia have been reported in Japan: 490 cases of pernicious anemia; 95 cases associated with pregnancy; 66 cases after gastrectomy; 22 cases of megaloblastic anemia of infants; 21 cases of folic acid deficiency other than pregnancy and 19 cases of vitamin B12 malabsorption after ileal resection. It is generally agreed among hematologists in Japan that pernicious anemia is relatively rare, as in other Asian countries. The diagnosis of pernicious anemia in Japan is usually made by stained marrow films, radioisotopic assay of serum vitamin B12, Schilling test and good response to vitamin B12 therapy. Serum folate level, intrinsic factor or its antibody, methylmalonic acid excretion, formiminoglutamic acid excretion and deoxyuridine suppression test are performed only at a small number of laboratories. The drugs of choice are hydroxocobalamin, deoxyadenosylcobalamin and methylcobalamin. Cyanocobalamin has nearly disappeared from commercial sources in Japan. Vitamin B12 administration is common in patients with neurological disorders. Megaloblastic anemia due to folic acid deficiency is extremely rare in Japan. Low serum folate levels are frequently observed among patients receiving anticonvulsants or in pregnant women, but in such samples megaloblastic anemia is almost never detected. The folic acid content of hospital diets indicates that satisfactory amounts of folate are taken in Japan. The intake of folic acid from rice is well over the minimum daily requirement of folate. Other factors in folic acid deficiency, such as food taboos, severe alcoholism and malabsorption syndrome are not frequently found in Japanese. The inadequate intake of folate was the critical factor in most reported cases.

  8. Determination of Cu/Zn and Fe in human serum of patients with sickle cell anemia using radiation synchrotron

    Energy Technology Data Exchange (ETDEWEB)

    Canellas, C.G.L. [Nuclear Instrumentation Laboratory, COPPE/UFRJ, P.O. Box 68509, 21.941-972 Rio de Janeiro (Brazil); Carvalho, S.M.F. [State Institute of Hematology Arthur de Siqueira Cavalcanti, 20.211-030 Rio de Janeiro (Brazil); Anjos, M.J. [Nuclear Instrumentation Laboratory, COPPE/UFRJ, P.O. Box 68509, 21.941-972 Rio de Janeiro (Brazil); Physics Institute, State University of Rio de Janeiro, 20.559-900 Rio de Janeiro (Brazil); Lopes, R.T., E-mail: ricardo@lin.ufrj.br [Nuclear Instrumentation Laboratory, COPPE/UFRJ, P.O. Box 68509, 21.941-972 Rio de Janeiro (Brazil)

    2012-07-15

    In this work we analyzed serum samples from patients with Sickle Cell Anemia (SCA) using Total Reflection X-Ray Fluorescence using Synchrotron Radiation (SRTXRF). The SRTXRF measurements were performed at the X-Ray Fluorescence Beamline at the Brazilian National Synchrotron Light Laboratory (LNLS). We studied forty-three patients aged 18-50 suffering from SCA and sixty healthy volunteers aged 18-60. It was possible to determine the concentrations of the following elements: P, S, Cl, K, Ca, Fe, Cu, Zn, Br and Rb. Moreover, there are evidences of an association among Fe, Cu, Zn and Cu/Zn in the SCA pathogenesis process. The concentrations of Fe and Cu in the serum samples of patients with SCA were larger, 120% and 20%, respectively, when compared with the CG. The serum level Cu/Zn ratio was significantly higher (60%) in the serum samples from patients suffering from SCA than from the CG. Therefore, the Cu/Zn ratio can be used as an adjuvant index in enhancement for diagnosis of SCA. - Highlights: Black-Right-Pointing-Pointer Serum samples from patients with Sickle Cell Anemia (SCA) were analyzed by SRTXRF. Black-Right-Pointing-Pointer It was possible to determine the concentrations of the P, S, Cl, K, Ca, Fe, Cu, Zn, Br and Rb. Black-Right-Pointing-Pointer There are evidences of an association among Fe, Cu, Zn and Cu/Zn in the SCA process. Black-Right-Pointing-Pointer The results indicate that the Cu/Zn ratio can be used as an adjuvant index for diagnosis of SCA.

  9. Determination of β haplotypes in patients with sickle-cell anemia in the state of Rio Grande do Norte, Brazil.

    Science.gov (United States)

    Cabral, Cynthia Hatsue Kitayama; Serafim, Edvis Santos Soares; de Medeiros, Waleska Rayane Dantas Bezerra; de Medeiros Fernandes, Thales Allyrio Araújo; Kimura, Elza Miyuki; Costa, Fernando Ferreira; de Fátima Sonati, Maria; Rebecchi, Ivanise Marina Moretti; de Medeiros, Tereza Maria Dantas

    2011-07-01

    β(S) haplotypes were studied in 47 non-related patients with sickle-cell anemia from the state of Rio Grande do Norte, Brazil. Molecular analysis was conducted by PCR/RFLP using restriction endonucleases XmnI, HindIII, HincII and HinfI to analyze six polymorphic sites from the beta cluster. Twenty-seven patients (57.5%) were identified with genotype CAR/CAR, 9 (19.1%) CAR/BEN, 6 (12.8%) CAR/CAM, 1 (2.1%) BEN/BEN, 2 (4.3%) CAR/Atp, 1 (2.1%) BEN/Atp and 1 (2.1%) with genotype Atp/Atp. The greater frequency of Cameroon haplotypes compared to other Brazilian states suggests the existence of a peculiarity of African origin in the state of Rio Grande do Norte. PMID:21931513

  10. About Anemia (For Kids)

    Science.gov (United States)

    ... Homework? Here's Help White House Lunch Recipes About Anemia KidsHealth > For Kids > About Anemia Print A A ... to every cell in your body. What Is Anemia? Anemia occurs when a person doesn't have ...

  11. Types of Hemolytic Anemia

    Science.gov (United States)

    ... from the NHLBI on Twitter. Types of Hemolytic Anemia There are many types of hemolytic anemia. The ... the condition, but you develop it. Inherited Hemolytic Anemias With inherited hemolytic anemias, one or more of ...

  12. Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors

    Science.gov (United States)

    Miotto, N.; Mendes, L.C.; Zanaga, L.P.; Goncales, E.S.L.; Lazarini, M.S.K.; Pedro, M.N.; Goncales, F.L.; Stucchi, R.S.B.; Vigani, A.G.

    2016-01-01

    The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin ≤8.5 mg/dL. We included 203 patients: 132 treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and anemia was the main reason (38.5%). Risk factors for treatment discontinuation were higher comorbidity index (OR=1.85, CI=1.05-3.25) for BOC, and higher bilirubin count (OR=1.02, CI=1.01-1.04) and lower BMI (OR=0.98, CI=0.96-0.99) for TVR. Severe anemia occurred in 35 (17.2%) patients. Risk factors for this outcome were lower estimated glomerular filtration rate (eGFR; OR=0.95, CI=0.91-0.98) for patients treated with TVR, and higher comorbidity index (OR=2.21, CI=1.04-4.67) and ribavirin dosage (OR=0.84, CI=0.72-0.99) for those treated with BOC. Fifty-five (57.3%) patients treated with TVR and 15 (27.3%) patients treated with BOC achieved sustained virological response (SVR). Among patients who received TVR and interrupted treatment due to AE (n=19), only 26.3% (n=5) achieved SVR (P=0.003). Higher number of comorbidities, lower eGFR and advanced liver disease are associated with severe anemia and early treatment cessation, which may compromise SVR achievement. PMID:27356107

  13. Pay great attention to the anemia in elder patients in diagnosis and treatment%重视老年人贫血的诊断和治疗

    Institute of Scientific and Technical Information of China (English)

    曹履先

    2010-01-01

    WHO对65岁以上老年人贫血的诊断标准为:男子血红蛋白低于130g/L,女子低于120g/L.65岁以上老年人贫血的发病率为9.2%~23.9%(男)及8.1%~24.7%(女).65岁以上老年人贫血多是比较轻的.仅<1%的患者血红蛋白低于100g/L,85岁以上老年人贫血的发生率可高达30%左右.老年贫血患者男性多于女性.引起老年人贫血的病因有造血原料缺乏、非造血原料缺乏、恶性肿瘤、药物引起的贫血、不能解释的贫血等.老年人的贫血不少见,且常为某些重要疾病的先导信号,故应重视其诊断治疗,不应以年事已高而忽视之.%The criteria of adults anemia older than 65 years is Hb <130 g/L (male), <120 g/L (fema le) (WHO). The incident rate of anemia in adults older than 65 year is 9.2 %-23.9 % (male), 8.1 %-24.7 % (female). Only <1 % patients the Hb is less than 100 g/L, the incident rate of anemia in patients older than 85 years old can be 30 %. The incident rate of anemia in elder patients in male is much higher than in female. The causes of anemia in elder patients attributed by lacking in haemopoiesis material, no haemopoietic material deficiency, malignant tumors, drugs induced anemia, unknown anemia. From these points of view, we must pay great attention to the anemia in elder patients in diagnosis and treatment.

  14. Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

    Science.gov (United States)

    Mouysset, Jean-Loup; Freier, Beata; van den Bosch, Joan; Levaché, Charles Briac; Bols, Alain; Tessen, Hans Werner; Belton, Laura; Bohac, G Chet; Terwey, Jan-Henrik; Tonini, Giuseppe

    2016-01-01

    Purpose To assess hemoglobin (Hb) outcomes and fatigue-related quality-of-life (QoL) (electronic assessment) in patients with solid tumors and symptomatic chemotherapy-induced anemia receiving cytotoxic chemotherapy and darbepoetin alfa (DA) or another erythropoiesis-stimulating agent according to European indication. Methods eAQUA was a Phase IV prospective observational study. The primary outcome (assessed in the primary analysis set [PAS]: patients receiving one or more DA dose who had baseline and week 9 assessments for Hb and QoL) was the proportion of patients receiving DA having both Hb increases ≥1 g/dL and improved QoL between baseline and week 9. Functional Assessment of Cancer Therapy-Fatigue (FACT-F) subscale scores were anchored to fatigue visual analog scale scores to determine the minimally important difference for improved QoL. Overall data/data over time are reported for the full analysis set (patients receiving one or more erythropoiesis-stimulating agent dose, n=1,158); week 9 data (ie, data relating to the primary and secondary outcomes) are reported for the PAS (n=510). Baseline and safety data are included for both the full analysis set and PAS. Results In the PAS, 69% of patients had stage IV disease and 96% were fatigued. The minimally important difference in FACT-F change score for QoL improvement was 3.5. From baseline to week 9, 32% (95% confidence interval: 28%–36%) of patients had both improved QoL and an Hb increase ≥1 g/dL; proportions were similar across the most common tumor types. At week 9, 49% and 58% of patients had improved QoL or Hb increases ≥1 g/dL, respectively; 70% and 76% had QoL or Hb improvements between baseline and study end, respectively. In the PAS, 16% of patients required transfusions and 32% required iron supplementation. Few patients (<1%) reported adverse drug reactions. Conclusion In this study, patients with solid tumors receiving DA per European indication for symptomatic chemotherapy-induced anemia

  15. Long-term follow-up of kidney allografts in patients with sickle cell hemoglobinopathy Transplante renal na anemia falciforme

    Directory of Open Access Journals (Sweden)

    João R. Friedrisch

    2003-06-01

    Full Text Available Although sickle cell anemia and sickle cell disease produce a variety of functional renal abnormalities they uncommonly cause end stage renal failure. Renal transplantation has been a successful alternative for the treatment of the rare terminal chronic renal failure with outcomes comparable with non-sickle recipients. This approach, however, has not been often described on patients with renal failure associated with SC hemoglobinopathy. Here we report the outcomes of two patients with chronic renal failure due to SC hemoglobinopathies who underwent renal transplantation. At the time of the transplantation they were both severely anemic and had frequent vasoocclosive pain crises. Both patients evolved with good allograft function, near normal hematological parameters, and very rare pain crisis, thirteen and eight years after transplant. These cases illustrate that terminal renal failure due to SC hemoglobinopathy can be successfully managed by renal transplantation and satisfactory long-term results are achievable not only in terms of renal allograft function but also of their hematological condition.Embora a anemia falciforme e as síndromes falciformes freqüentemente causem várias alterações funcionais renais, não é comum a insuficiência renal terminal. Nestes casos, o transplante renal é uma alternativa que se acompanha de resultados comparáveis aos obtidos em receptores sem hemoglobinopatias. Esta estratégia terapêutica tem sido, no entanto, pouco relatada para portadores de hemoglobinopatia SC. Este relato descreve a evolução de dois pacientes portadores de hemoglobinopatia SC que foram submetidos ao transplante renal. No momento do transplante ambos apresentavam severa anemia e crises dolorosas freqüentes. Os pacientes evoluíram com boa função do enxerto, parâmetros hematológicos quase normais e praticamente assintomáticos do ponto de vista da hemoglobinopatia, treze e oito anos após o transplante. Estes casos ilustram

  16. Prevalência de anemia e insuficiência renal em portadores de insuficiência cardíaca não-hospitalizados Prevalencia de anemia e insuficiencia renal en portadores de insuficiencia cardiaca no hospitalizados Prevalence of anemia and renal insufficiency in non-hospitalized patients with heart failure

    Directory of Open Access Journals (Sweden)

    Francisco José Farias Borges dos Reis

    2009-09-01

    ,6% presentaba insuficiencia renal de moderada a severa (TFG BACKGROUND: Heart Failure (HF is a common disease with a high rate of mortality. Anemia and renal failure (RF are often found in patients with HF associated with higher severity of the heart disease and a worse prognosis. OBJECTIVE: To evaluate the prevalence of anemia and RF, as well as the association between these two conditions, in non-hospitalized patients with HF. METHODS: Patients treated at the HF Outpatient Clinic of a university hospital were followed from July 2003 to November 2006. Anemia was defined as hemoglobin levels < 13 mg/dl for men and 12 mg/dl for women. Renal function was assessed by the glomerular filtration rate (GFR, calculated by the simplified formula of the MDRD (Modification of Diet in Renal Disease study. RESULTS: Of the 345 patients included in this study, 26.4% (n = 91 had anemia and 29.6% had moderate to severe renal failure (GFR < 60 ml/min. The association between anemia and a higher prevalence of renal failure was statistically significant (41.8% vs. 25.2%; p = 0.005. The patients at functional class III and IV presented a higher incidence of anemia (39.0% vs. 19.4%; p <0.001 and renal failure (38.2% vs. 24.8%; p = 0.007. No association was observed between anemia or renal failure and history of hypertension, diabetes, systolic function or etiology of HF. CONCLUSION: The prevalence of anemia and renal failure was high in this population and was associated with the severity of the HF (functional classes III and IV.

  17. Haploidentical stem cell transplantation as a salvage therapy for cord blood engraftment failure in a patient with Fanconi anemia.

    Science.gov (United States)

    Rihani, Rawad; Lataifeh, Isam; Halalsheh, Hadeel; Hussein, Ayad Ahmed; Al-Zaben, Abdulhadi; Abdel-Rahman, Fawzi; Sarhan, Mahmoud

    2010-09-01

    A 7-year-old male with Fanconi Anemia who developed primary graft failure following one antigen-mismatched unrelated cord blood transplantation and a nonradiation-based conditioning, underwent a second hematopoietic stem cell transplantation (HSCT) from his 2-loci mismatched haploidentical father, using a nonradiation-based regimen, 79 days after the first HSCT. A sustained hematological engraftment was achieved at 9 days post-second HSCT. At 15 months post-second HSCT; the patient demonstrated normal blood counts, sustained donor chimerism, and no evidence of GVHD. Haploidentical HSCTs as primary or secondary sources of stem cells, with appropriate T-cell depletion, may be a readily available option in the absence of HLA-matched related or unrelated donors. PMID:20658637

  18. Fatores de risco para aloimunização em pacientes com anemia falciforme Risk factors for alloimmunization in patients with sickle cell anemia

    OpenAIRE

    Patrícía Costa Alves Pinto; Josefina Aparecida Pellegrini Braga; Amélia Miyashiro Nunes dos Santos

    2011-01-01

    OBJETIVO: Determinar a imunofenotipagem eritrocitária em doadores de sangue e em pacientes com anemia falciforme (SS) atendidos no Hemocentro de Alagoas e descrever a frequência e os fatores associados à aloimunização eritrocitária. MÉTODOS: Estudo transversal com 102 pacientes SS e 100 doadores de sangue. Realizou-se a fenotipagem eritrocitária, teste de Coombs Direto e Indireto e detecção de anticorpos irregulares por painel de hemácias fenotipadas. Os dados foram comparados por meio do tes...

  19. Transfusiones en pacientes con pruebas de compatibilidad positivas y en aquellos con anemia hemolítica autoinmune Approach to transfusion support in patients with positive compatibility tests and in those with autoimmune hemolytic anemia

    Directory of Open Access Journals (Sweden)

    2007-12-01

    Full Text Available Es frecuente la presencia de pruebas de compatibilidad positivas en pacientes que requieren soporte transfusional. Los pacientes con anemia hemolítica autoinmune presentan autoanticuerpos calientes o fríos que reaccionan contra antígenos de los eritrocitos y producen reacciones hemolíticas, que pueden ir desde leves hasta graves. Los pacientes multitransfundidos o con insuficiencia renal crónica o con anemia de células falciformes, presentan aloanticuerpos que dificultan el tratamiento con derivados de la sangre. La frecuencia de los mismos es hasta de 32% en algunas series. Dado el perfeccionamiento de las técnicas de laboratorio, en la actualidad son posibles la detección y determinación de la especificidad de los autoanticuerpos y aloanticuerpos; el enfoque integral del paciente y el conocimiento de dichas técnicas son los mejores fundamentos para un soporte transfusional seguro. Positive compatibility tests in patients who need blood transfusions are common. Patients with autoimmune hemolytic anemia may have warm or cool autoantibodies that react with red blood cell antigens and produce hemolytic transfusion reactions. Multitransfused patients, and those with either chronic renal disease or sickle cell disease, have alloantibodies that make blood transfusion difficult. In some series the frequency of such antibodies is as high as 32%. Detection and determination of specificity of autoantibodies and alloantibodies are now possible because of technical developments in laboratory. An integral approach to patients and the knowledge of these procedures are the best bases to offer secure blood transfusions.

  20. Promoter region sequence differences in the A and G gamma globin genes of Brazilian sickle cell anemia patients

    Directory of Open Access Journals (Sweden)

    C.G. Barbosa

    2010-08-01

    Full Text Available Fetal hemoglobin (HbF, encoded by the HBG2 and HBG1 genes, is the best-known genetic modulator of sickle cell anemia, varying dramatically in concentration in the blood of these patients. This variation is partially associated with polymorphisms located in the promoter region of the HBG2 and HBG1 genes. In order to explore known and unknown polymorphisms in these genes, the sequences of their promoter regions were screened in sickle cell anemia patients and correlated with both their HbF levels and their βS-globin haplotypes. Additionally, the sequences were compared with genes from 2 healthy groups, a reference one (N = 104 and an Afro-descendant one (N = 98, to identify polymorphisms linked to the ethnic background.The reference group was composed by healthy individuals from the general population. Four polymorphisms were identified in the promoter region of HBG2 and 8 in the promoter region of HBG1 among the studied groups. Four novel single nucleotide polymorphisms (SNP located at positions -324, -317, -309 and -307 were identified in the reference group. A deletion located between -396 and -391 in the HBG2 promoter region and the SNP -271 C→T in the HBG1 promoter region were associated with the Central African Republic βS-globin haplotype. In contrast, the -369 C→G and 309 A→G SNPs in the HBG2 promoter region were correlated to the Benin haplotype. The polymorphisms -396_-391 del HBG2, -369 SNP HBG2 and -271 SNP HBG1 correlated with HbF levels. Hence, we suggest an important role of HBG2 and HBG1 gene polymorphisms on the HbF synthesis.

  1. Detection of High Risk Human Papillomavirus DNA Sequences in Head and Neck Squamous Cell Carcinoma in Iranian Fanconi Anemia Patients

    Directory of Open Access Journals (Sweden)

    Anahita Mohseni Meybodi

    2010-01-01

    Full Text Available Objective: Fanconi anemia (FA is an autosomal recessive disorder characterizedby congenital malformations, bone marrow failure, development of squamous cellcarcinoma (SCC, and other cancers. Human papillomavirus (HPV in the oral cavityor oropharynx has been associated with an increased risk of laryngeal papillomatosis,invasive squamous cell carcinoma of the head and neck (HNSCC and cervicaland other genital cancers. The prevalence of HPV DNA in the oral cavity/oropharynxin FA patients and controls was compared.Materials and Methods: A risk factor questionnaire and oral exfoliated cells werecollected from FA patients. The study group consisted of 22 FA patients with HNSCC(case subjects and 24 patients with HNSCC without FA (control subjects. HPVDNA was detected using polymerase chain reaction (PCR and specific primers thatcovered high risk types of HPV. Moreover, special serological assays were used forthe detection of specific antibodies against HPV in patient’s sera.Results: HPV DNA was detected in 82% of the SCC specimens from the case subjectswhich was statistically higher (p< 0.05 than the SCC specimens from the controlsubjects (62.5%. In all cases, the presence of HPV antibodies in patient’s serahas been shown. Among the case subject specimens, 14 cases, and in the controlsubjects, 11 cases were infected by high risk HPV (hr-HPV.Conclusion: These data confirm that HPV infection, especially with high risk types(16,18, could be one of several risk factors for HNSCC particularly in FA patients.

  2. Successful bone marrow transplantation in a patient with Diamond-Blackfan anemia with co-existing Duchenne muscular dystrophy: a case report

    Directory of Open Access Journals (Sweden)

    Kaur Jasmeet

    2011-06-01

    Full Text Available Abstract Introduction Diamond-Blackfan anemia and Duchenne muscular dystrophy are two rare congenital anomalies. Both anomalies occurring in the same child is extremely rare. Allogeneic hematopoietic stem cell transplantation is a well-established therapy for Diamond-Blackfan anemia. However, in patients with Duchenne muscular dystrophy, stem cell therapy still remains experimental. Case presentation We report the case of a nine-year-old boy of north Indian descent with Diamond-Blackfan anemia and Duchenne muscular dystrophy who underwent successful allogeneic hematopoietic stem cell transplantation. He is transfusion-independent, and his Duchenne muscular dystrophy has shown no clinical deterioration over the past 45 months. His creatine phosphokinase levels have significantly decreased to 300 U/L from 14,000 U/L pre-transplant. The patient is 100% donor chimera in the hematopoietic system, and his muscle tissue has shown 8% to 10.4% cells of donor origin. Conclusion Our patient's Diamond-Blackfan anemia was cured by allogeneic hematopoietic stem cell transplantation. The interesting clinical observation of a possible benefit in Duchenne muscular dystrophy cannot be ruled out. However, further clinical follow-up with serial muscle biopsies and molecular studies are needed to establish this finding.

  3. PREVALENCE OF ANEMIA IN PEDIATRIC AGE GROUP PATIENTS AND ITS CO - RELATION WITH SOCIO - DEMOGRAPHIC FACTORS IN PATIENTS PRESENTING AT DEPARTMENT OF PEDIATRICS AT ROHILKHAND MEDICAL COLLEGE AND HOSPITAL, BAREILLLY, U. P.

    Directory of Open Access Journals (Sweden)

    Tania

    2015-04-01

    Full Text Available BACKGROUND: About 2 billion people are suffering from iron deficiency anemia. India continues to be one of the countries to have highest prevalence of anemia NFHS 3 estimates reveals the prevalence of anemia to be 73% in children aged 5 - 11 years. Present study was und ertaken to determine the prevalence of anemia in pediatric age group from 6 months to 14 years. Aims and objective: To study prevalence of anemia in pediatric age group patients and its co - relation with socio - demographic factors in patients presenting at p ediatrics department R.M.C.H. Bareilly. MATERIAL METHOD S : Cross sectional study was carried out from July 2013 to December 2014. A total of 215 students (115 boys and 100 girls were studied. Parents of subjects aged less than 8 years and patients aged more than 8 years attendants were interviewed using a pretes ted questionnaire. Blood samples were taken by fingers prick method. Hb estimation was done by cyan - met hemoglobin method using calorimeter. SPSS Version 10.0, proportions were calculated and chi square test was used as a test for significance. RESULTS: Ou t of total 215 subjects, 82 (38% were found anemic. Girls were affected more as comp aired to boys. Prevalence of anemia was maximum in children belonging to lower social classes (100.0% followed by upper - lower (45%, lower middle (26% and upper middle ( 22% and this prevalence of anemia in relation to social class was found to be statistically significant (p<0.001 higher in children of illiterate mothers and working mothers (p<0.001. CONCLUSION: In India major factor responsible for nutritional anemia children is delayed weaning and insufficient semisolid and solid food intake.

  4. Atypical radiological and intraoperative findings of acute cerebral hemorrhage caused by ruptured cerebral aneurysm in a patient with severe chronic anemia.

    Science.gov (United States)

    Matano, Fumihiro; Murai, Yasuo; Nakagawa, Shunsuke; Kato, Taisei; Kitamura, Takayuki; Sekine, Tetsuro; Takagi, Ryo; Teramoto, Akira

    2014-01-01

    Acute intracerebral hemorrhage (ICH) associated with mild anemia is commonly observed on radiological examination, and there are several reports of ruptured aneurysms occurring with ICH but without accompanying subarachnoid hemorrhage. However, the relationship among computed tomography (CT), magnetic resonance imaging (MRI), and intraoperative findings of ICH caused by ruptured cerebral aneurysm in patients with severe chronic anemia has been rarely reported and is poorly understood. Here, we report atypical radiological and intraoperative findings of acute ICH caused by ruptured cerebral aneurysm in a patient with severe chronic anemia. A 64-year-old man with anemia was admitted to our hospital after he experienced left hemiparesis and a disturbance of consciousness. At a referring institution, he showed evidence of macrocytic anemia (white blood cell count, 9,000/μL; red blood cell count, 104×10(4)/μL; hemoglobin, 4.0 g/dL; hematocrit, 12.2%; and platelet count, 26.6×10(4)/μL). Both CT and MRI showed a right frontal ICH. The outer ring of the hematoma appeared as low-density area on CT, a low-intensity area on T1-weighted MRI, and a high-intensity area on T2-weighted MRI with a serous component. The patient received a blood transfusion and underwent surgical removal of the hematoma the following day. The white serous effusion visualized with CT and MRI was identified as a blood clot in the hematoma cavity. The blood that leaks from blood vessels appears as a high-intensity area on CT because it undergoes plasma absorption in a solidification shrinkage process, and is, therefore, concentrated. Although we did not examine the white effusion to determine if serous components were present, we speculated that the effusion may have contained serous components. Therefore, we removed the part of the effusion that appeared as a low-density area on CT. The presence of ICH without subarachnoid hemorrhage suggested the possible adhesion and rupture of a previous

  5. FEBRILE SEIZURE AND ANEMIA

    Directory of Open Access Journals (Sweden)

    A. Talebian

    2008-11-01

    Full Text Available ObjectiveConsidering the controversial results in present day literature regarding the relationship between febrile seizures and anemia and the high rate of such seizures in children, this study was conducted to evaluate the association between pediatric febrile seizures and anemia.Material and MethodsIn this case-control study, conducted in 2003, 60 children with febrile seizure(cases and 60 febrile children without seizure(controls were evaluated in the Kashan Shahid Beheshti hospital; all patients were matched for age, sex, type of feeding, and use of supplemental iron. Thirty-six (60% and 39 (65% of the patients in case and control groups respectively were male, and the remaining female. Levels of hemoglobin, hematocrit, and red blood cell indices were determined in all children and Chi-square and Fisher exact tests were used to analyze data.ResultsOf the case group, 13.3% (6 male, 2 female and of controls, 20% (9 male, 3 female of children had anemia (p= 0.327, the condition being more common in male children aged over 6 months. Febrile seizures were found to occur mostly between the ages of 6 to 24 months.ConclusionThe risk of febrile seizure occurrence in anemic children seems to be less than that in children who do not suffer from the condition.Keywords:Febrile seizure, Anemia, Children

  6. Orofacial manifestations of hematological disorders: Anemia and hemostatic disorders

    Directory of Open Access Journals (Sweden)

    Titilope A Adeyemo

    2011-01-01

    Full Text Available The aim of this paper is to review the literature and identify orofacial manifestations of hematological diseases, with particular reference to anemias and disorders of hemostasis. A computerized literature search using MEDLINE was conducted for published articles on orofacial manifestations of hematological diseases, with emphasis on anemia. Mesh phrases used in the search were: oral diseases AND anaemia; orofacial diseases AND anaemia; orofacial lesions AND anaemia; orofacial manifestations AND disorders of haemostasis. The Boolean operator "AND" was used to combine and narrow the searches. Anemic disorders associated with orofacial signs and symptoms include iron deficiency anemia, Plummer-Vinson syndrome, megaloblastic anemia, sickle cell anemia, thalassaemia and aplastic anemia. The manifestations include conjunctiva and facial pallor, atrophic glossitis, angular stomatitis, dysphagia, magenta tongue, midfacial overgrowth, osteoclerosis, osteomyelitis and paraesthesia/anesthesia of the mental nerve. Orofacial petechiae, conjunctivae hemorrhage, nose-bleeding, spontaneous and post-traumatic gingival hemorrhage and prolonged post-extraction bleeding are common orofacial manifestations of inherited hemostatic disorders such as von Willebrand′s disease and hemophilia. A wide array of anemic and hemostatic disorders encountered in internal medicine has manifestations in the oral cavity and the facial region. Most of these manifestations are non-specific, but should alert the hematologist and the dental surgeon to the possibilities of a concurrent disease of hemopoiesis or hemostasis or a latent one that may subsequently manifest itself.

  7. Evaluation of the Effects of Intravenous Ascorbic Acid on Correction of Anemia in Renal Failure Patients Undergoing Hemodialysis

    Directory of Open Access Journals (Sweden)

    AA Shojaie

    2006-04-01

    Full Text Available Introduction: Hemodialysis patients often develop resistance to recombinant human erythropoietin due to functional Iron Deficiency. In these patients iron therapy can be hazardous leading to hemosiderosis. Recent studies have suggested that intravenous ascorbic acid may be able to improve this hyporeponsiveness. The aim of this study was to evaluate the effect of intravenous ascorbic acid on functional iron deficiency and whether it results in better correction of anemia or not. Methods: Forty hemodialysis patients with serum ferritin >300ug/l, hemoglobin less than 10 gm/dl, and transferrin saturation less than 20% were selected. The reticulocyte index and KT/V was also calculated. Patients were later administered 500 mg intravenous ascorbic acid three times a week for three months. At the end of study, serum ferritin, transferrin saturation, hemoglobin, reticulocyte index and KT/V were rechecked and compared with the base line values by before and after method. Results: Serum ferritin decreased significantly (median base line ferritin 480.45 ug/dl as compared to final ferritin level of 363.78 (P=0.0001, whereas there was a significant rise in hemoglobin concentration (median baseline hemoglobin 8.92 gm/dl compared to 9.88gm/dl (P=0.0001. Transferrin saturation was also significantly raised (median baseline transferrin saturation 17.35% as compared to final level of 25.12% (P= 0.0001. KT/V before and after treatment with ascorbic acid had no significant change (P =0.396. Finally, the rate of decrease in serum ferritin and increase in hemoglobin according to age and duration of dialysis was studied. The effect of ascorbic acid was found to be significantly greater in older patients and those with longer duration of dialysis (P <0.05; but there was no significant relationship between transferrin saturation increase and age or duration of dialysis. Conclusion: Intravenous ascorbic acid may partially correct functional iron deficiency, although

  8. ANEMIA IN INFLAMMATORY BOWEL DISEASE MORE THAN AN EXTRAINTESTINAL COMPLICATION.

    Science.gov (United States)

    Nemeş, Roxana Maria; Pop, Corina Silvia; Calagiu, Dorina; Dobrin, Denisa; Chetroiu, Diana; Jantea, Petruta; Postolache, Paraschiva

    2016-01-01

    The most common hematologic complication of inflammatory bowel disease (IBD)--ulcerative colitis and Crohn's Disease is anemia. Anemia in patients with IBD may be a result of iron, vitamin B12 or folate deficiency; anemia of chronic disease and hemolytic anemia are other causes in these patients. Factors contributing to the development of anemia include chronic gastrointestinal blood loss, vitamin B12 malabsorption secondary to terminal ileitis, folate deficiency as a result of sulfasalazine therapy. Approximately 30% of patients with IBD have hemoglobin levels below 12 g/dl. The risk of developing anemia relates to disease activity, given that blood loss and inflammatory anemia are triggered by intestinal inflammation. In the management strategy of IBD patients with anemia it is important to distinguish between the different types of anemia in order to decide an appropriate manner of treatment.

  9. Effect of EPO erythropoietin combined with iron sucrose treatment on serum indexes and micro inflammation state of renal anemia patients who received hemodialysis

    Institute of Scientific and Technical Information of China (English)

    Yuan-Yuan Guan

    2015-01-01

    Objective:To study the effect of EPO erythropoietin combined with iron sucrose treatment on serum indexes and micro inflammation state of renal anemia patients who received hemodialysis.Methods: 90 cases of renal anemia patients who received hemodialysis in our hospital from May 2013 to September 2014 were enrolled and randomly divided into two groups. Observation group received recombinant human erythropoietin combined with iron supplementation treatment; control group only received recombinant human erythropoietin treatment. Then serum index, oxidative stress index and micro inflammation state were compared.Results: (1) serum index: after treatment, hemoglobin, hematocrit, serum ferritin, transferrin saturation of observation group were higher than those of control group; (2) oxidative stress index: serum NOX2, AOPP, MDA contents of observation group were lower than those of control group; CAT, SOD and GSH-Px were higher than those of control group;(3) micro inflammatory state: serum NF-毷B, AGEs, IL-6, IL-8, IL-17, IL-23 contents of observation group were lower than those of control group.Conclusion:EPO erythropoietin combined with iron sucrose treatment is helpful to improve anemia, alleviate oxidative stress and micro inflammatory state; it’s an ideal method of treating renal anemia with hemodialysis.

  10. Diagnosis treatment and medical evaluation of aircrew with anemia%飞行人员贫血的临床诊治及医学鉴定

    Institute of Scientific and Technical Information of China (English)

    刘静; 丁丽; 王恒湘; 薛梅; 王志东; 闫侠芳; 朱玲; 董磊; 闫洪敏; 郑晓丽; 韩冬梅

    2015-01-01

    with hemorrhagic anemia, and 3 cases were megaloblastic anemia(MA). Other 5 cases were, respectively, aplastic anemia (AA),β-thalassemia (minor), lung cancer with hemolytic anemia (HA), thymoma with anemia of chronic disease (ACD), and anemia of unknown cause. IDA, MA and hemorrhagic anemia were cured by etiological treatment, except 1 case with IDA who was not qualified for flying because of ground syncope, 1 MA patient with thymoma and 1 MA patient with hyperthyrea were temporarily grounded; the other IDA, MA and hemorrhagic anemia patients were qualified for flying. Two flying personnel were diagnosed asβ-thalassemia minor and mild anemia of unknown cause were, respectively, qualified for flying without any therapy. One case AA and 2 cases malignant tumor with anemia were alleviated by the primary disease treatment, but they were disqualified to fly.ConclusionsAnemia of flying personnel can be caused by a variety of reasons, in which IDA is the most common, especially among women, followed by MA and hemorrhagic anemia. Common causes are food preferences, vegetarian, female menorrhagia, hemorrhoids and peptic ulcer bleeding. Most of the patients can be cured and qualified for flying. Flying personnel once were diagnosed as AA or anemia secondary to malignant tumor would be disqualified to fly; but if the above mentioned patients were cured, they could be evaluated individually. Anemia secondary to other benign diseases was cured, the medical evaluation wouldbe determined according to the therapeutic outcome of the primary disease.

  11. 慢性肾脏病患者贫血发病情况分析%The Prevalence of Anemia in Patients with Chronic Kidney Disease

    Institute of Scientific and Technical Information of China (English)

    保红云; 荣冬靖; 邱敏; 李欣樾

    2011-01-01

    目的 探讨CKD 患者贫血的发病情况及其相关因素.方法 收集2007年1月至2010年1月在云南省第三人民医院肾脏血液风湿免疫科住院的CKD患者465例,对其临床和实验室资料进行回顾性分析.结果 465例CKD患者中,贫血的发病率为72.04%,其中年龄<30岁、30~50岁、50~70岁、>70岁的患者贫血的发病率依次为47.06%、60.94%、74.42%、86.26%;CKDⅠ~Ⅴ期的患者贫血的发病率依次为24.19%、43.84%、63.22%、88.61%和99.39%;经eGFR 矫正后,不同肾脏基础疾病患者贫血的发病率由高到低依次为糖尿病肾病(78.78%)、高血压肾病(66.00%)、慢性肾小球肾炎(65.61%)和多囊肾(60.00%);透析组与非透析组患者贫血的发病率分别为99.00%和51.75%(P<0.001).单因素分析表明,年龄、肾功能情况及透析与否均与贫血的发病率相关.结论 慢性肾脏病患者贫血的发病率较高,肾功能减退、年龄等是其发生的危险因素.%Objective To investigate the prevalence of anemia in the patients with chronic kidney disease (CKD) and the related factors.Method The data of 465 in-patients with CKD in our hospital from January 2007 to January 2010 were collected and retrospectively analyzed.Results In the 465 patients with CKD, the prevalence of anemia was 72.04%, the prevalence of anemia in patients <30 years, 30 ~ 50 years, 50 ~ 70 years, and > 70 years was 47.06%, 60.94%, 74.45% and 86.26%, respectively.The prevalence of anemia in patients with CKD in stage Ⅰ ~ Ⅴ was 24.19%, 43.84%, 63.22%, 88.61% and 99.39%, respectively.The prevalence of anemia in patients with CKD corrected by GFR was associated with varied underling diseases, and the sequence from high to low was diabetic nephropathy (78.78%) , hypertensive nephropathy (66.00%) ,chronic glomeruionephritis (65.61%) and ploycystic renal disease (60.00%).The prevalence of anemia in dialysis patients and non-dialysis patients was 97

  12. Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis

    Directory of Open Access Journals (Sweden)

    El-Nakib GA

    2013-08-01

    Full Text Available Gehad A El-Nakib,1 Tarek M Mostafa,2 Tarek M Abbas,4 Mamdouh M El-Shishtawy,3 Mokhtar M Mabrouk,2 Mohammed A Sobh41Mansoura University Hospitals, Mansoura, Egypt; 2Faculty of Pharmacy, Tanta University, Tanta, Egypt; 3Faculty of Pharmacy, Mansoura University, Mansoura, Egypt; 4Urology and Nephrology Centre, Faculty of Medicine, Mansoura University, Mansoura, EgyptIntroduction: Anemia associated with chronic kidney disease is a serious complication necessitating expenditure of huge medical efforts and resources. This study investigates the role of alpha-lipoic acid (ALA in end stage renal disease patients undergoing hemodialysis. By the virtue of its antioxidative effects, ALA is expected to act as an erythropoietin (EPO adjuvant, and also has extended beneficial effects on endothelial dysfunction.Methods: Forty-four patients undergoing hemodialysis and receiving EPO were randomized into two groups: the first group received ALA 600 mg once daily for 3 months; while the other group represented the control group. Parameters measured at baseline and at end of study were hemoglobin, EPO doses, EPO resistance index (ERI, iron store indices, malondialdehyde, oxidized low-density lipoprotein (ox-LDL, interleukin-6 (IL-6, tumor necrosis factor-α (TNF-α, and asymmetric dimethylarginine (ADMA, as well as routine laboratory follow-up.Results: EPO doses and ERI were significantly decreased in the treatment group, while they did not change in the control group. Hemoglobin, iron store indices, malondialdehyde, oxidized ox-LDL, IL-6, TNF-α, and ADMA were similar in both treatment and control groups at baseline, and did not change by the end of study period. Likewise, routine laboratory measures were not affected by the treatment.Conclusion: ALA could be used in hemodialysis patients to reduce requirements for EPO. However, larger and longer term studies are required to clarify the exact role of ALA in hemodialysis as well as in pre-hemodialysis patients

  13. Medical Resource Utilizations and Economic Burden in Chinese Cancer Patients with Chemotherapy-induced Anemia:A Populational Database Study

    Institute of Scientific and Technical Information of China (English)

    Chieh-Yu LIU; Tsang-Wu LIU; Jih-Shin LIU; Chin-Fu HSIAO; Li-Tzong CHEN

    2008-01-01

    Objective:Most of published studies emphasized the medical cost of treating chemotherapy-induced anemia(CIA)by using specific agents,for example,epoetin α,epoetin β,darbepoetin α or combined with red blood cell transfusions,however,the investigation of the overall medical resources utilizations and economic burden of CIA is still limited.Besides,such studies which emphasized Chinese population still lack.The aim of this study is to investigate the medical resource utilization and the economic burden of Chinese cancer patients with CIA by using a populational representative claim database. Methods:The data for this study are from the 2000-2003 Population Health Insurance Research Database(PHIRD)in Taiwan.On the basis of issuing catastrophic illness cards in the enrollment data files,a total of 26,053 beneficiaries were identified from the PHIRD,who were newly diagnosed with these four cancers in 2001 and 2002(2001:n=12,954;2002:n=13099).A generalized linear model(GLM)was employed for analyzing the differences of medical resource utilization and economic burden between the anemic and non-anemic groups. Results:Analyses showed that the anemic patients were significantly more likely to have longer length of hospital stay than non-anemic patients(P<0.05)across all these four cancers and in two study periods(except women breast cancer in 2002/03).As regards the health care expenditures,the average one-year total medical cost was USD$8,982(2001/02)and USD$8,990(2002/03)for anemic patients among these four cancers,and USD$7,769(2001/02)and USD$7713(2002/03)for non-anemic patients(P<0.0001).As for ambulatory costs,anemic patients'was significantly higher than non-anemic patients' for lung cancer(in 2001/02),women breast cancer(in 2001/02 and 2002/03)and the summarized data(in 2001/02).As for inpatient costs,anemic patients' was significantly higher than non-anemic patients'for gastric cancer(in 2002/03),colon and rectal cancer(in 2001/02 and 2002/03),lung cancer

  14. A study on biochemical facet of anemia in cancers: A strong link between erythropoietin and tumor necrosis factor alpha in anemic cancer patients

    Directory of Open Access Journals (Sweden)

    P Kalyani

    2015-01-01

    Full Text Available Background: The three direct factors that could lead cancer patients to anemia, apart from therapy are iron deficiency, inflammatory cytokines surge and decreased erythropoietin (Epo. Our aim was to quantify biochemical and hematologic markers serum Epo, ferritin (Fe and tumor necrosis factor-alpha (TNF-α along with hemoglobin (Hb to understand the associations between these factors, patient characteristics and anemia. Materials And Methods: The study group consisted of 100 anemic cancer patients and 80 controls. Biochemical marker levels were determined by the enzyme linked immunosorbent assay on an autoanalyser. Univarient analysis, t-test, ANOVA, Bonferroni test, linear regression was performed to find correlations and associations among various factors. Results: The baseline serum Epo (153.07 ± 173.88 vs. 23.607 ± 36.462 and Fe levels (233.53 ± 257.12 vs. 23.06 ± 20.04 were adequately high in cases compared with that controls (P ≤ 0.001. Considerable raise in TNF-α levels was also observed (16.26 ± 13.44 vs. 11.2375 ± 4.84 (P = 0.001. TNF-α correlated positively (P = 0.022 with Epo and Fe (P = 0.000, which was also evident from large effect size of Epo (r2 = 0.414, TNF-α (r2 = 0.369, Hb (r2 = 0.226. Epo and Hb were negatively correlated (β = −0.375, P = 0.001 and Epo production was found to be appropriate for the degree of anemia (O/P ratio of 3.51 ± 1.26 vs. 1.43 ± 0.47. A strong association was seen between Hb, Epo and TNF-α in hematological and gynecological malignancies for different grades of anemia. Men were more prone to life-threatening anemia (13% than women (9%. Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response. Further studies on molecular analysis of Epo, biochemical and molecular interplay between Epo and TNF-α could explain a rationale for anemia in cancers.

  15. Multidisciplinary approach to anemia

    Directory of Open Access Journals (Sweden)

    Anca Ghiațău

    2015-08-01

    Full Text Available Introduction: We present the case of a 65 years- old woman who was admitted with a severe macrocytic anemia Hb= 5.7g/dl and diffuse bone pain. Biologically she has moderate thrombocytopenia 35 000/µl, a hepatic cytolysis and cholestatic syndrome. Material and method: The patient was extensively evaluated before presentation for a mild iron - deficiency anemia for which she underwent endoscopic examination of the upper and lower gastrointestinal tract- normal. The bone marrow aspiration on admission revealed a marked hyperplasia of the erythroblastic line with ~50% basophilic erythroblasts suggesting a regenerative erythroid hyperplasia. These changes along with the marked reticulocytosis on the peripheral blood smear oriented us towards a hemolytic anemia; Folic acid, vitamin B12, autoimmune tests and hemolytic tests were all normal. We continued the investigations with a thoraco-abdominopelvic computed tomography which identified diffuse demineralization, vertebral compactation and pelvic stress fractures. The breast examination revealed a right breast nodule, but the breast ultrasonography pleaded for benignity. Lacking a clear definitive diagnosis we decided to perform a bone marrow biopsy. Results: The osteo- medullary biopsy pointed towards a medullar invasion from a lobular mammary carcinoma; In these circumstances we performed an ultrasound guided biopsy of the right mammary lump thus histologically confirming a tumoral invasion of the bone marrow with subsequent anemia. The patient started chemotherapy in the Oncology ward. Conclusion: The particularity of this case consists in the pattern of anemia, which initially seemed iron deficient and afterwards macrocytic – apparently hemolytic and was actually due to the tumoral medullar invasion and also the nonspecific ultrasonographic appearance of the breast tumor.

  16. Correlative study on anemia and radiotherapy effects in nasopharyngeal carcinoma

    International Nuclear Information System (INIS)

    Objective: To study the effect of oxygen-carrying ability of blood efficacy of radiotherapy for patients with nasopharyngeal carcinoma. Methods: Altogether 161 cases of patients with nasopharyngeal carcinoma were classified according to severity of anemia, and Hb, RBC, MCH, HCT, MCV, MCHC and RDW were tested before, during and after radiotherapy. The patients were followed-up for up to 5 years, the relationship and mechanism among anemia, radiotherapy effects and survival rate was discussed. Results: The survival rate between anemia group and non-anemia group was different significantly (P<0.05). Anemia before radiotherapy, anemia appearance or anemia deterioration during radiotherapy were sensitive factors affecting radiotherapy results. The anemia more severe, the radiotherapy worse. Conclusion: Anemia-hypohemoglobinemia leads to decrease of oxygen-carrying capacity of blood, resulting in oxygen deficiency of tumor cells and their radiotherapy resistance. Therefore this method is worthy of further studies

  17. Relationship Between Low Hemoglobin Levels and Outcomes After Treatment With Radiation or Chemoradiation in Patients With Cervical Cancer: Has the Impact of Anemia Been Overstated?

    Energy Technology Data Exchange (ETDEWEB)

    Bishop, Andrew J.; Allen, Pamela K.; Klopp, Ann H. [Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Meyer, Larissa A. [Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Eifel, Patricia J., E-mail: peifel@mdanderson.org [Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas (United States)

    2015-01-01

    Purpose: Previous reports have suggested that anemia increases rates of recurrence after radiation therapy for cervical cancer. However, these studies may not have fully corrected for confounding risk factors. Using a well-characterized cohort of cervical cancer patients, we examined the association between anemia and outcomes before and after the introduction of chemoradiation as standard of care. Methods and Materials: We reviewed the records of 2454 patients who underwent definitive radiation therapy from 1980 through 2011. Minimum hemoglobin level (Hgb{sub min}) was recorded for 2359 patients (96%). Endpoints included freedom from central recurrence (FFCR), freedom from distant metastasis (FFDM), and disease-specific survival (DSS). Results: For the entire cohort, hemoglobin concentrations of 9, 10, and 12 g/dL before and during radiation were all significantly associated with FFCR, FFDM, and DSS (all P<.001) on univariate analysis. However, on multivariate analysis, only Hgb{sub min} less than 10 g/dL during RT (RT-Hgb{sub <10}) remained significant, and it was correlated with lower DSS (P=.02, hazard ratio [HR] = 1.28) and FFDM (P=.03, HR = 1.33) but not with FFCR. In a subset analysis of patients receiving chemoradiation (n=678), RT-Hgb{sub <10} was associated only with DSS (P=.008, HR = 1.49), not with FFCR or FFDM. In this subgroup, despite an association between RT-Hgb{sub <10} and DSS, the use of transfusion was not correlated with benefit. Conclusions: No evidence was found supporting anemia as an independent predictor of central recurrence in patients treated with definitive radiation therapy with or without chemotherapy. Less emphasis on correcting anemia in cervical cancer patients may be warranted.

  18. Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

    Directory of Open Access Journals (Sweden)

    Mouysset JL

    2016-01-01

    Full Text Available Jean-Loup Mouysset,1 Beata Freier,2 Joan van den Bosch,3 Charles Briac Levaché,4 Alain Bols,5 Hans Werner Tessen,6 Laura Belton,7 G Chet Bohac,8 Jan-Henrik Terwey,9 Giuseppe Tonini101Department of Medical Oncology, Clinique Rambot Provencale, Aix en Provence, France; 2Clinical Oncology, Wojewodzki Szpital Specjalistyczny, Wroclaw, Poland; 3Department of Internal Medicine/Oncology, Albert Schweitzer Ziekenhuis locatie Dordwijk, Dordrecht, the Netherlands; 4Radiotherapy Service, Medical Oncology, Polyclinique Francheville, Périgueux, France; 5Central Pharmacy, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium; 6Private Oncology Practice. Goslar, Germany; 7LB Biostatistics, London, UK; 8Clinical Research, Amgen Inc., Thousand Oaks, CA, USA; 9Medical Development – Oncology, Amgen (Europe GmbH, Zug, Switzerland; 10Department of Medical Oncology, Università Campus Bio-Medico, Roma, ItalyPurpose: To assess hemoglobin (Hb outcomes and fatigue-related quality-of-life (QoL (electronic assessment in patients with solid tumors and symptomatic chemotherapy-induced anemia receiving cytotoxic chemotherapy and darbepoetin alfa (DA or another erythropoiesis-stimulating agent according to European indication.Methods: eAQUA was a Phase IV prospective observational study. The primary outcome (assessed in the primary analysis set [PAS]: patients receiving one or more DA dose who had baseline and week 9 assessments for Hb and QoL was the proportion of patients receiving DA having both Hb increases ≥1 g/dL and improved QoL between baseline and week 9. Functional Assessment of Cancer Therapy-Fatigue (FACT-F subscale scores were anchored to fatigue visual analog scale scores to determine the minimally important difference for improved QoL. Overall data/data over time are reported for the full analysis set (patients receiving one or more erythropoiesis-stimulating agent dose, n=1,158; week 9 data (ie, data relating to the primary and secondary outcomes are reported

  19. Sickle cell anemia - resources

    Science.gov (United States)

    Resources - sickle cell anemia ... The following organizations are good resources for information on sickle cell anemia : American Sickle Cell Anemia Association -- www.ascaa.org National Heart, Blood, and Lung Institute -- www. ...

  20. Folate-deficiency anemia

    Science.gov (United States)

    ... medlineplus.gov/ency/article/000551.htm Folate-deficiency anemia To use the sharing features on this page, please enable JavaScript. Folate-deficiency anemia is a decrease in red blood cells (anemia) ...

  1. Fanconi Anemia Research Fund

    Science.gov (United States)

    ... Support Publications Fundraising News What is the Fanconi Anemia Research Fund? Fanconi anemia is an inherited disease that can lead to ... population. Lynn and Dave Frohnmayer started the Fanconi Anemia Research Fund, in 1989 to find effective treatments ...

  2. Living with Anemia

    Science.gov (United States)

    ... page from the NHLBI on Twitter. Living With Anemia Often, you can treat and control anemia. If ... by an inherited or chronic disease or trauma. Anemia and Children/Teens Infants and young children have ...

  3. Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation

    Directory of Open Access Journals (Sweden)

    Beatriz Stela Pitombeira

    2013-01-01

    Full Text Available Background. Allogeneic hematopoietic stem cell transplantation (HSCT is still associated with a high transplant-related mortality rate. In 2009, the EBMT risk score was validated as a simple tool to predict the outcome after allogeneic HSCT for acquired hematological disorders. Objectives. The aim of this study was to validate the applicability of the EBMT risk score for allogeneic HSCT on South Brazilian patients. Methods. A retrospective observational study was performed based on patients' records and data base at http://dx.doi.org/10.13039/501100003810 Hospital de Clínicas de Porto Alegre, including all allogeneic transplants for malignant and severe aplastic anemia from 1994 to 2010. Patients were categorized according to EBMT risk score and overall survival (OS. Nonrelapse mortality (NRM and relapse rate (RR were analyzed. Results. There were 278 evaluable patients. OS, NRM, and RR at five years median followup were 48.7%, 40.7%, and 30.7%, respectively. The OS was 81.8% for risk score 0 and 0% for score 6 (P<0.001, and NRM was 13.6% and 80% for risk scores 0 and 6, respectively (P=0.001. Conclusion. The EBMT risk score can be utilized as a tool for clinical decision making before allogeneic HSCT for malignant hematological diseases and severe aplastic anemia at a single center in Brazil.

  4. Sequential swallows have no influence on esophageal contractions of patients with iron deficiency anemia Deglutições não modificam as contrações esofágicas de pacientes com anemia ferropriva

    Directory of Open Access Journals (Sweden)

    Roberto Oliveira Dantas

    2004-03-01

    Full Text Available BACKGROUND: An experimental study showed that thyropharyngeal, cricopharyngeal and cervical esophageal muscles of rabbits with iron deficiency anemia had morphological changes similar to those observed in muscular dystrophy, causing myastenic changes in muscles involved in swallowing. Our hypothesis is that patients with iron deficiency anemia may have a decrease in esophageal contractions with successive swallows. PATIENTS AND METHOD: We studied the esophageal motility of 12 women with iron deficiency anemia aged 31 to 50 years (median 36 years with serum iron from 11 to 40 mug/dL (median 21 mug/dL, and 13 asymptomatic women aged 26 to 49 years (median 35 years with serum iron over 60 mug/dL. We used the manometric method with continuous perfusion. The esophageal contractions were measured at 3, 9 and 15 cm from the upper margin of a sleeve that straddled the lower esophageal sphincter. Each subject performed 10 swallows of a 2 mL bolus of water alternated with 10 swallows of a 7 mL bolus, with an interval of 30 seconds between swallows. We measured the amplitude, duration, velocity and area under the curve of contractions. RESULTS: There was no difference between the swallows of a 2 mL or 7 mL bolus. The amplitude, duration and area under the curve were lower in patients with iron deficiency than in asymptomatic volunteers, mainly in the proximal and middle esophageal body. There was no difference in velocity. Sequential swallows did not change contraction amplitude, duration, velocity or area under curve in patients and volunteers. CONCLUSION: Although the power of esophageal contractions was decreased in patients with iron deficiency anemia, sequential swallows did not cause further impairment.RACIONAL: Estudo experimental encontrou que os músculos tirofaríngeo, cricofaríngeo e do esôfago cervical de coelhos com anemia ferropriva têm alterações morfológicas semelhantes às encontradas na distrofia muscular, provocando altera

  5. Comparison of Bone Marrow and Blood Cell Morphology Between Refractory Anemia and Other Anemia Disease%难治性贫血与其它贫血性疾病骨髓及血细胞形态学比较分析

    Institute of Scientific and Technical Information of China (English)

    程虹; 江明; 杜伟; 钟笛; 郝建萍; 李玲

    2012-01-01

    本研究观察骨髓增生异常综合征(MDS),主要是难治性贫血(RA)骨髓及外周血细胞形态学特点,并与其它贫血性疾病(慢性再生障碍性贫血、溶血性贫血、巨幼细胞性贫血)进行比较分析.取患者骨髓及外周血制成涂片行瑞氏染色,骨髓分类500个有核细胞,外周血分类100个有核细胞,观察红系、粒系、巨核系病态细胞特点.结果发现,外周血中性分叶核细胞浆内颗粒稀少或缺如、Pelger核异常改变、幼粒细胞数及检出率、单核细胞检出率以及骨髓粒系各阶段细胞出现颗粒缺如,红系奇数核、核出芽,巨核系小巨核及单圆核巨核细胞等在RA与慢性再生障碍性贫血、溶血性贫血、巨幼细胞性贫血比较均有显著性差异(P<0.05).结论:细胞形态学是MDS诊断的基础,外周血及骨髓细胞形态学异常在MDS与其他贫血性疾病的鉴别诊断中具有重要作用.%This study was purposed to investigate the cell morphological features of bone marrow and peripheral blood in patients with myelodysplastic syndrome, mainly with refractory anemia, and to compare them with other anemia diseases including chronic aplastic anemia, hemolytic anemia and megaloblastic anemia. The bone marrow and peripheral blood were taken from patients for preparing the smears with Wright staining. 500 karyocytes in bone marrow and 100 karyocytes in peripheral blood were detected, and the features of morbid cells of erythrocyte, granulocyte and megakaryocytic series were observed. The results showed that differences between refractory anemia, chronic aplastic anemias and hemolytic anemia as well as megaloblastic anemia were statistically significant (P < 0.05) in the granules scarce and absence in the intracytoplasm of segmented neutrocyte in peripheral blood, Pelger dyskaryosis, the numbers and detected rate of immature granulocytes, monocyte detected rate, the granules scarce in all stage of granulocytic series in bone

  6. Readmission and mortality one year after acute hospitalization in older patients with explained and unexplained anemia - a prospective observational cohort study

    OpenAIRE

    Abrahamsen, Jenny Foss; Monsen, Anne-Lise Bjorke; Landi, Francesco; Haugland, Cathrine; Nilsen, Roy Miodini; Ranhoff, Anette Hylen

    2016-01-01

    Background Few studies have examined whether specific subtypes of anemia in older persons are more related to adverse outcomes such as hospital readmissions and death after acute hospitalization and post-acute care. Methods An observational prospective cohort study was conducted between 2011 and 2014. A total of 884 community-dwelling patients, ≥70 years of age were transferred from acute medical and orthopaedic hospital departments to a skilled nursing home where they were examined by compre...

  7. Reticulocyte production index as a predictor of clinically significant anemia in chronic hepatitis C patients receiving pegylated interferon combination therapy

    Directory of Open Access Journals (Sweden)

    Sheng-Lei Yan

    2016-03-01

    Conclusion: Besides old age and low pretreatment hemoglobin level, our study showed that a reticulocyte production index < 0.9% at Week 4 was a significant factor associated with clinically significant anemia during pegylated interferon combination treatment.

  8. Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial.

    Science.gov (United States)

    Javidan, Abbas Norouzi; Shahbazian, Heshmatollah; Emami, Amirhossein; Yekaninejad, Mir Saeed; Emami-Razavi, Hassan; Farhadkhani, Masoumeh; Ahmadzadeh, Ahmad; Gorjipour, Fazel

    2014-08-26

    Recombinant human erythropoietin (rHuEPO) is available for correcting anemia. PDpoetin, a new brand of rHuEPO, has been certified by Food and Drug Department of Ministry of Health and Medical Education of Iran for clinical use in patients with chronic kidney disease. We conducted this post-marketing survey to further evaluate the safety and efficacy of PDpoetin for management of anemia in patients on maintenance hemodialysis. Patients from 4 centers in Iran were enrolled for this multicenter, open-label, uncontrolled phase IV clinical trial. Changes in blood chemistry, hemoglobin and hematocrit levels, renal function, and other characteristics of the patients were recorded for 4 months; 501 of the patients recruited, completed this study. Mean age of the patients was 50.9 (±16.2) years. 48.7% of patients were female. Mean of the hemoglobin value in all of the 4 centers was 9.29 (±1.43) g/dL at beginning of the study and reached 10.96 (±2.23) g/dL after 4 months and showed significant increase overall (Pcase of immunological reactions to PDpoetin was observed. Our study, therefore, showed that PDpoetin has significantly raised the level of hemoglobin in the hemodialysis patients (about 1.7±0.6 g/dL). Anemia were successfully corrected in 49% of patients under study. Use of this biosimilar was shown to be safe and effective for the maintenance of hemoglobin in patients on maintenance hemodialysis. PMID:25317316

  9. Safety and efficacy of PDpoetin for management of anemia in patients with end stage renal disease on maintenance hemodialysis: results from a phase IV clinical trial

    Directory of Open Access Journals (Sweden)

    Abbas Norouzi Javidan

    2014-09-01

    Full Text Available Recombinant human erythropoietin (rHuEPO is available for correcting anemia. PDpoetin, a new brand of rHuEPO, has been certified by Food and Drug Department of Ministry of Health and Medical Education of Iran for clinical use in patients with chronic kidney disease. We conducted this post-marketing survey to further evaluate the safety and efficacy of PDpoetin for management of anemia in patients on maintenance hemodialysis. Patients from 4 centers in Iran were enrolled for this multicenter, open-label, uncontrolled phase IV clinical trial. Changes in blood chemistry, hemoglobin and hematocrit levels, renal function, and other characteristics of the patients were recorded for 4 months; 501 of the patients recruited, completed this study. Mean age of the patients was 50.9 (±16.2 years. 48.7% of patients were female. Mean of the hemoglobin value in all of the 4 centers was 9.29 (±1.43 g/dL at beginning of the study and reached 10.96 (±2.23 g/dL after 4 months and showed significant increase overall (P<0.001. PDpoetin dose was stable at 50-100 U/kg thrice weekly. Hemorheologic disturbancesand changes in blood electrolytes was not observed. No case of immunological reactions to PDpoetin was observed. Our study, therefore, showed that PDpoetin has significantly raised the level of hemoglobin in the hemodialysis patients (about 1.7±0.6 g/dL. Anemia were successfully corrected in 49% of patients under study. Use of this biosimilar was shown to be safe and effective for the maintenance of hemoglobin in patients on maintenance hemodialysis.

  10. A comparative immunohistochemical study of aplastic thymuses for lymphocytic, epithelial, proliferative and apoptotic indices

    Directory of Open Access Journals (Sweden)

    Mahjoub F.

    2008-03-01

    Full Text Available Background: Immune deficiency is one of the major causes of morbidity and mortality in the modern world. Primary immunodeficiency comprises a wide range of disorders that mainly manifest in early childhood as devastating infections with opportunistic organisms. Thymic aplasia is found on autopsy of some patients afflicted with immune deficiency disorders, such as DiGeorge syndrome and severe combined immunodeficiency (SCID. After a thorough search of the literature, we found little information on the cellular characteristics of these thymuses. Our study aims to elucidate role of apoptosis in the pathogenesis of thymic aplasia and compare various lymphocytic and epithelial markers in normal and aplastic thymuses. Methods: We selected 12 subjects who died of severe infections with aplastic thymus found on autopsy, and 11 control subjects who died of unrelated causes, such as congenital heart disease. The presence of several markers, including Bcl2, P53, lymphocytic markers, and CD68, was examined using immunohistochemical methods on paraffin-embedded thymus sections. Positively-stained cells were counted per 1000 cells and the results stated as percentage of positive cells.                        Results: The mean age of the control group was between 7 days to 18 months (mean: 4.5 months. Parental consanguinity was present in 45.5% and 9.1% of the control and case groups, respectively; however, this was not statistically significant. We found significantly lower expression of Bcl2 in the case group (p value: 0.038. Furthermore, expression of CD68 was significantly higher in the case group. Epithelial markers were significantly higher in case subjects, although CD8 expression was higher in the control group. The presence of other markers was not significantly different between the two groups.Conclusions: Increase in apoptosis has a role in aplastic thymuses and prevention of apoptosis may halt this process. Also high CD68

  11. Effect of Shenkang injection combined with hemodialysis treatment on renal function, renal anemia and cytokine levels in patients with chronic renal failure

    Institute of Scientific and Technical Information of China (English)

    Rui Liu

    2016-01-01

    Objective:To study the effect of Shenkang injection combined with hemodialysis treatment on renal function, renal anemia and cytokine levels in patients with chronic renal failure. Methods: A total of 68 patients with chronic renal failure who received hemodialysis treatment in our hospital during between October 2013 and February 2016 were selected and randomly divided into two groups, the observation group received Shenkang injection treatment in the process of dialysis, and the control group only received conventional symptomatic and supportive treatment. 8 weeks after treatment, serum was collected to determine the levels of renal function indexes, nutritional status indexes, anemia indexes and cytokines, and urine was collected to determine renal function indexes.Results:β2-MG, UA, Cr, phosphorus, IL-17, IL-23, CTGF, TGF-β1, FGF-2 and FGF-23 levels in serum as well as NGAL, KIM-1 and RBP levels in urine of observation group were significantly lower than those of control group, and TP, Alb, PA, calcium, Hb, EPO, Fe, TRF and FER levels in serum were significantly higher than those of control group.Conclusion:Shenkang injection combined with hemodialysis treatment helps to improve renal function, nutritional status and renal anemia, and reduce the synthesis of inflammation and renal interstitial fibrosis-related cytokines in patients with chronic renal failure.

  12. 妊娠期贫血患者的血常规检验分析%Blood tests and analysis of patients with anemia in pregnant women

    Institute of Scientific and Technical Information of China (English)

    黄和明; 谢世营; 林楚楚; 邢园园; 马杰彦

    2014-01-01

    目的:探讨分析血液常规检查对妊娠期贫血患者的临床作用。方法选取2012年2月至2013年9月经妇产科治疗的138例妊娠期贫血患者,同时选取同期120例健康孕妇作为对照组,观察两组孕妇的血常规检验结果,对血红蛋白( Hb)、红细胞( RBC)、红细胞平均血红蛋白含量( MCH)、红细胞平均体积( MCV)、血细胞平均血红蛋白浓度(MCHC)和血细胞分布宽度(RDW)等检测指标开展统计分析。结果孕早期孕妇的小细胞性贫血发生率为76.32%,大细胞性贫血发生率为15.79%;孕中期的小细胞性贫血发生率为76.60%,大细胞性贫血发生率为14.89%;孕晚期的小细胞性贫血发生率为35.85%,大细胞性贫血发生率为60.38%。小细胞性贫血孕妇的RBC均值与健康孕妇相比较无明显差异,RDW均值高于健康孕妇,组间差异有统计学意义( P <0.05),Hb、MCV、MCH、MCHC的均值都低于健康孕妇,组间差异具有统计学意义( P <0.05)。大细胞性贫血孕妇,其MCHC均值与健康孕妇无统计学差异( P >0.05), RDW、MCV、MCH均值都高于健康孕妇,组间差异有统计学意义( P <0.05),Hb、RBC均值都低于健康孕妇,组间差异有统计学意义( P <0.05)。结论妊娠期发生贫血的几率较高,孕早期与孕中期主要为小细胞性贫血,孕晚期主要为大细胞性贫血,对孕妇定期开展Hb、RBC、MCH、MCV、MCHC、RDW等常规检查有重要意义,可尽早发现贫血程度,预防不良事件的发生。%Objective To investigate the clinical effect analysis of blood routine examination of patients with anemia in pregnant women. Methods One hundred and thirty-eight cases of anemia in pregnant women treated obstetrics and gynecology department in our hospital form February 2012 to September 2013 were included into this study. At the same time,120 healthy pregnant women were

  13. Blood tests and analysis of patients with anemia in pregnant women%妊娠期贫血患者的血常规检验分析

    Institute of Scientific and Technical Information of China (English)

    黄和明; 谢世营; 林楚楚; 邢园园; 马杰彦

    2014-01-01

    Objective To investigate the clinical effect analysis of blood routine examination of patients with anemia in pregnant women. Methods One hundred and thirty-eight cases of anemia in pregnant women treated obstetrics and gynecology department in our hospital form February 2012 to September 2013 were included into this study. At the same time,120 healthy pregnant women were selected as a control group at the same period. Blood test results were observed in pregnant women. The indexes including HB,RBC,MCH,MCV,MCHC,RDW were sta-tistical analyzed to detect indicators. Results Trimester pregnant women,rate of small-cell anemia was 76. 32%,large cell anemia incidence 15. 79%. At the second trimester,small-cell anemia was 76. 60%,large cell anemia incidence 14. 89%. The third trimester of small cell lines anemia was 35. 85%,large cell anemia incidence 60. 38%. Pregnant women in the first trimester and second trimester are mostly small-cell ane-mia. With the development of pregnancy,the third trimester pregnant women are mostly large-cell anemia. Small-cell anemia in pregnant women with healthy pregnant women did not show significant difference in RBC mean number. RDW mean is higher than healthy pregnant women. The Hb,MCV,MCH,MCHC mean are lower than those of healthy pregnant women. Large-cell anemia in pregnant women,pregnant women and health of its MCHC did not show statistical difference. The RDW,MCV,MCH mean were higher than healthy pregnant women. The Hb,RBC are lower than the average healthy pregnant women. Conclusion Higher probability of occurrence was found in anemia during pregnancy. Trimester and second trimester is mainly small-cell anemia. Third trimester is mainly large-cell anemia. Pregnant women regularly carrying Hb,RBC, MCH,MCV,MCHC,RDW and other routine testing is important. The degree of anemia can be detected early to prevent the occurrence of adverse events.%目的:探讨分析血液常规检查对妊娠期贫血患者

  14. Patients with Renal Anemia Blood Test Result Analysis%肾性贫血患者血液检验结果分析

    Institute of Scientific and Technical Information of China (English)

    汤琼健; 廖清霞; 董仁康

    2013-01-01

    Objective Investigated the relationship between blood test results and the degree of renal impairment in the patients with renal anemia. Method Selected 72 cases of chronic renal failure or uremia patients with renal anemia, and give them blood tests. Results The greater the degree of renal injury, the more severe the degree of renal anemia,The number of red blood cel s,serum ferritin, hematocrit and other erythrocyte index fel more obvious. Conclusion Renal anemia in patients with blood tests to be able to diagnose,treat diseases provide the basis of very great clinical significance.%目的考察肾性贫血患者血液检测的结果与肾脏损伤程度的关系。方法对72例慢性肾功能衰竭或尿毒症伴有肾性贫血的患者进行血液检测。结果肾损伤的程度越大,出现肾性贫血程度就越严重,红细胞个数、血清铁蛋白、红细胞压积或红细胞比容等红细胞指数下降越明显。结论肾性贫血患者的血液检测能够为诊断、治疗疾病提供依据,具有十分重大的临床意义。

  15. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients

    DEFF Research Database (Denmark)

    Mann, J; Kessler, M; Villa, Giulio Palludan;

    2007-01-01

    in a large cohort of dialysis patients. METHODS: Data were combined from eight similarly designed 24-week phase 3b European studies, in which patients receiving EPO alfa or beta once-weekly were converted to Q2W darbepoetin alfa. Darbepoetin alfa dosage was titrated to maintain hemoglobin (Hb) between 10......-tolerated. CONCLUSIONS: Q2W darbepoetin alfa is effective in maintaining Hb levels in dialysis patients switched from weekly rHuEPO, regardless of the route of administration and with no notable increase in the weekly equivalent dose....

  16. An audit of iron therapy in patients with iron deficiency anemia in a tertiary care hospital

    Directory of Open Access Journals (Sweden)

    Anusha Natarajan

    2015-12-01

    Conclusions: The results of the present study showed that majority of the patients with IDA did not receive the recommended WHO treatment. The present study shows that even though the treatment of a common nutritional disorder-IDA is simple and effective, the prevalence of the same is high, and the majority of the patients are being undertreated. Patients should also be educated about the implications of the disorder and the importance of its treatment. [Int J Basic Clin Pharmacol 2015; 4(6.000: 1198-1200

  17. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment.

    Science.gov (United States)

    Murawska, Natalia; Fabisiak, Adam; Fichna, Jakub

    2016-05-01

    Anemia coexists with inflammatory bowel disease (IBD) in up to two-thirds of patients, significantly impairing quality of life. The most common types of anemia in patients with IBD are iron deficiency anemia and anemia of chronic disease, which often overlap. In most cases, available laboratory tests allow successful diagnosis of iron deficiency, where difficulties appear, recently established indices such as soluble transferrin-ferritin ratio or percentage of hypochromic red cells are used. In this review, we discuss the management of the most common types of anemia in respect of the latest available data. Thus, we provide the mechanisms underlying pathophysiology of these entities; furthermore, we discuss the role of hepcidin in developing anemia in IBD. Next, we present the treatment options for each type of anemia and highlight the importance of individual choice of action. We also focus on newly developed intravenous iron preparations and novel, promising drug candidates targeting hepcidin. Concurrently, we talk about difficulties in differentiating between the true and functional iron deficiency, and discuss tools facilitating the process. Finally, we emphasize the importance of proper diagnosis and treatment of anemia in IBD. We conclude that management of anemia in patients with IBD is tricky, and appropriate screening of patients regarding anemia is substantial. PMID:26818422

  18. Treatment of chemotherapy-related anemia in malignant tumor patients%恶性肿瘤患者化疗相关贫血的治疗

    Institute of Scientific and Technical Information of China (English)

    潘海霞; 邓春美; 任刚; 朱学强; 邓颖; 杨兰; 敖睿; 胡洪林; 刘浩

    2011-01-01

    目的 本课题研究我科恶性肿瘤患者化疗后贫血的发生状况及药物干预治疗.方法 选择我科2008年1月~2010年7月收治的化疗前血红蛋白正常的肿瘤患者82例,统计化疗后贫血的发生率,贫血的程度,含铂与非含铂方案对贫血的影响,对发生贫血的患者分为两组,单药组单用促红细胞生成素10000U,皮下注射,每周3次,连续8周治疗36例;联合组给予促红细胞生成素10000U,皮下注射,每周3次,和蔗糖铁0.2g,静脉滴注,每周2次,连续8周治疗37例,观察治疗前后血红蛋白的变化及不良反应.结果 82例恶性肿瘤患者化疗后贫血的发生率为85.37%,其中轻度贫血37例(45.12%),中度贫血22例(26.83%),重度贫血9例(10.98%),极重度贫血2例(2.44%),无贫血12例(14.63%).单药组治疗后血红蛋白平均升高(20.1±3.3) g/L,联合组治疗后血红蛋白平均升高(22.1±3.5)g/L,两组比较差异有统计学意义.化疗后贫血发生以轻到中度为主(71.95%),含铂方案贫血发生率90.63%,非含铂方案贫血发生率66.67%,两组比较差异有统计学意义.未见促红细胞生成素和蔗糖铁的明显不良作用.结论 恶性肿瘤患者化疗后贫血的发生率高,含铂方案的化疗导致贫血的发生率更高.促红细胞生成素、蔗糖铁能纠正恶性肿瘤患者化疗所致的贫血,两者联合使用疗效更佳.%Objective This topic studies the anemia and drug intervention therapy after malignant tumor' chemotherapies in our division. Methods Recruit eighty two tumor* survivors whose hemoglobin are normal before chemotherapy from January 2008 to July 2010,and count the anemia's incidence rate and extent after chemotherapies. Discuss the effects in standard plati num-based regimen and no platinum-based regimen and divide these anemia' patients into two groups. Use 10000IU erythropoietin and hypodermically injection three times a week in monotherapy group,and cure 36 patients in continuous 8 weeks . Use

  19. Iron and Ferritin Levels in Saliva of Patients with Thalassemia and Iron Deficiency Anemia

    OpenAIRE

    Canatan, Duran; Akdeniz, Sevgi Kosaci

    2012-01-01

    Most of the techniques for measuring iron stores such as serum iron concentration, iron binding capacity, serum ferritin level, liver biopsy can be troublesome or invasive for patients with thalassemia. The salivary iron measurement could be of potential advantage being an easy and non invasive approach for diagnosis of iron deficiency and iron overload . The aim of this study was to compare the levels of iron and ferritin in saliva and serum of patients affected by thalassemia or iron defici...

  20. Mieloma Múltiplo e anemia Multiple Myeloma and anemia

    Directory of Open Access Journals (Sweden)

    Rodolfo D. Cançado

    2007-03-01

    Full Text Available Anemia é uma complicação comum em pacientes com mieloma múltiplo (MM e ocorre em mais de 2/3 dos pacientes. Anemia de doença crônica, deficiência de eritropoetina (EPO devido à insuficiência renal e efeito mielossupressivo da quimioterapia são os principais mecanismos patofisiológicos que contribuem para o desenvolvimento de anemia no MM. Nos pacientes que obtêm remissão completa com tratamento quimioterápico, anemia usualmente se normaliza. Nos pacientes que não respondem ou apresentam recaída do mieloma, anemia freqüentemente persiste. As opções de tratamento dos pacientes anêmicos com MM incluem transfusões de hemácias e EPO recombinante humana. Essa proteína é biologicamente equivalente à EPO endógena e sua administração promove aumento dos valores de hemoglobina por tempo mais prolongado sem os riscos das transfusões de sangue. Vários estudos têm relatado melhora significante da eritropoese, redução da necessidade transfusional e melhora da qualidade de vida com o uso da EPO como tratamento a longo prazo da anemia associada ao mieloma. Nesse artigo, propomos o tratamento da anemia do MM baseado nas recomendações propostas pela Sociedade Americana de Hematologia (ASH em conjunto com a Sociedade Americana de Oncologia Clínica (ASCO, pela Organização Européia para Pesquisa e Tratamento do Câncer (EORTC, pelo IMF (Internacional Myeloma Foundation e pelo NCCN (National Comprehensive Cancer Network.Anemia is a common complication in patients with multiple myeloma (MM occurring in more than two thirds of all patients. Anemia of chronic diseases, erythropoietin (EPO deficiency due to renal impairment and the myelosuppressive effect of chemotherapy are the most important pathophysiological mechanisms contributing to the development of anemia in MM. In patients who achieve complete remission after chemotherapy, anemia usually normalizes. Non-responders and relapsing myeloma patients often continue to suffer

  1. Tissue Iron Distribution Assessed by MRI in Patients with Iron Loading Anemias

    Science.gov (United States)

    Gutiérrez, Lucía; House, Michael J.; Vasavda, Nisha; Drašar, Emma; Gonzalez-Gascon y Marin, Isabel; Kulasekararaj, Austin G.; St Pierre, Tim G.; Thein, Swee L.

    2015-01-01

    Bone marrow, spleen, liver and kidney proton transverse relaxation rates (R2), together with cardiac R2* from patients with sickle cell disease (SCD), paroxysmal nocturnal hemoglobinuria (PNH) and non-transfusion dependent thalassemia (NTDT) have been compared with a control group. Increased liver and bone marrow R2 values for the three groups of patients in comparison with the controls have been found. SCD and PNH patients also present an increased spleen R2 in comparison with the controls. The simultaneous measurement of R2 values for several tissue types by magnetic resonance imaging (MRI) has allowed the identification of iron distribution patterns in diseases associated with iron imbalance. Preferential liver iron loading is found in the highly transfused SCD patients, while the low transfused ones present a preferential iron loading of the spleen. Similar to the highly transfused SCD group, PNH patients preferentially accumulate iron in the liver. A reduced spleen iron accumulation in comparison with the liver and bone marrow loading has been found in NTDT patients, presumably related to the differential increased intestinal iron absorption. The correlation between serum ferritin and tissue R2 is moderate to good for the liver, spleen and bone marrow in SCD and PNH patients. However, serum ferritin does not correlate with NTDT liver R2, spleen R2 or heart R2*. As opposed to serum ferritin measurements, tissue R2 values are a more direct measurement of each tissue’s iron loading. This kind of determination will allow a better understanding of the different patterns of tissue iron biodistribution in diseases predisposed to tissue iron accumulation. PMID:26406992

  2. Hematological parameters in association with outcomes in sickle cell anemia patients

    Directory of Open Access Journals (Sweden)

    Okocha Emmanuelchide

    2011-01-01

    Full Text Available Introduction: Sickle cell disease (SCD has a wide range of clinical presentation. We evaluated hematological parameters, which are widely evaluable and assessable, as indices of clinical outcome in SCD. These parameters, although largely established as indices of clinical outcome in other SCD populations, have not been widely evaluated in African patients. Materials and Methods: One hundred and thirty six consecutive stable SCD patients who presented in the sickle cell clinic of a teaching hospital were studied retrospectively using a questionnaire. Hematological parameters of full blood count (FBC for each patient were obtained using a cell counter. FBC parameters such as White blood cell count (WBC were then statistically correlated with complications such as ankle ulcers, osteomylitis and others. A Chi-square text was used to compare frequencies and generate P values. Results: The presence of sickle cell complications was significantly associated with raised white blood cell count (WBC above 11 × 10 >9 /l (P0 = 0.03.The WBC of the patients increased with increasing numbers of complications ( P = 0.07. Mean packed cell volume (PCV and WBC tended toward the reference range for age and sex (in apparently normal individuals as the age at diagnosis of SCD increased. This trend was significant for PCV (P = 0.01. Conclusion: Our data provide additional support that widely evaluable and assessable hematological parameters such as PCV and WBC can be used as indices to predict SCD outcome in African patients. This is likely to impart positively on individualized therapy.

  3. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    Science.gov (United States)

    2016-03-10

    Bone Marrow Failure Syndrome; Severe Aplastic Anemia; Severe Congenital Neutropenia; Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Schwachman Diamond Syndrome; Primary Immunodeficiency Syndromes; Acquired Immunodeficiency Syndromes; Histiocytic Syndrome; Familial Hemophagocytic Lymphocytosis; Lymphohistiocytosis; Macrophage Activation Syndrome; Langerhans Cell Histiocytosis (LCH); Hemoglobinopathies; Sickle Cell Disease; Sickle Cell-beta-thalassemia

  4. Cooley's Anemia: A Psychosocial Directory.

    Science.gov (United States)

    National Center for Education in Maternal and Child Health, Washington, DC.

    The directory is intended to aid patients and their families who are coping with the genetic disorder of Cooley's anemia. A brief review of the disease covers background, genetics, symptoms, effect on the patient, treatment, and current research. The next section looks at psychosocial needs at various times (time of diagnosis, infancy and toddler…

  5. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients

    Directory of Open Access Journals (Sweden)

    Souqiyyeh Muhammad

    2009-01-01

    Full Text Available We aimed in this study to assess the opinion of medical directors of dialysis centers in the Kingdom of Saudi Arabia (KSA about updates of strategies for treatment of anemia in patients with chronic kidney disease (CKD. A questionnaire was sent to the medical directors of the 174 active dialysis centers in the KSA including centers under the Ministry of Health (MOH (67 %, the governmental non-MOH sector (12% and private hospitals (21 % that together care for a population of more than 11,300 chronic dialysis patients. The study was performed between November 2008 and March 2009. A total of 143 of the 174 (82.1% medical directors answered the questionnaire. This covered 9563 (84% dialysis patients in the KSA. There were 95 (68.8% respondents who believed that the mechanism of action of ESAs is due to both blood concentration and direct action on the stem cells that form red cells. Only 81 (57% respondents believed that the half-life of the short-acting ESAs is less than one day, 67 (46.9% believed the half-life of darbepoetin is 2-4 days, and 52 (36.6% believed the half-life of CERA is 5-10 days; 79 (55.6% respondents believed that the interval of dosing of darbepoetin is once biweekly, and 92 (71.9% believed that the interval of dosing of CERA is once a month. There were 110 (76.9% respondents who believed the CKD should receive a long-acting than short-acting ESAs for the more stable hemoglobin levels, 64 (44.8% believed that pharmacodynamics of the CERA are better than other ESAs and warrant its use over all of them, and 115 (80.6% believed that the target hemoglobin is 11-13 g/dL in CKD patients is well established. Finally, 65 (51.5% respondents would request more than 30% of the stock of ESAs in the future as short-acting ESAs vs 71 (55% for darbepoetin and 40 (37.4% for CERA. There were no statistically significant differences among the respondents according to their affiliations (MOH, non MOH and private sector on any of the issues in the

  6. [Treatment of anemia in patients with chronic renal insufficiency with recombinant human erythropoietin].

    Science.gov (United States)

    Djukanović, Lj; Lezaić, V

    1996-01-01

    The discovery of recombinant human erythropoietin has enabled treatment of anaemia in patients whose anaemia was primarily caused by the lack of erythropoietin. This agent was most widely used in the treatment of anaemia in chronic renal failure patients. Non-regulated hypertension is considered to be the only absolute contraindication for recombinant human erythropoietin application, but thrombocytosis, predisposition to thromboses of arterio-venous fistulae, and convulsions are regarded as relative contraindications. Recombinant human erythropoietin may be administered intravenously, but the subcutaneous route is considered more rational. The treatment is initiated by low doses with gradual dose increase, what enables gradual anaemia correction and prevents the appearance of adverse effects. Haemoglobin level of around 100 g/l is considered the target haemoglobin level. The majority of patients respond well to treatment by human recombinant erythropoietin and the absence of anaemia improvement may be the result of iron deficiency, occult haemorrhages, chronic infection, inadequate dialysis, secondary hyperparathyroidism, aluminium intoxication. Anaemia improvement during the treatment with recombinant erythropoietin leads to the improvement of function of most organs and the quality of life in general as well as avoidance of blood transfusions and their adverse effects. The most frequent adverse effect of recombinant erythropoietin is the development of iron deficiency or hypertension aggravation. PMID:9102827

  7. 老年贫血218例病因分析%Etiopathogenisis analysis of 218 cases of anemia in the elderly

    Institute of Scientific and Technical Information of China (English)

    高丽霞; 吴克雄; 冀红红; 谢静荣

    2010-01-01

    目的 探讨老年贫血的诊断特点.方法 分析218例老年贫血病例的血常规、骨髓红系增生情况、骨髓形态学及病理学诊断、病因诊断等项目为观察指标.结果 218例老年贫血病例中,男性数量稍多于女性,中位年龄67.9岁.中重度贫血占绝大多数,形态学上以小细胞性贫血比例最高,占42.66%;其次为正细胞性贫血,占35.85%.骨髓红系增生活跃以上者占82.35%;缺铁性贫血为老年贫血最常见的病种(39.44%),其次为巨幼细胞性贫血、骨髓增生异常综合征.缺铁性贫血的病因中摄入不足最常见,占25.66%,肿瘤、溃疡及胃大部切除术后也较多见.骨髓增生异常综合征、巨幼细胞性贫血和慢性再生障碍性贫血为老年全血细胞减少病例的常见病种.结论 老年人属弱势群体,老年贫血病例中缺铁性贫血和营养不良性贫血比例高.%Objective To explore the diagnostic characteristics of anemia in the elderly. Methods To measure and analyze the eric status of bone marrow, diagnosis according to morphology and biopsy of bone marrow, and etiology of anemia(IDA) in 218 cases of anemia in the aged. Results In these 218 cases male patients were slightly more than female patients. Median age was 68.9. Ratio of cases with macrocytic anemia was the highest(42.66%), ratio of cases with active erythropoietic status was 82. 35%. Iron deficiency anemia was the most common anemia in the elderly(39. 44%), and megaloblastic anemia and myelodysplastic syndrome (MDS) were also frequent. Insufficient ingestion was the most common cause of IDA(25.66 %),and tumors,digestive ulcers and postgastrectomy were also the common causes. MDS,megaloblastic anemia and chronic aplastic anemia(CAA) were the common anemia in geriatric population with pancytopenia. Conclusions Geriatric population is the fragile group. Ratio of cases with anemia due to IDA and malnutrition is high in cases of anemia in the elderly.

  8. Anemia and survival in human immunodeficiency virus

    DEFF Research Database (Denmark)

    Lundgren, Jens Dilling; Mocroft, Amanda

    2003-01-01

    The prospective, multicenter cohort study EuroSIDA has previously reported on predictors and outcomes of anemia in patients infected with human immunodeficiency virus. In a Cox proportional-hazards model with serial measures of CD4+ cell count, plasma viral load, and degrees of anemia fitted...

  9. Allogeneic hematopoietic stem cell transplantation from an alternative stem cell source in Fanconi anemia patients: analysis of 47 patients from a single institution

    Directory of Open Access Journals (Sweden)

    C.R. de Medeiros

    2006-10-01

    Full Text Available We transplanted 47 patients with Fanconi anemia using an alternative source of hematopoietic cells. The patients were assigned to the following groups: group 1, unrelated bone marrow (N = 15; group 2, unrelated cord blood (N = 17, and group 3, related non-sibling bone marrow (N = 15. Twenty-four patients (51% had complete engraftment, which was not influenced by gender (P = 0.87, age (P = 0.45, dose of cyclophosphamide (P = 0.80, nucleated cell dose infused (P = 0.60, or use of anti-T serotherapy (P = 0.20. Favorable factors for superior engraftment were full HLA compatibility (independent of the source of cells; P = 0.007 and use of a fludarabine-based conditioning regimen (P = 0.046. Unfavorable factors were > or = 25 transfusions pre-transplant (P = 0.011 and degree of HLA disparity (P = 0.007. Intensity of mucositis (P = 0.50 and use of androgen prior to transplant had no influence on survival (P = 0.80. Acute graft-versus-host disease (GVHD grade II-IV and chronic GVHD were diagnosed in 47 and 23% of available patients, respectively, and infections prevailed as the main cause of death, associated or not with GVHD. Eighteen patients are alive, the Kaplan-Meyer overall survival is 38% at ~8 years, and the best results were obtained with related non-sibling bone marrow patients. Three recommendations emerged from the present study: fludarabine as part of conditioning, transplant in patients with <25 transfusions and avoidance of HLA disparity. In addition, an extended family search (even when consanguinity is not present seeking for a related non-sibling donor is highly recommended.

  10. ßS-Haplotypes in sickle cell anemia patients from Salvador, Bahia, Northeastern Brazil

    Directory of Open Access Journals (Sweden)

    Gonçalves M.S.

    2003-01-01

    Full Text Available ßS-Globin haplotypes were studied in 80 (160 ßS chromosomes sickle cell disease patients from Salvador, Brazil, a city with a large population of African origin resulting from the slave trade from Western Africa, mainly from the Bay of Benin. Hematological and hemoglobin analyses were carried out by standard methods. The ßS-haplotypes were determined by PCR and dot-blot techniques. A total of 77 (48.1% chromosomes were characterized as Central African Republic (CAR haplotype, 73 (45.6% as Benin (BEN, 1 (0.63% as Senegal (SEN, and 9 (5.63% as atypical (Atp. Genotype was CAR/CAR in 17 (21.3% patients, BEN/BEN in 17 (21.3%, CAR/BEN in 37 (46.3%, BEN/SEN in 1 (1.25%, BEN/Atp in 1 (1.25%, CAR/Atp in 6 (7.5%, and Atp/Atp in 1 (1.25%. Hemoglobin concentrations and hematocrit values did not differ among genotype groups but were significantly higher in 25 patients presenting percent fetal hemoglobin (%HbF > or = 10% (P = 0.002 and 0.003, respectively. The median HbF concentration was 7.54 ± 4.342% for the CAR/CAR genotype, 9.88 ± 3.558% for the BEN/BEN genotype, 8.146 ± 4.631% for the CAR/BEN genotype, and 4.180 ± 2.250% for the CAR/Atp genotype (P = 0.02, although 1 CAR/CAR individual presented an HbF concentration as high as 15%. In view of the ethnic and geographical origin of this population, we did not expect a Hardy-Weinberg equilibrium for CAR/CAR and BEN/BEN homozygous haplotypes and a high proportion of heterozygous CAR/BEN haplotypes since the State of Bahia historically received more slaves from Western Africa than from Central Africa.

  11. AN UNUSUAL CASE OF ASYMPTOMATIC APLASTIC RENAL DYSPLASIA

    Institute of Scientific and Technical Information of China (English)

    LouisTsun-CheungChow; Wing-HingChow

    1995-01-01

    The postmortem examination of a 59-year-old man who had suffered from acute abdominal pain for two days revealed that the cause of death was peritonitis secondary to perforated peptic ulceration. During examination,it was found that the urinary tract was abnormal. Here,we report a postmortem finding of aplastic renal dysplasia of the kidney and malformation of Lhe urinary tract.

  12. Inborn anemias in mice

    International Nuclear Information System (INIS)

    hereditary anemias of mice have been the chief objects of investigation. At present under study are four macrocytic anemias, five hemolytic anemias, nonhemolytic microcytic anemia, transitory siderocytic anemia, sex-linked iron-transport anemia, an α-thalassemia, and a new target-cell anemia. Each of these blood dyscrasias is caused by the action of a unique mutant gene, which determines the structure of different intracellular molecules, and thus controls a different metabolic process. Thus our wide range of different hereditary anemias has considerable potential for uncovering many different aspects of hemopoietic homeostatic mechanisms in the mouse. Each anemia is studied through: (a) characterization of peripheral blood values, (b) determinations of radiosensitivity under a variety of conditions, (c) measurements of iron metabolism and heme synthesis, (d) histological and biochemical study of blood-forming tissue, (e) functional tests of the stem cell component, (f) examination of responses to erythroid stimuli, and (g) transplantation of tissue between individuals of differently affected genotypes

  13. CQI in anemia management: using the fishbone approach to improve outcomes. Case study of the anemic patient.

    Science.gov (United States)

    Breiterman-White, R

    1999-04-01

    Anemia management outcomes can be improved through a concentrated effort by nephrology nurses and other members of the nephrology team. This article focuses on the use of a Fishbone CQI diagram that can help clinicians identify and manage specific etiologies that effect erythropoiesis.

  14. CQI in anemia management: using the fishbone approach to improve outcomes. Case study of the anemic patient.

    Science.gov (United States)

    Breiterman-White, R

    1999-04-01

    Anemia management outcomes can be improved through a concentrated effort by nephrology nurses and other members of the nephrology team. This article focuses on the use of a Fishbone CQI diagram that can help clinicians identify and manage specific etiologies that effect erythropoiesis. PMID:10418356

  15. Risk Factors of Neonatal Anemia in Placenta Previa

    Directory of Open Access Journals (Sweden)

    Dong Gyu Jang, Yun Sung Jo, Sung Jong Lee, Gui Se Ra Lee

    2011-01-01

    Full Text Available Objectives: Placenta previa is a major cause of neonatal anemia. The purpose of this study was to elucidate the risk factors of neonatal anemia in placenta previa.Methods: The study was conducted on 158 placenta previa patients at 3 hospitals in affiliation with the Catholic Medical Center, Seoul, Korea from May 1999 through December 2009. The subjects were divided in to 2 groups: 47 placenta previa patients with neonatal anemia, and 113 placenta previa patients without neonatal anemia. The subjects' characteristics were compared. Logistic regression was used to control for confounding factors.Results: Anterior placental location (OR 2.48; 95% CI: 1.20-5.11 was an independent risk factor of neonatal anemia after controlling for potential confounders.Conclusion: To manage neonatal anemia in placenta previa patients, obstetricians should do their best to detect placental location. Pediatricians should consider the high possibility of neonatal anemia in cases involving anterior placental location.

  16. Hereditary nonspherocytic hemolytic anemia caused by red cell glucose-6-phosphate isomerase (GPI) deficiency in two Portuguese patients: Clinical features and molecular study.

    Science.gov (United States)

    Manco, Licínio; Bento, Celeste; Victor, Bruno L; Pereira, Janet; Relvas, Luís; Brito, Rui M; Seabra, Carlos; Maia, Tabita M; Ribeiro, M Letícia

    2016-09-01

    Glucose-6-phosphate isomerase (GPI) deficiency cause hereditary nonspherocytic hemolytic anemia (HNSHA) of variable severity in individuals homozygous or compound heterozygous for mutations in GPI gene. This work presents clinical features and genotypic results of two patients of Portuguese origin with GPI deficiency. The patients suffer from a mild hemolytic anemia (Hb levels ranging from 10 to 12.7g/mL) associated with macrocytosis, reticulocytosis, hyperbilirubinemia, hyperferritinemia and slight splenomegaly. Genomic DNA sequencing revealed in one patient homozygosity for a new missense mutation in exon 3, c.260G>C (p.Gly87Ala), and in the second patient compound heterozygosity for the same missense mutation (p.Gly87Ala), along with a frameshift mutation resulting from a single nucleotide deletion in exon 14, c.1238delA (p.Gln413Arg fs*24). Mutation p.Gln413Arg fs*24 is the first frameshift null mutation to be described in GPI deficiency. Molecular modeling suggests that the structural change induced by the p.Gly87Ala pathogenic variant has direct impact in the structural arrangement of the region close to the active site of the enzyme. PMID:27519939

  17. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen

    Directory of Open Access Journals (Sweden)

    Galactéros Frédéric

    2011-05-01

    Full Text Available Abstract Background Hydroxyurea (HU is the first approved pharmacological treatment of sickle cell anemia (SCA. The objectives of this study were to develop population pharmacokinetic(PK-pharmacodynamic(PD models for HU in order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by simulations and develop some recommendations for monitoring the treatment. Methods The models were built using population modelling software NONMEM VII based on data from two clinical studies of SCA adult patients receiving 500-2000 mg of HU once daily. Fetal hemoglobin percentage (HbF% and mean corpuscular volume (MCV were used as biomarkers for response. A sequential modelling approach was applied. Models were evaluated using simulation-based techniques. Comparisons of two dosing regimens were performed by simulating 10000 patients in each arm during 12 months. Results The PK profiles were described by a bicompartmental model. The median (and interindividual coefficient of variation (CV of clearance was 11.6 L/h (30%, the central volume was 45.3 L (35%. PK steady-state was reached in about 35 days. For a given dosing regimen, HU exposure varied approximately fivefold among patients. The dynamics of HbF% and MCV were described by turnover models with inhibition of elimination of response. In the studied range of drug exposures, the effect of HU on HbF% was at its maximum (median Imax was 0.57, CV was 27%; the effect on MCV was close to its maximum, with median value of 0.14 and CV of 49%. Simulations showed that 95% of the steady-state levels of HbF% and MCV need 26 months and 3 months to be reached, respectively. The CV of the steady-state value of HbF% was about 7 times larger than that of MCV. Simulations with two different dosing regimens showed that continuous dosing led to a stronger HbF% increase in some patients. Conclusions The high variability of response to HU was related in part to pharmacokinetics and

  18. Molecular analysis and pathogenesis of the feline aplastic anemia retrovirus, feline leukemia virus C-Sarma.

    OpenAIRE

    N. Riedel; Hoover, E. A.; Gasper, P W; Nicolson, M O; Mullins, J I

    1986-01-01

    We describe the molecular cloning of an anemogenic feline leukemia virus (FeLV), FeLV-C-Sarma, from the productively infected human rhabdomyosarcoma cell line RD(FeLV-C-S). Molecularly cloned FeLV-C-S proviral DNA yielded infectious virus (mcFeLV-C-S) after transfection of mammalian cells, and virus interference studies using transfection-derived virus demonstrated that our clone encodes FeLV belonging to the C subgroup. mcFeLV-C-S did not induce viremia in eight 8-week-old outbred specific-p...

  19. Evaluation of nonsurgical periodontal therapy in chronic periodontitis patients with anemia by estimating hematological parameters and high-sensitivity C-reactive protein levels

    Directory of Open Access Journals (Sweden)

    S V V S Musalaiah

    2014-01-01

    Full Text Available Background: Periodontal tissues mount an immune inflammatory response to bacteria and their products. Certain inflammatory cytokines produced during periodontal inflammation increase the production of acute phase proteins like high-sensitivity C-reactive protein (hs-CRP and can depress erythropoietin production leading to the development of anemia. Aim: The aim of this study is to investigate the efficacy of nonsurgical periodontal therapy on red blood cell (RBC parameters and hs-CRP in chronic periodontitis patients with anemia. Materials and Methods: This is a longitudinal, interventional study with 6-month follow-up. A total of 30 subjects with anemia and chronic periodontitis with age group of 33-55 years were selected by screening hemoglobin (Hb levels and examining periodontal findings. The clinical parameters plaque index (PI, gingival index (GI, probing pocket depth (PPD and clinical attachment level (CAL were recorded at baseline. Laboratory blood investigations were performed to evaluate RBC count, Hb, packed cell volume (PCV, erythrocyte sedimentation rate (ESR and red cell indices, hs-CRP at baseline. Nonsurgical periodontal therapy was performed for all patients. Patients were recalled after 6 months. The clinical and hematological parameters were re-evaluated to analyze the changes after nonsurgical periodontal therapy. Results: The results showed that there was a significant increase in Hb levels, RBC count and PCV from baseline to 6 months after nonsurgical periodontal therapy. There is significant decrease in levels of ESR and hs-CRP levels after nonsurgical periodontal therapy indicating resolution of periodontal inflammation. There is a significant decrease in PPD, scores of PI and GI and significant increase in CAL gain. Minimal changes in mean corpuscular volume, mean corpuscular hemoglobin (MCH and MCH concentration indicated that the lower values of red cell parameters are not due to any vitamin and mineral deficiencies

  20. MA和AIHA患者LDH和RET%检测的临床意义%Detection and clinical significance of serum LDH level and reticulocyte percentage in the megaloblastic anemia and autoimmune hemolytic anemia patients

    Institute of Scientific and Technical Information of China (English)

    马丽娜; 李兴; 杨晓阳; 崔晓红; 吴和弟

    2012-01-01

    目的 通过检测巨幼细胞贫血(MA)和自身免疫性溶血性贫血(AIHA)患者血清乳酸脱氢酶(LDH)和网织红细胞百分比(RET%),探讨LDH和RET%在MA和AIHA诊断中的作用.方法 对40例MA组、30例AIHI组以及40例正常对照组LDH、RET%的水平变化作回顾性分析比较.结果 MA组、AIHI组血清LDH水平明显高于正常组,差异有统计学意义(均P<0.01);MA组LDH明显高于AIHI组,差异有统计学意义(P<0.01); AIHI组RET%明显高于MA组和正常组,差异有统计学意义(P<0.01);MA组RET%与正常组对比无差异(P>0.05).结论 血清LDH和RET%水平对临床鉴别MA和AIHA具有临床指导意义.%Objective In older to identify the clinical diagnosis significance of serum lactate dehydrogenase (LDH) and reticulocyte percentage (RET%)in patients of megaloblastic anemia (MA)and autoimmune hemolytic anemia (AIHA). Methods The serum lactate dehydrogenase(LDH)and reticulocyte percentage(RET%)levels of the 40 MA group,30 AIHI group and 40 normal group,were retrospectively compared and analyzed. Results LDH levels were significantly higher in the MA and AIHI group than the normal group's (P<0.0l). Meanwhile,the levels of LDH were also significantly different between the MA group and the AIHA group (P<0.0l). RET% levels were significantly higher in the AIHA group than the levels of MA and normal group (P<0.01) but RET% levels were not different between the MA group and the normal group (P>0.05). Conclusion The levels of Serum LDH and RET% are important for the clinical diagnosis of MA and AIHA patients.

  1. Sickle cell anemia.

    OpenAIRE

    ŘÍHOVÁ, Tereza

    2013-01-01

    This thesis is about the disease called sickle cell anemia, or drepanocytosis. In this thesis is described the history of the disease, pathophysiology, laboratory features, various clinical features, diferencial diagnosis, quality of life in sickle cell anemia and therapy.

  2. Cooley's Anemia Foundation

    Science.gov (United States)

    Cooley's Anemia Foundation Leading the Fight against Thalassemia About Us Mission/Purpose History About Thomas Benton Cooley Medical Research ... Gabriella was diagnosed with thalassemia, and the Cooley’s Anemia Foundation continues to play an almost-daily role ...

  3. Anemia and Pregnancy

    Science.gov (United States)

    ... most recent scientific research View all publications Home Anemia and Pregnancy Your body goes through significant changes ... becoming anemic. back to top Is Pregnancy-Related Anemia Preventable? Good nutrition is the best way to ...

  4. Anemia in the Newborn

    Science.gov (United States)

    ... Video) Meconium Aspiration Syndrome Additional Content Medical News Anemia in the Newborn By Arthur E. Kopelman, MD ... Prematurity (ROP) Necrotizing Enterocolitis (NEC) Jaundice in Newborns Anemia in the Newborn Polycythemia in the Newborn Thyroid ...

  5. Iron-Deficiency Anemia

    Medline Plus

    Full Text Available ... Deficiency Anemia What Is... CAUSES WHO IS AT RISK SIGNS & SYMPTOMS DIAGNOSIS TREATMENTS PREVENTION LIVING WITH CLINICAL ... and women are the two groups at highest risk for iron-deficiency anemia. Outlook Doctors usually can ...

  6. Iron-Deficiency Anemia

    Medline Plus

    Full Text Available ... This Content: NEXT >> Featured Video Living With and Managing Iron-Deficiency Anemia 05/18/2011 This video— ... treatment. For more information about living with and managing iron-deficiency anemia, go to the Health Topics ...

  7. CORRELATION STUDY BETWEEN BONE MARROW IRON AND SERUM IRON AND SERUM FERRITIN IN PATIENTS OF MODERATE TO SEVERE ANEMIA

    OpenAIRE

    Ankita; Nigam; Reeni; Jain; Atul

    2014-01-01

    BACKGROUND: Iron deficiency anemia is one of the most prevalent forms of malnutrition. The list of diagnostic tools is quite long starting from the basic hemogram, p.s for comment, reticulocyte count to iron studies including serum ferritin, serum iron, total iron binding capacity. Evaluation of the bone marrow iron stores is the gold standard. AIM: To perform a correlation study between Perl’s Prussian blue stained bone marrow aspirate smears and serum iron and serum ferr...

  8. Epidural anesthesia for laparoscopic cholecystectomy in a patient with sickle cell anemia, beta thalassemia, and Crohn's disease -A case report-

    OpenAIRE

    Baş, Sema Şanal; Özlü, Onur

    2012-01-01

    A 37-year-old woman diagnosed with sickle cell anemia (SCA), beta (+) thalassemia, Crohn's disease, and liver dysfunction was scheduled for laparoscopic cholecystectomy (LC) due to acute cholecystitis with gall bladder. Regional anesthesia was performed. An epidural catheter was inserted into the 9-10 thoracal epidural space and then 15 ml of 0.5% bupivacaine was injected through the catheter. The level of sensorial analgesia tested with pinprick test reached up to T4. Here we describe the fi...

  9. Iron-Deficiency Anemia

    Science.gov (United States)

    ... page from the NHLBI on Twitter. What Is Iron-Deficiency Anemia? Español Iron-deficiency anemia is a common, ... Content: NEXT >> Featured Video Living With and Managing Iron-Deficiency Anemia 05/18/2011 This video—presented by ...

  10. Iron-Deficiency Anemia

    Medline Plus

    Full Text Available ... the NHLBI on Twitter. What Is Iron-Deficiency Anemia? Español Iron-deficiency anemia is a common, easily ... Featured Video Living With and Managing Iron-Deficiency Anemia 05/18/2011 This video—presented by the ...

  11. Iron-Deficiency Anemia

    Medline Plus

    Full Text Available ... body. Low iron levels usually are due to blood loss, poor diet, or an inability to absorb enough iron from food. Overview Iron-deficiency anemia is a common type of anemia . The term "anemia" usually refers to ...

  12. Novel nonsense mutation (p.Ile411Metfs*12) in the SLC19A2 gene causing Thiamine Responsive Megaloblastic Anemia in an Indian patient.

    Science.gov (United States)

    Manimaran, Paramasivam; Subramanian, Veedamali S; Karthi, Sellamuthu; Gandhimathi, Krishnan; Varalakshmi, Perumal; Ganesh, Ramasamy; Rathinavel, Andiappan; Said, Hamid M; Ashokkumar, Balasubramaniem

    2016-01-15

    Thiamine-responsive megaloblastic anemia (TRMA), an autosomal recessive disorder, is caused by mutations in SLC19A2 gene encodes a high affinity thiamine transporter (THTR-1). The occurrence of TRMA is diagnosed by megaloblastic anemia, diabetes mellitus, and sensorineural deafness. Here, we report a female TRMA patient of Indian descent born to 4th degree consanguineous parents presented with retinitis pigmentosa and vision impairment, who had a novel homozygous mutation (c.1232delT/ter422; p.Ile411Metfs*12) in 5th exon of SLC19A2 gene that causes premature termination of hTHTR-1. PROSITE analysis predicted to abrogate GPCRs family-1 signature motif in the variant by this mutation c.1232delT/ter422, suggesting uncharacteristic rhodopsin function leading to cause RP clinically. Thiamine transport activity by the clinical variant was severely inhibited than wild-type THTR-1. Confocal imaging had shown that the variant p.I411Mfs*12 is targeted to the cell membrane and showed no discrepancy in membrane expression than wild-type. Our findings are the first report, to the best of our knowledge, on this novel nonsense mutation of hTHTR-1 causing TRMA in an Indian patient through functionally impaired thiamine transporter activity. PMID:26549656

  13. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

    Directory of Open Access Journals (Sweden)

    Ávila-Albuerne Yisel

    2005-05-01

    Full Text Available Abstract Background Recombinant human erythropoietin (EPO is used for the treatment of last stage renal anemia. A new EPO preparation was obtained in Cuba in order to make this treatment fully nationally available. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of two recombinant EPO formulations in patients with anemia due to end-stage renal disease on hemodialysis. Methods A parallel, randomized, double blind study was performed. A single 100 IU/Kg EPO dose was administered subcutaneously. Heberitro (Heber Biotec, Havana, formulation A, a newly developed product and Eprex (CILAG AG, Switzerland, formulation B, as reference treatment were compared. Thirty-four patients with anemia due to end-stage renal disease on hemodialysis were included. Patients had not received EPO previously. Serum EPO level was measured by enzyme immunoassay (EIA during 120 hours after administration. Clinical and laboratory variables were determined as pharmacodynamic and safety criteria until 216 hours. Results Both groups of patients were similar regarding all demographic and baseline characteristics. EPO kinetics profiles were similar for both formulations; the pharmacokinetic parameters were very close (i.e., AUC: 4667 vs. 4918 mIU.h/mL; Cmax: 119.1 vs. 119.7 mIU/mL; Tmax: 13.9 vs. 18.1 h; half-life, 20.0 vs. 22.5 h for formulations A and B, respectively. The 90% confidence intervals for the ratio between both products regarding these metrics were close to the 0.8 – 1.25 range, considered necessary for bioequivalence. Differences did not reach 20% in any case and were not determined by a formulation effect, but probably by a patients' variability effect. Concerning pharmacodynamic features, a high similitude in reticulocyte counts increments until 216 hours and the percentage decrease in serum iron until 120 hours was observed. There were no differences between formulations regarding the adverse events and their

  14. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

    Science.gov (United States)

    Pérez-Oliva, Jorge F; Casanova-González, Martha; García-García, Idrian; Porrero-Martín, Pedro J; Valenzuela-Silva, Carmen M; Hernández-Montero, Tairí; Lagarde-Ampudia, Marcia; Casanova-Kutsareva, Yuri; Ávila-Albuerne, Yisel; Vargas-Batista, Alicia; Bobillo-López, Hailen; Herrera-Valdés, Raúl; López-Saura, Pedro A

    2005-01-01

    Background Recombinant human erythropoietin (EPO) is used for the treatment of last stage renal anemia. A new EPO preparation was obtained in Cuba in order to make this treatment fully nationally available. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of two recombinant EPO formulations in patients with anemia due to end-stage renal disease on hemodialysis. Methods A parallel, randomized, double blind study was performed. A single 100 IU/Kg EPO dose was administered subcutaneously. Heberitro (Heber Biotec, Havana, formulation A), a newly developed product and Eprex (CILAG AG, Switzerland, formulation B), as reference treatment were compared. Thirty-four patients with anemia due to end-stage renal disease on hemodialysis were included. Patients had not received EPO previously. Serum EPO level was measured by enzyme immunoassay (EIA) during 120 hours after administration. Clinical and laboratory variables were determined as pharmacodynamic and safety criteria until 216 hours. Results Both groups of patients were similar regarding all demographic and baseline characteristics. EPO kinetics profiles were similar for both formulations; the pharmacokinetic parameters were very close (i.e., AUC: 4667 vs. 4918 mIU.h/mL; Cmax: 119.1 vs. 119.7 mIU/mL; Tmax: 13.9 vs. 18.1 h; half-life, 20.0 vs. 22.5 h for formulations A and B, respectively). The 90% confidence intervals for the ratio between both products regarding these metrics were close to the 0.8 – 1.25 range, considered necessary for bioequivalence. Differences did not reach 20% in any case and were not determined by a formulation effect, but probably by a patients' variability effect. Concerning pharmacodynamic features, a high similitude in reticulocyte counts increments until 216 hours and the percentage decrease in serum iron until 120 hours was observed. There were no differences between formulations regarding the adverse events and their intensity. The more

  15. A Study of Pancytopenia in Adult Patients More than 12 Years of Age in North West Region of Saurashtra

    Directory of Open Access Journals (Sweden)

    Bhaskar B Thakkar

    2013-02-01

    Full Text Available Introduction: Pancytopenia is a manifestation of many serious & life threatening diseases with an extensive differential diagnosis. Major causes of pancytopenia in developing countries are megaloblastic anemia, parasitic infection, hypersplenism and aplastic anemia. Methodology: In this study total 100 cases were studied by examining Peripheral smears of blood samples obtained by routine phlebotomy procedure and stained by Romanowsky stains. Bone marrow sampleswere obtained by routine bone marrow aspiration and biopsy procedures if indicated. Biochemical and other special investigations were done to confirm the diagnosis. Results: Among the 100 cases studied, age of the patients ranged from 13 to 86 years with a mean age of 42.9 years and slight male predominance. Most of the patients presented with generalized weakness and fever. The commonest physical finding was pallor, followed by splenomegaly and hepatomegaly. The commonest marrow finding was hypercellularity with megaloblastic erythropoiesis. The commonest cause for pancytopenia was megaloblastic anemia followed by malaria. Conclusion: The present study concludes that detailed primary hematological investigations along with other supportive tests are helpful to diagnose or to rule out the causes of pancytopenia. Megloblatic anemia is commnest cause of pancytopenia in most Indian and subcontinent studies. Present study also shows that invasive procedures like bone marrow aspiration and biopsy is avoided in most cases of pancytopenia. [Natl J of Med Res 2013; 3(1.000: 48-52

  16. Iron-deficiency anemia caused by a proton pump inhibitor.

    Science.gov (United States)

    Hashimoto, Rintaro; Matsuda, Tomoki; Chonan, Akimichi

    2014-01-01

    A 59-year-old man was orally administered rabeprazole, a proton pump inhibitor (PPI), for gastroesophageal reflux disease, after which he gradually developed iron-deficiency anemia. The anemia did not improve following the administration of ferrous fumarate, and endoscopic screening of the entire gastrointestinal tract, including the small intestine, did not reveal any findings indicating the cause of the anemia. The patient was then switched from rabeprazole to famotidine and the anemia was cured within three months. There is much debate as to whether the long-term use of PPIs causes iron-deficiency. However, this case strongly suggests that PPIs can induce iron-deficiency anemia.

  17. The Evidence-Based Evaluation of Iron Deficiency Anemia.

    Science.gov (United States)

    Hempel, Eliana V; Bollard, Edward R

    2016-09-01

    Anemia is a prevalent disease with multiple possible etiologies and resultant complications. Iron deficiency anemia is a common cause of anemia and is typically due to insufficient intake, poor absorption, or overt or occult blood loss. Distinguishing iron deficiency from other causes of anemia is integral to initiating the appropriate treatment. In addition, identifying the underlying cause of iron deficiency is also necessary to help guide management of these patients. We review the key components to an evidence-based, cost-conscious evaluation of suspected iron deficiency anemia. PMID:27542426

  18. Clinical observational study of anemia in mechanically ventilated patients%机械通气患者贫血的临床观察研究

    Institute of Scientific and Technical Information of China (English)

    王美平; 姜利; 朱波; 姜琦; 席修明

    2012-01-01

    目的 观察贫血对机械通气患者预后的影响.方法 采用前瞻性研究方法,收集入住重症监护病房(ICU)预计机械通气时间≥72 h,血红蛋白(Hb)浓度≥100 g/L的患者.根据患者机械通气第3日的Hb浓度分为贫血组和非贫血组.比较两组患者1、3、7d血清促红细胞生成素(EPO)、Fe3+、转铁蛋白(TRF)水平,14 d 内人均输血量,3、7、14 d内人均日采血量以及机械通气时间、28 d脱机存活率、住院时间和28 d病死率.结果 共入选40例患者,贫血组18例,非贫血组22例.与非贫血组比较,贫血组患者血清Fe3+较低,血清EPO、TRF较高;贫血组患者14 d内人均输血量(U)较多[4.0(2.0,6.0)比2.0 (0.0,2.0),P<0.01],ICU病死率较高(44.4%比13.6%,P<0.05),住院时间(d)较长[35.0( 16.5,51.6)比24.5( 10.0,35.8),P< 0.05 ],28 d脱机存活率较低(44.4%比72.7%,P< 0.05).而贫血组和非贫血组机械通气时间(d:18.3±10.8比11.6±8.2,P>0.05)、ICU住院时间[d:16.5(8.0,21.5)比11.0(5.8,18.3),P>0.05]和住院病死率(61.1%比31.8%,P>0.05)比较差异无统计学意义.结论 贫血患者机械通气时间及住院时间较长,ICU病死率较高,28 d脱机存活率较低.%Objective To explore the prognostic effects of anemia among the mechanically ventilated patients.Methods A prospective observational study was undertaken in a 12-bed intensive care unit (ICU).Patients requiring mechanical ventilation for at least 72 hours and hemoglobin (Hb)≥100 g/L were enrolled.Serum erythropoietin (EPO),Fe3+,transferrin (TRF) levels were measured as baseline when they were enrolled and were repeated at day 3,7 and 14.According to Hb concentration at day 3,patients were divided into anemia group (defined as Hb< 100 g/L)and non-anemia group.Serum EPO,Fe3+,TRF at day 1,3 and 7,and mean amount of blood transfusion within 14 days,mean volume of blood drawn daily in 3,7 and 14 days,the survival rate with unassisted breathing at day 28,ICU mortality

  19. Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin Anemia hemolítica auto-imune durante o tratamento da hepatite crônica com interferon peguilado alfa 2a e ribavirina, em pacientes com co-infecção HCV/HIV

    Directory of Open Access Journals (Sweden)

    Fernando Crivelenti Vilar

    2007-12-01

    Full Text Available Two cases of autoimmune hemolytic anemia that occurred during the treatment of chronic hepatitis C with pegylated alpha-2a interferon and ribavirin, in HIV coinfected patients, are presented and described. The late occurrence (after six months of therapy of this severe hemolytic anemia leads to the recommendation that hemoglobin levels should be monitored throughout the treatment period, even among patients who presented stable hemoglobin levels in the preceding months.São apresentados e discutidos dois casos de anemia hemolítica auto-imune que ocorreram durante o tratamento da hepatite crônica pelo vírus C, com interferon peguilado alfa 2a e ribavirina, em pacientes co-infectados pelo HIV. A ocorrência de anemia hemolítica grave em etapa tardia, após o sexto mês da terapêutica, recomenda que o controle dos níveis de hemoglobina deva ser feito durante todo o período do tratamento , mesmo nos pacientes que apresentam níveis estáveis de hemoglobina nos meses precedentes.

  20. The cardio-renal anemia syndrome

    Directory of Open Access Journals (Sweden)

    Dimković Siniša

    2007-01-01

    Full Text Available Introduction. The problem of anemia in congestive heart failure and chronic kidney disease was thought to be insignificant for a long period of time. Recent investigations pointed out that the problem of anemia should be defined in the context of the cardio-renal anemia syndrome. A positive feedback mechanism indicates that cardio-renal anemia syndrome is due to an interaction between congestive heart failure, chronic renal failure and anemia. The aim of the study was to present the possible pathophysiological mechanisms of this syndrome, epidemiological characteristics and therapeutic results of the former investigations. Results. The results of the retrospective and prospective controlled trails have shown that management of anemia with subcutaneous administration of recombinant human erythropoietin together with intravenous iron infusion for at least 3-6 months lead to: relief of symptoms (improved NYHA functional class; increased left ventricular ejection fraction; reduced cardiovascular morbidity and mortality; reduced number of rehospitalizations; reduced requirements for usual therapeutic agents (especially diuretics; and improved renal function. Conclusion. In patients with heart and kidney disease anemia should be routinely identified and appropriately treated. Subcutaneous recombinant erythropoietin and intravenous iron may significantly improve overall survival and quality of life of these patients. .

  1. Determination of βS haplotypes in patients with sickle-cell anemia in the state of Rio Grande do Norte, Brazil

    Directory of Open Access Journals (Sweden)

    Cynthia Hatsue Kitayama Cabral

    2011-01-01

    Full Text Available βS haplotypes were studied in 47 non-related patients with sickle-cell anemia from the state of Rio Grande do Norte, Brazil. Molecular analysis was conducted by PCR/RFLP using restriction endonucleases XmnI, HindIII, HincII and HinfI to analyze six polymorphic sites from the beta cluster. Twenty-seven patients (57.5% were identified with genotype CAR/CAR, 9 (19.1% CAR/BEN, 6 (12.8% CAR/CAM, 1 (2.1% BEN/BEN, 2 (4.3% CAR/Atp, 1 (2.1% BEN/Atp and 1 (2.1% with genotype Atp/Atp. The greater frequency of Cameroon haplotypes compared to other Brazilian states suggests the existence of a peculiarity of African origin in the state of Rio Grande do Norte.

  2. Prognostic Impact of Anemia in Patients with Cervical Cancer%贫血与子宫颈癌预后的关系

    Institute of Scientific and Technical Information of China (English)

    赵辉; 孔为民

    2011-01-01

    Objective:To study the prognostic factor and evaluate the effect of anemia on disease-free survival in patients with cervical cancer. Methods: The clinical data of 291 patients with cervical cancer were analyzed retrospectively. Age, weight,blood type, histological type, International Federation of Gynecology and obstetrics (FIGO) stage, histological grade, the first treatment, anemia, the time of operation, blood loss, blood transfusion, the kind of blood transfusion were studied. Univariate analysis and multivariate Cox proportional hazards regression models were used. Results: The univariate analysis showed that tumor differentiation, tumor size, age, blood transfusion, anemia and FIGO stage had significant effect on prognosis, while age, weight, blood type, pathological type, the first treatment method, operative time, blood loss, and blood transfusion had not. Multivariate Cox model analysis showed that the independent factors include FIGO stage and tumor differentiation. Conclusions: FIGO stage and tumor differentiation are the independent factors of patients with cervical cancer. Anemia may affect the prognosis of cervical cancer, however, multivariate analysis in this study do not prove that anemia is the independent prognostic factors.%目的:探讨子宫颈癌患者的预后相关因素,研究贫血对子宫颈癌患者无病生存期(disease free survival,DFS)的影响,为子宫颈癌合并贫血患者的治疗提供参考.方法:回顾分析291例有病理诊断、完整随访的子宫颈癌患者的临床资料,以无病生存期为观察指标,将年龄、体质量、血型、病理类型、国际妇产科协会(FIGO)分期、分化程度、首次治疗方式、是否贫血、手术时间、术中出血量、是否输血、输血种类、输血量等纳入寿命表.计算1年、2年和5年生存率,通过单因素Kaplan-Meier法进行分析,多因素分析采用Cox比例风险回归模型.结果:单因素分析显示肿瘤分化程度、肿瘤大小

  3. Embolic Stroke due to a Common Carotid Artery Thrombus in a Young Patient with Severe Iron-Deficiency Anemia without Thrombocytosis

    Science.gov (United States)

    2016-01-01

    This case report describes a 41-year-old previously healthy male who presented with stuttering transient ischemic symptoms and radiographic evidence of a left common carotid artery thrombus as well as acute and subacute ischemic infarcts in the left middle cerebral artery territory. An exhaustive stroke work-up did not provide a plausible etiology for his symptoms. His complete blood count and iron studies, however, revealed evidence of severe iron-deficiency anemia without reactive thrombocytosis. His stool guaiac test was positive. He was discharged home on oral antithrombotic agents and aggressive iron replacement therapy with a plan for repeat vascular imaging in 3 months and a colonoscopy. This case report suggests that severe iron-deficiency anemia with or without reactive thrombocytosis should be viewed as a possible hematologic condition associated with thrombotic tendencies and a risk factor for ischemic stroke, especially in young adults. Aggressive iron supplementation and short-term antithrombotic therapy with follow-up vascular imaging are a reasonable treatment for these patients.

  4. 探究骨髓细胞学检查在贫血诊断中的临床应用价值%Clinical Value of Bone Marrow Cytology in Diagnosis of Anemia

    Institute of Scientific and Technical Information of China (English)

    尹立

    2015-01-01

    目的 探究骨髓细胞学检查在基层医院临床贫血中的应用价值. 方法 回顾性分析2012年6月—2014年6月期间该院收治的105例贫血患者的临床资料,对105例贫血患者的骨髓细胞学检查结果进行分析,统计确诊率和贫血类型. 结果该次回顾性分析的105例患者中,确诊97例,不明原因8例,临床确诊率为92.38%;其中,缺铁性贫血32例(30.47%),急性白血病7例(6.67%)、再生障碍性贫血4例(3.81%)、骨髓增生异常综合征3例(2.85%)、溶血性贫血4例(3.81%)、感染性贫血11例(10.48%)、慢性粒细胞性白血病6例(5.71%)、巨幼红细胞性贫血4例(3.81%)、肝(肾)性贫血24例(22.86%)、淋巴瘤1例(0.95%)、多发性骨髓瘤1例(0.95%)、原因不明8例(7.62%). 结论 骨髓细胞学检查在诊断贫血、确定贫血分型方面具有积极意义,具有较高的临床应用价值.%Objective To explore the clinical value of bone marrow cytology in the diagnosis of anemia. Methods A retrospective analysis concerning the results of bone marrow cytology was carried out on the clinical data of 105 patients with anemia admitted to the hospital from June 2012 and June 2014 to determine the diagnosis rates and type of anemia. Results Of the 105 patients en-rolled in this study, in terms of the type of anemia, 97 were confirmed while 8 (7.62%) were not with a diagnosis rate of 92.38%. There were 32(30.47%) cases of iron deficiency anemia, 7(6.67%) cases of acute leukemias, 4(3.81%) cases of aplastic anemia, 3 (2.85%) cases of myelodysplastic syndromes, 4 (3.81%) cases of hemolytic anemia, 11 (10.48%)cases of infectious anemia, 6 (5.71%)cases of chronic myeloid leukemia, 4(3.81%) cases of megaloblastic anemia, 24(22.86%) cases of liver (kidney) anemia, 1 (0.95%)cases of lymphoma, 1 (0.95%)cases of multiple myeloma. Conclusion Bone marrow cytology can play a positive role in the diagnosis of anemia and in determining the type of anemia, therefore it is of high clinical

  5. Efficacy and Safety of Oral Lactoferrin Supplementation in Combination with rHuEPO-β for the Treatment of Anemia in Advanced Cancer Patients Undergoing Chemotherapy: Open-Label, Randomized Controlled Study

    Science.gov (United States)

    Madeddu, Clelia; Gramignano, Giulia; Mulas, Carlo; Sanna, Eleonora; Mantovani, Giovanni

    2010-01-01

    Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia of chronic inflammatory diseases characterized by specific changes in iron homeostasis and absorption. i.v. iron improves the efficacy of recombinant human erythropoietin (rHuEPO) in anemic cancer patients undergoing chemotherapy. We report the results of an open-label, randomized, prospective trial aimed at testing the efficacy and safety of treatment with oral lactoferrin versus i.v. iron, both combined with rHuEPO, for the treatment of anemia in a population of 148 advanced cancer patients undergoing chemotherapy. All patients received s.c. rHuEPO-β, 30,000 UI once weekly for 12 weeks, and were randomly assigned to ferric gluconate (125 mg i.v. weekly) or lactoferrin (200 mg/day). Both arms showed a significant hemoglobin increase. No difference in the mean hemoglobin increase or the hematopoietic response, time to hematopoietic response, or mean change in serum iron, C-reactive protein, or erythrocyte sedimentation rate were observed between arms. In contrast, ferritin decreased in the lactoferrin arm whereas it increased in the i.v. iron arm. In conclusion, these results show similar efficacy for oral lactoferrin and for i.v. iron, combined with rHuEPO, for the treatment of anemia in advanced cancer patients undergoing chemotherapy. PMID:20647390

  6. Pyrexia due to megaloblastic anemia: An Unusual Case

    OpenAIRE

    Singh PS, Vijay Verma, Vidyasagar, Granth Kumar

    2014-01-01

    Postmenopausal vegetarian female presented with short febrile illness associated with generalized weakness Clinical and investigative findings evidenced megaloblastic anemia Since none of investigations could pinpoint the cause for pyrexia and patient did not respond to empirical antibiotic and conservative antimalarial therapy, megaloblastic anemia itself was suspected to be cause for febrile episode Patient was treated with parenteral B12 and oral folic acid for megaloblastic anemia an...

  7. Does the extracorporeal circulation worsen anemia in hemodialysis patients? Investigation with advanced microscopes of red blood cells drawn at the beginning and end of dialysis

    Directory of Open Access Journals (Sweden)

    Stamopoulos D

    2013-10-01

    Full Text Available Dimosthenis Stamopoulos,1 Nerantzoula Bakirtzi,2,3 Efthymios Manios,1 Eirini Grapsa41Institute of Advanced Materials, Physicochemical Processes, Nanotechnology and Microsystems, National Center for Scientific Research 'Demokritos,' Athens, Greece; 2Department of Nephrology, Hospital 'G. Gennimatas,' Athens, Greece; 3Renal Unit, Hospital 'Alexandra,' Athens, Greece; 4Renal Unit, Hospital 'Aretaieion,' Athens, GreeceBackground: In hemodialysis (HD patients, anemia relates to three main factors: insufficient production of erythropoietin; impaired management of iron; and decreased lifespan of red blood cells (RBCs. The third factor can relate to structural deterioration of RBCs due to extrinsic (extracorporeal circuit; biochemical activation and/or mechanical stress during dialysis and intrinsic (uremic milieu; biochemical interference of the RBC membrane constituents with toxins mechanisms. Herein, we evaluate information accessed with advanced imaging techniques at the cellular level.Methods: Atomic force and scanning electron microscopes were employed to survey intact RBCs (iRBCs of seven HD patients in comparison to seven healthy donors. The extrinsic factor was investigated by contrasting pre- and post-HD samples. The intrinsic environment was investigated by comparing the microscopy data with the clinical ones.Results: The iRBC membranes of the enrolled HD patients were overpopulated with orifice-like (high incidence; typical size within 100–1,000 nm and crevice-like (low incidence; typical size within 500–4,000 nm defects that exhibited a statistically significant (P < 0.05 relative increase (+55% and +350%, respectively in respect to healthy donors. The relative variation of the orifice and crevice indices (mean population of orifices and crevices per top membrane surface between pre- and post-HD was not statistically significant (−3.3% and +4.5%, respectively. The orifice index correlates with the concentrations of urea, calcium, and

  8. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism

    Directory of Open Access Journals (Sweden)

    Dilek Torun

    2016-01-01

    Full Text Available The aim of this study was to investigate the effects of cinacalcet therapy on anemia parameters, bone mineral metabolism, left ventricular mass index (LVMI and parathyroid gland volume in hemodialysis (HD patients with secondary hyperparathyroidism. Twenty-five HD patients (M/F: 11/14, mean age: 45.2 ± 17.9 years, mean HD duration: 96.4 ± 32.7 months were included in this prospective pilot study. The indication to start calcimimetic therapy was persistent serum levels of parathyroid hormone (PTH >1000 pg/mL, refractory to intravenous (i.v. vitamin D and phosphate-binding therapy. The initial and one-year results of adjusted serum calcium (Ca +2 , phosphate (P, Ca × P product, PTH, hemoglobin (Hb and ferritin levels, transferrin saturation index (TSAT, median weekly erythropoietin (EPO dose, LVMI, and parathyroid volume by parathyroid ultrasonography were determined. There were no differences between pre- and post-treatment levels of serum Ca +2 (P = 0.853, P (P = 0.447, Ca × P product (P = 0.587, PTH (P = 0.273, ferritin (P = 0.153 and TSAT (P = 0.104. After 1 year of calcimimetic therapy, the Hb levels were significantly higher than the initial levels (P = 0.048. The weekly dose of EPO decreased with no statistical significance. The dose of cinacalcet was increased from 32.4 ± 12.0 to 60.0 ± 24.4 mg/day (P = 0.01. There were no differences between the pre- and post-treatment results regarding weekly vitamin D dose, parenteral iron dose, LVMI and parathyroid volume. The results of our study suggest that cinacalcet therapy might have an additional benefit in the control anemia in HD patients.

  9. Complement in hemolytic anemia.

    Science.gov (United States)

    Brodsky, Robert A

    2015-01-01

    Complement is increasingly being recognized as an important driver of human disease, including many hemolytic anemias. Paroxysmal nocturnal hemoglobinuria (PNH) cells are susceptible to hemolysis because of a loss of the complement regulatory proteins CD59 and CD55. Patients with atypical hemolytic uremic syndrome (aHUS) develop a thrombotic microangiopathy (TMA) that in most cases is attributable to mutations that lead to activation of the alternative pathway of complement. For optimal therapy, it is critical, but often difficult, to distinguish aHUS from other TMAs, such as thrombotic thrombocytopenic purpura; however, novel bioassays are being developed. In cold agglutinin disease (CAD), immunoglobulin M autoantibodies fix complement on the surface of red cells, resulting in extravascular hemolysis by the reticuloendothelial system. Drugs that inhibit complement activation are increasingly being used to treat these diseases. This article discusses the pathophysiology, diagnosis, and therapy for PNH, aHUS, and CAD.

  10. Inheritance of the Bantu/Benin haplotype causes less severe hemolytic and oxidative stress in sickle cell anemia patients treated with hydroxycarbamide.

    Science.gov (United States)

    Okumura, Jéssika V; Silva, Danilo G H; Torres, Lidiane S; Belini-Junior, Edis; Barberino, Willian M; Oliveira, Renan G; Carrocini, Gisele C S; Gelaleti, Gabriela B; Lobo, Clarisse L C; Bonini-Domingos, Claudia R

    2016-07-01

    Beta S-globin gene cluster haplotypes (β(S)-haplotypes) can modulate the response to hydroxycarbamide (HC) treatment in sickle cell anemia (SCA) patients. In Brazil, the most common haplotypes are Bantu and Benin, and both confer a poor prognosis for patients when untreated with HC. We evaluated oxidative and hemolytic biomarkers in 48 SCA patients undergoing HC treatment separated in three subgroups: Bantu/Bantu, Bantu/Benin and Benin/Benin haplotype. On the basis of reduced haptoglobin (HP) levels, patients with Bantu/Bantu haplotypes had 3.0% higher hemolysis degree when compared with those with Bantu/Benin haplotypes (P=0.01). The Benin/Benin patients had 53.6% greater lipid peroxidation index than the Bantu/Bantu patients (P=0.01) because of evaluated thiobarbituric acid reactive species levels. The Bantu/Benin subgroup had intermediate levels of hemolytic and oxidative stress markers compared with the homozygous subgroups. Through strict inclusion criteria adopted, as well as consolidated and well-described hemolytic and the oxidative parameters evaluated, we suggest a haplotype-interaction response to HC treatment mediated by a 'balance' between the genetic factors of each haplotype studied. PMID:26961071

  11. Laboratory Evaluation of Anemia

    OpenAIRE

    Wallerstein, Ralph O.

    1987-01-01

    The laboratory evaluation of anemia begins with a complete blood count and reticulocyte count. The anemia is then categorized as microcytic, macrocytic or normocytic, with or without reticulocytosis. Examination of the peripheral smear and a small number of specific tests confirm the diagnosis. The serum iron level, total iron-binding capacity, serum ferritin level and hemoglobin electrophoresis generally separate the microcytic anemias. The erythrocyte size-distribution width may be particul...

  12. Albuminuria as a Risk Factor for Anemia in Chronic Kidney Disease: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD.

    Directory of Open Access Journals (Sweden)

    Ji Suk Han

    Full Text Available Anemia is a common complication among patients with chronic kidney disease (CKD, and it is associated with unfavorable clinical outcomes in patients with CKD independent of the estimated glomerular filtration rate (eGFR. We assessed the association of the urinary albumin-to-creatinine ratio (ACR and eGFR with anemia in CKD patients.We conducted a cross-sectional study using baseline data from the KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD. Multiple regression analysis was performed to identify the independent association of albuminuria with anemia. Furthermore, odds ratios for anemia were calculated by cross-categorization of ACR and eGFR.Among 1,456 patients, the mean age was 53.5 ± 12.4 years, and the mean eGFR and ACR were 51.9 ± 30.5 mL/min per 1.73 m2 and 853.2 ± 1,330.3 mg/g, respectively. Anemia was present in 644 patients (40.5%. Multivariate analysis showed that the odds ratio of anemia increased according to ACR levels, after adjusting for age, sex, eGFR, body mass index, pulse pressure, cause of CKD, use of erythropoiesis stimulating agents, serum calcium and ferritin (ACR < 30 mg/g as a reference group; 30-299 mg/g, adjusted odds ratio (OR = 1.43, 95% confidence interval (CI = 0.88-2.33; ≥300 mg/g, adjusted OR = 1.86, 95% CI = 1.12-3.10. In addition, graded associations were observed in cross-categorized groups of a higher ACR and eGFR compared to the reference group with an ACR <30 mg/g and eGFR ≥60 mL/min per 1.73 m2.The present study demonstrated that albuminuria was a significant risk factor for anemia in CKD patients independent of the eGFR.

  13. Effect of early correction of anemia with erythropoietin on left ventricular mass in predialysis patients:a multi-center trial

    Institute of Scientific and Technical Information of China (English)

    Fanfan HOU; Weihua PENG; Jianping WU; Zhongmin YANG; Jianping JIANG; Lizhen GAO; Yangbin PAN; Niansheng YANG; Wei CHEN; Guiyang SHU; Youming CHEN; Jian CHEN

    2005-01-01

    Objective To assess the effects of early correction of anemia with recombinant human erythropoietin (rHuEPO) on the development and progression of left ventricular hypertrophy (LVH) in patients with mild-to-moderate chronic renal insufficiency (CRI) who are not on hemodialysis. Methods A total of 158 patients with serum creatinine from 147μmol/L to 400μmol/L were nrolled in this prospective, multicenter study. Eighty-six patients with hemoglobin (Hb)<110g/L received rHuEPO treatment with a target Hb of ≥110g/L (Group A). Forty patients with comparable Hb concentration (<110g/L) but did not receive rHuEPO (Group B) and 32 patients with Hb≥110g/L and without rHuEPO treatment (Group C) were served as controls. Left ventricular mass index (LVMI) was evaluated by echocardiography at baseline and every 3 months for 2 years. Results There was no difference in age, gender, etiology of renal failure, blood pressure and cardiovascular risk factors among the 3 groups. At baseline, the prevalence of LVH was 72.1% in group A,72.5% in group B and 59.4% in group C. LVMI was inversely correlated with Hb levels (r=0.70, P<0.01). During the 2-year period, the mean LVMI decreased from 142.6±25.7g/m2 to 132.4±18.5 g/m2 in group A, while increased significantly in both group B and group C. The mean Hb concentration increased from 93.8±14.6g/L to 111.2±10.3g/L (P<0.05) in group A, but tended to decrease in group B and group C. There was no significant change of the mean blood pressure, number of anti-hypertensive drugs and serum creatinine concentrations in all 3 groups. However, patients' serum creatinine doubled more often in group B and group C than in group A.Conclusions LVH was common in predialysis CRI patients and was associated with the severity of anemia. Early intervention with rHuEPO may reverse LVH in these patients.

  14. [Neuropsychiatric manifestations ushering pernicious anemia].

    Science.gov (United States)

    Mrabet, S; Ellouze, F; Ellini, S; Mrad, M F

    2015-12-01

    Biermer disease or pernicious anemia is an autoimmune atrophic gastritis characterized by the lack of secretion of gastric intrinsic factor. This leads to an insufficient absorption of vitamin B12 in the ileum. Clinical manifestations are mainly hematologic. Neuropsychiatric manifestations are known but are less frequent especially early in the disease. Inaugural neuropsychiatric arrays are rare and various thus making diagnosis difficult. In this article, we report through two clinical cases different neuropsychiatric manifestations revealing pernicious anemia. Mrs. C.O., aged 56, presented after surgery for gallstones, an acute psychiatric array associated with gait disorders. She had no history of neurological or psychiatric problems. The psychiatric interview revealed delirious syndrome, depressive symptoms and anxiety. Neurological examination noted a flaccid paraplegia with peripheral neuropathic syndrome and myoclonus in the upper limbs. At the full blood count, a macrocytosis (VGM: 112.2fl) without anemia was found. The level of vitamin B12 in the blood was low. Cerebro-spinal MRI was suggestive of a neuro-Biermer and showed hyper signal in the cervical cord on T2-weighted sagittal section. In axial section, hyper signal appears at the posterior columns in the form of V. There were no brain abnormalities. A sensorimotor axonal polyneuropathy was diagnosed. The patient received vitamin B12 intramuscularly for ten days associated with neuroleptic treatment. Mrs. R.M., aged 40, was brought to the psychiatry consultation for acute behavioral disorders progressively worsening over a month. An anxiety syndrome, depressive syndrome and delirious syndrome were identified. Neurological examination showed a posterior cordonal syndrome with quadripyramidal syndrome. Full blood count showed a macrocytic anemia. Serum B12 level was collapsed. Cerebro-spinal MRI was normal. She received vitamin B12 with clinical and biological improvement. Features of pernicious anemia

  15. Fetal Intra-Peritoneal Transfusion for the Management of Very Early Spontaneous Twin Anemia-Polycythemia Sequence in an Obese Patient With a Whole Anterior Placenta.

    Science.gov (United States)

    Guenot, Cécile; Robyr, Romaine; Jastrow, Nicole; Vial, Yvan; Raio, Luigi; Baud, David

    2016-04-01

    Twin anemia-polycythemia sequence (TAPS) is a rare condition in monochorionic twin pregnancies. Small intertwin placental vascular communications allow transfusion, which results in a hemoglobin difference in the twins in the absence of oligohydramnios or polyhydramnios. We report here a case of TAPS diagnosed at 17 weeks' gestation in an obese patient (BMI 42) with a whole anterior placenta. The only possible treatment at this stage of pregnancy was intra-uterine transfusion (IUT), which was repeated weekly until photocoagulation of placental anastomoses was feasible. Fetoscopic laser surgery is the only curative treatment, but is challenging in TAPS because of the absence of polyhydramnios and the presence of minuscule anastomoses. An anterior placenta and high BMI can make the procedure even more challenging. This case report demonstrates that very early and rapidly progressing TAPS with technically complicated conditions (elevated BMI and anterior placenta) can be successfully managed with IUT until laser procedure is achievable. PMID:26996223

  16. Evaluation of Anemia.

    Science.gov (United States)

    Kujovich, Jody L

    2016-06-01

    Anemia is a common problem in primary care. Classification based on mean cell volume narrows the differential diagnosis and directs testing. A marked macrocytosis is characteristic of vitamin B12 and folate deficiencies, certain medications, and primary bone marrow disorders. The three most common causes of microcytic anemia are iron deficiency, thalassemia trait, and anemia of inflammation. Additional laboratory testing is required for diagnosis. Determination of the rate of development of anemia and examination of a blood smear may provide diagnostic clues to guide more specialized testing. Diagnosis of iron, vitamin B12, or folate deficiency mandates determination of the underlying cause. PMID:27212091

  17. Fanconi's anemia and clinical radiosensitivity. Report on two adult patients with locally advanced solid tumors treated by radiotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Bremer, M.; Karstens, J.H. [Hannover Medical School, Hannover (Germany). Dept. of Radiation Oncology; Schindler, D.; Gross, M. [Univ. Wuerzburg (Germany). Inst. of Human Genetics; Doerk, T. [Hannover Medical School, Hannover (Germany). Dept. of Obstetrics and Gynecology; Morlot, S. [Hannover Medical School, Hannover (Germany). Inst. of Human Genetics

    2003-11-01

    Background: Patients with Fanconi's anemia (FA) may exhibit an increased clinical radiosensitivity of various degree, although detailed clinical data are scarce. We report on two cases to underline the possible challenges in the radiotherapy of FA patients. Case Report and Results: Two 24- and 32-year-old male patients with FA were treated by definitive radiotherapy for locally advanced squamous cell head and neck cancers. In the first patient, long-term tumor control could be achieved after delivery of 67 Gy with a - in part - hyperfractionated split-course treatment regimen and, concurrently, one course of carboplatin followed by salvage neck dissection. Acute toxicity was marked, but no severe treatment-related late effects occurred. 5 years later, additional radiotherapy was administered due to a second (squamous cell carcinoma of the anus) and third (squamous cell carcinoma of the head and neck) primary, which the patient succumbed to. By contrast, the second patient experienced fatal acute hematologic toxicity after delivery of only 8 Gy of hyperfractionated radiotherapy. While the diagnosis FA could be based on flow cytometric analysis of a lymphocyte culture in the second patient, the diagnosis in the first patient had to be confirmed by hypersensitivity to mitomycin of a fibroblast cell line due to complete somatic lymphohematopoietic mosaicism. In this patient, phenotype complementation and molecular genetic analysis revealed a pathogenic mutation in the FANCA gene. The first patient has not been considered to have FA until he presented with his second tumor. Conclusion: FA has to be considered in patients presenting at young age with squamous cell carcinoma of the head and neck or anus. The diagnosis FA is of immediate importance for guiding the optimal choice of treatment. Radiotherapy or even radiochemotherapy seems to be feasible and effective in individual cases. (orig.)

  18. Myocardial disease,anemia and heart failure

    Institute of Scientific and Technical Information of China (English)

    Donald S Silverberg; Dov Wexler; Adrian Iaina; Doron Schwartz

    2005-01-01

    Abstract Many patients with congestive heart failure (CHF) fail to respond to maximal CHF therapy and progress to end stage CHF with many hospitalizations, very poor quality of life, end stage renal failure, or die of cardiovascular complications within a short time. One factor that has generally been ignored in many of these patients is the fact that they are often anemic.The anemia is due mainly to renal failure but also to the inhibitory effects of cytokines on the bone marrow. Anemia itself may further worsen the cardiac function and make the patients resistant to standard CHF therapies. Indeed anemia has been associated with increased severity of CHF, increased hospitalization, worse cardiac function and functional class, higher doses of diuretics,worsening of renal function and reduced quality of life. In both controlled and uncontrolled studies the correction of the anemia with erythropoietin (EPO) and oral or Ⅳ iron is associated with improvement in all these parameters. EPO itself may also play a direct role in improving the heart unrelated to the improvement of the anemia. Anemia may also play a role in the worsening of coronary heart disease even without CHF.

  19. Sickle Cell Anemia (For Teens)

    Science.gov (United States)

    ... Can You Do to Stay Well? en español Anemia falciforme What Is Sickle Cell Disease? Sickle cell ... about 10 to 20 days. This usually causes anemia . Anemia is what happens when the body's number ...

  20. Genetics Home Reference: Fanconi anemia

    Science.gov (United States)

    ... Understand Genetics Home Health Conditions Fanconi anemia Fanconi anemia Enable Javascript to view the expand/collapse boxes. Download PDF Open All Close All Description Fanconi anemia is a condition that affects many parts of ...

  1. How Is Pernicious Anemia Treated?

    Science.gov (United States)

    ... from the NHLBI on Twitter. How Is Pernicious Anemia Treated? Doctors treat pernicious anemia by replacing the missing vitamin B12 in the body. People who have pernicious anemia may need lifelong treatment. The goals of treating ...

  2. Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts

    Directory of Open Access Journals (Sweden)

    Régis T. Costello

    2015-01-01

    Full Text Available Epigenetic drugs modify DNA methylation and are used in refractory anemia with excess of blasts (RAEB. These drugs may reactivate anti-oncogene expression and restore a normal phenotype instead of inducing antitumor toxicity, although they also have immunosuppressive effects on T-lymphocytes [1] In RAEB and acute myeloid leukemia, a defect in natural killer (NK cell cytotoxicity has been shown, which relies on abnormal expression of activating receptors. Previous study has shown that 5-azacytidine impaired mRNA synthesis and induced apoptosis in NK cells [2]. In this study we investigated the effect of the demethylating drug 5-azacytidine (Vidaza® on NK receptors with the hypothesis that demethylation of the promoters of activating NK receptor genes induces gene reactivation and thus may increase their expression.

  3. Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts

    Science.gov (United States)

    Costello, Régis T.; Leclercq, Amélie; Treut, Thérèse Le; Sanchez, Carole; Mercier, Delphine; Sébahoun, Gérard

    2015-01-01

    Epigenetic drugs modify DNA methylation and are used in refractory anemia with excess of blasts (RAEB). These drugs may reactivate anti-oncogene expression and restore a normal phenotype instead of inducing antitumor toxicity, although they also have immunosuppressive effects on T-lymphocytes [1] In RAEB and acute myeloid leukemia, a defect in natural killer (NK) cell cytotoxicity has been shown, which relies on abnormal expression of activating receptors. Previous study has shown that 5-azacytidine impaired mRNA synthesis and induced apoptosis in NK cells [2]. In this study we investigated the effect of the demethylating drug 5-azacytidine (Vidaza®) on NK receptors with the hypothesis that demethylation of the promoters of activating NK receptor genes induces gene reactivation and thus may increase their expression. PMID:25709892

  4. Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts.

    Science.gov (United States)

    Costello, Régis T; Leclercq, Amélie; Treut, Thérèse Le; Sanchez, Carole; Mercier, Delphine; Sébahoun, Gérard

    2015-01-01

    Epigenetic drugs modify DNA methylation and are used in refractory anemia with excess of blasts (RAEB). These drugs may reactivate anti-oncogene expression and restore a normal phenotype instead of inducing antitumor toxicity, although they also have immunosuppressive effects on T-lymphocytes [1] In RAEB and acute myeloid leukemia, a defect in natural killer (NK) cell cytotoxicity has been shown, which relies on abnormal expression of activating receptors. Previous study has shown that 5-azacytidine impaired mRNA synthesis and induced apoptosis in NK cells [2]. In this study we investigated the effect of the demethylating drug 5-azacytidine (Vidaza(®)) on NK receptors with the hypothesis that demethylation of the promoters of activating NK receptor genes induces gene reactivation and thus may increase their expression. PMID:25709892

  5. Effects of r—HuEPO on the biophysical characteristics of erythrocyte membrane in patients with anemia of chronic renal failure

    Institute of Scientific and Technical Information of China (English)

    SHIHONGLIAN; FAJUNYANG; 等

    1994-01-01

    Using electron spin resonance (ESR) spin labeling technique,we have studied the conformation of sulfhydryl groups(-SH) binding sites in membrane proteins and mem brane fluidity of red blood cells(RBCs) from two groups of patients with anemia of chronic renal failure(ACRF).One of the groups is composed of patients who were untreated with recombinant human erythropoietin(r-HuEPO),and the other is composed of patients who were treated with r-HuEPO.The results indicated:1)the conformation of SH group binding site in RBC membrane proteins from former group was different from those of healty people.2)the fluidity in the region near the surface of RBC membrane from former group was lower than those of healthy people.3)However,the above biophysical properties of RBC membrane from later group were normal.We concluded that RBC membrane in patients with ACRF was abnormal,and the treatment of r-HuEPO may promote the production of normal RBCs,thus ameliorate the biophysical properties of RBCs from the patients with ACRF.

  6. Pyrexia due to megaloblastic anemia: An Unusual Case

    Directory of Open Access Journals (Sweden)

    Singh PS, Vijay Verma, Vidyasagar, Granth Kumar

    2014-07-01

    Full Text Available Postmenopausal vegetarian female presented with short febrile illness associated with generalized weakness Clinical and investigative findings evidenced megaloblastic anemia Since none of investigations could pinpoint the cause for pyrexia and patient did not respond to empirical antibiotic and conservative antimalarial therapy, megaloblastic anemia itself was suspected to be cause for febrile episode Patient was treated with parenteral B12 and oral folic acid for megaloblastic anemia and she responded to it and became afebrile within 72 hours. Subsequently megaloblastic anemia was correlated to be cause of febrile illness.

  7. Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood

    DEFF Research Database (Denmark)

    Baumann, Irith; Führer, Monika; Behrendt, Sonja;

    2012-01-01

    To evaluate the reproducibility and reliability of the histomorphological criteria differentiating severe aplastic anaemia (SAA) and hypoplastic refractory cytopenia of childhood (RCC), the most frequently acquired hypocellular bone marrow conditions of childhood.......To evaluate the reproducibility and reliability of the histomorphological criteria differentiating severe aplastic anaemia (SAA) and hypoplastic refractory cytopenia of childhood (RCC), the most frequently acquired hypocellular bone marrow conditions of childhood....

  8. 400例早期乳腺癌化疗过程中贫血发生率及相关因素%Incidence and risk factors of anemia in 400 patients with early breast cancer treated by chemotherapy

    Institute of Scientific and Technical Information of China (English)

    蔡耿喜; 刘情; 姚广裕; 陈路嘉; 叶长生

    2015-01-01

    Objective To explore the incidence and predictive factors of anemia induced by chemothera-py in early breast cancer patients. Methods 400 early breast cancer patients treated by taxane-based regimens from 2009 to 2011 in our hospital were analyzed to obtain the incidence of anemia. Univariate analysis and multivariate logistic regression analysis were used to search for risk factors linked to the occurrence of anemia. Results Incidence of anemia was 72.2% in early breast cancer patients undergoing chemotherapy. The occur-rence of anemia was related to 5 risk factors: chemotherapy regiments, Hb at baseline 60 years old, BMI ≤ 25 kg/m2 and HBV antigen positive. Conclusion The anemia incidence during chemothera-py is high in early breast cancer patients. Such factors,as chemotherapy regiments, Hb at baseline, age, BMI and HBV antigen, should be taken into account in identifying high risk patients and prevent anemia.%目的:探讨早期乳腺癌患者化疗过程中贫血的发生率及相关因素.方法:对2009-2011年本院乳腺外科共400例接受含紫杉烷方案化疗的早期乳腺癌患者进行回顾性分析, 统计化疗过程中贫血发生率,并进行单因素分析及多因素Logistic回归分析探讨贫血相关因素. 结果:400例早期乳腺癌患者接受含紫杉烷方案化疗期间贫血发生率为72.2%;化疗过程中发生贫血的相关因素包括:化疗方案、化疗前Hb 60 岁、BMI≤25 kg/m2和乙肝. 结论:早期乳腺癌化疗过程中贫血发生率较高,可根据化疗方案、化疗前Hb水平、年龄、BMI及是否有乙肝识别贫血高危患者,预测贫血发生率.

  9. The Value of Erythrocyte Indices and Red Cell Volume Distribution Width in Differential Diagnosis of Iron Deficiency Anemia and Anemia of Chronic Disease

    Directory of Open Access Journals (Sweden)

    Abdullah Altıntaş

    2007-01-01

    Full Text Available Iron deficiency anemia (IDA and anemia of chronic disease are the most commonly confused anemias. We investigate the diagnostic value of erythrocyte indices, red cell volume distribution width, and serum ferritin levels to make differential diagnosis of anemia in controls and anemic patients.Iron deficiency anemia (44 patients, anemia of chronic disease (41, IDA with anemia of chronic disease (17 and control (50 groups were compared. We performed serum ferritin, CBC, and sedimentation rate in all patientsand bone marrow aspiration in patients with anemia of chronic disease.Although mean cell volume (MCV and mean corpuscular hemoglobin (MCH are low in IDA and anemia of chronic disease, it is much striking in the former one (p<0.001, p<0.001. Only 7.3% of patients with anemia of chronic disease had a MCV<70 fL and MCH<24 pg, 90.0% of patients with IDA were below that cut-off point. Serum ferritin means were in patients with IDA and anemia of chronic disease were 4.6±3.3 and 489.6 ±519.9 ng/ml, respectively.The probability of IDA is low when RDW is normal in microcytic anemias. RDW is high in half of patients with anemia of chronic disease. Reference values for ferritin must be changed in patients with anemia of chronic disease and IDA. If serum ferritin is 57.6-146.4 ng/ml anemia of chronic disease and iron deficiency must ruled out by other diagnostic tests.

  10. The Study of HFE Genotypes and Its Expression Effect on Iron Status of Iranian Haemochromatosis, Iron Deficiency Anemia Patients, Iron-Taker and Non Iron-Taker Controls.

    Science.gov (United States)

    Beiranvand, Elham; Abediankenari, Saeid; Rostamian, Mosayeb; Beiranvand, Behnoush; Naazeri, Saeed

    2015-01-01

    The role of HFE gene mutations or its expression in regulation of iron metabolism of hereditary haemochromatosis (HH) patients is remained controversial. Therefore here the correlation between two common HFE genotype (p.C282Y, p.H63D) and HFE gene expression with iron status in HH, iron deficiency anemia (IDA) and healthy Iranian participants was studied. For this purpose genotype determination was done by polymerase chain reaction--restriction fragment length polymorphism (PCR-RFLP). Real-Time PCR was applied for evaluation of HFE gene expression. Biochemical parameters and iron consumption were also assessed. Homozygote p.H63D mutation was seen in all HH patients and p.C282Y was not observed in any member of the population. A significant correlation was observed between serum ferritin (SF) level and gender or age of HH patients. p.H63D homozygote was seen to be able to significantly increase SF and transferrin saturation (TS) level without affecting on liver function. Our results also showed that iron consumption affects on TS level increasing. HFE gene expression level of IDA patients was significantly higher than other groups. Also the HFE gene expression was negatively correlated with TS. Finally, the main result of our study showed that loss of HFE function in HH is not derived from its gene expression inhibition and much higher HFE gene expression might lead to IDA. However we propose repeating of the study for more approval of our finding. PMID:25687342

  11. Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital.

    Science.gov (United States)

    Wang, Meng; Wang, Wenjia; Abeywardane, Ayesha; Adikarama, Malinthi; McLornan, Donal; Raj, Kavita; de Lavallade, Hugues; Devereux, Stephen; Mufti, Ghulam J; Pagliuca, Antonio; Potter, Victoria T; Mijovic, Aleksandar

    2015-01-01

    Autoimmune hemolytic anemia (AIHA) is a recognized complication of hematopoietic stem cell transplantation (HSCT); it is often refractory to treatment and carries a high mortality. To improve understanding of the incidence, risk factors, and clinical outcome of post-transplantation AIHA, we analyzed 533 patients who received allogeneic HSCT, and we identified 19 cases of AIHA after HSCT (overall incidence, 3.6%). The median time to onset, from HSCT to AIHA, was 202 days. AIHA was associated with HSCT from unrelated donors (hazard ratio [HR], 5.28; 95% confidence interval [CI], 1.22 to 22.9; P = .026). In the majority (14 of 19; 74%) of AIHA patients, multiple agents for treatment were required, with only 9 of 19 (47%) patients achieving complete resolution of AIHA. Patients with post-transplantation AIHA had a higher overall mortality (HR, 2.48; 95% CI, 1.33 to 4.63; P = .004), with 36% (4 of 11 cases) of deaths attributable to AIHA. PMID:25262883

  12. Sickle Cell Anemia

    Science.gov (United States)

    Sickle cell anemia is a disease in which your body produces abnormally shaped red blood cells. The cells are shaped like a crescent or sickle. They ... last as long as normal, round red blood cells. This leads to anemia. The sickle cells also ...

  13. Iron-Deficiency Anemia

    Medline Plus

    Full Text Available ... Blood Tests Blood Transfusion Restless Legs Syndrome Send a link to NHLBI to someone by E-MAIL | ... Iron-Deficiency Anemia? Español Iron-deficiency anemia is a common, easily treated condition that occurs if you ...

  14. Early colonoscopy confers survival benefits on colon cancer patients with pre-existing iron deficiency anemia: a nationwide population-based study.

    Directory of Open Access Journals (Sweden)

    Chieh-Lin Jerry Teng

    Full Text Available This study aimed to examine the prognostic significance of pre-existing iron deficiency anemia (IDA and the benefits of early colonoscopy in patients with colon cancer, since these have not been clearly established to date. Using the Taiwanese National Health Insurance Research Database, we retrieved and retrospectively reviewed the records of patients aged ≥ 55 years who were diagnosed with colon cancer between 2000 and 2005. The patient cohort was divided into two groups: patients with (n = 1,260 or without (n = 15,912 an IDA diagnosis during ≤ 18 months preceding the date of colon cancer diagnosis. We found that diabetes (27.9% vs. 20.3%, p<0.0001, cardiovascular disease (61.6% vs. 54.7%, p<0.001, and chronic kidney disease (4.6% vs. 2.2%, p<0.0001 were more common among patients with IDA than among those without IDA. The median overall survival times for patients with IDA and those without IDA were 4.6 and 5.7 years, respectively (p = 0.002. Patients who underwent colonoscopy ≤ 30 days, 31-90, and ≥ 91 days after IDA diagnosis showed median overall survival times of 5.79, 4.43, and 4.04 years, respectively (p = 0.003. Delayed colonoscopy was an independent factor associated with poor overall survival (adjusted hazard ratio, 1.28; 95% confidence interval, 1.07-1.53; p = 0.01. In conclusion, colon cancer patients with IDA were more likely to experience comorbidities than were those without IDA. Pre-existing IDA was a poor prognostic factor in adult men and postmenopausal women who had colon cancer. Early colonoscopy could improve overall survival possibly by facilitating early diagnosis and treatment.

  15. Successful Treatment of Liver Aspergilloma by Caspofungin Acetate First-Line Therapy in a Non-Immunocompromised Patient

    Directory of Open Access Journals (Sweden)

    Hong-Juan Dong

    2012-09-01

    Full Text Available Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.

  16. Analysis of anemia status among 141 331 cases of infants and young children in out-patient department%门诊就诊141331例婴幼儿贫血患病情况分析

    Institute of Scientific and Technical Information of China (English)

    孙宝苓; 王洛平; 马丽娟; 李静; 戴耀华

    2012-01-01

    [Objective] To analyze the anemia status among infants and young children in out-patient department of hospital from Beijing area resident population. [Methods] A retrospective analysis of January to December 2011 in our hospital,141 331 cases of 6 months~3 years old in children with peripheral blood or blood routine test results of five classification. In accordance with the hemoglobin of less than 110 g/L for anemia screening criteria,MCV and MCHC level differences were screening criteria of anemia type. The population were divided into 6 months age group, 1 age group and 2 age group and statistically analyzed. [Results] The results showed that total anemia prevalence rate was 10. 29% from the survey population in infants and young children,in which iron-deficiency anemia was accounted for 12. 43% ,macrocytic anemia accounted for 0. 24% ,normocytic anemia accounting for 17. 03% and Simple microcytic anemia accounting for 69. 78%. Anemia prevalence rate of 6 months of age (from 6~12 months) group was 22. 1 % , 1 age group was 8. 52% as well as 2 age group was 1. 97% , respectively. The prevalence of anemia was 9. 39% in mild anemia of 13 276 patients,the prevalence of anemia was 0. 88% in moderate anemia of 1 247 patients; severe anemia was found in 19 cases. [Conclusion] The prevalence of anemia among children with 6 rnonth old group was the highest prevalence of anemia. Mild anemia prevalence ranks first. The result of the statistical analysis data would be provided as much help as infants and young children nutrition and health intervention experiment basis in out-patient department.%[目的]对来院就诊北京地区常住人口婴幼儿贫血患病情况进行统计分析,为保健干预提供依据. [方法]回顾分析2011年1-12月来首都儿科研究所附属儿童医院就诊141 331例6月龄~3岁儿童末梢血或静脉血血常规五分类检测结果.按照血红蛋白低于110g/L为贫血筛查标准,MCV和MCHC水平差

  17. Relationship between anemia and stable chronic obstructive pulmonary disease in elderly patients%老年稳定期慢性阻塞性肺疾病贫血临床分析

    Institute of Scientific and Technical Information of China (English)

    李蔚; 陈果

    2011-01-01

    目的 探讨老年稳定期慢性阻塞性肺疾病(COPD)患者贫血的发生情况及其影响因素.方法 选择老年稳定期COPD患者60例,测定其血常规、C反应蛋白(CRP)、肺功能(FEV1%预计值、FEV1/FVC)、身高和体重,计算体重指数(BMI).根据血红蛋白浓度(Hb)分为贫血组和非贫血组,比较两组性别、年龄、吸烟指数(包年数)、CRP、肺功能、BMI、近一年因急性加重使用抗生素次数的差异.结果 贫血组11例,非贫血组49例,贫血发生率为18.3%;贫血组平均年龄、CRP水平及近一年因急性加重使用抗生素次数高于非贫血组(P0.05).结论 老年COPD患者贫血发生率较高,贫血可能与反复气道感染及慢性炎症有关,高龄可能为影响COPD患者贫血的相关因素.%Objective To evaluate the incidence of anemia and its relevant factors in elderly patients with stable chronic obstructive pulmonary disease ( COPD).Methods Sixty elderly patients with stable COPD were enrolled.Routine blood test, C-reactive protein ( CRP) pulmonary function ( FEVl/pred,FEV1/FVC) and body mass index ( BMI) were measured or calculated in all cases.All the patients were further divided into two groups based on whether anemia existed, and patients' sex, age, smoking index,CRP, pulmonary function, BMI and antibiotic usage frequency were observed in the two groups.Results The degrees of anemia correlated with patients' age, CRP and repeated airway infection (P < 0.05 ).Sex, smoking index, pulmonary function and BMI were not different significantly between the two groups ( P > 0.05 ).Conclusions In elderly COPD patients, the incidence of anemia is high.Anemia may be correlated with repeated airway infection and chronic inflammation.Advanced age is a relevant factor of anemia in COPD patients.

  18. Whole body 59Fe-elimination rates and corresponding blood losses in patients with factitious anemia induced by self-blood letting

    International Nuclear Information System (INIS)

    Within a year two cases were identified and quantitated for blood losses by whole body counting of retained iron. Whereas the 2 patients did not lose much blood during their observation within the hospital their blood losses increased upon release from the hospital. Although they lost about 5 liter blood in 50 days faecal occult blood tests were always negative and the daily faecal and urinary 59Fe-excretion was within the normal range. Haemoglobin and erythrocyte levels were stable during the periods of clinical observation when the whole body 59Fe-elimination rates were only just above the normal range. These values dropped however to very low values during or following periods of extremely elevated whole body 59Fe-elimination rates immediately after release of the patients from the hospital. Blood losses of up to 145 ml/d (=50 mg Fe/d) can be compensated by oral ferrous iron therapy with 4 x 50 = 200 mg Fe2+ /d. The patients did however refuse to take oral or parenteral iron and insisted in one case on regular blood transfusions twice per week. Two more probable cases of factitious anemia were subsequently observed and partially investigated. (orig./MG)

  19. 慢性阻塞性肺疾病合并贫血患者BODE变化%Study on the Changes of BODE Indexes in Patients with Chronic Obstructive Pulmonary Disease Complicated by Anemia

    Institute of Scientific and Technical Information of China (English)

    黄洁; 李承红

    2015-01-01

    目的:探讨慢性阻塞性肺疾病( COPD )急性加重期合并贫血患者的 BODE 指数变化。方法选择2010年5月至2013年1月江汉大学附属医院呼吸内科确诊的COPD急性加重期患者共273例。根据贫血标准分为两组,合并贫血的COPD患者(贫血组)40例,非贫血的COPD患者(非贫血组)随机选取40例。比较两组患者 BODE 指数,并对结果进行统计学分析。结果合并贫血的COPD患者发生率为14.6%,贫血组BODE指数高于非贫血组,差异有统计学意义( P<0.01)。其中体质指数、6 min步行试验距离、呼吸困难量表与非贫血组差异均有统计学意义(均 P<0.01);两组患者肺功能指标( FEV1%,第1秒用力呼气容积占预计值百分比)比较差异无统计学意义( P >0.05)。结论贫血可恶化COPD运动耐量,影响患者生活质量,预后更差。%Objective To study the changes of BODE indexes in patients with chronic obstructive pul-monary disease(COPD) complicated by anemia.Methods A total of 273 patients diagnosed as acute exac-erbation of COPD in Department of Respiratory Medicine,the Affiliated Hospital of Jianghan University from May 2010 to Jan.2013 were selected as research objects,according to the standard of anemia,the patients were divided into two groups,patients with anemia as anemia group(40 cases) and patients without anemic as non-anemia group(40 cases).BODE indexes of the two groups were compared and statistically analyzed. Results Incidence of anemia in patients with COPD was 14.6%,BODE indexes of the anemia group were higher than non-anemic group,there were statistically significant differences(P0.05 ) .Conclusion Although the influence of anemia on pulmonary function in COPD patients has no statistically significant difference , anemia will worsen the COPD exercise tolerance , and impact on the quality of life in patients with poor prognosis .

  20. The Analysis of Anemia in Chronic Heart Failure

    Institute of Scientific and Technical Information of China (English)

    Yuan Guiyi; Wu Wei; Luo Yilong; Li Yiqing; Zhou Shuxian; Fang Chang

    2006-01-01

    objectives To demonstrate the phenomena and explore the causes of anemia in patients with chronic heart failure (CHF). Methods To observe the phenomena of anemia in patients with CHF, a total of 276 patients with CHF were included in this retrospective study. The clinical characteristics of the patients are: mean age 69.2±11.0 years; male 151,female 125; NYHA Ⅲ and Ⅳ 115 (41.7%). Results ①Among the 276 patients with CHF, 81 (29.4%)had anemia (Mean hemoglobulin concentration 101.5±13.0g/L). ② Patients with Anemia were more likely to be female and to have greater NYHA (Ⅲ or Ⅳ) (P<0.05), higher serum creatinine, as well as lower serum albumin and low-density lipoprotein levels (P<0.01).③ A weak negative correlation was also noted between the level of NYHA and hemoglobulin. ④ There was no significant difference in age, the primary cardiac etiology of the CHF, the history of diabetes, left ventricular end diastolic diameter, and left ventricular ejection fraction between CHF patient with and without anemia. Conclusions The prevalence of anemia is high among patients with CHF. The anemia patients with CHF tend to be female, have greater cardiac and renal functional impairment, but with lower serum albumin and LDL that suggests some degree of malnutrition.

  1. 158例老年贫血患者骨髓细胞学检查结果分析%Bone marrow cytology examination results analysis of 158 case elderly anemia patients

    Institute of Scientific and Technical Information of China (English)

    占颖奇; 陈速

    2014-01-01

    Objective:Cytological analysis of characteristics of the patients with bone marrow anemia in the elderly, to investigate the causes of anemia, improvement of anemia in the elderly attention.Methods:A retrospective analysis of 158 cases of anemia in the elderly patients (≥ 60 years) bone marrow cytology results and clinical data were performed.Results:158 cases of 48 cases with anemia in the elderly patients with mild anemia (30.4%); moderate anemia in 71 cases (44.9%); 39 cases (24.7%) in severe anemia. Diagnosis of 136 cases (86.1%): among the 26 cases of megaloblastic anemia (16.5%); anemia of chronic disease in 23 cases (14.6%); 20 cases with iron deficiency anemia (12.7%); 13 cases of multiple myeloma (8.2%); 12 cases of acute leukemia (7.6%); 9 patients with thrombocytopenia (5.7%); infectious anemia in 7 cases (4.3%); 5 cases of chronic lymphocytic leukemia (3.2%); 5 cases of myelodysplastic syndrome (3.2%); 4 cases of hemolytic anemia (2.5%); 3 cases of lymphoma (1.9%); 3 cases of hypersplenism (1.9%); 2 cases of chronic myelogenous leukemia (1.3%); 2 cases of malignant tumors (1.3%); 1 cases with pure red cell aplasia (0.6%); 1 cases of bone marrow fibrosis (0.6%). 22 cases of unknown causes (13.9%).Conclusions: Anemia in the elderly complex etiology, onset occult, should be thought highly by the elderly and medical workers;Bone marrow cytology for diagnosis of anemia, anemia in elderly type determination has important clinical significance.%目的:分析老年贫血患者骨髓细胞学特点,探讨老年贫血病因,提高对老年贫血的重视。方法:回顾分析158例老年贫血患者(≥60岁)骨髓细胞学检查结果及临床资料。结果:158例老年贫血患者中轻度贫血48例(30.4%);中度贫血71例(44.9%);重度贫血39例(24.7%)。明确病因的有136例(86.1%):其中巨幼细胞性贫血26例(16.5%);慢性病贫血23例(14.6%);缺铁性贫血20例(12.7%);多发性骨髓瘤13例(8.2%)

  2. Reação transfusional hiper-hemolítica em pacientes portadores de anemia falciforme: relato de dois casos Hyper-hemolytic transfusional reaction in sickle cell patients: two case reports

    Directory of Open Access Journals (Sweden)

    Cláudia C.S. Naufel

    2002-12-01

    Full Text Available O caráter crônico da anemia, nos pacientes portadores de anemia falciforme, associado à maior capacidade de liberação de oxigênio pela Hb S, faz com que sejam pouco sintomáticos em relação à anemia e não necessitem de forma rotineira de transfusão de hemácias. Contudo, na vigência de complicações agudas, a queda adicional da hemoglobina pode precipitar descompensação da função cardio-respiratória e colocar em risco a vida do paciente, tornando a transfusão de sangue um recurso terapêutico de grande importância. Em virtude da elevada freqüência de transfusões a que esses pacientes são submetidos, é de fundamental importância o conhecimento dos principais riscos e o diagnóstico adequado das complicações decorrentes da terapia transfusional. Uma forma atípica de reação transfusional, denominada reação transfusional hiperhemolítica, foi descrita recentemente em pacientes com anemia falciforme após transfusão de hemácias aparentemente compatíveis. (4,5,6,7 Nesta condição, transfusões ulteriores podem exacerbar o quadro hemolítico e colocar em risco a vida do paciente. Os mecanismos patofisiológicos exatos dessa entidade ainda não são bem conhecidos e o tratamento consiste na suspensão da transfusão, corticoterapia e/ou administração de imunoglobulina. O objetivo deste trabalho é apresentar o relato de dois casos de reação transfusional hiperhemolítica em pacientes portadores de anemia falciforme.The chronic character of sickle cell anemia associated with the greater capacity to liberate oxygen by the Hb S, results in patients exhibiting few symptoms in relation to the anemia and they do not require regular hemacias transfusions. Nevertheless, in the face of acute complications, the additional drop in hemoglobin can precipitate an imbalance in the cardio-respiratory function and put the life of the patient at risk, making blood transfusion therapy of utmost importance. In the light of the

  3. Pathophysiology of anemia and erythrocytosis.

    Science.gov (United States)

    Hodges, Vivien M; Rainey, Susan; Lappin, Terence R; Maxwell, A Peter

    2007-11-01

    An increasing understanding of the process of erythropoiesis raises some interesting questions about the pathophysiology, diagnosis and treatment of anemia and erythrocytosis. The mechanisms underlying the development of many of the erythrocytoses, previously characterised as idiopathic, have been elucidated leading to an increased understanding of oxygen homeostasis. Characterisation of anemia and erythrocytosis in relation to serum erythropoietin levels can be a useful addition to clinical diagnostic criteria and provide a rationale for treatment with erythropoiesis stimulating agents (ESAs). Recombinant human erythropoietin as well as other ESAs are now widely used to treat anemias associated with a range of conditions, including chronic kidney disease, chronic inflammatory disorders and cancer. There is also heightened awareness of the potential abuse of ESAs to boost athletic performance in competitive sport. The discovery of erythropoietin receptors outside of the erythropoietic compartment may herald future applications for ESAs in the management of neurological and cardiac diseases. The current controversy concerning optimal hemoglobin levels in chronic kidney disease patients treated with ESAs and the potential negative clinical outcomes of ESA treatment in cancer reinforces the need for cautious evaluation of the pleiotropic effects of ESAs in non-erythroid tissues. PMID:17656101

  4. Unexplained Anemia in the Elderly

    OpenAIRE

    Makipour, Sasan; Kanapuru, Bindu; Ershler, William B.

    2008-01-01

    Among the elderly, anemia occurs with increasing frequency with each advancing decade. Unlike when anemia occurs in younger adults, the cause of anemia in the elderly is oftentimes not readily apparent or attributable to a single cause. However, this commonly observed form of anemia in the elderly (termed unexplained anemia [UA]) can generally be dissected to its root causes, which include renal insufficiency, inflammation, testosterone deficiency, and stem cell proliferative decline. Myelody...

  5. Experience of Perinatal Care of Iron Deficiency Anemia in Pregnant Women Around%浅析缺铁性贫血孕产妇围产期护理体会

    Institute of Scientific and Technical Information of China (English)

    车辐顺

    2015-01-01

    目的 研究分析缺铁性贫血孕妇围产期护理方式,对该类患者提供积极有效的护理.方法 整理收集我院2013年接收的76例缺铁性贫血患者来进行研究分析,患者年龄22~37岁,孕周19~40周.对其进行围产期护理观察,总结护理体会.结果 产后42 d门诊复查分析,除1例妊娠合并再生障碍性贫血患者的血红蛋白低于100 g/L外,其他产妇的血红蛋白均在110 g/L以上,母乳喂养率95%以上,新生儿的体重、身长、各项营养指标均达到中上水平,无1例发生营养不良.结论 对妊娠合并缺铁性贫血患者提供有效的围产期护理,能够让患者的抵抗力增强,对母婴提供保障,促进患者的生活改善.%Objective To study the analysis of iron deficiency anemia in pregnant women in perinatal nursing mode, provide active and effective nursing for the patients.Methods Colected in our hospital in 2013 received 76 cases of iron deficiency anemia patients to carry on the research analysis, patients aged 22 to 37 years of age, pregnant weeks 19 to 40. The perinatal nursing observation, to sum up the nursing experience.Results Analysis of 42 d postpartum clinic reexamination, except for 1 cases of pregnancy complicated with aplastic anemia hemoglobin below 100 g/L, other maternal hemoglobin were above 110 g/L, the breastfeeding rate above 95%, birth weight, length, nutritional inde